NZ616834B2 - Novel compounds as modulators of protein kinases - Google Patents
Novel compounds as modulators of protein kinases Download PDFInfo
- Publication number
- NZ616834B2 NZ616834B2 NZ616834A NZ61683412A NZ616834B2 NZ 616834 B2 NZ616834 B2 NZ 616834B2 NZ 616834 A NZ616834 A NZ 616834A NZ 61683412 A NZ61683412 A NZ 61683412A NZ 616834 B2 NZ616834 B2 NZ 616834B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- substituted
- unsubstituted
- ethyl
- fluorophenyl
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Disclosed are benzopyran (chromene) PI3K protein kinase modulator compounds of formula (I), wherein the substituents are as described in the specification. Also disclosed are methods of preparing compounds of formula (I), pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders. Examples of the compounds for formula (I) are: 2-(6-Amino-9H-purin-9-yl) methyl)-3-(3-fluorophenyl)-5-methoxy-4H-chromen-4-one 2-((4-Amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(3-fluorophenyl)-5-methoxy-4H-chromen-4-one 4-(4-amino-1-(1-(5-fluoro-3-(3-fluorophenyl)-4-oxo-4H-chromen-2-yl)ethyl)-1Hpyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropylbenzenesulfonamide on and/or amelioration of kinase mediated diseases or disorders. Examples of the compounds for formula (I) are: 2-(6-Amino-9H-purin-9-yl) methyl)-3-(3-fluorophenyl)-5-methoxy-4H-chromen-4-one 2-((4-Amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl) methyl)-3-(3-fluorophenyl)-5-methoxy-4H-chromen-4-one 4-(4-amino-1-(1-(5-fluoro-3-(3-fluorophenyl)-4-oxo-4H-chromen-2-yl)ethyl)-1Hpyrazolo[3,4-d]pyrimidin-3-yl)-N-cyclopropylbenzenesulfonamide
Description
NOVEL COMPOUNDS AS
MODULATORS OF PROTEIN KINASES
Related Applications
This application claims the benefit of Indian Provisional Patent Application Nos.
th th
1542/CHE/2011 dated 4 May 2011 and 81/CHE/2012 dated 9 January 2012, each of
which is hereby incorporated by reference.
Field of the Invention
The present invention provides PI3K protein kinase modulators, methods of
preparing them, pharmaceutical compositions containing them and methods of
treatment, prevention and/or amelioration of kinase mediated diseases or disorders with
them.
Background of the Invention
Any discussion of the prior art throughout the specification should in no way be
considered as an admission that such prior art is widely known or forms part of common
general knowledge in the field.
In the recent past immense research has been dedicated to the discovery and
understanding of the structure and functions of enzymes and bio-molecules associated
with various diseases. One such important class of enzymes that has been the subject of
extensive research is Protein Kinase.
In general, protein kinases represent a set of structurally related phosphoryl
transferases having conserved structures and catalytic functions. These enzymes modify
proteins by chemically adding phosphate groups (phosphorylation). Phosphorylation
involves the removal of a phosphate group from ATP and covalently attaching it to
amino acids that have a free hydroxyl group such as serine, threonine or tyrosine.
Phosphorylation usually results in a functional change of the target protein (substrate)
by altering enzyme activity, cellular localization or association with other proteins. Up
to 30% of all proteins may be modified by kinase activity.
This class of proteins are classified into subsets depending upon the substrate
they act upon such as tyrosine kinase, serine/theronine kinase, histidine kinase and the
139095.01203/7122633v.1
like. These proteins can also be classified based on their localization into receptor
tyrosine kinases (RTKs) or non-receptor tyrosine kinases.
Receptor tyrosine kinases (RTKs) have an extracellular portion, a
transmembrane domain, and an intracellular portion, while non-receptor tyrosine
kinases are entirely intracellular. Receptor tyrosine kinase mediated signal transduction
is typically initiated by an extracellular interaction with a specific growth factor
(ligand), followed by receptor dimerization, stimulation of the intrinsic protein tyrosine
kinase activity, and phosphorylation of amino acid residues. The ensuing
conformational change leads to the formation of complexes with a spectrum of
cytoplasmic signalling molecules and facilitates a myriad of responses such as cell
division, differentiation, metabolic effects, and changes in the extracellular
microenvironment.
Protein kinases are known to control a wide variety of biological processes such
as cell growth, survival and differentiation, organ formation and morphogenesis,
neovascularisation, tissue repair and regeneration. In addition to their functions in
normal tissues/organs, many protein kinases also play specialized roles in a host of
human diseases including cancer. A subset of protein kinases (also referred to as
oncogenic protein kinases), when dysregulated, can cause tumor formation and growth
and contribute to tumor maintenance and progression (Blume- Jensen P et al, Nature
2001, 411(6835):355-365). Thus far, oncogenic protein kinases represent one of the
largest and most attractive groups of protein targets for therapeutic intervention and
drug development.
Both receptor and non-receptor protein kinases have been found to be attractive
targets for small molecule drug discovery due to their impact on cell physiology and
signalling. Dysregulation of protein kinase activity thus leads to altered cellular
responses including uncontrolled cell growth associated with cancer. In addition to
oncological indications, altered kinase signalling is implicated in numerous other
pathological diseases. These include, but are not limited to immunological disorders,
cardiovascular diseases, inflammatory diseases, and degenerative diseases.
Modulation (particularly inhibition) of cell proliferation and angiogenesis, the
two key cellular processes needed for tumor growth and survival is an attractive goal for
development of small-molecule drugs (Matter A. Drug Disc Technol 2001, 6, 1005-
1024). Anti-angiogenic therapy represents a potentially important approach for the
139095.01203/7122633v.1
treatment of solid tumors and other diseases associated with dysregulated
vascularisation including ischemic coronary artery disease, diabetic retinopathy,
psoriasis and rheumatoid arthritis. Similarly, cell antiproliferative agents are desirable to
slow or inhibit the growth of tumors.
Phosphatidylinositol (hereinafter abbreviated as "PI") is one of a number of
phospholipids found in cell membranes. In recent years it has become clear that PI plays
an important role in intracellular signal transduction. Cell signaling via 3'-
phosphorylated phosphoinositides has been implicated in a variety of cellular processes,
e.g., malignant transformation, growth factor signaling, inflammation, and immunity
(Rameh et al (1999) J. Biol Chem, 274:8347-8350). The enzyme responsible for
generating these phosphorylated signaling products, phosphatidylinositol 3-kinase (also
referred to as PI 3-kinase or PI3K), was originally identified as an activity associated
with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylate
phosphatidylinositol (PI) and its phosphorylated derivatives at the 3'-hydroxyl of the
inositol ring (Panayotou et al (1992) Trends Cell Biol 2:358-60).
The phosphoinositide 3-kinases (PI3Ks) are a family of enzymes that regulate
diverse biological functions in every cell type by generating phosphoinositide second-
messenger molecules. As the activity of these phosphoinositide second messengers is
determined by their phosphorylation state, the kinases and phosphatises that act to
modify these lipids are central to the correct execution of intracellular signaling events.
Phosphoinositide 3-kinases (PI3K) phosphorylate lipids at the 3-hydroxyl residue of an
inositol ring (Whitman et al (1988) Nature, 332:664) to generate phosphorylated
phospholipids (PIP3s) which act as second messengers recruiting kinases with lipid
binding domains (including plekstrin homology (PH) regions), such as Akt and
phosphoinositide-dependent kinase-1 (PDK1). Binding of Akt to membrane PIP3s
causes the translocation of Akt to the plasma membrane, bringing Akt into contact with
PDK1, which is responsible for activating Akt. The tumor-suppressor phosphatase,
PTEN, dephosphorylates PIP3 and therefore acts as a negative regulator of Akt
activation. The PI3-kinases Akt and PDK1 are important in the regulation of many
cellular processes including cell cycle regulation, proliferation, survival, apoptosis and
motility and are significant components of the molecular mechanisms of diseases such
as cancer, diabetes and immune inflammation (Vivanco et al (2002) Nature Rev. Cancer
2:489; Phillips et al (1998) Cancer 83:41).
139095.01203/7122633v.1
The PI3K family is constituted by four different classes: classes I, II and III are
lipid kinases while members of class IV are Ser/Thr protein kinases.
The members of the class I family of PI3Ks are dimers of a regulatory and a
catalytic subunit. The class I family consists of four isoforms, determined by the
catalytic subunits α, β, γ and δ (see Engelman JA, Nat Rev Genet 2006;7:606-19;
Carnero A, Curr Cancer Drug Targets 2008;8:187-98; Vanhaesebroeck B, Trends
Biochem Sci 2005;30:194-204). Class I can be subdivided into two subclasses: Ia,
formed by the combination of p110 α β and δ and a regulatory subunit (p85, p55 or p50)
and Ib, formed by p110 γ and p101 regulatory subunits. The regulatory subunit p85
contains Src homology 2 domains, which bind to phosphotyrosines and bring the
attached catalytic subunit p110 into the complexes located in the membrane around the
receptor. The activation of PI3K is induced by growth factors and insulin targeting the
catalytic subunit to the membrane where it is in close proximity with its substrates,
mainly PIP2. Alternatively, GTP-bound Ras can bind and activate p110 subunits in a
p85-independent manner. Class I phosphoinositide 3-kinases (PI3Ks) are lipid kinases
that phosphorylate phosphatidyl-inositide lipids (PI) at the D3 position of the inositol
ring producing lipid second messengers (PIPs). The products of PI3K activity, mainly
PI(3,4,5)-P3 (PIP3), are present in very low level in quiescent cells but are rapidly
produced during cell stimulation and are involved in the regulation of several biological
responses including mitogenesis, apoptosis, vesicular trafficking and cytoskeleton
rearrangement. The result of rising PIP3 levels is the activation of 3-phosphoinositide-
dependent protein kinase-1 and its substrate AKT, which triggers most of the biological
activities of the pathway. Phosphatase and tensin homolog in chromosome 10 (PTEN) is
a lipidic phosphatase which constitutes the main negative regulator of the route by
dephosphorylating PIP3 to PI(4,5)-P2 (PIP2). Class II displays the ability to
phosphorylate PI and PI-4 phosphate in vitro. Class III, composed by Vps34 only
member, phosphorylates PI at position 3 generating PI 3-phosphate. Vps34 has been
implicated in Golgi trafficking of proteins, autophagy and activation of mammalian
target of rapamycin (mTOR) by amino acids (see Backer JM. Biochem J 2008; 410:1-
17). These classes are generally resistant to class I PI3K inhibitors. Class IV, however,
is important because it constitutes the major cross-activity proteins for class I inhibitors.
This class includes enzymes involved in signal transduction and DNA damage response
such as mTOR, DNA-dependent protein kinase (DNA-PK) or ATM. This fourth class of
139095.01203/7122633v.1
PI3K-related enzymes contains a catalytic core similar to the PI3K, which can account
for the cross-inhibition by class I ‘selective’ compounds. However, small differences,
especially in the hinge region, and the solving of the PI3K-related structures might lead
to the fine tuning of different paralog selective PI3K-members. (see Expert Opin.
Investig. Drugs (2009) 18(9): 1265-1277 )
There is now considerable evidence indicating that Class Ia PI3K enzymes
contribute to tumourigenesis in a wide variety of human cancers, either directly or
indirectly (Vivanco and Sawyers, Nature Reviews Cancer, 2002, 2, 489-501). For
example, the pi 10a subunit is amplified in some tumours such as those of the ovary
(Shayesteh et al, Nature Genetics. 1999, 21: 99-102) and cervix (Ma et al, Oncogene,
2000, 19: 2739-2744). More recently, activating mutations within the catalytic site of pi
10a have been associated with various other tumours such as those of the colorectal
region and of the breast and lung (Samuels et al, Science, 2004, 304, 554). Tumour-
related mutations in p85 α have also been identified in cancers such as those of the ovary
and colon (Philp et al., Cancer Research, 2001, 61, 7426-7429). In addition to direct
effects, it is believed that activation of Class Ia PI3K contributes to tumourigenic events
that occur upstream in signalling pathways, for example by way of ligand-dependent or
ligand-independent activation of receptor tyrosine kinases, GPCR systems or integrins
(Vara et al, Cancer Treatment Reviews, 2004, 30, 193-204). Examples of such upstream
signalling pathways include over-expression of the receptor tyrosine kinase Erb2 in a
variety of tumours leading to activation of PI3K-mediated pathways (Harari et al.,
Oncogene, 2000, 19, 6102-6114) and over-expression of the oncogene Ras (Kauffmann-
Zeh et al., Nature, 1997, 385, 544-548). In addition, Class Ia PBKs may contribute
indirectly to tumourigenesis caused by various downstream signalling events. For
example, loss of the effect of the PTEN tumour-suppressor phosphatase that catalyses
conversion of PI(3,4,5)P3 back to PI(4,5)P2 is associated with a very broad range of
tumours via deregulation of PI3K-mediated production of PI(3,4,5)P3 (Simpson and
Parsons, Exp. Cell Res.. 2001, 264, 29-41). Furthermore, augmentation of the effects of
other PI3K-mediated signalling events is believed to contribute to a variety of cancers,
for example by activation of Akt (Nicholson and Anderson, Cellular Signalling, 2002,
H, 381-395).
In addition to a role in mediating proliferative and survival signalling in tumour
cells, there is also good evidence that Class Ia PI3K enzymes will also contribute to
139095.01203/7122633v.1
tumourigenesis via its function in tumour-associated stromal cells. For example, PI3K
signalling is known to play an important role in mediating angiogenic events in
endothelial cells in response to pro-angiogenic factors such as VEGF (Abid et al.,
Arterioscler. Thromb. Vase. Biol., 2004, 24, 294-300). As Class I PI3K enzymes are
also involved in motility and migration (Sawyer, Expert Opinion Investig. Drugs, 2004,
JJ., 1-19), PI3K inhibitors should provide therapeutic benefit via inhibition of tumour
cell invasion and metastasis.
In addition, Class I PI3K enzymes play an important role in the regulation of
immune cells with PI3K activity contributing to pro-tumourigenic effects of
inflammatory cells (Coussens and Werb, Nature, 2002, 420, 860-867). These findings
suggest that pharmacological inhibitors of Class I PI3K enzymes should be of
therapeutic value for treatment of the various forms of the disease of cancer comprising
solid tumours such as carcinomas and sarcomas and the leukaemias and lymphoid
malignancies. In particular, inhibitors of Class I PI3K enzymes should be of therapeutic
value for treatment of, for example, cancer of the breast, colorectum, lung (including
small cell lung cancer, non-small cell lung cancer and bronchioalveolar cancer) and
prostate, and of cancer of the bile duct, bone, bladder, head and neck, kidney, liver,
gastrointestinal tissue, oesophagus, ovary, pancreas, skin, testes, thyroid, uterus, cervix
and vulva, and of leukaemias (including ALL and CML), multiple myeloma and
lymphomas.
A recent review by Romina Marone et. al., Biochimica et Biophysica Acta 1784
(2008) 159-185, describes the activation of the PI3K signalling cascade having a
positive effect on cell growth, survival and proliferation. Constitutive up-regulation of
PI3K signaling can have a deleterious effect on cells leading to uncontrolled
proliferation, enhanced migration and adhesion-independent growth. These events favor
not only the formation of malignant tumors, but also the development of inflammatory
and autoimmune disease indicating the role of PI3K in various diseases including
chronic inflammation & allergy, Cardiovascular diseases, cancer and metabolic
disorders.
Several components of the PI3-kinase/Akt/PTEN pathway are implicated in
oncogenesis. In addition to growth factor receptor tyrosine kinases, integrin-dependent
cell adhesion and G-protein coupled receptors activate PI3-kinase both directly and
indirectly through adaptor molecules. Functional loss of PTEN (the most commonly
139095.01203/7122633v.1
mutated tumor-suppressor gene in cancer after p53), oncogene mutations in PI3 kinase
(Samuels et al (2004) Science 304:554), amplification of PI3-kinase and overexpression
of Akt have been established in many malignancies. In addition, persistent signaling
through the PI3-kinase/Akt pathway by stimulation of the insulin-like growth factor
receptor is a mechanism of resistance to epidermal growth factor receptor inhibitors
such as AG1478 and trastuzumab. Oncogenic mutations of p110alpha have been found
at a significant frequency in colon, breast, brain, liver, ovarian, gastric, lung, and head
and neck solid tumors. PTEN abnormalities are found in glioblastoma, melanoma,
prostate, endometrial, ovarian, breast, lung, head and neck, hepatocellular, and thyroid
cancers.
The levels of phosphatidylinositol-3,4,5-triphosphate (PIP3), the primary
product of PI3-kinase activation, increase upon treatment of cells with a variety of
agonists. PI3-kinase activation, therefore, is believed to be involved in a range of
cellular responses including cell growth, differentiation, and apoptosis (Parker et al
(1995) Current Biology, 5:577-99; Yao et al (1995) Science, 267:2003-05). Though the
downstream targets of phosphorylated lipids generated following PI3 kinase activation
have not been well characterized, emerging evidence suggests that pleckstrin-homology
domain- and FYVE-finger domain-containing proteins are activated when binding to
various phosphatidylinositol lipids (Sternmark et al (1999) J Cell Sci, 112:4175-83;
Lemmon et al (1997) Trends Cell Biol, 7:237-42). In vitro, some isoforms of protein
kinase C (PKC) are directly activated by PIP3, and the PKC-related protein kinase,
PKB, has been shown to be activated by PI3 kinase (Burgering et al (1995) Nature,
376:599-602).
PI3 kinase also appears involved in leukocyte activation. A p85-associated PI3
kinase activity has been shown to physically associate with the cytoplasmic domain of
CD28, which is an important costimulatory molecule for the activation of T-cells in
response to antigen (Pages et al (1994) Nature, 369:327-29; Rudd, (1996) Immunity
4:527-34). Activation of T cells through CD28 lowers the threshold for activation by
antigen and increases the magnitude and duration of the proliferative response. These
effects are linked to increases in the transcription of a number of genes including
interleukin-2 (IL2), an important T cell growth factor (Fraser et al (1991) Science,
251:313-16). Mutation of CD28 such that it can no longer interact with PI3 kinase leads
139095.01203/7122633v.1
to a failure to initiate IL2 production, suggesting a critical role for PI3 kinase in T cell
activation.
Inhibition of class I PI3 kinase induces apoptosis, blocks tumor induced
angiogenesis in vivo, and increases the radiosensitivity of certain tumors. At least two
compounds, LY294002 and wortmannin, have been widely used as PI3 kinase
inhibitors. These compounds, however, are nonspecific PI3K inhibitors, as they do not
distinguish among the four members of Class I PI3 kinases. For example, the IC50
values of wortmannin (U.S. Pat. No. 6,703,414) against each of the various Class I PI3
kinases are in the range of 1-10 nanomolar (nM). LY294002 (2-(4-morpholinyl)
phenyl-4Hbenzopyranone) is a well known specific inhibitor of class I PI3 kinases
and has anti-cancer properties (Chiosis et al (2001) Bioorganic & Med. Chem. Lett.
11:909-913; Vlahos et al (1994) J. Biol. Chem. 269(7):5241-5248; Walker et al (2000)
Mol. Cell 6:909-919; Fruman et al (1998) Ann Rev Biochem, 67:481-507).
Patent literature belonging to various research groups around the world includes
several such patents and/or patent applications viz., US 6,608,056; US 6,608,053; US
6,838,457; US 6,770,641; US 6,653,320; US 6,403,588; WO 2004017950; US
2004092561; WO 2004007491; WO 2004006916; WO 2003037886; US 2003149074;
WO 2003035618; WO 2003034997; US 2003158212; EP 1417976; US 2004053946; JP
2001247477; JP 08175990; JP 08176070).WO 97/15658, US 7,173,029; US 7,037,915;
US 6,703,414; ; ; ; WO
2007/042806; ; ; US 2004/092561; WO
2004/007491; WO2004/006916; ; US 2003/149074; WO
2003/035618; ; including p110 alpha binding activity US
2008/0207611; US 2008/0039459; US 2008/0076768; ; WO
2008/070740; US20090270430A1; US2006270673 A1; WO2009129211A1; US2009
0263398A1; US20090263397A1; WO2009129259A2; US7605160; US7605155;
US7608622; US20090270621; US20090270445; US20090247567A1; US7592342;
US2009 0239847A1; US7595320; US20090247538A1; US20090239936A1;
US7595330; US20090239859A1; WO2009117482A1;
WO2009117097A1;US20090247565A1; WO2009 120094A2; US20090258852A1;
US7601724; WO2009126635A1; US7601718 ; US7598245; US20090239859A1;
US20090247554; US20090238828; WO2009114874A2; WO2009114870A2;
US20090234132A1; WO2009112565A1; US20090233950A1; US20090233926A1;
139095.01203/7122633v.1
US7589101; WO2009111547A1; WO2009111531A1; WO2009109867A2 and
WO2009105712A1.
Reviews and studies regarding PI3K and related protein kinase pathways have
been given by Pixu Liu et. al. (Nature Reviews Drug Discovery, 2009, 8, 627-644);
Nathan T. et. al. (Mol Cancer Ther., 2009;8 (1) Jan., 2009); Romina Marone et, al.
(Biochimica et Biophysica Acta 1784 (2008) 159-185) and B. Markman et. al. (Annals
of oncology Advance access published August 2009). All of these patents and/or patent
applications and literature disclosures are incorporated herein as reference in their
entirety for all purposes.
It is an object of the present invention to overcome or ameliorate at least one of
the disadvantages of the prior art, or to provide a useful alternative.
It is an object of an especially preferred form of the present invention to provide
for small molecule kinase modulators in order to regulate and/or modulate transduction
of kinases, particularly PI3K and related protein kinase for the treatment of diseases and
disorders associated with kinases-mediated events.
Further a reference is made herein to International patent Application No.
, filed November 3, 2010, and U.S. Patent Application No.
12/938,609 filed November 3, 2010 which generally disclose 2,3 disubstituted-4H-
chromenone and are incorporated herein by reference in their entirety for all
purposes.
Unless the context clearly requires otherwise, throughout the description and the
claims, the words “comprise”, “comprising”, and the like are to be construed in an
inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the
sense of “including, but not limited to”.
Although the invention will be described with reference to specific examples it
will be appreciated by those skilled in the art that the invention may be embodied in
many other forms.
Summary of the Invention
139095.01203/7122633v.1
According to a first aspect of the present invention there is provided a compound
of formula
or a tautomer thereof, N-oxide thereof, pharmaceutically acceptable ester thereof, or
pharmaceutically acceptable salt thereof, wherein
each occurrence of R is independently selected from fluoro, methyl, methoxy or
morpholine;
R and R may be the same or different and are independently selected from
hydrogen, halogen, and substituted or unsubstituted C alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted
1 2
cycloalkylalkyl, and substituted or unsubstituted heterocyclyl, or both R and R directly
bound to a common atom, may be joined to form an oxo group (=O) or a substituted or
unsubstituted, saturated or unsaturated 3-10 member ring (including the carbon atom to
which R and R are bound), which may optionally include one or more heteroatoms
which may be the same or different and are selected from O, NR and S;
Cy is selected from substituted or unsubstituted cycloalkyl, substituted or
unsubstituted heterocyclic group, substituted or unsubstituted aryl and substituted or
unsubstituted heteroaryl;
Cy is selected from a substituted or unsubstituted heterocyclic group,
substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;
a b a
L is absent or selected from –(CR R ) -, -O-, -S(=O) -, -NR - or –C(=Y)-.
1 q q
each occurrence of R and R may be the same or different and are independently
selected from hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted (C
c d c d
)alkyl, -NR R (wherein R and R are independently hydrogen, halogen, hydroxy,
cyano, substituted or unsubstituted (C )alkyl, or (C )alkoxy) and -OR (wherein R is
1-6 1-6
substituted or unsubstituted (C )alkyl) or when R and R are directly bound to a
139095.01203/7122633v.1
common atom, they may be joined to form an oxo group (=O) or form a substituted or
unsubstituted, saturated or unsaturated 3-10 member ring (including the common atom
to which R and R are directly bound), which may optionally include one or more
heteroatoms which may be the same or different and are selected from O, NR (wherein
R is hydrogen or substituted or unsubstituted (C )alkyl) or S;
Y is selected from O, S, and NR ; and
q is 0, 1 or 2,
wherein the term substituted refers to a substitution selected from hydroxy,
halogen, carboxyl, cyano, nitro, oxo (=0), thio(=S), substituted or unsubstituted C -
C alkyl, substituted or unsubstituted C -C alkoxy, substituted or unsubstituted C -C
8 1 8 2 10
alkenyl, substituted or unsubstituted C -C alkynyl, substituted or unsubstituted C -C
2 12 3 12
cycloalkyl, substituted or unsubstituted C -C cycloalkenyl, -COOR , -C(O)R , -
X x y x y z x y x y x y
C(S)R , -C(O)ONR R , -NR CONR R , -N(R )SOR , -N(R )S0 R , -(=N-N(R )R ), -
X y x y x y x y x y z x y
NR C(O)OR , -NR R , -NR C(0)R -, - R C(S)R -NR C(S)NR R , -SONR R -, -SO
x y x x y z x y x x y
NR R-, -OR, -OR C(O)NR R, -OR C(O)OR-, -OC(0)R, -OC(O)NR R, -
x y z x y x y x y z x x x y X
R NR C(0)R , -R OR , -R C(0)OR , -R C(0)NR R , -R C(0)R , -R OC(0)R , -SR , -
x x x y z
SOR , -S0 R , and -ONO , wherein (i) R , R and R in each of the above groups can be
hydrogen, substituted or unsubstituted C -C alkyl, substituted or unsubstituted C -C
1 8 1 8
alkoxy, substituted or unsubstituted C -C alkenyl, substituted or unsubstituted C -C
2 10 2 12
alkynyl, substituted or unsubstituted C -C aryl, substituted or unsubstituted C -C
6 20 6 20
aryl(C -C alkyl), substituted or unsubstituted C -C cycloalkyl, substituted or
1 8 3 12
unsubstituted C -C cycloalkyl(C -C alkyl), substituted or unsubstituted C -C
3 12 1 8 3 8
cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted 5-14
membered heteroaryl (wherein the hetero atoms are selected from N, O, and S),
substituted or unsubstituted 5-14 membered heteroaryl(C -C alkyl) (wherein the hetero
atoms are selected from N, O, and S), substituted or unsubstituted 3-15 member
heterocyclic ring (wherein the hetero atoms are selected from N, P, O, and S), or
x y z
substituted 3-15 member heterocyclyl(C -C alkyl), or any two of R , R and R may be
joined to form a substituted or unsubstituted saturated or unsaturated 3-10 membered
ring, which may optionally include heteroatoms which may be the same or different and
are selected from O, NR (R is hydrogen or C alkyl) or S, and (ii) the substituents in
the aforementioned “substituted” groups cannot be further substituted.
139095.01203/7122633v.1
According to a second aspect of the present invention there is provided a
compound of formula (IA-VI)
(IA-VI)
or a pharmaceutically acceptable salt thereof, wherein
1 2 3 ’ ’’
R, R , R , R R , R and X are as defined in any one of claims 1 to 10;
each occurrence of R is hydrogen, C alkyl or halogen; and
p is 0, 1, 2, 3, 4 or 5.
According to a third aspect of the present invention there is provided a
compound of formula (IA-VIII)
(IA-VIII)
or a pharmaceutically acceptable salt thereof, wherein
R, R , R and X are as defined in any one of claims 1 to 10;
each occurrence of R is hydrogen, C alkyl or halogen; and
p is 0, 1, 2, 3, 4 or 5.
According to a fourth aspect of the present invention there is provided a
compound of formula
139095.01203/7122633v.1
or a tautomer thereof, N-oxide thereof, pharmaceutically acceptable ester thereof, or
pharmaceutically acceptable salt thereof, wherein
each occurrence of R is independently selected from hydroxy, halogen,
carboxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted
cycloalkenylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted
heterocyclylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted
arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted
x x x x y x y x y
heteroarylalkyl, –COOR , -C(O)R , -C(S)R , -C(O)NR R , -C(O)ONR R , -NR R , -
x x y x x x y x y x y x y
NR CONR R , -N(R )SOR , -N(R )SO R , -(=N-N(R )R ), - NR C(O)OR , -NR R , -
x y x y x x y x y x y x
NR C(O)R-, -NR C(S)R –NR C(S)NR R, -SONR R-, -SO NR R-, -OR, -
x x y x x x x y x y z x y
OR C(O)NR R , -OR C(O)OR -, -OC(O)R , -OC(O)NR R , - R NR C(O)R , -R OR , -
x y x x y x y x y x x x
R C(O)OR , -R C(O)NR R , -R C(O)R , -R OC(O)R , -SR , -SOR , -SO R , -ONO
2 2,
x y z
wherein R , R and R in each of the above groups can be hydrogen, substituted or
unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl,
substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl,
substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, or
substituted or unsubstituted amino, or (i) any two of R and R may be joined to form a
substituted or unsubstituted, saturated or unsaturated 3-14 membered ring, which may
optionally include heteroatoms which may be the same or different and are selected
139095.01203/7122633v.1
z x y
from O, NR or S, or (ii) any two of R and R join to form a oxo (=O), thio (=S) or
imino (=NR ) (wherein R is hydrogen or substituted or unsubstituted alkyl);
R and R may be the same or different and are independently selected from
hydrogen, halogen, and substituted or unsubstituted C alkyl, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted
1 2
cycloalkylalkyl, and substituted or unsubstituted heterocyclyl, or both R and R directly
bound to a common atom, may be joined to form an oxo group (=O) or a substituted or
unsubstituted, saturated or unsaturated 3-10 member ring (including the carbon atom to
which R and R are bound), which may optionally include one or more heteroatoms
which may be the same or different and are selected from O, NR and S;
Cy is selected from substituted or unsubstituted cycloalkyl, substituted or
unsubstituted heterocyclic group, substituted or unsubstituted aryl and substituted or
unsubstituted heteroaryl;
L -Cy is selected from
wherein
X is CR ;
each occurrence of R is independently selected from H, halogen,
139095.01203/7122633v.1
wherein
each occurrence of X is independently CR4 or N;
X1 is O, S, or NR4; and
each occurrence of R4 is independently selected from hydrogen, hydroxy,
halogen, carboxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or
unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted
alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted
cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted
aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclic
ring, substituted or unsubstituted heterocyclylalkyl ring, substituted or unsubstituted
heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted
x x x x y x y y z
guanidine, –COOR, -C(O)R, -C(S)R, -C(O)NR R, -C(O)ONR R, -NR R , -
x y z x y x y x y x y x y
NR CONR R , -N(R )SOR , -N(R )SO R , -(=N-N(R )R ), - NR C(O)OR , -NR R , -
139095.01203/7122633v.1
x y x y x y z x y x y x
NR C(O)R-, -NR C(S)R -NR C(S)NR R, -SONR R-, -SO NR R-, -OR, -
x y z x y x x y x y z x y
OR C(O)NR R , -OR C(O)OR -, -OC(O)R , -OC(O)NR R , - R NR C(O)R , -R OR , -
x y x y z x x x y x x x
R C(O)OR , -R C(O)NR R , -R C(O)R , -R OC(O)R , -SR , -SOR , -SO R , or -
x y z
ONO , wherein R , R and R in each of the above groups can be hydrogen, substituted
or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted
alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl,
substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl,
substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl,
substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl,
substituted or unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, or
x y z
substituted or unsubstituted amino, or any two of R , R and R may be joined to form a
substituted or unsubstituted, saturated or unsaturated 3-10 membered ring, which may
optionally include heteroatoms which may be the same or different and are selected
from O, NR (wherein R is hydrogen or substituted or unsubstituted alkyl) or S
each occurrence of R and R may be the same or different and are independently
selected from hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted (C
c d c d
)alkyl, -NR R (wherein R and R are independently hydrogen, halogen, hydroxy,
cyano, substituted or unsubstituted (C )alkyl, or (C )alkoxy) and -OR (wherein R is
1-6 1-6
substituted or unsubstituted (C )alkyl) or when R and R are directly bound to a
common atom, they may be joined to form an oxo group (=O) or form a substituted or
unsubstituted, saturated or unsaturated 3-10 member ring (including the common atom
to which R and R are directly bound), which may optionally include one or more
heteroatoms which may be the same or different and are selected from O, NR (wherein
R is hydrogen or substituted or unsubstituted (C )alkyl) or S;
Y is selected from O, S, and NR ; and
q is 0, 1 or 2;
wherein the term substituted refers to a substitution selected from hydroxy,
halogen, carboxyl, cyano, nitro, oxo (=0), thio(=S), substituted or unsubstituted C -
C alkyl, substituted or unsubstituted C -C alkoxy, substituted or unsubstituted C -C
8 1 8 2 10
alkenyl, substituted or unsubstituted C -C alkynyl, substituted or unsubstituted C -C
2 12 3 12
cycloalkyl, substituted or unsubstituted C -C cycloalkenyl, -COOR , -C(O)R , -
X x y x y z x y x y x y
C(S)R , -C(O)ONR R , -NR CONR R , -N(R )SOR , -N(R )S0 R , -(=N-N(R )R ), -
X y x y x y x y x y z x y
NR C(O)OR , -NR R , -NR C(0)R -, - R C(S)R -NR C(S)NR R , -SONR R -, -SO
139095.01203/7122633v.1
x y x x y z x y x x y
NR R-, -OR, -OR C(O)NR R, -OR C(O)OR-, -OC(0)R, -OC(O)NR R, -
x y z x y x y x y z x x x y X
R NR C(0)R , -R OR , -R C(0)OR , -R C(0)NR R , -R C(0)R , -R OC(0)R , -SR , -
x x x y z
SOR , -S0 R , and -ONO , wherein (i) R , R and R in each of the above groups can be
hydrogen, substituted or unsubstituted C -C alkyl, substituted or unsubstituted C -C
1 8 1 8
alkoxy, substituted or unsubstituted C -C alkenyl, substituted or unsubstituted C -C
2 10 2 12
alkynyl, substituted or unsubstituted C -C aryl, substituted or unsubstituted C -C
6 20 6 20
aryl(C -C alkyl), substituted or unsubstituted C -C cycloalkyl, substituted or
1 8 3 12
unsubstituted C -C cycloalkyl(C -C alkyl), substituted or unsubstituted C -C
3 12 1 8 3 8
cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted 5-14
membered heteroaryl (wherein the hetero atoms are selected from N, O, and S),
substituted or unsubstituted 5-14 membered heteroaryl(C -C alkyl) (wherein the hetero
atoms are selected from N, O, and S), substituted or unsubstituted 3-15 member
heterocyclic ring (wherein the hetero atoms are selected from N, P, O, and S), or
x y z
substituted 3-15 member heterocyclyl(C -C alkyl), or any two of R , R and R may be
joined to form a substituted or unsubstituted saturated or unsaturated 3-10 membered
ring, which may optionally include heteroatoms which may be the same or different and
are selected from O, NR (R is hydrogen or C alkyl) or S, and (ii) the substituents in
the aforementioned “substituted” groups cannot be further substituted
According to a fifth aspect of the present invention there is provided a
compound selected from:
2-(6-Amino-9H-purinyl) methyl)(3-fluorophenyl)methoxy-4H-
chromenone;
2-((4-Amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl) methyl)(3-fluorophenyl)methoxy-4H-chromenone;
2-((4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl) methyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-((4-amino(3-fluoromethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)methyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-((4-amino(3-fluorohydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)methyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl) ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
139095.01203/7122633v.1
(+)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl) ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(-)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl) ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-methyl-1H-indazolyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(+)(1-(4-amino(3-methyl-1H-indazolyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl) ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(-)(1-(4-amino(3-methyl-1H-indazolyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl) ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(1H-pyrazolyl)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(6-amino-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromen
one;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl) ethyl)fluoro(4-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl) ethyl)fluorophenyl-4H-chromenone;
2-(1-(4-amino(benzofuranyl)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(9H-purinylamino)ethyl)fluoro(3-fluorophenyl)-4H-chromen
one;
2-(1-(4-amino-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone;
(+)(1-(4-amino-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone;
(-)(1-(4-amino-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl) ethyl)fluoro(1H-pyrazolyl)-4H-chromenone;
139095.01203/7122633v.1
2-(1-(4-amino(3-fluoro(tetrahydro-2H-pyranyloxy)phenyl)-1H-
pyrazolo[3,4-d] pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-isopropyl-1H-indazolyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoro(piperidinyloxy)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoro(2-hydroxyethylamino)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoro(isopropylamino)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-(dimethylamino)fluorophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoromorpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(2-methyl-1H-benzo[d]imidazolyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoro(4-methylpiperazinyl)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro
(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluorophenyl-4H-
chromenone;
2-(1-(4-amino-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(4-
fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluorophenyl-4H-chromenone;
2-(1-(4-aminomethyl-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone;
2-(1-(4-aminoethyl-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone;
139095.01203/7122633v.1
2-(1-(4-aminoisopropyl-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro
(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(benzo[b]thiophenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-aminomorpholino-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro-
3-(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(dimethylamino)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(piperidinyl)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(6-isopropoxypyridinyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(methylthio)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate;
2-(1-(4-amino(3-methyl-1H-indazolyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate;
2-(1-(4-amino(4-(1-benzhydrylazetidinyloxy)fluorophenyl)-1H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoro(trifluoromethoxy)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoro(oxetanyloxy)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(pyrrolidinyl)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone;
N-(4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide;
2-(1-(4-amino(4-isobutylphenyl)-1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-isopropoxymethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
139095.01203/7122633v.1
2-(1-(4-amino(4-(5,6-dihydro-4H-1,3-oxazinyl)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1H-pyrazolo[3,4-d]pyrimidinyl)-N-methylbenzenesulfonamide;
4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1H-pyrazolo[3,4-d]pyrimidinyl)fluoro-N-isopropylbenzamide;
2-(1-(4-amino(4-(5-(methylamino)-1,3,4-thiadiazolyl)phenyl)-1H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
N-(4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)benzyl)methanesulfonamide;
4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1H-pyrazolo[3,4-d]pyrimidinyl)-N-isopropylbenzenesulfonamide;
4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1H-pyrazolo[3,4-d]pyrimidinyl)-N-cyclopropylbenzenesulfonamide;
2-(1-(4-amino(2-isopropoxypyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(R)/(S)(1-(4-amino(3-fluoromorpholinophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1H-pyrazolo[3,4-d]pyrimidinyl)benzenesulfonamide;
methyl 4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)thiophenecarboxylate;
2-(1-(4-amino(5-methylthiophenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(1H-pyrrolo[2,3-b]pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
methyl 4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)fluorobenzoate;
2-(1-(9H-purinylamino)propyl)fluorophenyl-4H-chromenone;
2-(1-(4-amino(3-hydroxypropynyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
139095.01203/7122633v.1
(S)/(R)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone 4-
methylbenzenesulfonate;
(+)(1-(9H-purinylamino)ethyl)fluoro(3-fluorophenyl)-4H-chromen-
4-one
2-(1-(9H-purinylamino)ethyl)fluoro(3-fluorophenyl)-4H-chromen
one;
(R)/(S)(1-(4-amino(3-fluoromorpholinophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-methoxy-3,5-dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-(methoxymethyl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(imidazo[1,2-a]pyridinyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone ;
tert-butyl (5-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)furanyl)methylcarbamate;
2-(1-(4-amino(2,4-dimethylthiazolyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(5-(morpholinomethyl)thiophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(4-(5-amino-1,3,4-thiadiazolyl)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(-)(1-(9H-purinylamino)ethyl)fluoro(3-fluorophenyl)-4H-chromen
one;
2-(1-(4-amino(1,3-dimethyl-1H-indazolyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(2,3-dimethyl-2H-indazolyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
N-(4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)isobutyramide;
N-(4-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)acetamide;
139095.01203/7122633v.1
2-(1-(4-(dimethylamino)(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
-fluoro(1-(3-(3-fluoroisopropoxyphenyl)(methylamino)-1H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone;
5-fluoro(1-(3-(3-fluoroisopropoxyphenyl)morpholino-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone;
N-(2-fluoro(1-(1-(5-fluoro(4-fluorophenyl)oxo-4H-chromen
yl)ethyl)morpholino-1H-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide;
N-(2-fluoro(1-(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)morpholino-1H-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide;
(S)/(R)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone sulphate;
(S)/(R)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone ;
(S)/(R)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
camphorsulphonate;
2-(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(1H-pyrazolyl)-4H-chromenone;
2-(1-(4-amino(3-fluoromorpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluorophenyl-4H-chromenone;
2-(1-(4-amino(3-fluoromorpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone;
(S)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone;
(R)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone;
(S)(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone;
(R)(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-d]
pyrimidinyl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone;
2-(1-(4-(dimethylamino)(3-fluoromorpholinophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
139095.01203/7122633v.1
-fluoro(1-(3-(3-fluoromorpholinophenyl)(methylamino)-1H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone;
(S)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluorophenyl-4H-chromenone;
(R)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluorophenyl-4H-chromenone;
(S)(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-d]
pyrimidinyl)ethyl)fluorophenyl-4H-chromenone;
(R)(1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1H-pyrazolo[3,4-d]
pyrimidinyl)ethyl)fluorophenyl-4H-chromenone;
(+)fluoro(1-(3-(3-fluoroisopropoxyphenyl)(methylamino)-1H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone;
(-)fluoro(1-(3-(3-fluoroisopropoxyphenyl)(methylamino)-1H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone;
2-(1-(6-aminofluoro-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-4H-
chromenone;
2-(1-(6-aminofluoro-9H-purinyl)ethyl)fluoro(4-fluorophenyl)-4H-
chromenone;
-fluoro(4-fluorophenyl)(1-(6-morpholino-9H-purinyl)ethyl)-4H-
chromenone;
-fluoro(4-fluorophenyl)(1-(6-(4-methylpiperazinyl)-9H-purin
yl)ethyl)-4H-chromenone;
2-(1-(6-(dimethylamino)-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-4H-
chromenone;
2-(1-(6-(dimethylamino)-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-4H-
chromenone;
-fluoro(3-fluorophenyl)(1-(3-(3-methyl-1H-indazolyl)morpholino-
1H-pyrazolo[3,4-d]pyrimidinyl)ethyl)-4H-chromenone;
2-(1-(4-amino(3-chloromorpholinophenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(+)(1-(4-amino(4-isopropoxymethylphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
139095.01203/7122633v.1
(-)(1-(4-amino(4-isopropoxymethylphenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(S)/(R)fluoro(1-(3-(3-fluoroisopropoxyphenyl)morpholino-1H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-chloroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(2-methylbenzo[d]oxazolyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
-fluoro(3-fluorophenyl)(1-(6-morpholino-9H-purinyl)ethyl)-4H-
chromenone;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)(3-fluorophenyl)morpholino-4H-chromenone;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)morpholinophenyl-4H-chromenone;
6-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1H-pyrazolo[3,4-d]pyrimidinyl)isoindolinone;
-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1H-pyrazolo[3,4-d]pyrimidinyl)isoindolinone;
2-(1-(3-(4-acetylfluorophenyl)amino-1H-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
-fluoro(3-fluorophenyl)(1-(6-(4-methylpiperazinyl)-9H-purin
yl)ethyl)-4H-chromenone;
(S)(1-(4-amino(3-chloromorpholinophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
(R)(1-(4-amino(3-chloromorpholinophenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
N-(3-(4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidinyl)phenyl)methanesulfonamide;
(S)(1-(6-(dimethylamino)-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-
4H-chromenone;
(R)(1-(6-(dimethylamino)-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-
4H-chromenone ;
139095.01203/7122633v.1
2-(1-(9H-purinylamino)ethyl)fluoro(2-fluorophenyl)-4H-chromen
one;
2-(1-(4-amino(4-ethoxy(trifluoromethyl)phenyl)-1H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone;
2-(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin
yl)propyl)fluoro(3-fluorophenyl)-4H-chromenone;
(S)fluoro(3-fluorophenyl)(1-(2-methoxy-9H-purinylamino)ethyl)-
4H-chromenone;
(R)fluoro(3-fluorophenyl)(1-(2-methoxy-9H-purinylamino)ethyl)-
4H-chromenone;
(S)/(R)- 5-fluoro(1-(2-fluoro-9H-purinylamino)ethyl)(3-fluoro phenyl)-
4H-chromenone;
(S)/(R)(1-(4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]
pyrimidinyl)ethyl)methylphenyl-4H-chromenone;
2-(1-(9H-purinylamino)ethyl)fluoroo-tolyl-4H-chromenone;
and pharmaceutically acceptable salts thereof.
According to a sixth aspect of the present invention there is provided a
pharmaceutical composition, comprising a compound of the first, second, third, fourth
or fifth aspects of the invention and a pharmaceutically acceptable carrier.
According to a seventh aspect of the present invention there is provided use of a
compound as defined according to the first, second, third, fourth or fifth aspects of the
invention in the manufacture of a medicament for inhibiting a catalytic activity of a PI3
kinase present in a cell.
According to an eighth aspect of the present invention there is provided use of a
compound as defined according to the first, second, third, fourth or fifth aspects of the
invention, in the manufacture of a medicament for the treatment of a disease, disorder,
or condition that would benefit from inhibiting catalytic activity of a kinase.
According to a ninth aspect of the present invention there is provided use of a
compound as defined according to first, second, third, fourth or fifth aspects of the
139095.01203/7122633v.1
invention in the manufacture of a medicament for the treatment of a PI3K associated
disease or disorder.
According to a tenth aspect of the present invention there is provided a
compound selected from formulas (10), (12), (14) and (15)
(10)
(12) (14) (15)
wherein
1 2 1
R, R , R , and Cy are as defined in the first, second, third, fourth or fifth aspects, and
X is as defined in claim 8 of the claims appended hereto.
The present invention is directed to compounds, which are useful as PI3K
protein kinase modulators and in particular as PI3K inhibitors. In one embodiment, the
compound of the present invention has the formula:
wherein
139095.01203/7122633v.1
WO 20121151525
each occurrence of R is independently selected from hydroxy, halogen, carboxyl,
cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted alkenyl, substituted or un substituted alkynyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or
unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or
unsubstituted heterocyclyl, substituted or unsubstituted heierocyclylalkyl, substituted or
unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted
heteroaryl, substituted or un substituted heteroarylalkyl, -COORX, -CCO)R , -CCS)R , -
C(O)NRxR , -CCO)ONRxRY, -NRXR , -NRxCONRxRY, -N(RX)SOR , -N(RX)S02RY, -(=N
N(RX)RY), - NRXCCO)ORY, -NRxRY, -NRXCCO)RY-, -NRXCCS)RY -NRXCCS)NRxRY, -SONRxRY-,
x X X
-S02 R -, _OR , -ORXC(O)NRxRY, -ORXCCO)OR -, -OCCO)R , -OCCO)NRxRY,
RXNRYCCO)R , -RxORY, -RXC(O)ORY, -RXCCO)NRxRY, -RXC(O)RY, -RXOCCO)RY, _SR , -
SORX, -S02Rx, -ON0 , wherein RX, RY and R in each of the above groups can be hydrogen,
substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or
unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl,
substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or
unsubstituted heteroarylalkyl, substituted or un substituted cycloalkyl, substituted or
unsubstituted cycloalkylalkyl, substituted or un substituted cycloalkenyl, substituted or
unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, or substituted or
unsubstituted amino, or (i) any two of R and RY may be joined to form a substituted or
unsubstituted, saturated or unsaturated 3-14 membered ring, which may optionally include
heteroatoms which may be the same or different and are selected from 0, NR or S, or (ii) any
two of R and RY join to form a oxo (=0), thio (=S) or imino (=NR ) (wherein Rf is hydrogen
or substituted or unsubstituted alkyl).
Rl and R2 may be the same or different and are independently selected from hydrogen,
halogen, substituted or unsubstituted C - alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl and substituted or
unsubstituted heterocyclyl or both R I and R2 directly bound to a common atom, may be
joined to form an oxo group (=0) or a substituted or unsubstituted, saturated or unsaturated 3-
member ring (including the carbon atom to which Rl and R2 are bound), which may
optionally include one or more heteroatoms which may be the same or different and are
selected from 0, NR and S;
WO 20121151525
Cyl is selected from substituted or unsubstituted cycloalkyl, substituted or
unsubstituted heterocyclic group, substituted or unsubstituted aryl and substituted or
un substituted heteroaryl;
C/ is selected from a substituted or unsubstituted heterocyclic group, substituted or
unsubstituted aryl and substituted or unsubstituted heteroaryl;
LI is absent or selected from _(CR3Rbk, , -S(=O)q-, _NR _ or -C(=Y)-.
each occurrence of R and Rb may be the same or different and are independently
selected from hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted (C _6)alkyl, -
NRcR (wherein R and Rd are independently hydrogen, halogen, hydroxy, cyano, substituted
or unsubstituted (C -6)alkyl, or (CI_6)alkoxy) and _OR (wherein R is substituted or
unsubstituted (C _6)alkyl) or when R3 and Rb are directly bound to a common atom, they may
be joined to form an oxo group (=0) or form a substituted or unsubstituted, saturated or
unsaturated 3-10 member ring (including the common atom to which R3 and Rb are directly
bound), which may optionally include one or more heteroatoms which may be the same or
different and are selected from 0, NR (wherein Rd is hydrogen or substituted or
unsubstituted (C _6)alkyl) or S;
Y is selected from 0, S, and NR ; and
q is 0, I or 2
or a tautomer thereof, N-oxide thereof, pharmaceutically acceptable ester thereof, prodrug
thereof, or pharmaceutically acceptable salt thereof.
Yet another embodiment is a compound having the formula (I-A)
(IA)
wherein
each occurrence of R is independently selected from halogen. CN, substituted or
unsubstituted C -6 alkyl. substituted or unsubstituted alkoxy, substituted or unsubstituted C -6
alkenyl. substituted or unsubstituted C - alkynyl. substituted or un substituted C - cycloalkyl.
26 3 8
and substituted or unsubstituted heterocyclic group;
R I and R2 may be the same or different and are independently selected from hydrogen.
halogen. and substituted or unsubstituted C -6 alkyl. or both RI and R2 directly bound to a
WO 20121151525
common atom, may be joined to form an oxo group (=0) or a substituted or unsubstituted,
saturated or unsaturated 3-10 member ring (including the carbon atom to which R' and R2 are
bound), which may optionally include one or more heteroatoms which may be the same or
different and are selected from 0, NR and S;
C/ is a monocyclic group selected from substituted or unsubstituted cycloalkyl,
substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl and
substituted or unsubstituted heteroaryl;
C/ is selected from a substituted or unsubstituted heterocyclic group, substituted or
un substituted aryl and substituted or unsubstituted heteroaryl;
L, is absent or selected from _(CRaRb)q-, , -S(=O)q-, _NRa_ or -C(=Y)-.
each occurrence of R and Rb may be the same or different and are independently
selected from hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted (C'_6)alkyl, -
NRcR (wherein R and Rd are independently hydrogen, halogen, hydroxy, cyano, substituted
or unsubstituted (C'_6)alkyl or (C'_6)alkoxy) and _ORc (wherein R is substituted or
unsubstituted (C'_6)alkyl) or when R and Rb are directly bound to a common atom, they may
be joined to form an oxo group (=0) or form a substituted or unsubstituted, saturated or
unsaturated 3-10 member ring (including the common atom to which R and R b are directly
bound), which may optionally include one or more heteroatoms which may be the same or
different and are selected from 0, NR (wherein Rd is hydrogen or substituted or
unsubstituted (C'_6)alkyl) or S;
Y is selected from 0, S, and NR ; and
q is 0, I or 2
or a tautomer thereof, N-oxide thereof, pharmaceutically acceptable ester thereof, prodrug
thereof, or pharmaceutically acceptable salt thereof..
Yet another embodiment is a compound having the formula (I) or (IA) wherein R is
selected from halogen, substituted or unsubstituted C'-6 alkyl, substituted or unsubstituted C -
cycloalkyl, and substituted or unsubstituted heterocyclic group or ORa.
Yet another embodiment is a compound having the formula (I) or (IA) wherein R is
selected from fluoro, methyl, morpholine or -OCH3.
Further preferred is a compound having the formula (I) or (IA) wherein Cy' ,s
selected from substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
Illustrative examples of optionally substituted Cy' groups include those shown below:
WO 20121151525
Further preferred is a compound h~ving the formula (I) or (IA), wherein Cyl is
selected from
j), F:O )) f)~ ):) Ji or
Further preferred is a compound having the formula (I) or (IA), wherein Cyl is
substituted or unsubstituted phenyl or pyrazole.
Further preferred is a compound having the formula (I) or (IA) wherein ci IS
substituted phenyl.
Further preferred is a compound having the formula (I) or (IA), wherein Cyl is 2-
methyl phenyl, 2-f1uoro phenyl, 3-f1uoro phenyl, 4-f1uoro phenyl or pyrazolyl.
Yet another embodiment is a compound having the formula (I) or (IA), wherein R
and R2 independently represent hydrogen or substituted or unsubstituted C -6 alkyl (for
example, methyl).
Yet another embodiment is a compound having the formula (I) or (IA), wherein Ll is
selected from -S(=O) q- or _NRa.
Yet another embodiment is a compound having the formula (I) or (IA), wherein q is o.
Yet another embodiment is a compound having the formula (I) or (IA)," wherein R
hydrogen.
Yet another embodiment is a compound having the formula (I) or (IA), wherein Ll is
absent.
WO 20121151525
Yet another embodiment is a compound having the formula (I) or (IA), wherein L)-
C/ is selected from
NH X:ASIO), HN N,
II X;x
~. r "X X0
Nh 3 ... d~J
~. r "X N h
N, r ":< -"{:
N ' N
"{: -N
R3 -N
HN-X NH2
HN-X
H2N H2N
a b c d e f
wherein
X is CR ; and
each occurrence of R3 is independently selected from hydrogen, hydroxy, halogen,
carboxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl,
substituted or un substituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, or
unsubstituted heterocyclyalkyl ring, substituted or unsubstituted aryl, substituted or
unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted
heteroarylalkyl, substituted or unsubstituted guanidine, -COOR , -CCO)RX, -CCS)RX, -
CCO)NRxRY, -CCO)ONRxRY, -NRYRZ, -NRxCONRYR , -N(RX)SORY, -N(RX)S02RY, -(=N
N(RX)R ), - NRxC(O)ORY, -NRxRY, -NRXCCO)RY-, -NRXCCS)RY -NRXCCS)NRYR , -
x z X
SONRxRY-, -S02NRxRY-, _OR , -ORXCCO)NRYR , -ORXCCO)ORY-, -OCCO)R ,
Z z X
OCCO)NRxRY, - RXNRYCCO)R , -RxORY, -RXCCO)ORY, -RXCCO)NRYR , -RXCCO)R , -
x x Z
RXOCCO)RY, _SR , -SOR , -S02Rx, or -ON0 , wherein RX, R and R in each of the above
groups can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or
unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or
unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, substituted
heterocyclylalkyl ring, or substituted or un substituted amino, or any two of R , RY and R
may be joined to form a substituted or unsubstituted, saturated or unsaturated 3-10
membered ring, which may optionally include heteroatoms which may be the same or
different and are selected from 0, NRf or S (wherein Rf is hydrogen or substituted or
unsubstituted alkyl).
WO 20121151525
Yet another embodiment is a compound having the formula (I) and (IA), wherein L -
C/ is selected from
wherein
X and R3 are the same as defined above; and
each occurrence of R' and R" is independently selected from hydrogen, hydroxy,
halogen, carboxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted
or un substituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted
cycloalkenyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted
heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted
heterocyclylalkyl ring, substituted or unsubstituted guanidine, -COOR\ -C(O)RX, -C(S)R , -
C(O)NRxRY, -C(O)ONRxRY, -NRYR , -NRxCONRYR , -N(RX)SORY, -N(RX)S02RY, -(=N
N(RX)R ), - NRxC(O)ORY, -NRxRY, -NRxC(O)RY-, -NRxC(S)RY -NRxC(S)NRYR , -SONRxRY-,
x z X
-S02NRxRY-, _OR , -ORxC(O)NRYR , -ORxC(O)ORY-, -OC(O)R , -OC(O)NRxRY,
RXNRYC(O)R , -RxORY, -RxC(O)ORY, -RxC(O)NRYR , -RxC(O)RX, -RxOC(O)RY, -SRX, -
SOR , -S02Rx, and -ON0 , or both the R' and R" together with the nitrogen atom may be
joined to form a substituted or unsubstituted, saturated or unsaturated 3-10 membered ring,
which may optionally include heteroatoms which may be the same or different and are
selected from 0, NRf (wherein Rf is hydrogen or substituted or unsubstituted alkyl) or S;
R , RY and R in each of the above groups can be hydrogen, substituted or
unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl,
substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or
unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted
heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted
cycloalkylalky\, substituted or unsubstituted cycloa\keny\, substituted or unsubstituted
heterocyclic ring, substituted heterocycly\a\kyl ring, or substituted or unsubstituted amino, or
any two of R , RY and R may be joined to form a substituted or unsubstituted, saturated or
unsaturated 3-\ 0 membered ring, which may optionally include heteroatoms which may be
WO 20121151525
the same or different and are selected from 0, NRf or S (wherein Rf is hydrogen or substituted
or unsubstituted alkyl); and
q is 0, 1 or 2.
Yet another embodiment is a compound having the formula (I) and (IA), wherein L -
C/ is selected from
wherein
X and R3 are the same as defined above.
For example, LI-C/ is represented as formula a, b c, d e, or f above can be
WO 20121151525
Yet another embodiment is a compound having the formula (I) and (IA) wherein LI
e/ is selected from
WO 20121151525
N N N' \ " ~
I -J.!l~ N ~ N ~'~ N
N' N \ 7 ~ \ r ~ I I
\ r ~ -N -N _ -N
-N - - CI
N ',N "t"" ,-$ , t '"
,HO OH OH
N, ~ '7
F ~ ~ H2N
N, 7 '7
~ S H2N
,N N N
I ~~ N
N, r ~ \ 7 ~
\ V ~
-N _ -N
MeO ~ ~ H2N
~ ~ H2N
WO 20121151525
.... N N
N~ ~ )
WO 20121151525
N\ r ~
N\ ~ ~
N\ ~ ~
N\ r ~
N\ ~ ~ -N
N\ ~ ~
N~_ ~ H2N g
fj ~ I+.!N
o fj ~ I+.!N
fj -
N~ $ ~ I+.!N fj_~ H:
~ o 0-... H2N
o fj ~H2N
-\ - r/.3
~ rN F
HO ~ )
o-.J
WO 20121151525
-~ N cp-~ N
N, r ~ ,~~
-N -N
,1 H2N ~ 0 H2N
HN-S0 Me
Yet another embodiment is a compound having the formula (I) or (IA) wherein LI
e/ is selected from
WO 20121151525
'I..:XeN
l::.N NH2
Yet another embodiment is a compound having the formula (lA-I), (lA-II), (lA-III),
(lA-IV) or (IA-V).
(lA-I) (lA-II) (lA-III) (lA-IV) (lA-V)
or a tautomer thereof, N-oxide thereof, pharmaceutically acceptable ester thereof, prodrug
thereof, or pharmaceutically acceptable salt thereof,
wherein:
R is selected from hydrogen, halogen, _ORa, CN, substituted or unsubstituted C -6
alkyl, substituted or unsubstituted C - alkenyl, substituted or unsubstituted C -6 alkynyl,
2 6 2
substituted or unsubstituted C - cycloalkyl, and substituted or unsubstituted heterocyclic
group;
R I and R may be the same or different and are independently selected from hydrogen,
halogen, and substituted or unsubstituted C - alkyl or both R I and R2 directly bound to a
common atom, may be joined to form an oxo group (=0) or may be joined to form a
substituted or unsubstituted saturated or unsaturated 3-10 member ring (including the
common atom to which RI and R2 are directly bound), which may optionally include one or
more heteroatoms which may be the same or different and are selected from 0, NR and S;
Cyl is a monocyclic group selected from substituted or unsubstituted cycloalkyl,
substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl and
substituted or unsubstituted heteroaryl;
each occurrence of X is independently selected from CR or N;
each occurrence of R3 is independently selected from hydrogen, hydroxy, halogen,
carboxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or
WO 20121151525
unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, or unsubstituted
heterocyclyalkyl ring, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl,
substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl,
substituted or unsubstituted guanidine, -COORX, -C(O)R , -CCS)R , -C(O)NRxRY, -
CCO)ONRxR , -NRYR , -NRxCONRYR , -N(RX)SOR , -N(R )S02 , -(=N-N(RX)RY), -
NRXCCO)ORY, -NRxRY, -NRXC(O)RY-, -NRXCCS)RY -NRXC(S)NRYR , -SONRxRY-, -
x z X
S02NRxRY-, _OR , -ORxCCO)NRYR , -ORXCCO)ORY-, -OC(O)R , -OCCO)NRxRY,
RXNRYCCO)R , -RxORY, -RXC(O)ORY, -RXCCO)NRYR , -RXC(O)RX, -RXOCCO)RY, -SRX, -
SOR , -S02RX, or -ON0 , wherein RX, RY and R in each of the above groups can be
hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted
or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted
aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted
or unsubstituted heteroarylalkyl, substituted or unsubstituted cycloalkyl, substituted or
unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or
unsubstituted heterocyclic ring, substituted heterocyclylalkyl ring, or substituted or
unsubstituted amino, or any two of R , RY and R may be joined to form a substituted or
unsubstituted, saturated or unsaturated 3-10 membered ring, which may optionally include
heteroatoms which may be the same or different and are selected from 0, NRf (wherein Rf is
hydrogen or substituted or unsubstituted alkyl) or S; and
q is 0, 1 or 2.
Yet another embodiment is a compound having the formula (IA-Ia), (IA-IIa), (IA
IIla),(IA-Ib) or (lA-lIb).
,Ny<;
~, 1 "X
(IA-IIa)
(IA-Ia) (lA-IlIa) (IA-Ib) (lA-lIb).
wherein X, R , R' and R" are the same as defined above.
Yet another embodiment is a compound having the formula (lA-I), (lA-II), (lA-III),
(lA-IV), (lA-V), (IA-Ia), (IA-IIa), (lA-Ilia), (IA-Ib) or (lA-lIb) wherein R is selected from
hydrogen, halogen, substituted or unsubstituted C - alkyl, ORa or morpholine.
WO 20121151525
Yet another embodiment is a compound having the formula (lA-I), (lA-D), (lA-III),
(lA-IV), (lA-V), (IA-Ia), (IA-IIa), (lA-IDa), (IA-Ib) or (lA-lIb) wherein R is selected from
hydrogen, halogen, ORa or morpholine.
Yet another embodiment is a compound having the formula (lA-I), (lA-D), (lA-III),
(lA-IV), (lA-V), (IA-Ia), (IA-IIa), (lA-lila), (IA-I b) or (lA-lIb) wherein Cyl is selected
from
.j}~ X) hF t:NH
Yet another embodiment is a compound having the formula (lA-I), (lA-II), (lA-III),
(lA-IV), (lA-V), (IA-Ia), (IA-IIa), (lA-lila), (IA-Ib) or (lA-lib) wherein RI and R2
independently represent hydrogen or substituted or unsubstituted C -6 alkyl
Yet another embodiment is a compound having the formula (lA-II), (lA-III), (lA
lla), (lA-fila) or (lA-Db) wherein R3 is selected from iodo, cyano, substituted or
unsubstituted alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl.
Yet another embodiment is a compound having the formula (lA-II), (lA-III), (lA
lla), (lA-Ilia) or (lA-lIb) wherein R3 is selected from substituted or unsubstituted alkynyl,
substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl
Yet another embodiment is a compound having the formula (lA-II), (lA-III), (lA
lla), (lA-Ilia) or (lA-lib) wherein R3 is selected from
,<=="\ lC} 4
R-/ """'-=\ xyS G
/=:-<"0#R !~ 0,R
~ ,N-R4
R4 V
(R4)O -4
0, R4 R4 (R4)O -4
N Ny)
9 9 4 4
(R4)O -4 (R4)O -4
4 (R4)O -4 (R )O-4
(R )o-4
(R4)O -4 (R4)O -4 (R )o-4
x-x ..
}(;"x
\px,x
• x ~x 53
xy{x
J-fx
x;-J\
x;-J\ I ~x
~~ 4 :-,N'R
R4 N X'N'
x' ,NH
NH x' ,NH x- R X
'x R4
'x S
x-x.
• x '1 'x
X-yJZx
X;-J\
9 9.9 xJ---t
x~ x I ":
X~X,N~ Xl'
X'N'
x' ,N~ X'X
x "'x ,
Xl' X'X
WO 20121151525
wherein
of X is independently CR or N;
each occurrence
Xl is 0, S, or NR4; and
each occurrence of R4 is independently selected from hydrogen, hydroxy, halogen,
carboxyl, cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted
or unsubstituted alkynyl,
alkoxy, substituted or unsubstituted alkenyl, substituted
substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl,
substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, or
unsubstituted heterocyclyalkyl ring, substituted or unsubstituted aryl, substituted or
unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted
heteroarylalkyl, substituted or unsubstituted guanidine, -COORX, -C(O)R , -C(S)R , -
C(O)NRxRY, -C(O)ONRxRY, -NRYR , -NRxCONRYR , -N(RX)SORY, -N(RX)S02RY, -(=N
N(RX)R ), -NRxC(O)ORY, -NRxRY, -NRxC(O)RY-, -NRxC(S)RY -NRxC(S)NRYR , -
SONRxRY-, -S02NRxRY-, -ORX, -ORxC(O)NRYR , -ORXC(O)ORY-, -OC(O)R ,
-RxORY, -RxC(O)ORY, -RXC(O)NRYR -RxC(O)RX, -
OC(O)NRxRY, -RxNRYC(O)R , ,
x X Z
RXOC(O)R , _SR , -SORX, -S02Rx, or -ONOz, wherein R , R and R in each of the above
groups can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted
alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl,
substituted or unsubstituted aryl, substituted or unsubstituted aryl alkyl, substituted or
unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or
unsubstituted cycloalkyl, substituted or un substituted cycloalkylalkyl, substituted or
unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclic ring, substituted
heterocyclylalkyl ring, or substituted or unsubstituted amino, or any two of R , RY and R
may be joined to form a substituted or un substituted, saturated or unsaturated 3-10
membered ring, which may optionally include heteroatoms which may be the same or
WO 20121151525
different and are selected from 0, NRf (wherein Rf is hydrogen or substituted or
unsubstituted alkyl) or S;
For example, R3 can be anyone of the following:
F~yy
Yet another embodiment is a compound having the formula (lA-III) or (lA-IlIa)
wherein R3 is selected from iodo, cyano and substituted or unsubstituted alkynyl.
WO 20121151525
Yet another embodiment is a compound having the formula (lA-I), (lA-II), (lA-III),
(lA-IV), (lA-V), (IA-Ia), (IA-IIa), (lA-IlIa), (IA-Ib) or (lA-lIb) wherein X is CR and each
occurrence of R3 is independently hydrogen, halogen, hydroxyl or NH •
Yet another embodiment is a compound of formula (lA-VI)
(lA-VI)
or a pharmaceutically acceptable salt thereof, wherein
123 • "
R, R , R , R , R, R and X are as defined above with respect to any of formulas (I),
(IA) or (lA-II);
each occurrence of R is hydrogen, C - alkyl or halogen; and
pis 0, I, 2, 3, 4 or 5.
Yet another embodiment IS a compound having the formula (lA-II) or (lA-VI)
wherein R3 is selected from
QQdld ~ /HOVH~~H0-oF~f
OMe OH N~ ~ OH .~ HO~ H~' V V F ~ OH
I , I I I , I I , I I
'-d AoHN ~ H~ D ,)) '-q ~,~ "co~ If- d
MeO ~ N~ HO OH OH OM. V H HO
I I I I I I I I " I
HN - - - ~ ~S N ~ -
HOo oj-R? :< ~
N ~ ~ ~ ~ - I ~ 8 - )= N~ /, ~ ~
" ~N N N J-N
, -d H " NH NH, MeO H,N OHC-f)
I I I I I " I I I I
WO 20121151525
o _ "" s
/ Cql?
- - ~ b - F
H ,o-d NH I, 0 d -¢
~ )J 0 A /<.,.)LN -0
,F ,CI , /, 0 0 , H, F
F-($
c1 c1
H~P -p ~-d
o CI r- F (N CI
oJ oJ
F )- N
HN ~ n HNrp
EtO CF
HN-S0 Me
Yet another embodiment is a compound of formula (lA-VII)
WO 20121151525
HNIiN"""i
R3~N
(lA-VII)
or a pharmaceutically acceptable salt thereof, wherein
R, R', R2, R3 and X are as defined above with respect to any of formulas (I), (IA) or
(lA-III);
each occurrence of R is hydrogen, C'-6 alkyl or halogen; and
p is 0, 1, 2, 3,4 or 5.
Yet another embodiment is a compound having the formula (lA-VII) wherein R3 is
halogen or cyano.
Yet another embodiment is a compound of formula (lA-VIII)
--=:: NH
< "f N
N II
HN---X
(lA-VIII)
or a pharmaceutically acceptable salt thereof, wherein
R, R', R2 and X are as defined above with respect to any of formulas are as defined
above with respect to any of formulas (I), (IA) or (lA-IV);
each occurrence of R is hydrogen, C'-6 alkyl or halogen; and
p is 0, 1, 2, 3,4 or 5.
Yet another embodiment is a compound having the formula (lA-VI), (lA-VII) or (IA
VIII) wherein R is halogen (such as fluoro) or C'-6 alkyl (such as methyl).
Yet another embodiment is a compound having the formula (lA-VI), (lA-VII) or (IA
VIII) wherein p is 0.
Yet another embodiment is a compound having the formula (lA-VI), (lA-VII) or (IA
VIII) wherein p is 1 and R is 3-fluoro, 2-fluoro, 4-fluoro or 2-methyl.
WO 20121151525
Yet another embodiment is a compound having the formula (lA-VI), (lA-VII) or (IA
VIII) wherein RI is methyl and R2 is hydrogen.
Yet another embodiment is a compound having the formula (lA-VI), (lA-VII) or (IA
VIII) wherein RI is ethyl and R2 is hydrogen.
Yet another embodiment is a compound having the formula (lA-VI), (lA-VII) or (IA
VIII) wherein R I and R2 are hydrogen.
Yet another embodiment is a compound having the formula (lA-VI), (lA-VII) or (IA
VIII) wherein X is C-H, C-F, C-Cl, C-NH2 or C-OH.
Further preferred is a compound having the formula (lA-VI), (lA-VII) or (lA-VIII)
wherein X is C-H.
Yet another embodiment is a compound having the formula (lA-VI) wherein each of
R' and R" is selected from is hydrogen or C -6 alkyl (such as methyl).
Yet another embodiment is a compound having the formula (IA-VI) wherein -NR'R"
together represents
Representative compounds of the present invention include those specified below and
pharmaceutically acceptable salts thereof. The present invention should not be construed to be
limited to them.
I. 2-(6-Amino-9H-purinyl) methyl)(3-fluorophenyl)-S-methoxy-
4H-chromenone
2. 2-«4-Amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)methyl)(3-fluorophenyl)-S-methoxy-4H-chromenone
3. 2-«4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)methyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
4. 2-« 4-amino(3-fluoro-S-methoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)methyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
S. 2-«4-amino(3-fluoro-S-hydroxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)methyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
6. 2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
7. (+)( 1-(4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
WO 20121151525
8. (-)(1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
9. 2-(1-( 4-amino(3-methyl-1 H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
9a. (+)- 2-( 1-(4-amino(3-methyl-1 H-indazolyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)AH-chromenA-one
9b. (-)- 2-( 1-( 4-amino(3-methyl-1 H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)AH-chromenA-one
. 2-( 1-( 4-amino( 1 H-pyrazolyl)-IH-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro-
3-(3-fl uorophen y 1 )-4 H -chromen A-one
II. 2-( 1-(6-amino-9H-purinyl)ethyl)fluoro(3-fluoropheny1)-4H-chromenA-one
12. 2-(I-(4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone
13. 2-( 1-(4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluorophenyl-4H-chromenone
14. 2-( 1-( 4-amino(benzofuranyl)-IH-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro-
3-(3-fl uorophen y 1 )-4 H -chromenA-one
. 2-( 1-(9H-purinylamino )ethyl)fluoro(3-fluorophenyl)-4H -chromenA-one
16. 2-( 1-( 4-amino-l H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-
4H-chromenone
16a.( + )( 1-(4-amino-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)fluoro(3-
fl uoropheny 1 )-4 H -chromenA-one
16b.( -)( 1-( 4-amino-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fl uoropheny 1)-4 H -chromenone
17. 2-( 1-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
18. 2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro( I H -pyrazolyl)-4H-chromenone
19. 2-( 1-(4-amino(3-fluoro(tetrahydro-2H-pyranyloxy)phenyl)-l H-pyrazolo[3,4-
d]pyri midin-l-y 1 )eth y 1)fl uoro-3 -(3-fl uoropheny 1 )-4 H -chromen A-one
. 2-( 1-( 4-amino(3-isopropyl-1 H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
21. 2-( 1-( 4-amino(3-fluoro(piperidinyloxy)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)f1uoro(3-fluorophenyl)-4H-chromenone
WO 20121151525
22. 2-( 1-( 4-amino(3-fluoro(2-hydroxyethylamino )phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
23. 2-( 1-( 4-amino(3-fluoro(isopropylamino )phenyl)-1 H-pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
24. 2-( 1-( 4-amino( 4-(dimethylamino )fluorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
. 2-( 1-( 4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
26. 2-( 1-( 4-amino(2-methyl-l H-benzo[d]imidazolyl)-1 H-pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
27. 2-( 1-( 4-amino(3-fluoro( 4-methylpiperazin-l-yl)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fl uoro(3-fluoropheny I )-4H-chromenone
28. 2-( 1-( 4-(dimethylamino )-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fl uoropheny I )-4 H -chromenone
29. 2-( 1-( 4-amino-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluorophenyl-4H
chromenone
. 2-( 1-( 4-amino-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro( 4-f1uorophenyl)-
4H-chromenone
31. 2-( 1-(4-amino(4-(difluoromethoxy)f1uorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fl uoro( 4-fl uorophenyl)-4H -chromenone
32. 2-( 1-( 4-amino( 4-( difluoromethoxy)fI uorophenyl)-1 H -pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fluorophenyl-4H-chromenone
33. 2-(1-( 4-aminomethyl-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone
34. 2-( 1-( 4-aminoethyl-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fl uoropheny I )-4 H -chromenone
. 2-( 1-(4-aminoisopropyl-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fl uoropheny I )-4 H -chromenone
36. 2-( 1-( 4-amino(benzo[b ]thiophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone
37. 2-( 1-( 4-aminomorpholino-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)f1uoro(3-
fluorophenyl)-4H-chromenone
38. 2-(l-(4-amino(dimethylamino)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)f1uoro-
3-(3-fluorophenyl)-4H-chromenone
WO 20121151525
39. 2-( 1-(4-amino(piperidin-l-yl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro
(3-fluorophenyl)-4H-chromenone
40. 2-( 1-( 4-amino(6-isopropoxypyridinyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
S-fluoro(3-fluorophenyl)-4H-chromenone
41. 2-( 1-( 4-amino(methylthio )-IH-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro(3-
fluorophenyl)-4H-chromenone
42. 2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate
43. 2-( 1-( 4-amino(3-methyl-l H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate
44. 2-( 1-( 4-amino( 4-( I-benzhydrylazetidinyloxy)fluorophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
4S. 2-( 1-( 4-amino(3-fluoro(trifluoromethoxy)phenyl)-1 H -pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
46. 2-(I-(4-amino(3-fluoro(oxetanyloxy)phenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
47. 2-( 1-( 4-amino(pyrrolidin-l-yl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro-
3-(3-fl uoropheny 1 )-4 H -chromenone
48. N-( 4-( 4-amino-l-( 1-(S-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide
49. 2-( 1-( 4-amino( 4-isobutylphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)-S
fluoro(3-fluorophenyl)-4H-chromenone
SO. 2-( 1-( 4-amino( 4-isopropoxymethylphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
SI. 2-(l-(4-amino(4-(S,6-dihydro-4H-l ,3-oxazinyl)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)eth yl)-S-fl uoro(3-fluorophenyl)-4H-chromenone
S2. 4-( 4-amino-l-( 1-(S-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethy1)-1 H
pyrazolo[3,4-d]pyrimidinyl)-N-methylbenzenesulfonamide
S3. 4-(4-amino-l-(l-(S-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyl)fluoro-N-isopropylbenzamide
S4. 2-( 1-( 4-amino( 4-(S-(methylamino )-1 ,3,4-thiadiazolyl)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-fl uoro(3-fluorophen y 1)-4H-chromenone
SS. N-( 4-( 4-amino-l-( 1-(S-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-I H
pyrazolo[3,4-d]pyrimidinyl)benzyl)methanesulfonamide
WO 20121151525
56. 4-( 4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyl)-N-isopropylbenzenesulfonamide
57. 4-( 4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-I H
pyrazolo[3,4-d]pyrimidinyl)-N-cyclopropylbenzenesulfonamide
58. 2-( 1-( 4-amino(2-isopropoxypyrimidinyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
59. (R)/(S)( 1-( 4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
60. 4-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyl)benzenesulfonamide
61. methyl 4-(4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)
I H-pyrazolo[3,4-d]pyrimidinyl)thiophenecarboxylate
62. 2-( 1-( 4-amino(5-methylthiophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)
fl uoro(3-fl uorophen y 1)-4 H -chromenone
63. 2-( 1-( 4-amino(1 H-pyrrolo[2,3-b ]pyridinyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
64. methyl 4-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1 H -pyrazolo[3 ,4-d]pyrimidi n yl)fl uorobenzoa te
65. 2-( 1-(9H-purinylamino )propyl)fl uorophenyl-4H -chromenone
66. 2-( 1-(4-amino(3-hydroxyprop-I-ynyl)-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone
67. (S)/(R)( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
methylbenzenesulfonate
68. (+)( 1-(9H-purinylamino )ethyl)fluoro(3-fluorophenyl)-4H-chromenone
69. 2-( 1-(9H -purinylamino )ethyl)fluoro(3-fluorophenyl)-4 H -chromenone
70. (R)/(S)( 1-(4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
71. 2-( 1-( 4-amino( 4-methoxy-3,5-dimethylphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
72. 2-(1-( 4-amino( 4-(methoxymethyl)phenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone or
73. 2-( 1-( 4-amino(imidazo[ 1 ,2-a]pyridinyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
WO 20121151525
74. tert-butyl (5-( 4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl )ethy I )-1 H -pyrazol 0[3 ,4-d]pyrimidin-3 -y I )furany I )methy lcarbamate
75. 2-( 1-( 4-amino(2,4-dimethylthiazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-
-fl uoro-3 -(3 -fl uoropheny I )-4 H -chromenone
76. 2-( 1-( 4-amino(5-(morpholinomethyl)thiophenyl)-1 H-pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
77. 2-( 1-( 4-amino( 4-(5-amino-l ,3,4-thiadiazolyl)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
78. (-)( 1-(9H-purinylamino )ethyl)fluoro(3-fluorophenyl)-4H-chromenone
79. 2-(l-(4-amino( 1 ,3-dimethyl-l H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
80. 2-( 1-( 4-amino(2,3-dimethyl-2H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
81. N-(4-(4-amino-l-(l-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-IH
pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)isobutyramide
82. N-(4-(4-amino-I-(l-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)acetamide
83. 2-( 1-( 4-(dimethylamino )(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
84. 5-fluoro( 1-(3-(3-fluoroisopropoxyphenyl)(methylamino )-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)(3-fluorophenyl)-4H -chromenone
85. 5-fluoro( 1-(3-(3-fluoroisopropoxyphenyl)morpholino-l H -pyrazolo[3,4-
d]pyrimidin-l-y I )eth y 1)-3 -(3 -fl uorophenyl )-4 H -chromen one
86. N-(2-fluoro( 1-( 1-(5-fluoro(4-fluorophenyl)oxo-4H-chromenyl)ethyl)
morpholino-I H-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide
87. N-(2-fluoro( 1-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)
morpholino-l H -pyrazo 10[3, 4-d]pyri midiny I )phen y I )isobutyramide
88. (S)/(R)( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d] pyrimidin-l-y I )eth y 1)-5 -fl uoro(3-fl uoropheny I )-4 H -chromenone su Iphate
89. (S)/(R)- 2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
90. (S)/(R)- 2-( 1-(4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fl uoro(3-fluoropheny I )-4H -chromenone
camphorsulphonate
91. 2-( 1-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fluoro( 1 H -pyrazolyl)-4 H -chromenone
34 .
WO 20121151525
92. 2-( 1-( 4-amino(3-f1uoromorpholinophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-f1uorophenyl-4H-chromenone
93. 2-( 1-( 4-amino(3-f1uoromorpholinophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-f1uoro(4-f1uorophenyl)-4H-chromenone
94. and 9S. (S)(l-(4-amino(3-f1uoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-f1uoro( 4-f1uorophenyl)-4H-chromenone and (R)( 1-
(4-amino(3-f1uoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
S-f1uoro(4-f1uorophenyl)-4H-chromenone.
96. and 97. (S)( 1-( 4-amino( 4-(difluoromethoxy)f1uorophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-f1uoro(4-f1uorophenyl)-4H-chromenone and (R)- 2-( 1-
(4-amino( 4-(difluoromethoxy)f1uorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-f1uoro(4-f1uorophenyl)-4H-chromenone
9S. 2-( 1-( 4-(dimethylamino )(3-f1uoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-f1uoro(3-f1uorophenyl)-4H-chromenone
99. S-f1uoro( 1-(3-(3-f1uoromorpholinophenyl)(methylamino)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)(3-fI uorophenyl)-4H -chromenone
100. and 10 1.(S)( 1-( 4-amino(3-f1uoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-f1uorophenyl-4H-chromenone and (R)- 2-( 1-( 4-
amirio(3-f1uoroisopropox yphenyl)-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S
f1uorophenyl-4H-chromenone.
102. and 103. (S)- 2-(I-(4-amino(4-(difluoromethoxy)f1uorophenyl)-IH-
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-f1uorophenyl-4H-chromenone and (R)-
2-( 1-( 4-amino( 4-(difluoromethoxy)f1uorophenyl)-1 H-pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)-S-f1uorophenyl-4H-chromenone
104. (+ )-S-f1uoro( 1-(3-(3-f1uoroisopropoxyphenyl)(methylamino )-1 H-
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)(3-f1uorophenyl)-4H-chromenone and
lOS. (-)- S-f1uoro( 1-(3-(3-f1uoroisopropoxyphenyl)(methylamino)-1 H-
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)(3-fluorophenyl)-4H-chromenone.
106. 2-( 1-( 6-aminof1uoro-9H-purinyl)ethyl)-S-fluoro(3-fluorophenyl)-4H-
chromenone
107. 2-( 1-( 6-aminofluoro-9H-purinyl)ethyl)-S-fluoro( 4-fluorophenyl)-4 H-
chromenone
lOS. S-f1 uoro( 4-f1uorophenyl)( 1-(6-morpholino-9H-purinyl)ethyl)-4H-
chromenone
WO 20121151525
109. 5-fluoro( 4-fluorophenyI)(1-(6-( 4-methylpiperazin-l-yl)-9H-purin
yl)ethyl)-4H-chromenone
110. 2-( 1-(6-( dimethyl amino )-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-
4H-chromenone
Ill. 2-(l-(6-(dimethylamino )-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-
4H-chromenone
112. 5-fluoro(3-fluorophenyl)( I-(3-(3-methyl-I H-indazolyl)
morpholino-I H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)-4H-chromenone
113. 2-( 1-( 4-amino(3-chloromorpholinophenyl)-I H-pyrazolo[3,4-
d]pyrimidin-I-y I)eth yl)-5 -fl uoro(3-fl uorophen y I )-4 H -chromen one
114. (+ )( 1-( 4-amino( 4-isopropoxymethylphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
115. (-)(1-( 4-amino( 4-isopropoxymethylphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-y l)ethyl)fl uoro(3-fluoropheny 1)-4H-chromenone
116. (S)/(R)- 5-fluoro( 1-(3-(3-fluoroisopropoxyphenyl)morpholino-l H-
pyrazol 0[3 ,4-d]pyrimidin-l-y I )eth y 1)-3 -(3-fl uoropheny I )-4 H -chromenone
117. 2-( 1-( 4-amino(3-chloroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
118. 2-(1-(4-amino(2-methylbenzo[d]oxazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
119. 5-fluoro(3-fluorophenyl)( 1-(6-morpholino-9H-purinyl)ethyl)-4H-
chromenone
120. 2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)(3-fluorophenyl)morpholino-4H-chromenone
121. 2-( 1-( 4~amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)morpholinophenyl-4H-chromenone
122. 6-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
I H-pyrazolo[3,4-d]pyrimidinyl)isoindolin-l-one
123. 5-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
I H-pyrazolo[3,4-d]pyrimidinyl)isoindolin-l-one
124. 2-( 1-(3-( 4-acetylfluorophenyl)amino-l H-pyrazolo[3,4-d]pyrimidin- i-
yI)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
125. 5-fluoro(3-fluorophenyl)( 1-(6-(4-methylpiperazin-l-yl)-9H-purin
yl)ethyl)-4H-chromenone
WO 20121151525
126. and 127. (S)- 2-(1-( 4-amino(3-chloromorpholinophenyl)-1 H-
pyrazolo[3 ,4-d] pyrimidin-I-y I )eth y 1)-5 -fI uoro(3 -fI uorophen yl )-4 H -chromenone
2-( 1-( 4-amino(3-chloromorpholinophenyl)-1 H-pyrazolo[3,4-
and (R)-
d]pyrimidin-I-yl)ethyl)fI uoro(3-f1uorophenyl)-4H-chromenone
128. N-(3-(4-amino-I-( 1-(5-f1uoro(3-f1uorophenyl)oxo-4H-chromen
y 1 )eth y I )-1 H -pyrazolo[3,4-d]pyrimidiny 1 )phen y l)methanesulfonamide
129. and 130. (S)- 2-(1-(6-(dimethylamino)-9H-purinyl)ethyl)f1uoro(3-
f1uorophenyl)-4H-chromenone and (R)- 2-(1-(6-(dimethylamino )-9H-purin
yl)ethyl)f1uoro(3-f1uorophenyl)-4H-chromenone
131. 2-( 1-(9H-purinylamino)ethyl)f1uoro(2-f1uorophenyl)-4H-chromen
132. 2-( 1-( 4-amino( 4-ethoxy(trifluoromethyl)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)f1uoro(3-f1uorophenyl)-4H-chromenone
133. 2-(1-( 4-amino(3-f1uoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)propyl)f1uoro(3-f1uorophenyl)-4H-chromenone
134. and 135. (S)f1uoro(3-f1uorophenyl)( 1-(2-methoxy-9H-purin
ylamino )ethyl)-4H -chromenone and (R)f1 uoro(3-fI uorophenyl)( 1-(2-
methoxy-9H-purinylamino)ethyl)-4H-chromenone.
136. (S)/(R)- 5-f1uoro( 1-(2-f1uoro-9H-purinylamino )ethyl)(3-f1uoro
phenyl)-4H-chromenone
137. (S)/(R)( 1-( 4-amino(3-f1uoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]
pyrimidin-I-yl)ethyl)methylphenyl-4H -chromenone
138. 2-( 1-(9H -purinylamino )ethyl)f1uoroo-tolyl-4H -chromenone
and pharmaceutically acceptable salts thereof
Table-l
Ex. Structure Ex. Structure Ex. Structure Ex. Structure
6b. 11. 16b
WO 20121151525
3. 8.
4. 9.
'" I
I h 0
;NrN"')
H!" ~bH,N
. 15.
6. 16.
""" I
I h 0
;~NrN"')
H!"~bH2N
6a. 10. 16a
.N N
'r"')
F ~ b H2N
)-NH F
WO 20121151525
24. 32.
40. 48.
N, r "I
N, r .,
N, r .,
_ -N
N, r "I
F ~~ H,N
_ -N
~ b H,N
~ I. H,N
-rfS JS
~ J.i H,N 0
F /- :H
-N, F
. 33.
41. 49.
H, 1 .,
_ -N
(is H,N N, V ~
N, V ~
-N 5 -N
(N F
\ H,N
26. 34. 42. 50.
C&:?
0 so,H
-J3)
I r ') N r "I
F - H,N
_ -N
FN N, V ~
$f;:
y~bH,N -N ~ b H,N
-d3 r-
27. 35. 43. 51.
N, r ., so,H
N, r ..,
N, r .., 0
_ -N -H _ -N
"l'~bH,N
~ b H,N )"S ~ b H,N
N, 7 "'J
(N F -N ~
N..J Z
H:!N
28. 36. 44. 52.
F 0 r
0 ""
N, r .,
,N N
N, r ') N, r "I
NJ:;"I
_ -N
Ph ~AH,N
V _ .... S H,N ~ ~ b H,N
.j--N~O F
, JS
MeHNO,S
29. 37. 45. 53.
N, 1 .,
N, r "I
_ FN
N, 7 "'J N, V ~
_ -N
ff5'
~ A H,N
6(; 0:;
-N N -N
J!; ~ J.i H,N
(--.JH,N NH
H:!N
F3 F
38. 46. 54.
.<' I
N'l.,
_ N, r :J
N, r "'J N, r "I
~ H,N
Q:; JS
0(; -N -N j$
'H,N
H:!N Q
MeHN.4 ,N
Ex. Ex. Structure Ex.
Structure Structure Ex. Structure
WO 20121151525
55. 62.
69. 76.
"'I F
N, r ")
N, r '7
_ -N NH
_ -N
NI r ~
~ b H,N
~ 5 H,N
_ -N
t~N~
MsHNH,C
"" S H,N
0--./
56. 70. 77.
N, r ")
_ -N
N, r '7 N, r '7
~ A H,N
-N -N
~_ ~ H,N
o,s.
~ b H,N
J!; p
A 5 \
(N F
H,N--ZN·N
H oJ
57. 64. 7l. 78.
N, ¥ ")
_ -N F. N, r ")
N, r ") NH
_ -N
~ b H,N
!S ~_ ~ H,N
t~N;
~ b H,N
Meo,c ~
MeO H
58. 65. 72. 79.
0 ./
_ -N
~' '-l
J-":H,N
t~N~ ~ ~bH,N
59. 66. 73. 80.
N, r ")
N, r ")
_ -N N, r '7
N, r "'7
-N -N
,p -N
~ b H,N
~ ~ H,N
!"- b H,N
~ H,N
('N F JS
/N ~
oJ OH ~
60. 67. 74. 8l.
o . 1 A
1 9 0
,N H
H, r ")
~~:J
_ f'H
H, r "'7 _ -N
-N F-0 H,N ~ A H,N
'" 0 H,N
~ A H,N
d'S HN -?OF
H,NO,S
6l. 68. 75.
H, ¥ ")
N, r ")
N, r ") _ -H
_ -N
~ A H,N
r ~ ~
tJ-JC,
H,co,c 5 H,N
NyS H,N HN F
Ex. Ex. Structure Ex. Structure Ex.
Structure Structure
WO 20121151525
F F F F
90. 97. 104.
'" '"
o . 0
f.. 0
N, r '?
N, r '?
N ~ , r '?
_ TN
F ~ n _N, F ~ ~ ~N
F ~ - H..N
F ~ n _NH
ifi'
if!; n . -J3;
)-...F
F r-
84. 9l. 98.
105.
1)11
6¢¢"
1 "'" 1
N, r ')
N, r ~
N, V ~
-N _ -N
N, r '?
F ~~H2N ~ n _N, F ~ ~ _NH
-d'S J5:
F ~ n _NH
0 (N F
)-...F
oJ r-
)---
85. 92. 99.
106.
N, V ')
N, r ~ N, r ~
_ -N
_ -N
_ -N
~ n H,N
J?; ,fi
" 0 _NH
" 0 (N is ~Jr;"rF
(N F
("N F
)-.F 0)
oJ oJ ~N
86. 93. 100. 107.
,N'-N
N, r ~
N, r ~
_ -N _ -N
d?;~
~Jr;"rF
~ 0 (N J:; F ~ 0 H,N
" 0 H,N -if;
HN F 0)
(N F
87. 94.
10l. 108.
N, r "'J N, r ')
N, r ')
~~::
-N -N
_ -N
F ~~ H,N F ~ ~ H,N
if:; (N
J?; -if;
" 0 _N
HN F~)
-(0 r-
88. 95. 102. 109.
F 0 .1
....•
.H,SO,
N, r ~ N N
N, r ~
N, r ~
F ~~H,N
-if;
F ,,~H,N
-if!; F ~~ ~N
if:;
0 (N
)- N)
89. 96. 103. 110.
\ r "l
N, r '?
N, r ~
-N -N
;fS \\,N N
F ~~H2N
~~ H,N F if; ~~ H,N
)--F
)---
)--F
F _N
WO 20121151525
Yet another embodiment of the present invention is a compound of formula
lA \:R
X R2
(10)
wherein the variables are the same as defined above.
Yet another embodiment of the present invention is a process for prepanng the
compound of formula
(10)
comprising the steps as depicted in scheme 1 below.
Yet another embodiment of the present invention is a compound of formula
~Cy1
lA \:R
HO R2
(12)
wherein the variables are the same as defined above.
Yet another embodiment of the present invention IS a process for preparing the
compound of formula
(12)
comprising the steps as depicted and described in scheme 1A below.
Yet another embodiment of the present invention is a process for preparing the
compound of formula (I) comprsing the steps of converting a compound of formula (10) as
depicted and described in Scheme 2,3 or 4 below.
WO 20121151525
Yet another embodiment of the present invention is a process for preparing the
compound of formula (I) comprsing the steps of converting compound of formula (12) as
depicted and described in Scheme 2,3 or 4 below.
Yet another embodiment of the present invention is a process for preparing the
compound of formula (10), (14) or (15) comprsing the steps of converting compound of
formula (12) as depicted and described in Scheme 1A below.
Yet another embodiment of the present invention is a method for inhibiting PI3K in a
patient by administering to the patient an effective amount of at least one compound of the
present invention (for instance, a compound of formula (I), (IA), (lA-I), (lA-II), (lA-III)
(lA-IV), (lA-V), (lA-VI), (lA-VII), (lA-VIII), (IA-Ia), (IA-IIa), (lA-IlIa), (IA-Ib) or (IA
lIb) as defined above).
Yet another embodiment of the present invention is a method for treating a
proliferative disease via modulation of a protein kinase (such as PI3K) by administering to a
patient in need of such treatment an effective amount of at least one compound of the present
invention. In one embodiment, the compound of the present invention inhibits a protein
kinase (such as PI3K).
Yet another embodiment of the present invention is a method for treating a
proliferative disease via modulation of a protein kinase (such as PI3K) by administering to a
patient in need of such treatment an effective amount of at least one compound of the present
invention, in combination (simultaneously or sequentially) with at least one other anti-cancer
agent. In one embodiment, the compound of formula I), (IA), (lA-I), (lA-II), (lA-III) (IA
IV), (lA-V), (lA-VI), (lA-VII), (lA-VIII), (IA-Ia), (IA-IIa), (lA-IlIa), (IA-Ib) or (lA-lIb)
inhibits a protein kinase (such as PI3K).
More particularly, the compounds of formula I), (IA), (lA-I), (lA-II), (lA-III) (IA
IV), (lA-V), (lA-VI), (lA-VII), (lA-VIII), (IA-Ia), (IA-IIa), (lA-IlIa), (IA-I b) or (lA-lIb)
and pharmaceutically acceptable esters or salts thereof can be administered for the treatment,
prevention and/or amelioration of PI3K and related protein kinase mediated diseases or
disorders, including but not limited to, cancer and other proliferative diseases or disorders.
The compounds of the present invention are useful in the treatment of a variety of
cancers, including, but not limited to, the following:
• carcinoma, including that of the bladder, breast, colon, kidney, liver, lung,
including small cell lung cancer, esophagus, gall bladder, ovary, pancreas,
stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma;
WO 20121151525
• hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic
leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma,
Hodgkin's lymphoma, non-Hodgkins lymphoma, hairy cell lymphoma and
Burkett's lymphoma;
• hematopoietic tumors of myeloid lineage, including acute and chronic
myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia;
• tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma;
• tumors of the central and peripheral nervous system, including astrocytoma,
neuroblastoma, glioma and schwannomas; and
• other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma,
xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and
Kaposi's sarcoma.
Due to the key role of protein kinases in the regulation of cellular proliferation in
general, the protein kinase inhibitors of the present invention could act as reversible cytostatic
agents which may be useful in the treatment of any disease process which features abnormal
cellular proliferation, e.g., benign prostatic hyperplasia, familial adenomatosis polyposis,
neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis,
glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar
formation, inflammatory bowel disease, transplantation rejection, endotoxic shock, and fungal
infections.
The compounds of the present invention as modulators of apoptosis are useful in the
treatment of cancer (including but not limited to those types mentioned herein above), viral
infections (including but not limited to herpevirus, poxvirus, Epstein-Barr virus, Sindbis virus
and adenovirus), prevention of AIDS development in HIV -infected individuals, autoimmune
diseases (including but not limited to systemic lupus, erythematosus, autoimmune mediated
glomerulonephritis, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and
autoimmune diabetes mellitus), neurodegenerative disorders (including but not limited to
Alzheimer's disease, AIDS-related dementia, Parkinson's disease, amyotrophic lateral
sclerosis, retinitis pigmentosa, spinal muscular atrophy and cerebellar degeneration),
myelodysplastic syndromes, aplastic anemia, ischemic injury associated with myocardial
infarctions, stroke and reperfusion injury, arrhythmia, atherosclerosis, toxin-induced or alcohol
related liver diseases, hematological diseases (including but not limited to chronic anemia and
aplastic anemia), degenerative diseases of the musculoskeletal system (including but not
WO 20121151525
limited to osteoporosis and arthritis) aspirin-sensitive rhinosinusitis, cystic fibrosis, multiple
sclerosis, kidney diseases and cancer pain.
The compounds of present invention can modulate the level of cellular RNA and
DNA synthesis. These agents are therefore useful in the treatment of viral infections
(including but not limited to HIV, human papilloma virus, herpesvirus, poxvirus, Epstein-Barr
virus, Sindbis virus and adenovirus).
The compounds of the present invention are useful in the chemoprevention of cancer.
Chemoprevention is defined as inhibiting the development of invasive cancer by either
blocking the initiating mutagenic event or by blocking the progression of pre-malignant cells
that have already suffered an insult or inhibiting tumor relapse. The compounds are also
useful in inhibiting tumor angiogenesis and metastasis. One embodiment of the invention is a
method of inhibiting tumor angiogenesis or metastasis in a patient in need thereof by
administering an effective amount of one or more compounds of the present invention.
Another embodiment of the present invention is a method of treating an immune
system-related disease (e.g., an autoimmune disease), a disease or disorder involving
inflammation (e.g., asthma, chronic obstructive pulmonary disease, rheumatoid arthritis,
inflammatory bowel disease, glomerulonephritis, neuroinflammatory diseases, multiple
sclerosis, uveitis and disorders of the immune system), cancer or other proliferative disease, a
hepatic disease or disorder, a renal disease or disorder. The method includes administering an
effective amount of one or more compounds of the present invention.
Examples of immune disorders include psoriasis, rheumatoid arthritis, vasculitis,
inflammatory bowel disease, dermatitis, osteoarthritis, asthma, inflammatory muscle disease,
allergic rhinitis, vaginitis, interstitial cystitis, scleroderma, osteoporosis, eczema, allogeneic or
xenogeneic transplantation (organ, bone marrow, stem cells and other cells and tissues) graft
rejection, graft-versus-host disease, lupus erythematosus, inflammatory disease, type I
diabetes, pulmonary fibrosis, dermatomyositis, Sjogren's syndrome, thyroiditis (e.g.,
Hashimoto's and autoimmune thyroiditis), myasthenia gravis, autoimmune hemolytic anemia,
multiple sclerosis, cystic fibrosis, chronic relapsing hepatitis, primary biliary cirrhosis, allergic
conjunctivitis and atopic dermatitis.
In one embodiment, the compounds described herein are used as immunosuppresants
to prevent transplant graft rejections, allogeneic or xenogeneic transplantation rejection
(organ, bone marrow, stem cells, other cells and tissues), and graft - versus - host disease. In
other embodiments, transplant graft rejections result from tissue or organ transplants. In
further embodiments, graft-versus-host disease results from bone marrow or stem cell
WO 20121151525
transplantation. One embodiment is a method of preventing or decreasing the risk of
transplant graft rejection, allogeneic or xenogeneic transplantation rejection (organ, bone
marrow, stem cells, other cells and tissues), or graft - versus - host disease by administering an
effective amount of one or more compounds of the present invention.
The compounds of the present invention are also useful in combination (administered
together or sequentially) with known anti-cancer treatments such as radiation therapy or with
cytostatic or cytotoxic or anticancer agents, such as for example, but not limited to, DNA
interactive agents, such as cisplatin or doxorubicin; topoisomerase II inhibitors, such as
etoposide; topoisomerase I inhibitors such as CPT-II or topotecan; tubulin interacting agents,
such as paclitaxel, docetaxel or the epothilones (for example ixabepilone), either naturally
occurring or synthetic; hormonal agents, such as tamoxifen; thymidilate synthase inhibitors,
such as 5-fluorouracil; and anti-metabolites, such as methotrexate, other tyrosine kinase
inhibitors such as Iressa and OSI-774; angiogenesis inhibitors; EGF inhibitors; VEGF
inhibitors; CDK inhibitors; SRC inhibitors; c-Kit inhibitors; HerI12 inhibitors and monoclonal
antibodies directed against growth factor receptors such as erbitux (EGF) and herceptin (Her2)
and other protein kinase modulators as well.
The compounds of the present invention are also useful in combination (administered
tog~ther or sequentially) with one or more steroidal anti-inflammatory drugs, non-steroidal
anti-inflammatory drugs (NSAIDs) or Immune Selective Anti-Inflammatory Derivatives
(ImSAIDs).
The invention further provides a pharmaceutical composition comprising one or more
compounds of the present invention (such as a compound having formula (I), (IA), (lA-I),
(lA-II), (lA-III) (lA-IV), (lA-V), (lA-VI), (lA-VII), (lA-VIII), (IA-Ia), (IA-IIa), ·(IA
IlIa), (IA-Ib) or (lA-lIb» together with a pharmaceutically acceptable carrier. The
pharmaceutical composition may further comprise one or more of the active ingredients
identified above, such as other anti-cancer agents.
In one embodiment, the pharmaceutical composition includes a therapeutically
effective amount of one or more compounds of formula (I), (IA), (lA-I), (lA-II), (lA-III)
(lA-IV), (lA-V), (lA-VI), (lA-VII), (lA-VIII), (IA-Ia), (IA-IIa), (lA-IlIa), (IA-Ib) or (IA
lIb).
Yet another embodiment is a method of treating leukemia in a patient in need thereof
by administering a therapeutically effective amount of a compound of the present invention.
For example, the compounds of the present invention are effective for treating chronic
lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), acute myeloid leukemia
WO 20121151525
(AML), multiple myeloma (MM), small lymphocytic lymphoma (SLL), and indolent non
Hodgkin's lymphoma (I-NHL).
Yet another embodiment is a method of treating allergic rhinitis in a patient in need
thereof by administering a therapeutically effective amount of a compound of the present
invention.
DETAILED DESCRIPTION OF THE INVENTION
As used herein the following definitions shall apply unless otherwise indicated.
Further many of the groups defined herein can be optionally substituted. The listing of
substituents in the definition is exemplary and is not to be construed to limit the substituents
defined elsewhere in the specification.
The term "alkyl", unless otherwise specified, refers to a straight or branched
hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no
unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the
molecule by a single bond, e.g., methyl, ethyl, n-propyl, I-methylethyl (isopropyl), n-butyl, n
pentyl, and 1, I-dimethylethyl (t-butyl). The term "(C _6)alkyl" refers to an alkyl group as
defined above having up to 6 carbon atoms.
The term "alkenyl", unless otherwise specified, refers to an aliphatic
hydrocarbon group containing a carbon-carbon double bond and which may be a straight or
branched or branched chain having about 2 to about 10 carbon atoms, e.g., ethenyl, 1-
propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-l-propenyl, I-butenyl, and 2-butenyl.
The term "(C _6)alkenyl" refers to an alkenyl group as defined above having up to 6 carbon
atoms.
The term "alkynyl", unless otherwise specified, refers to a straight or branched
chain hydrocarbyl radical having at least one carbon-carbon triple bond, and having in the
range of 2 to up to 12 carbon atoms (with radicals having in the range of 2 to up to 10 carbon
atoms presently being preferred) e.g., ethynyl, propynyl, and butnyl. The term "(C -6) alkynyl"
refers to an alkynyl group as defined above having up to 6 carbon atoms.
[l02] The term "alkoxy" unless otherwise specified, denotes an alkyl, cycloalkyl, or
cycloalkylalkyl group as defined above attached via an oxygen linkage to the rest of the
molecule. The term "substituted alkoxy" refers to an alkoxy group where the alkyl constituent
is substituted (i.e., -O-(substituted alkyl) wherein the term "substituted alkyl" is the same as
defined above for "alkyl". For example "alkoxy" refers to the group -O-alkyl, including from
to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof
WO 20121151525
attached to the parent structure through oxygen. Examples include methoxy, ethoxy, propoxy,
isopropoxy, cyclopropyloxy, and cyclohexyloxy.
The term "cycloalkyl", unless otherwise specified, denotes a non-aromatic
mono or multicyclic ring system of about 3 to 12 carbon atoms such as cyclopropyl,
cyclobutyl, cyclopentyl, and cyclohexyl. Examples of multicyclic cycloalkyl groups include
perhydronaphthyl, adamantyl and norbornyl groups, bridged cyclic groups, and sprirobicyclic
groups, e.g., sprio (4,4) nonyl. The term "(C -g) cycloalkyl" refers to a cycloalkyl group as
defined above having up to 8 carbon atoms.
The term "cycloalkylalkyl", unless otherwise specified, refers to a cyclic ring-
containing radical containing in the range of about 3 up to 8 carbon atoms directly attached to
an alkyl group which are then attached to the main structure at any carbon from the alkyl
group that results in the creation of a stable structure such as cyclopropylmethyl,
cyclobutylethyl, and cyclopentylethyl.
[lOS] The term "cycloalkenyl", unless otherwise specified, refers to cyclic ring-
containing radicals containing in the range of about 3 up to 8 carbon atoms with at least one
carbon-carbon double bond such as cyclopropenyl, cyclobutenyl, and cyclopentenyl. The term
"cycloalkenylalkyl" refers to a cycloalkenyl group directly attached to an alkyl group which
are then attached to the main structure at any carbon from the alkyl group that results in the
creation of a stable structure.
The term "aryl", unless otherwise specified, refers to aromatic radicals having
in the range of 6 up to 20 carbon atoms such as phenyl, naphthyl, tetrahydronaphthyl, indanyl,
and biphenyl.
The term "aryl alkyl", unless otherwise specified, refers to an aryl group as
defined above directly bonded to an alkyl group as defined above, e.g., -CH C H and -
C H C6 S.
The term "heterocyclic ring", unless otherwise specified, refers to a non-
aromatic 3 to 15 member ring radical which consists of carbon atoms and at least one
heteroatom selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this
invention, the heterocyclic ring radical may be a mono-, bi-, tri- or tetracyclic ring system,
which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon,
oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various
oxidation states. In addition, the nitrogen atom may be optionally quaternized. The
heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon
atom that results in the creation of a stable structure.
WO 20121151525
The tenn "heterocyclyl", unless otherwise specified, refers to a heterocylic
ring radical as defined above. The heterocylcyl ring radical may be attached to the main
structure at any heteroatom or carbon atom that results in the creation of a stable structure.
The term "heterocyclylalkyl", unless otherwise specified, refers to a
heterocylic ring radical as defined above directly bonded to an alkyl group. The
heterocyclylalkyl radical may be attached to the main structure at carbon atom in the alkyl
group that results in the creation of a stable structure. Examples of such heterocycloalkyl
radicals include, but are not limited to, dioxolanyl, thienyl[ 1 ,3]dithianyl,
decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazoliclinyl,
morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-
oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrroliclinyl,
pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl,
thiomorphol inyl, thiamorpholinyl, l-oxo-thiomorpholinyl, and 1,I-dioxo-thiol11orpholinyl.
The term "heteroaryl", unless otherwise specified, refers to an optionally
substituted 5 to 14 member aromatic ring having one or more heteroatoms selected from N, 0,
and S as ring atoms. The heteroaryl may be a mono-, bi- or tricyclic ring system. Examples of
such "heterocyclic ring" or "heteroaryl" radicals include, but are not limited to, oxazolyl,
thiazolyl, imidazolyl, pyrrolyl, furanyl, pyridinyl, pyrimidinyl, pyrazinyl, benzofuranyl,
indolyl, benzothiazolyl, benzoxazolyl, carbazolyl, quinolyl, isoquinolyl, azetidinyl, acridinyl,
benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl,
naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl,
pteridinyl, purinyl, quinazolinyl, quinoxalinyl, tetrazoyl, tetrahydroisoquinolyl, piperidinyl,
piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl,
4-piperidonyl, pyrrolidinyl, pyridazinyl, oxazolinyl, oxazolidinyl, triazolyl, indanyl,
isoxazolyl, isoxazolidinyl, morpholinyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl,
isothiazolidinyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl,
decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, tetrahydrofuryl,
tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide,
thiamorpholinyl sulfone, dioxaphospholanyl, oxadiazolyl, chromanyl, and isochromanyl. The
heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom
that results in the creation of a stable structure. The term "substituted heteroaryl" also
includes ring systems substituted with one or more oxide () substituents, such as pyridinyl
N-oxides.
WO 20121151525
The term "heteroarylalkyl", unless otherwise specified, refers to a heteroaryl
ring radical as defined above directly bonded to an alkyl group. The heteroarylalkyl radical
may be attached to the main structure at any carbon atom from alkyl group that results in the
creation of a stable structure.
The term "cyclic ring" refers to a cyclic ring containing 3 to 10 carbon atoms.
The term "substituted" unless otherwise specified, refers to substitution with
anyone or any combination of the following substituents which may be the same or different
and are independently selected from hydrogen, hydroxy, halogen, carboxyl, cyano, nitro, oxo
(=0), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or
unsubstituted aryl, substituted or unsubstituted aryl alkyl, substituted or unsubstituted
cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted
cycloalkenyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted
heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted
heterocyclic ring, substituted heterocyclylalkyl ring, substituted or unsubstituted guanidine, -
X X z z
COORX, -C(O)R , -C(S)R , -C(O)NRxRY, -C(O)ONRxRY, -NRYR , -NRxCONRYR , -
Y Y Y Y
N(RX)SOR , -N(R )S02 , -(=N-N(RX)R ), - NRxC(O)OR , -NRxR , -NRXC(O)RY-, -
z x z
NRxC(S)RY -NRXC(S)NRYR , -SONRxRY-, -S02NRxRY-, _OR , -ORxC(O)NRYR ,
ORxC(O)ORY-, -OC(O)RX, -OC(O)NRxRY, - RXNRYC(O)R , -RxORY, -RxC(O)ORY, -
z x x
RXC(O)NRYR , -RxC(O)RX, -RxOC(O)RY, _SR , -SOR , -S02RX, and -ON0 , wherein RX, RY
and R in each of the above groups can be hydrogen, substituted or unsubstituted alkyl,
substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or
unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl,
substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl,
substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or
unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or
unsubstituted heterocyclic ring, or substituted heterocyclylalkyl ring, or any two of R , RY and
R may be joined to form a substituted or unsubstituted saturated or unsaturated 3-10
membered ring, which may optionally include heteroatoms which may be the same or
different and are selected from 0, NR (e.g., R can be hydrogen or C - alkyl) or S.
Substitution or the combinations of substituents envisioned by this invention are preferably
those that result in the formation of a stable or chemically feasible compound. The term stable
as used herein refers to the compounds or the structure that are not substantially altered when
subjected to conditions to allow for their production, detection and preferably their recovery,
WO 20121151525
purification and incorporation into a pharmaceutical composition. The substituents in the
aforementioned "substituted" groups cannot be further substituted. For example, when the
substituent on "substituted alkyl" is "substituted aryl", the substituent on "substituted aryl"
cannot be "substituted alkenyl".
The term "halo", "halide", or, alternatively, "halogen" means f1uoro, chloro,
bromo or iodo. The terms "haloalkyl," "haloalkenyl," "haloalkynyl" and "haloalkoxy" include
alkyl, alkenyl, alkynyl and alkoxy structures that are substituted with one or more halo groups
or with combinations thereof. For example, the terms "f1uoroalkyl" and "f1uoroalkoxy" include
haloalkyl and haloalkoxy groups, respectively, in which the halo is fluorine.
The term "protecting group" or "PG" refers to a substituent that is employed to
block or protect a particular functionality. Other functional groups on the compound may
remain reactive. For example, an "amino-protecting group" is a substituent attached to an
amino group that blocks or protects the amino functionality in the compound. Suitable amino
protecting groups include, but are not limited to, acetyl, trifluoroacetyl, tert-butoxycarbonyl
(BOC), benzyloxycarbonyl (CBz) and 9-f1uorenylmethylenoxycarbonyl (Fmoc). Similarly, a
"hydroxy-protecting group" refers to a substituent of a hydroxy group that blocks or protects
the hydroxy functionality. Suitable hydroxy-protecting groups include, but are not limited to,
acetyl and silyl. A "carboxy-protecting group" refers to a substituent of the carboxy group that
blocks or protects the carboxy functionality. Suitable carboxy-protecting groups include, but
are not limited to, -CH2CH2S02Ph, cyanoethyl, 2-(trimethylsilyl)ethyl, 2-
(trimethylsilyl)ethoxymethyl, - 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-
(diphenylphosphino)-ethyl, and nitroethyl. For a general description of protecting groups and
their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New
York, 1991.
Certain of the compounds described herein contain one or more asymmetric
centers and can thus give rise to enantiomers, diastereomers, and other stereoisomeric forms
that can be defined, in terms of absolute stereochemistry, as (R)- or (S)-. The present chemical
entities, pharmaceutical compositions and methods are meant to include all such possible
isomers, including racemic mixtures, optically pure forms and intermediate mixtures. For the
instance the non-limiting example of intermediate mixutures include a mixture of isomers in a
ratio of 10:90, 13:87, 17:83,20:80, or 22:78. Optically active (R)- and (S)- isomers can be
prepared using chiral synthons or chiral reagents, or resolved using conventional techniques.
When the compounds described herein contain olefinic double bonds or other centers of
WO 20121151525
geometric asymmetry, and unless specified otherwise, it is intended that the compounds
include both E and Z geometric isomers.
The term "tautomers" refers to compounds, which are characterized by
relatively easy interconversion of isomeric forms in equilibrium. These isomers are intended to
be covered by this invention. "Tautomers" are structurally distinct isomers that interconvert
by tautomerization. "Tautomerization" is a form of isomerization and includes prototropic or
proton-shift tautomerization, which is considered a subset of acid-base chemistry. "Prototropic
tautomerization" or "proton-shift tautomerization" involves the migration of a proton
accompanied by changes in bond order, often the interchange of a single bond with an
adjacent double bond. Where tautomerization is possible (e.g. in solution), a chemical
equilibrium of tautomers can be reached. An example of tautomerizati0!1 is keto-enol
tautomerization. A specific example of keto-enol tautomerization is the interconversion of
pentane-2,4-dione and 4-hydroxypentenone tautomers. Another example of
tautomerization is phenol-keto tautomerization. A specific example of phenol-keto
tautomerization is the interconversion of pyridin01 and pyridin-4( 1 H)-one tautomers.
A "leaving group or atom" is any group or atom that will, under the reaction
conditions, cleave from the starting material, thus promoting reaction at a specified site.
Suitable examples of such groups unless otherwise specified are halogen atoms and mesyloxy,
p-nitrobenzensulphonyloxy and tosyloxy groups.
The term "prodrug" refers to a compound, which is an inactive precursor of a
compound, converted into its active form in the body by normal metabolic processes. Prodrug
design is discussed generally in Hardma, et al. (Eds.), Goodman and Gilman's The
Pharmacological Basis of Therapeutics, 9th ed., pp. 11-16 (1996). A thorough discussion is
provided in Higuchi, et aI., Prodrugs as Novel Delivery Systems, Vol. 14, AS CD Symposium
Series, and in Roche (ed.), Bioreversible Carriers in Drug Design, American Pharmaceutical
Association and Pergamon Press (1987). To illustrate, prodrugs can be converted into a
pharmacologically active form through hydrolysis of, for example, an ester or amide linkage,
thereby introducing or exposing a functional group on the resultant product. The prodrugs can
be designed to react with an endogenous compound to form a water-soluble conjugate that
further enhances the pharmacological properties of the compound, for example, increased
circulatory half-life. Alternatively, prod rugs can be designed to undergo covalent modification
on a functional group with, for example, glucuronic acid, sulfate, glutathione, amino acids, or
acetate. The resulting conjugate can be inactivated and excreted in the urine, or rendered more
potent than the parent compound. High molecular weight conjugates also can be excreted into
WO 20121151525
the bile, subjected to enzymatic cleavage, and released back into the circulation, thereby
effectively increasing the biological half-life of the originally administered compound.
The term "ester" refers to a compound, which is formed by reaction between
an acid and an alcohol with elimination of water. An ester can be represented by the general
formula RCOOR'.
These prodrugs and esters are intended to be covered within the scope of this
invention.
Additionally the instant invention also includes the compounds which differ
only in the presence of one or more isotopically enriched atoms for example replacement of
hydrogen with deuterium or tritium, or the replacement of a carbon by 13C_ or 14c- iched
carbon.
The compounds of the present invention may also contain unnatural
proportions of atomic isotopes at one or more of atoms that constitute such compounds. For
example, the compounds may be radiolabeled with radioactive isotopes, such as for example
tritium eH), iodine-125 (1251) or carbon-14 ct C). All isotopic variations of the compounds of
the present invention, whether radioactive or not, are encompassed within the scope of the
present invention.
Pharmaceutically acceptable salts forming part of this invention include salts
derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn; salts of organic
bases such as N,N'-diacetylethylenediamine, glucamine, triethylamine, choline, hydroxide,
dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine; chiral bases such as
alkylphenylamine, glycinol, and phenyl glycinol; salts of natural amino acids such as glycine,
alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline,
hydroxy proline, histidine, ornithine, lysine, arginine, and serine; quaternary ammonium salts
of the compounds of invention with alkyl halides, alkyl sulphates such as Mel and (MehS04;
non-natural amino acids such as D-isomers or substituted amino acids; guanidine; and
substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl,
alkynyl, ammonium or substituted ammonium salts and aluminum salts. Salts may include
acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates,
borates, hydrohalides, acetates, tartrates, maleates, citrates, fumarates, succinates, palmoates,
methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates,
and ketoglutarates.
When ranges are used herein for physical properties, such as molecular weight,
or chemical properties, such as chemical formulae, all combinations and subcombinations of
WO 20121151525
ranges and specific embodiments therein are intended to be included. The term "about" when
referring to a number or a numerical range means that the number or numerical range referred
to is an approximation within experimental variability (or within statistical experimental
error), and thus the number or numerical range may vary from, for example, between 1 % and
% of the stated number or numerical range. The term "comprising" (and related terms such
as "comprise" or "comprises" or "having" or "including") includes those embodiments, for
example, an embodiment of any composition of matter, composition, method, or process, or
the like, that "consist of' or "consist essentially of' the described features.
The following abbreviations and terms have the indicated meanings
throughout: PI3-K = Phosphoinositide 3-kinase; PI = phosphatidylinositol; PDK =
Phosphoinositide Dependent Kinase; DNA-PK = Deoxyribose Nucleic Acid Dependent
Protein Kinase; PTEN = Phosphatase and Tensin homolog deleted on chromosome Ten; PIKK
= Phosphoinositide Kinase Like Kinase; AIDS = Acquired Immuno Deficiency Syndrome;
HIV = Human Immunodeficiency Virus; Mel = Methyl Iodide; POCI = Phosphorous
Oxychloride; KCNS = Potassium IsoThiocyanate; TLC = Thin Layer Chromatography;
MeOH = Methanol; and CHCI = Chloroform.
Abbreviations used herein have their conventional meaning within the
chemical and biological arts.
The term "cell proliferation" refers to a phenomenon by which the cell number
, has changed as a result of division. This term also encompasses cell growth by which the cell
morphology has changed (e.g., increased in size) consistent with a proliferative signal.
The term "co-administration," "administered in combination with," and their
grammatical equivalents, as used herein, encompasses administration of two or more agents to
an animal so that both agents and/or their metabolites are present in the animal at the same
time. Co-administration includes simultaneous administration in separate compositions,
administration at different times in separate compositions, or administration in a composition
in which both agents are present.
The term "effective amount" or "therapeutically effective amount" refers to
that amount of a compound described herein that is sufficient to effect the intended application
including but not limited to disease treatment, as defined below. The therapeutically effective
amount may vary depending upon the intended application (in vitro or in vivo), or the subject
and disease condition being treated, e.g., the weight and age of the subject, the severity of the
disease condition, the manner of administration and the like, which can readily be determined
by one of ordinary skill in the art. The term also applies to a dose that will induce a particular
WO 20121151525
response in target cells, e.g. reduction of platelet adhesion and/or cell migration. The specific
dose will vary depending on the particular compounds chosen, the dosing regimen to be
followed, whether it is administered in combination with other compounds, timing of
administration, the tissue to which it is administered, and the physical delivery system in
which it is carried.
As used herein, "treatment," "treating," or "ameliorating" are used
interchangeably. These terms refers to an approach for obtaining beneficial or desired results
including but not limited to therapeutic benefit and/or a prophylactic benefit. By therapeutic
benefit is meant eradication or amelioration of the underlying disorder being treated. Also, a
therapeutic benefit is achieved with the eradication or amelioration of one or more of the
physiological symptoms associated with the underlying disorder such that an improvement is
observed in the patient, notwithstanding that the patient may still be afflicted with the
underlying disorder. For prophylactic benefit, the compositions may be administered to a
patient at risk of developing a particular disease, or to a patient reporting one or more of the
physiological symptoms of a disease, even though a diagnosis of this disease may not have
been made.
A "therapeutic effect," as that term is used herein, encompasses a therapeutic
benefit and/or a prophylactic benefit as described above. A prophylactic effect includes
delaying or eliminating the appearance of a disease or condition, delaying or eliminating the
onset of symptoms of a disease or condition, slowing, halting, or reversing the progression of a
disease or condition, or any combination thereof.
The term "subject" or "patient" refers to an animal, such as a mammal, for
example a human. The methods described herein can be useful in both human therapeutics and
veterinary applications. In some embodiments, the patient is a mammal, and in some
embodiments, the patient is human.
"Radiation therapy" means exposing a patient, using routine methods and
compositions known to the practitioner, to radiation emitters such as alpha-particle emitting
radionuclides (e.g., actinium and thorium radionuclides), low linear energy transfer (LET)
radiation emitters (i.e. beta emitters), conversion electron emitters (e.g. strontium-89 and
samarium- 153-EDTMP, or high-energy radiation, including without limitation x-rays, gamma
rays, and neutrons.
"Signal transduction" is a process during which stimulatory or inhibitory
signals are transmitted into and within a cell to elicit an intracellular response. A modulator of
a signal transduction pathway refers to a compound which modulates the activity of one or
WO 20121151525
more cellular proteins mapped to the same specific signal transduction pathway. A modulator
may augment (agonist) or suppress (antagonist) the activity of a signaling molecule.
The term "selective inhibition" or "selectively inhibit" as applied to a
biologically active agent refers to the agent's ability to selectively reduce the target signaling
activity as compared to off-target signaling activity, via direct or indirect interaction with the
target.
The term "pharmaceutically acceptable carrier" or "pharmaceutically
acceptable excipient" includes, but is not limited to, any and all solvents, dispersion media,
coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, one or
more suitable diluents, fillers, salts, disintegrants, binders, lubricants, glidants, wetting agents,
controlled release matrices, colorantslflavoring, carriers, excipients, buffers, stabilizers,
solubilizers, and combinations thereof. Except insofar as any conventional media or agent is
incompatible with the active ingredient, its use in the therapeutic compositions of the
invention is contemplated. Supplementary active ingredients can also be incorporated into the
compositions.
In some embodiments, one or more subject compounds bind specifically to a
PI3 kinase or a protein kinase selected from the group consisting of mTor, DNA-dependent
protein kinase (Pubmed protein accession number (PPAN) AAA 79184), AbI tyrosine kinase
(CAAS2387), Bcr-Abl, hemopoietic cell kinase (PPAN CAlI969S), Src (PPAN CAA2449S),
vascular endothelial growth factor receptor 2 (PPAN ABB82619), epidermal growth factor
receptor (PPAN AG43241), EPH receptor B4 (PPAN EAL23820), stem cell factor receptor
(PPAN AAF22141), Tyrosine-protein kinase receptor TlE-2 (PPAN Q028S8), fms-related
tyrosine kinase 3 (PPAN NP_004110), platelet-derived growth factor receptor alpha (PPAN
NP _990080), RET (PPAN CAA 73131), and any other related protein kinases, as well as any
functional mutants thereof.
In some embodiments, the ICSO of a subject compound for pi IOu, pi lOp, pi
lOy, or pi 108 is less than about 1 uM, less than about 100 nM, less than about SO nM, less
than about 10 nM, less than 1 nM or even less than about O.SnM. In some embodiments, the
IC50 of a subject compound for mTor is less than about I uM, less than about 100 nM, less
than about SO nM, less than about 10 nM, less than 1 nM or even less than about O.SnM. In
some other embodiments, one or more subject compounds exhibit dual binding specificity and
are capable of inhibiting a PI3 kinase (e.g., a class I PI3 kinase) as well as a protein kinase
(e.g., mTor) with an ICSO value less than about I uM. less than about 100 nM. less than about
SO nM, less than about 10 nM, less than I nM or even less than about O.S nM.
WO 20121151525
In some embodiments, the compounds of the present invention exhibit one or
more functional characteristics disclosed herein. For example, one or more subject compounds
bind specifically to a PT3 kinase. In some embodiments, the ICSO of a subject compound for pi
lOa, pi lOp, pi lOy, or pi 108 is less than about 1 uM, less than about 100 nM, less than about
SO nM, less than about 10 nM, less than about 1 nM, less than about O.SnM, less than about
100pM, or less than about SO pM.
In some embodiments, one or more of the subject compounds may selectively
inhibit one or more members of type I or class I phosphatidylinositol 3-kinases (PI3-kinase)
with an ICSO value of about 100 nM, SO nM, 10 nM, S nM, 100 pM, 10 pM or I pM, or less as
measured in an in vitro kinase assay.
In some embodiments, one or more of the subject compound may selectively
inhibit one or two members of type I or class I phosphatidylinositol 3-kinases (PI3-kinase)
consisting of PI3-kinase a, Pl3-kinase p, PI3-kinase y, and P13-kinase 8. In some aspects,
some of the subject compounds selectively inhibit Pl3-kinase 8 as compared to all other type I
PI3-kinases. In other aspects, some of the subject compounds selectively inhibit PI3-kinase 8
and PI3- kinase y as compared to the rest of the type I PI3-kinases. In yet other aspects, some
of the subject compounds selectively inhibit PI3-kinase a and PI3-kinase p as compared to the
rest of the type I PI3-kinases. In still yet some other aspects, some of the subject compounds
selectively inhibit PI3-kinase 8 and PI3-kinase a as compared to the rest of the type I PI3-
kinases. In still yet some other aspects, some of the subject compounds selectively inhibit PI3-
kinase 8 and PI3-kinase p as compared to the rest of the type I P13-kinases, or selectively
inhibit PI3-kinase 8 and PI3-kinase a as compared to the rest of the type I PB-kinases, or
selectively inhibit PI3-kinase a and PI3-kinase y as compared to the rest of the type I Pl3-
kinases, or selectively inhibit PI3-kinase y and PB-kinase p as compared to the rest of the type
I PI3-kinases.
In yet another aspect, an inhibitor that selectively inhibits one or more
members of type I PI3-kinases, or an inhibitor that selectively inhibits one or more type I PI3-
kinase mediated signaling pathways, alternatively can be understood to refer to a compound
that exhibits a SO% inhibitory concentration (lCSO) with respect to a given type I PI3-kinase,
that is at least at least IO-fold, at least 20-fold, at least SO-fold, at least 100-fold, at least 1000-
fold, or lower, than the inhibitor's ICSO with respect to the rest of the other type I PI3 -kinases.
As used herein, the term "PI3-kinase 8 selective inhibitor" generally refers to a
compound that inhibits the activity of the PI3-kinase 0 isozyme more effectively than other
isozymes of the PI3K family. A PI3-kinase 0 selective inhibitor compound is therefore more
WO 20121151525
selective for PI3-kinase () than conventional PI3K inhibitors such as wortmannin and
L Y294002, which are "nonselective PI3K inhibitors."
Inhibition of P13-kinase () may be of therapeutic benefit in treatment of various
conditions, e.g., conditions characterized by an inflammatory response including but not
limited to autoimmune diseases, allergic diseases, and arthritic diseases. Importantly,
inhibition of PI3-kinase () function does not appear to affect biological functions such as
viability and fertility.
"Inflammatory response" as used herein is characterized by redness, heat,
swelling and pain (i.e., inflammation) and typically involves tissue injury or destruction. An
inflammatory response is usually a localized, protective response elicited by injury or
destruction of tissues, which serves to destroy, dilute or wall off (sequester) both the injurious
agent and the injured tissue. Inflammatory responses are notably associated with the influx of
leukocytes and/or leukocyte (e.g., neutrophil) chemotaxis. Inflammatory responses may result
from infection with pathogenic organisms and viruses, noninfectious means such as trauma or
reperfusion following myocardial infarction or stroke, immune responses to foreign antigens,
and autoimmune diseases. Inflammatory responses amenable to treatment with the methods
and compounds according to the invention encompass conditions associated with reactions of
the specific defense system as well as conditions associated with reactions of the non-specific
defense system ..
The therapeutic methods of the invention include methods for the amelioration
of conditions associated with inflammatory cell activation. "Inflammatory cell activation"
refers to the induction by a stimulus (including but not limited to, cytokines, antigens or auto
antibodies) of a proliferative cellular response, the production of soluble mediators (i~cluding
but not limited to cytokines, oxygen radicals, enzymes, prostanoids, or vasoactive amines), or
cell surface expression of new or increased numbers of mediators (including but not limited to,
major histocompatibility antigens or cell adhesion molecules) in inflammatory cells (including
but not limited to monocytes, macrophages, T lymphocytes, B lymphocytes, granulocytes
(polymorphonuclear leukocytes including neutrophils, basophils, and eosinophils) mast cells,
dendritic cells, Langerhans cells, and endothelial cells). It will be appreciated by persons
skilled in the art that the activation of one or a combination of these phenotypes in these cells
can contribute to the initiation, perpetuation, or exacerbation of an inflammatory condition.
"Autoimmune disease" as used herein refers to any group of disorders in which
tissue injury is associated with humoral or cell-mediated responses to the body's own
constituents. "Transplant rejection" as used herein refers-to any immune response directed
WO 20121151525
against grafted tissue (including organs or cells (e.g., bone marrow), characterized by a loss of
function of the grafted and surrounding tissues, pain, swelling, leukocytosis, and
thrombocytopenia). "Allergic disease" as used herein refers to any symptoms, tissue damage,
or loss of tissue function resulting from allergy. "Arthritic disease" as used herein refers to any
disease that is characterized by inflammatory lesions of the joints attributable to a variety of
etiologies. "Dermatitis" as ~sed herein refers to any of a large family of diseases of the skin
of the skin attributable to a variety of etiologies.
that are characterized by inflammation
As previously described, the term "PI3-kinase 8 selective inhibitor" generally
refers to a compound that inhibits the activity of the PI3-kinase 8 isozyme more effectively
than other isozymes of the PI3K family. The relative efficacies of compounds as inhibitors of
an enzyme activity (or other biological activity) can be established by determining the
concentrations at which each compound inhibits the activity to a predefined extent and then
comparing the results. Typically, the preferred determination is the concentration that inhibits
50% of the activity in a biochemical assay, i.e., the 50% inhibitory concentration or "IC50".
IC50 determinations can be accomplished using conventional techniques known in the art. In
general, an IC50 can be determined by measuring the activity of a given enzyme in the
presence of a range of concentrations of the inhibitor under study. The experimentally
obtained values of enzyme activity then are plotted against the inhibitor concentrations used.
The concentration of the inhibitor that shows 50% enzyme activity (as compared to the
activity in the absence of any inhibitor) is taken as the IC50 value. Analogously, other
inhibitory concentrations can be defined through appropriate determinations of activity. For
example, in some settings it can be desirable to establish a 90% inhibitory concentration, i.e.,
Ie90, etc.
Accordingly, a Pl3-kinase 8 selective inhibitor alternatively can be understood
to refer to a compound that exhibits a 50% inhibitory concentration (IC50) with respect to PI3-
kinase 0, that is at least lO-fold, in another aspect at least 20-fold, and in another aspect at least
-fold, lower than the IC50 value with respect to any or all of the other class I PI3K family
members. In an alternative embodiment of the invention, the term PI3-kinase 0 selective
inhibitor can be understood to refer to a compound that exhibits an IC50 with respect to PI3-
kinase 0 that is at least 50-fold, in another aspect at least 100-fold, in an additional aspect at
least 200-fold, and in yet another aspect at least 500-fold, lower than the IC50 with respect to
any or all of the other PI3K class I family members. A PI3-kinase 8 selective inhibitor is
typically administered in an amount such that it selectively inhibits PI3-kinase 0 activity, as
described above.
WO 20121151525
The methods of the invention may be applied to cell populations in vivo or ex
vivo. "In vivo" means within a living individual, as within an animal or human or in a subject's
body. In this context, the methods of the invention may be used therapeutically or
prophylactically in an individual. "Ex vivo" or "In vitro" means outside of a living individual.
Examples of ex vivo cell populations include in vitro cell cultures and biological samples
including but not limited to fluid or tissue samples obtained from individuals. Such samples
may be obtained by methods known in the art. Exemplary biological fluid samples include
blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and
biopsies thereof. In this context, the invention may be used for a variety of purposes, including
therapeutic and experimental purposes. For example, the invention may be used ex vivo or in
vitro to determine the optimal schedule and/or dosing of administration of a PI3-kinase 0
selective inhibitor for a given indication, cell type, individual, and other parameters.
Information gleaned from such use may be used for experimental or diagnostic purposes or in
the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the invention
may be suited are described below or will become apparent to those skilled in the art.
Pharmaceutical Compositions
The invention provides a pharmaceutical composition comprising one or more
compounds of the present invention. The pharmaceutical composition may include one or
more additional active ingredients as described herein. The pharmaceutical composition may
be administered for any of the disorders described herein
In some embodiments, the invention provides pharmaceutical compositions for
treating diseases or conditions related to an undesirable, over-active, harmful or deleterious
immune response in a mammal. Such undesirable immune response can be associated with or
result in, e.g., asthma, emphysema, bronchitis, psoriasis, allergy, anaphylaxsis, auto-immune
diseases, rhuematoid arthritis, graft versus host disease, and lupus erythematosus. The
pharmaceutical compositions of the present invention can be used to treat other respiratory
diseases including but not limited to diseases affecting the lobes of lung, pleural cavity,
bronchial tubes, trachea, upper respiratory tract, or the nerves and muscle for breathing.
In some embodiments, the invention provides pharmaceutical compositions for
the treatment of disorders such as hyperproliferative disorder including but not limited to
cancer such as acute myeloid leukemia, thymus, brain, lung, squamous cell, skin, eye,
retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric,
stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian,
WO 20121151525
prostate, colorectal, esophageal, testicular, gynecological, thyroid, eNS, PNS, AIDS related
(e.g. Lymphoma and Kaposi's Sarcoma) or Viral-Induced cancer. In some embodiments, the
pharmaceutical composition is for the treatment of a non-cancerous hyperproliferative disorder
such as benign hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate (e. g., benign
prostatic hypertrophy (BPH)).
The invention also relates to a composition for treating a disease related to
vasculogenesis or angiogenesis in a mammal which can manifest as tumor angiogenesis,
chronic inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease,
atherosclerosis, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic
retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma,
glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and
epidermoid cancer.
The invention also provides compositions for the treatment of liver diseases
(including diabetes), pancreatitis or kidney disease (including proliferative glomerulonephritis
and diabetes- induced renal disease) or pain in a mammal.
The invention further provides a composition for the prevention of blastocyte
implantation in a mammal.
The subject pharmaceutical compositions are typically formulated to provide a
therapeutically effective amount of a compound of the present invention as the active
ingredient, or a pharmaceutically acceptable salt, ester, or prodrug thereof. Where desired, the
pharmaceutical compositions contain a compound of the present invention as the active
ingredient or a pharmaceutically acceptable salt and/or coordination complex thereof, and one
or more pharmaceutically acceptable excipients, carriers, such as inert solid diluents and
fillers, diluents, including sterile aqueous solution and various organic solvents, permeation
enhancers, solubilizers and adjuvants.
The subject pharmaceutical compositions can be administered alone or in
combination with one or more other agents, which are also typically administered in the form
of pharmaceutical compositions. Where desired, the subject compounds and other agent(s)
may be mixed into a preparation or both components may be formulated into separate
preparations to use them in combination separately or at the same time.
Methods include administration of an inhibitor by itself, or in combination as
described herein, and in each case optionally including one or more suitable diluents, fillers,
salts, disintegrants, binders, lubricants, glidants, wetting agents, controlled release matrices,
WO 20121151525
colorantslflavoring, carriers, excipients, buffers, stabilizers, solubilizers, and combinations
thereof.
Preparations of various pharmaceutical compositions are known in the art. See,
e.g., Anderson, Philip 0.; Knoben, James E.; Troutman, William G, eds., Handbook of
Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of
Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and
Clinical Pharmacology, Ninth Edition, McGraw Hill, 2003; Goodman and Gilman, eds., The
Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 200 I; Remingtons
Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The
Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999), all of
which are incorporated by reference herein in their entirety.
The compounds or pharmaceutical composition of the present invention can be
administered by any route that enables delivery of the compounds to the site of action, such
asoral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial,
subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical administration
(e.g. transdermal application), rectal administration, via local delivery by catheter or stent or
through inhalation. The compounds can also be administered intraadiposally or intrathecally.
The compositions can be administered in solid, semi-solid, liquid or gaseous
form, or may be in dried powder, such as lyophilized form. The pharmaceutical compositions
can be packaged in forms convenient for delivery, including, for example, solid dosage forms
such as capsules, sachets, cachets, gelatins, papers, tablets, capsules, suppositories, pellets,
pills, troches, and lozenges. The type of packaging will generally depend on the desired route
of administration. Implantable sustained release formulations are also contemplated, as are
transdermal formulations.
Routes of Administration
In the methods according to the invention, the inhibitor compounds may be
For example, pharmaceutical compositions may be for
administered by various routes.
injection, or for oral, nasal, transdermal or other forms of administration, including, e.g., by
intravenous, intradermal, intramuscular, intramammary, intraperitoneal, intrathecal,
intraocular, retrobulbar, intrapulmonary (e.g., aerosolized drugs) or subcutaneous injection
(including depot administration for long term release e.g., embedded-under the-splenic
capsule, brain, or in the cornea); by sublingual, anal, or vaginal administration, or by surgical
implantation, e.g., embedded under the splenic capsule, brain, or in the cornea. The treatment
WO 20121151525
may consist of a single dose or a plurality of doses over a period of time. In general, the
methods of the invention involve administering effective amounts of a modulator of the.
invention together with one or more pharmaceutically acceptable diluents, preservatives,
solubilizers, emulsifiers, adjuvants and/or carriers, as described above.
The subject pharmaceutical composition may, for example, be in a form
suitable for oral administration as a tablet, capsule, pill, powder, sustained release
formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or
emulsion, for topical administration as an ointment or cream or for rectal administration as a
suppository. The pharmaceutical composition may be in unit dosage forms suitable for single
administration of precise dosages. The pharmaceutical composition will include a
conventional pharmaceutical carrier or excipient and a compound according to the invention
as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents,
carriers, and adjuvants.
In one aspect, the invention provides methods for oral administration of a
pharmaceutical composition of the invention. Oral solid dosage forms are described generally
in Remington's Pharmaceutical Sciences, supra at Chapter 89. Solid dosage forms include
tablets, capsules, pills, troches or lozenges, and cachets or pellets. Also, liposomal or
proteinoid encapsulation may be used to formulate the compositions (as, for example,
proteinoid microspheres reported in U.S. Pat. No. 4,925,673). Liposomal encapsulation may
include liposomes that are derivatized with various polymers (e.g., U.S. Pat. No. 5,013,556).
The formulation may include a compound of the invention and inert ingredients which protect
against degradation in the stomach and which permit release of the biologically active material
in the intestine.
Toxicity and therapeutic efficacy of the PI3-kinase 0 selective compounds can
be determined by standard pharmaceutical procedures in cell cultures or experimental animals,
e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the
dose therapeutically effective in 50% of the population). Additionally, this information can be
determined in cell cultures or experimental animals additionally treated with other therapies
including but not limited to radiation, chemotherapeutic agents, photodynamic therapies,
radiofrequency ablation, anti-angiogenic agents, and combinations thereof.
The amount of the compound administered will be dependent on the mammal
being treated, the severity of the disorder or condition, the rate of administration, the
disposition of the compound and the discretion of the prescribing physician. However, an
effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day,
WO 20121151525
preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this
would amount to about 0.05 to 7 g/day, preferably about 0.05 to about 2.5 g/day. In some
instances, dosage levels below the lower limit of the aforesaid range may be more than
adequate, while in other cases still larger doses may be employed without causing any harmful
side effect, e.g. bydividing such larger doses into several small doses for· administration
throughout the day.
In some embodiments, a compound of the invention is administered in a single
dose. Typically, such administration will be by injection, e.g., intravenous injection, in order
to introduce the agent quickly. However, other routes may be used as appropriate. A single
dose of a compound of the invention may also be used for treatment of an acute condition.
In practice of the methods of the invention, the pharmaceutical compositions
are generally provided in doses ranging from 1 pg compound/kg body weight to 1000 mg/kg,
0.1 mg/kg to 100 mg/kg, 0.1 mg/kg to 50 mg/kg, and 1 to 20 mg/kg, given in daily doses or in
equivalent doses at longer or shorter intervals, e.g., every other day, twice weekly, weekly, or
twice or three times daily. The inhibitor compositions may be administered by an initial bolus
followed by a continuous infusion to maintain therapeutic circulating levels of drug product.
Those of ordinary skill in the art will readily optimize effective dosages and administration
regimens as determined by good medical practice and the clinical condition of the individual
to be treated. The frequency of dosing will depend on the pharmacokinetic parameters of the
agents and the route of administration. The optimal pharmaceutical formulation will be
determined by one skilled in the art depending upon the route of administration and desired
dosage [see, for example, Remington's Pharmaceutical Sciences, pp. 1435-1712, the disclosure
of which is hereby incorporated by reference]. Such formulations may influence the physical
state, stability, rate of in vivo release, and rate of in vivo clearance of the administered agents.
Depending on the route of administration, a suitable dose may be calculated according to body
weight, body surface area or organ size. Further refinement of the calculations necessary to
determine the appropriate dosage for treatment involving each of the above mentioned
formulations is routinely made by those of ordinary skill in the art without undue
experimentation, especially in light of the dosage information and assays disclosed herein, as
well as the pharmacokinetic data observed in human clinical trials. Appropriate dosages may
be ascertained by using established assays for determining blood level dosages in conjunction
with an appropriate physician considering various factors which modify the action of drugs,
e.g., the drug's specific activity, the severity of the indication, and the responsiveness of the
individual, the age, condition, body weight, sex and diet of the individual, the time of
WO 20121151525
administration and other clinical factors. As studies are conducted, further information will
emerge regarding the appropriate dosage levels and duration of treatment for various diseases
and conditions capable of being treated with the methods of the invention.
In some embodiments, a compound of the invention IS administered in
multiple doses. Dosing may be about once, twice, three times, four times, five times, six times,
or more than six times per day. Dosing may be about once a month, once every two weeks,
once a week, or once every other day. In another embodiment a compound of the invention
and another agent are administered together about once per day to about 6 times per day. In
another embodiment the administration of a compound of the invention and an agent continues
for less than about 7 days. In yet another embodiment the administration continues for more
than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous
dosing is achieved and maintained as long as necessary.
Administration of the agents of the invention may continue as long as
necessary. In some embodiments, an agent of the invention is administered for more than 1, 2,
3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, an agent of the invention is administered
for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, an agent of the invention
is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.
An effective amount of a compound of the invention may be administered in
either single or multiple doses by any of the accepted modes of administration of agents
having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra- .
arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly,
subcutaneously, orally, topically, or as an inhalant.
The compounds of the invention may be administered in dosages. It is known
in the art that due to intersubject variability in compound pharmacokinetics, individualization
of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention
may be found by routine experimentation in light of the instant disclosure.
When a compound of the invention, is administered in a composition that
comprises one or more agents, and the agent has a shorter half-life than the compound of the
invention unit dose forms of the agent and the compound of the invention may be adjusted
accordingly.
The inhibitors of the invention may be covalently or noncovalently associated
with a carrier molecule including but not limited to a linear polymer (e.g., polyethylene glycol,
polylysine, dextran, etc.), a branched-chain polymer (see U.S. Pat. Nos. 4,289,872 and
,229,490; peT Publication No. WO 93/21259), a lipid, a cholesterol group (such as a
WO 20121151525
steroid), or a carbohydrate or oligosaccharide. Specific examples of carriers for use in the
pharmaceutical compositions of the invention include carbohydrate-based polymers such as
trehalose, mannitol, xylitol, sucrose, lactose, sorbitol, dextrans such as cyclodextran, cellulose,
and cellulose derivatives. Also, the use of liposomes, microcapsules or microspheres,
inclusion complexes, or other types of carriers is contemplated.
Other carriers include one or more water soluble polymer attachments such as
polyoxyethylene glycol, or polypropylene glycol as described U.S. Pat. Nos. 4,640,835,
4,496,689,4,301,144,4,670,417,4,791,192 and 4,179,337. Still other useful carrier polymers
known in the art include monomethoxy-polyethylene glycol, poly-(N-vinyl pyrrolidone)
polyethylene glycol, propylene glycol homopolymers, a polypropylene oxidelethylene oxide
co-polymer, polyoxyethylated polyols (e.g., glycerol). and polyvinyl alcohol, as well as
mixtures of these polymers.
Derivitization with bifunctional agents is useful for cross-linking a compound
of the invention to a support matrix or to a carrier. One such carrier is polyethylene glycol
(PEG). The PEG group may be of any convenient molecular weight and may be straight chain
or branched. The average molecular weight of the PEG can range from about 2 kDa to about
100 kDa, in another aspect from about 5 kDa to about 50 kDa, and in a further aspect from
about 5 kDa to about 10 kDa. The PEG groups will generally be attached to the compounds of
the invention via acylation, reductive alkylation, Michael addition, thiol alkylation or other
chemoselective conjugation/ligation methods through a reactive group on the PEG moiety
(e.g., an aldehyde, amino, ester, thiol, ci-haloacetyl, maleimido or hydrazino group) to a
reactive group on the target inhibitor compound (e.g., an aldehyde, amino, ester, thiol, a
haloacetyl, maleimido or hydrazino group). Cross-linking agents can include, e.g., esters with
4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as
3,3'-dithiobis (succinimidylpropionate), and bifunctional maleimides such as bis-N
maleimido-1,8-octane. Deri vatizing agents such as methyl[(p
azidophenyl)dithiolpropioimidate yield photoactivatable intermediates that are capable of
forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices
such as cyanogen bromide-activated carbohydrates and the reactive substrates described in
U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 may be
employed for inhibitor immobilization.
WO 20121151525
Method of Treatment
The invention also provides methods of using the compounds or
pharmaceutical compositions of the present invention to treat disease conditions, including but
not limited to diseases associated with malfunctioning of one or more types of PI3 kinase. A
detailed description of conditions and disorders mediated by pi 108 kinase activity is set forth
in and US 2005/043239, both of which are incorporated herein by reference
in their entireties for all purposes.
The treatment methods provided herein comprise administering to the subject
a therapeutically effective amount of a compound of the invention. In one embodiment, the
present invention provides a method of treating an inflammation disorder, including
autoimmune diseases in a mammal. The method comprises administering to said mammal a
therapeutically effective amount of a compound of the present invention, or a
pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof.
The disorders, diseases, or conditions treatable with a compound provided
herein, include, but are not limited to,
• inflammatory or allergic diseases, including systemic anaphylaxis and hypersensitivity
disorders, atopic dermatitis, urticaria, drug allergies, insect sting allergies, food
allergies (including celiac disease and the like), anaphylaxis, serum sickness, drug
reactions, insect venom allergies, hypersensitivity pneumonitis, angioedema,
erythema multiforme, Stevens-Johnson syndrome, atopic keratoconjunctivitis,
venereal keratoconjunctivitis, giant papillary conjunctivitis, and mastocytosis;
• inflammatory bowel diseases, including Crohn's disease, ulcerative colitis,
ileitis,enteritis, and necrotizing enterocolitis;
• vasculitis, and Behcet's syndrome;
• psoriasis and inflammatory dermatoses, including dermatitis, eczema, allergic contact
dermatitis, viral cutaneous pathologies including those derived from human
papillomavirus, HIV or RLV infection, bacterial, flugal, and other parasital cutaneous
pathologies, and cutaneous lupus erythematosus;
• asthma and respiratory allergic diseases, including allergic asthma, exercise induced
asthma, allergic rhinitis, otitis media, hypersensitivity lung diseases, chronic
obstructive pulmonary disease and other respiratory problems;
• autoimmune diseases and inflammatory conditions, including but are not limited to
acute disseminated encephalomyelitis (ADEM), Addison's disease, anti phospholipid
antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, coeliac disease,
Crohn's disease, Diabetes mellitus (type 1), Goodpasture's syndrome, Graves' disease,
Guillain-Barre syndrome (GBS), Reynaud's syndrome, Hashimoto's disease, lupus
erythematosus, systemic lupus erythematosus (SLE), multiple sclerosis, myasthenia
gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis,
oemphigus, polyarthritis, primary biliary cirrhosis, psoriasis, rheumatoid arthritis,
WO 20121151525
psonatIc arthritis, gouty arthritis, spondylitis, reactive arthritis, chronic or acute
glomerulonephritis, lupus nephritis, Reiter's syndrome. Takayasu's arteritis, temporal
arteritis (also known as "giant cell arteritis"), warm autoimmune hemolytic anemia,
Wegener's granulomatosis. alopecia universalis, Chagas' disease. chronic fatigue
syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis,
neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, connective tissue disease,
autoimmune pulmonary inflammation, autoimmune thyroiditis, autoimmune
inflammatory eye disease, vitiligo, and vulvodynia. Other disorders include bone
resorption disorders and thromobsis;
• tissue or organ transplant rejection disorders including but not limited to graft
rejection (including allograft rejection and graft-v-host disease (GYHD», e.g., skin
graft rejection, solid organ transplant rejection, bone marrow transplant rejection;
• fever;
• cardiovascular disorders, including acute heart failure, hypotension, hypertension,
angina pectoris, myocardial infarction, cardiomyopathy, congestive heart failure,
atherosclerosis, coronary artery disease, restenosis, and vascular stenosis;
• cerebrovascular disorders, including traumatic brain injury, stroke, ischemic
reperfusion injury and aneurysm;
• cancers of the breast, skin, prostate, cervix, uterus, ovary, testes, bladder, lung, liver,
larynx, oral cavity, colon and gastrointestinal tract (e.g., esophagus, stomach,
pancreas), brain, thyroid, blood, and lymphatic system;
• fibrosis, connective tissue disease, and sarcoidosis;
• genital and reproductive conditions, including erectile dysfunction;
• gastrointestinal disorders, including gastritis, ulcers, nausea, pancreatitis, and
vomiting;
• neurologic disorders, including Alzheimer's disease;
• sleep disorders, including insomnia, narcolepsy, sleep apnea syndrome, and Pickwick
Syndrome;
• pain, myalgias due to infection;
• renal disorders;
• ocular disorders, including glaucoma;
• infectious diseases, including HIY;
• sepsis; septic shock; endotoxic shock; gram negative sepsis; gram POSItIve sepsis;
toxic shock syndrome; multiple organ injury syndrome secondary to septicemia,
trauma, or hemorrhage;
• pulmonary or respiratory conditions including but not limited to asthma, chronic
bronchitis, allergic rhinitis, adult respiratory distress syndrome (ARDS), severe acute
respiratory syndrome (SARS), chronic pulmonary inflammatory diseases (e.g.,
chronic obstructive pulmonary disease), silicosis, pulmonary sarcoidosis, pleurisy,
alveoli tis, vasculitis, pneumonia, bronchiectasis, hereditary emphysema, and
pulmonary oxygen toxicity;
• ischemic-reperfusion injury, e.g., of the myocardium, brain, or extremities;
• fibrosis including but not limited to cystic fibrosis; keloid formation or scar tissue
formation;
WO 20121151525
• central or peripheral nervous system inflammatory conditions including but not
limited to meningitis (e.g., acute purulent meningitis), encephalitis, and brain or spinal
cord injury due to minor trauma;
• Sjorgren's syndrome; diseases involving leukocyte diapedesis; alcoholic hepatitis;
bacterial pneumonia; community acquired pneumonia (CAP); Pneumocystis carinii
pneumonia (PCP); antigen-antibody complex mediated diseases; hypovolemic shock;
acute and delayed hypersensitivity; disease states due to leukocyte dyscrasia and
metastasis; thermal injury; granulocyte transfusion associated syndromes; cytokine
induced toxicity; stroke; pancreatitis; myocardial infarction, respiratory syncytial virus
(RSV) infection; and spinal cord injury.
In certain embodiments, the cancer or cancers treatable with the methods
provided herein includes, but is or are not limited to,
• leukemias, including, but not limited to, acute leukemia, acute lymphocytic leukemia,
acute myelocytic leukemias such as myeloblasts, promyelocyte, myelomonocytic,
monocytic, erythroleukemia leukemias and myelodysplastic syndrome or a symptom
thereof (such as anemia, thrombocytopenia, neutropenia, bicytopenia or
pancytopenia), refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with
excess blasts (RAEB), RAEB in transformation (RAEB-T), preleukemia, and chronic
myelomonocytic leukemia (CMML);
• chronic leukemias, including, but not limited to, chronic myelocytic (granulocytic)
leukemia, chronic lymphocytic leukemia, and hairy cell leukemia;
• polycythemia vera;
• lymphomas, including, but not limited to, Hodgkin's disease and non-Hodgkin's
disease;
• multiple myelomas, including, but not limited to, smoldering mUltiple myeloma,
nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary
plasmacytoma, and extramedullary plasmacytoma;
• Waldenstrom's macroglobulinemia;
• monoclonal gammopathy of undetermined significance;
• benign monoclonal gammopathy;
• heavy chain disease;
• bone and connective tissue sarcomas, including, but not limited to, bone sarcoma,
osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor,
fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas,
angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma,
liposarcoma, lymphangiosarcoma, metastatic cancers, neurilemmoma,
rhabdomyosarcoma, and synovial sarcoma;
• brain tumors, including, but not limited to, glioma, astrocytoma, brain stem glioma,
ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma,
craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, and
primary'brain lymphoma;
WO 20121151525
• breast cancer, including, but not limited to, adenocarcinoma, lobular (small cell)
carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer,
tubular breast cancer, papillary breast cancer, primary cancers, Paget's disease, and
inflammatory breast cancer;
• adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical
carcinoma;
• thyroid cancer, including, but not limited to, papillary or follicular thyroid cancer,
medullary thyroid cancer, and anaplastic thyroid cancer;
• pancreatic cancer, including, but not limited tO,insulinoma, gastrinoma, glucagonoma,
vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor;
• pituitary cancer, including, but limited to, Cushing's disease, prolactin-secreting
tumor, acromegaly, and diabetes insipidus;
• eye cancer, including, but not limited, to ocular melanoma such as iris melanoma,
choroidal melanoma, and cilliary body melanoma, and retinoblastoma;
• vaginal cancer, including, but not limited to, squamous cell carcinoma,
adenocarcinoma, and melanoma;
• vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma,
adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease;
• cervical cancers, including, but not limited to, squamous cell carCllloma, and
adenocarcinoma;
• uterine cancer, including, but not limited to, endometrial carcinoma and uterine
sarcoma;
• ovarian cancer, including, but not limited to, ovarian epithelial carcinoma, borderline
tumor, germ cell tumor, and stromal tumor;
• esophageal cancer, including, but not limited to, squamous cancer, adenocarcinoma,
adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma,
sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell)
carCInoma;
• stomach cancer, including, but not limited to, adenocarcinoma, fungating (polypoid),
ulcerating, superficial spreading, diffusely spreading, malignant lymphoma,
liposarcoma, fibrosarcoma, and carcinosarcoma;
• colon cancer;
• rectal cancer;
• liver cancer, including, but not limited to, hepatocellular carcinoma and
hepatoblastoma;
gallbladder cancer, including, but not limited to, adenocarcinoma;
cholangiocarcinomas, including, but not limited to, pappillary, nodular, and diffuse;
• lung cancer, including, but not limited to, non-small cell lung cancer, squamous cell
carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma, and small
cell lung cancer;
testicular cancer, including, but not limited to, germinal tumor, seminoma, anaplastic,
classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma
carcinoma, and choriocarcinoma (yolk-sac tumor);
WO 20121151525
• prostate cancer, including, but not limited to, adenocarcinoma, leiomyosarcoma, and
rhabdomyosarcoma;
• penal cancer;
• oral cancer, including, but not limited to, squamous cell carcinoma;
• basal cancer;
• salivary gland cancer, including, but not limited to, adenocarcinoma, mucoepidermoid
carcinoma, and adenoidcystic carcinoma;
• pharynx cancer, including, but not limited to, squamous cell cancer and verrucous;
• skin cancer, including, but not limited to, basal cell carcinoma, squamous cell
carcinoma and melanoma, superficial spreading melanoma, nodular melanoma,
lentigo malignant melanoma, and acral lentiginous melanoma;
• kidney cancer, including, but not limited to, renal cell cancer, adenocarcinoma,
hypernephroma, fibrosarcoma, and transitional cell cancer (renal pelvis and/or uterer);
• Wilms' tumor;
• bladder cancer, including, but not limited to, transitional cell carcinoma, squamous
cell cancer, adenocarcinoma, and carcinosarcoma; and other cancer, including, not
limited to, myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangio
endotheliosarcoma, mesothelioma, synovioma, hemangioblastoma, epithelial
carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma,
sebaceous gland carcinoma, papillary carcinoma, and papillary adenocarcinomas
See Fishman et ai., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et
ai., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and
Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States of America.
It will be appreciated that the treatment methods of the invention are useful in
the fields of human medicine and veterinary medicine. Thus, the individual to be treated may
be a mammal, preferably human, or other animals. For veterinary purposes, individuals
include but are not limited to farm animals including cows, sheep, pigs, horses, and goats;
companion animals such as dogs and cats; exotic and/or zoo animals; laboratory animals
including mice, rats, rabbits, guinea pigs, and hamsters; and poultry such as chickens, turkeys,
ducks, and geese.
In some embodiments, the method of treating inflammatory or autoimmune
diseases comprises administering to a subject (e.g. a mammal) a therapeutically effective
amount of one or more compounds of the present invention that selectively inhibit PI3K-o
and/or PI3K-y as compared to all other type I PI3 kinases. Such selective inhibition of PI3K- 0
and/or PI3K-y may be advantageous for treating any of the diseases or conditions described
herein. For example, selective inhibition of PI3K- 0 may inhibit inflammatory responses
associated with inflammatory diseases, autoimmune disease, or diseases related to an
undesirable immune response including but not limited to asthma, emphysema, allergy,
WO 20121151525
dermatitis, rhuematoid arthritis, psoriasis, lupus erythematosus, or graft versus host disease.
Selective inhibition of POK-8 may further provide for a reduction in the inflammatory or
undesirable immune response without a concomittant reduction in the ability to reduce a
bacterial, viral, and/or fungal infection. Selective inhibition of both PI3K- 8 and PI3K-y may
be advantageous for inhibiting the inflammatory response in the subject to a greater degree
than that would be provided for by inhibitors that selectively inhibit PI3K -8 or PI3K-y alone.
In one aspect, one or more of the subject methods are effective in reducing antigen specific
antibody production in vivo by about 2-fold, 3-fold, 4-fold, 5-fold, 7.5-fold, lO-fold, 25-fold,
50-fold, 100-fold, 250-fold, 500-fold, 750-fold, or about 1000-fold or more. In another aspect,
one or more of the subject methods are effective in reducing antigen specific IgG3 and/or
IgGM production in vivo by about 2-fold, 3-fold, 4-fold, 5-fold, 7.5-fold, lO-fold, 25-fold, 50-
fold, 100- fold, 250-fold, 500-fold, 750-fold, or about 1000-fold or more.
In one aspect, one of more of the subject methods are effective in ameliorating
symptoms assoicated with rhuematoid arthritis including but not limited to a reduction in the
swelling of joints, a reduction in serum anti-collagen levels, and/or a reduction in joint
pathology such as bone resorption, cartilage damage, pannus, and/or inflammation. In another
aspect, the subject methods are effective in reducing ankle inflammation by at least about 2%,
%, 10%, 15%, 20%, 25%, 30%, 50%, 60%, or about 75% to 90%. In another aspect, the
subject methods are effective in reducing knee inflammation by at least about 2%, 5%, 10%,
%, 20%, 25%, 30%, 50%, 60%, or about 75% to 90% or more. In still another aspect, the
subject methods are effective in reducing serum anti-type II collagen levels by at least about
%, 12%, 15%, 20%, 24%, 25%, 30%, 35%, 50%, 60%, 75%, 80%, 86%, 87%, or about
90% or more. In another aspect, the subject methods are effective in reducing ankle
histopathology scores by about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%,
90% or more. In still another aspect, the subject methods are effective in reducing knee
histopathology scores by about 5%, 10%, 15%,20%, 25%, 30%, 40%, 50%, 60%, 75%, 80%,
90% or more.
In other embodiments, the present invention provides methods of using the
compounds or pharmaceutical compositions to treat respiratory diseases including but not
limited to diseases affecting the lobes of lung, pleural cavity, bronchial tubes, trachea, upper
respiratory tract, or the nerves and muscle for breathing. For example, methods are provided to
(COPD) is an
treat obstructive pulmonary disease. Chronic obstructive pulmonary disease
umbrella term for a group of respiratory tract diseases that are characterized by airflow
WO 20121151525
obstruction or limitation. Conditions included in this umbrella term are: chronic bronchitis,
emphysema, and bronchiectasis.
In another embodiment, the compounds described herein are used for the
treatment of asthma. Also, the compounds or pharmaceutical compositions described herein
may be used for the treatment of endotoxemia and sepsis. In one embodiment, the compounds
or pharmaceutical compositions described herein are used to for the treatment of rheumatoid
arthritis (RA). In yet another embodiment, the compounds or pharmaceutical compositions
described herein is used for the treatment of contact or atopic dermatitis. Contact dermatitis
includes irritant derrriatitis, phototoxic dermatitis, allergic dermatitis, photoallergic dermatitis,
contact urticaria, systemic contact-type dermatitis and the like. Irritant dermatitis can occur
when too much of a substance is used on the skin of when the skin is sensitive to certain
substance. Atopic dermatitis, sometimes called eczema, is a kind of dermatitis, an atopic skin
disease.
The invention also relates to a method of treating a hyperproliferative disorder
in a mammal that comprises administering to said mammal a therapeutically effective amount
of a compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug,
solvate, hydrate or derivative thereof. In some embodiments, said method relates to the
treatment of cancer such as acute myeloid leukemia, thymus, brain, lung, squamous cell, skin,
eye, retinoblastoma, intraocular melanoma, oral cavity and oropharyngeal, bladder, gastric,
stomach, pancreatic, bladder, breast, cervical, head, neck, renal, kidney, liver, ovarian,
prostate, colorectal, esophageal, testicular, gynecological, thyroid, eNS, PNS, AIDS-related
(e.g. Lymphoma and Kaposi's Sarcoma) or viral-induced cancer. In some embodiments, said
method relates to the treatment of a non-cancerous hyperproliferative disorder such as benign
hyperplasia of the skin (e. g., psoriasis), restenosis, or prostate (e.g., benign prostatic
hypertrophy (BPH».
The invention also relates to a method of treating diseases related to
vasculogenesis or angiogenesis in a mammal that comprises administering to said mammal a
therapeutically effective amount of a compound of the present. invention, or a
pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. In some
embodiments, said method is for treating a disease selected from the group consisting of tumor
angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis,
inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma,
diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration,
WO 20121151525
hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic,
prostate, colon and epidermoid cancer.
Patients that can be treated with compounds of the present invention, or
pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative of said
compounds, according to the methods of this invention include, for example, patients that have
been diagnosed as having psoriasis; restenosis; atherosclerosis; BPH; breast cancer such as a
ductal carcinoma in duct tissue in a mammary gland, medullary carcinomas, colloid
carcinomas, tubular carcinomas, and inflammatory breast cancer; ovarian cancer, including
epithelial ovarian tumors such as adenocarcinoma in the ovary and an adenocarcinoma that has
migrated from the ovary into the abdominal cavity; uterine cancer; cervical cancer such as
adenocarcinoma in the cervix epithelial including squamous cell carcinoma and
adenocarcinomas; prostate cancer, such as a prostate cancer selected from the following: an
adenocarcinoma or an adenocarinoma that has migrated to the bone; pancreatic cancer such as
epitheliod carcinoma in the pancreatic duct tissue and an adenocarcinoma in a pancreatic duct;
bladder cancer such as a transitional cell carcinoma in urinary bladder, urothelial carcinomas
(transitional cell carcinomas), tumors in the urothelial cells that line the bladder, squamous cell
carcinomas, adenocarcinomas, and small cell cancers; leukemia such as acute myeloid
leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic
myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute
myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic
lymphocytic leukemia (CLL), multiple myeloma (MM), and myelodysplastic syndrome
(MDS); bone cancer; lung cancer such as non-small cell lung cancer (NSCLC), which is
divided into squamous cell carcinomas, adenocarcinomas, and large cell undifferentiated
carcinomas, and small cell lung cancer; skin cancer such as basal cell carcinoma, melanoma,
squamous cell carcinoma and actinic keratosis, which is a skin condition that sometimes
develops into squamous cell carcinoma; eye retinoblastoma; cutaneous or intraocular (eye)
melanoma; primary liver cancer (cancer that begins in the liver); kidney cancer; thyroid cancer
such as papillary, follicular, medullary and anaplastic; AIDS-related lymphoma such as diffuse
large B-cell lymphoma, B-cell immunoblastic lymphoma and small non-cleaved cell
lymphoma; Kaposi's Sarcoma; viral-induced cancers including hepatitis B virus (HBY),
hepatitis C virus (HCY), and hepatocellular carcinoma; human lymphotropic virus-type 1
(HTLY-I) and adult T-cell leukemia/lymphoma; and human papilloma virus (HPY) and
(CNS) such as primary brain tumor, which
cervical cancer; central nervous system cancers
includes gliomas (astrocytoma, anaplastic astrocytoma, or glioblastoma multiforme),
WO 20121151525
Oligodendroglioma, Ependymoma, Meningioma, Lymphoma, Schwannoma, and
Medulloblastoma; peripheral nervous system (PNS) cancers such as acoustic neuromas and
malignant peripheral nerve sheath tumor (MPNST) including neurofibromas and
schwannomas, malignant fibrous cytoma, malignant fibrous histiocytoma, malignant
meningioma, malignant mesothelioma, and malignant mixed Mullerian tumor; oral cavity and
oropharyngeal cancer such as, hypopharyngeal cancer, laryngeal cancer, nasopharyngeal
cancer, and oropharyngeal cancer; stomach cancer such as lymphomas, gastric stromal tumors,
and carcinoid tumors; testicular cancer such as germ cell tumors (GCTs), which include
seminomas and nonseminomas, and gonadal stromal tumors, which include Leydig cell
tumors and Sertoli cell tumors; thymus cancer such as to thymomas, thymic carcinomas,
Hodgkin disease, non-Hodgkin lymphomas carcinoids or carcinoid tumors; rectal cancer; and
colon cancer.
The invention also relates to a method of treating diabetes in a mammal that
comprises administering to said mammal a therapeutically effective amount of a compound of
the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or
derivative thereof.
In addition, the compounds described herein may be used to treat acne.
In addition, the compounds described herein may be used for the treatment of
arteriosclerosis, including atherosclerosis. Arteriosclerosis is a general term describing any
hardening of medium or large arteries. Atherosclerosis is a hardening of an artery specifically
due to an atheromatous plaque.
Further the compounds described herein may be used for the treatment of
glomerulonephritis. Glomerulonephritis is a primary or secondary autoimmune renal disease
characterized by inflammation of the glomeruli. It may be asymptomatic, or present with
hematuria and/or proteinuria. There are many recognized types, divided in acute, subacute or
chronic glomerulonephritis. Causes are infectious (bacterial, viral or parasitic pathogens),
autoimmune or paraneoplastic.
Additionally, the compounds described herein may be used for the treatment
of bursitis, lupus, acute disseminated encephalomyelitis (ADEM), addison's disease,
antiphospholipid antibody syndrome (APS), aplastic anemia, autoimmune hepatitis, coeliac
disease, Crohn's disease, diabetes mellitus (type I), goodpasture's syndrome, graves' disease,
guillain-barre syndrome (GBS), hashimoto's disease, inflammatory bowel disease, lupus
erythematosus, myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis,
ord's thyroiditiSjOstheoarthritis, uveoretinitis, pemphigus, polyarthritis, primary biliary
WO 20121151525
cirrhosis, reiter's syndrome, takayasu's artentls, temporal arteritis, warm autoimmune
hemolytic anemia, Wegener's granulomatosis, alopecia universalis, chagas disease, chronic
fatigue syndrome, dysautonomia, endometriosis, hidradenitis suppurativa, interstitial cystitis,
neuromyotonia, sarcoidosis, scleroderma, ulcerative colitis, vitiligo, vulvodynia, appendicitis,
arteritis, arthritis, blepharitis, bronchiolitis, bronchitis, cervicitis, cholangitis, cholecystitis,
chorioamnionitis, colitis, conjunctivitis, cystitis, dacryoadenitis, dermatomyositis,
endocarditis, endometritis, enteritis, enterocolitis, epicondylitis, epididymitis, fasciitis,
fibrositis, gastritis, gastroenteritis, gingivitis, hepatitis, hidradenitis, ileitis, iritis, laryngitis,
mastitis, meningitis, myelitis, myocarditis, myositis, nephritis, omphalitis, oophoritis, orchitis,
osteitis, otitis, pancreatitis, parotitis, pericarditis, peritonitis, pharyngitis, pleuritis, phlebitis,
pneumonitis, proctitis, prostatitis, pyelonephritis, rhinitis, salpingitis, sinusitis, stomatitis,
synovitis, tendonitis, tonsillitis, uveitis, vaginitis, vasculitis, or vulvitis.
The invention also relates to a method of treating a cardiovascular disease in a
mammal that comprises administering to said mammal a therapeutically effective amount of a
compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug,
solvate, hydrate or derivative thereof. Examples of cardiovascular conditions include, but are
not limited to, atherosclerosis, restenosis, vascular occlusion and carotid obstructive disease.
In another aspect, the present invention provides methods of disrupting the
function of a leukocyte or disrupting a function of an osteoclast. The method includes
contacting the leukocyte or the osteoclast with a function disrupting amount of a compound of
the invention.
In another aspect of the present invention, methods are provided for treating
ophthalmic disease by administering one or more of the subject compounds or pharmaceutical
compositions to the eye of a subject.
The invention further provides methods of modulating kinase activity by
contacting a kinase with an amount of a compound of the invention sufficient to modulate the
activity of the kinase. Modulate can be inhibiting or activating kinase activity. In some
embodiments, the invention provides methods of inhibiting kinase activity by contacting a
kinase with an amount of a compound of the invention sufficient to inhibit the activity of the
kinase. In some embodiments, the invention provides methods of inhibiting kinase activity in a
solution by contacting said solution with an amount of a compound of the invention sufficient
to inhibit the activity of the, kinase in said solution. In some embodiments, the invention
of inhibiting kinase activity in a cell by contacting said cell with an amount
provides methods
of a compound of the invention sufficient to inhibit the activity of the kinase in said cell. In
WO 20121151525
some embodiments, the invention provides methods of inhibiting kinase activity in a tissue by
contacting said tissue with an amount of a compound of the invention sufficient to inhibit the
activity of the kinase in said tissue. In some embodiments, the invention provides methods of
inhibiting kinase activity in an organism by contacting said organism with an amount of a
compound of the invention sufficient to inhibit the activity of the kinase in said organism. In
some embodiments, the invention provides methods of inhibiting kinase activity in an animal
by contacting said animal with an amount of a compound of the invention sufficient to inhibit
the activity of the kinase in said animal. In some embodiments, the invention provides
methods of inhibiting kinase activity in a mammal by contacting said mammal with an amount
of a compound of the invention sufficient to inhibit the activity of the kinase in said mammal.
In some embodiments, the invention provides methods of inhibiting kinase activity in a human
by contacting said human with an amount of a compound of the invention sufficient to inhibit
the activity of the kinase in said human. In some embodiments, the % of kinase activity after
contacting a kinase with a compound of the invention is less than I, 5, 10, 20, 30, 40, 50, 60,
70, 80,90,95, or 99% of the kinase activity in the absence of said contacting step.
In some embodiments, the kinase is a lipid kinase or a protein kinase. In some
embodiments, the kinase is selected from the group consisting of PI3 kinase including
different isorforms such as PI3 kinase a, PI3 kinase p, PI3 kinase y, PI3 kinase 0; DNA-PK;
mTor; AbI, VEGFR, Ephrin receptor B4 (EphB4); TEK receptor tyrosine kinase (HE2); FMS
related tyrosine kinase 3 (FLT-3); Platelet derived growth factor receptor (PDGFR); RET;
ATM; ATR; hSmg-l; Hck; Src; Epidermal growth factor receptor (EGFR); KIT; Inulsin
Receptor (IR) and IGFR.
The invention further provides methods of modulating PI3 kinase activity by
contacting a PI3 kinase with an amount of a compound of the invention sufficient to modulate
the activity of the PI3 kinase. Modulate can be inhibiting or activating PI3 kinase activity. In
some embodiments, the invention provides methods of inhibiting PI3 kinase activity by
contacting a PI3 kinase with an amount of a compound of the invention sufficient to inhibit the
activity of the PI3 kinase. In some embodiments, the invention provides methods of inhibiting
PI3 kinase activity. Such inhibition can take place in solution, in a cell expressing one or more
PI3 kinases, in a tissue comprising a cell expressing one or more PI3 kinases, or in an
organism expressing one or more PI3 kinases. In some embodiments, the invention provides
methods of inhibiting PI3 kinase activity in an animal (including mammal such as humans) by
contacting said animal with an amount of a compound of the invention sufficient to inhibit the
activity of the PI3 kinase in said animal.
WO 20121151525
The ability of the compounds of the invention to treat arthritis can be
demonstrated in a murine collagen-induced arthritis model [Kakimoto, et aI., Cell. ImmunoI.,
142:326-337 (1992)], in a rat collagen-induced arthritis model [Knoerzer, et aI., Toxicoi.
PathoI., 25: 13(1997)], in a rat adjuvant arthritis model [Halloran, et aI., Arthritis Rheum.,
39:810-819 (1996)], in a rat streptococcal cell wall-induced arthritis model [Schimmer, et aI.,
J. ImmunoI., 160:1466-1477 (1998)], or in a SCID-mouse human rheumatoid arthritis model
[Oppenheimer-Marks, et aI., J. Clin. Invest., 101: 1261-1272(1998)].
The ability of the compounds of the invention to treat Lyme arthritis can be
demonstrated according to the method of Gross, et aI., Science, 218:703-706, (1998).
The ability of the compounds of the invention to treat asthma can be
demonstrated in a murine allergic asthma model according to the method of Wegner, et aI.,
Science, 247:456-459 (1990), or in a murine non-allergic asthma model according to the
method of Bloemen, et aI, Am. J. Respir. Crit. Care Med., 153:521-529 (1996).
The ability of the compounds of the invention to treat inflammatory lung
injury can be demonstrated in a murine oxygen-induced lung injury model according to the
method of Wegner, et aI., Lung, 170:267-279 (1992), in a murine immune complex-induced
lung injury model according to the method of Mulligan, et aI., J. ImmunoI., 154: 1350-1363
(1995), or in a murine acid-induced lung injury model according to the method of Nagase, et
aI., Am. J. Respir. Crit. Care Med., 154:504-51 O( 1996).
The ability of the compounds of the invention to treat inflammatory bowel
disease can be demonstrated in a murine chemical-induced colitis model according to the
method of Bennett, et aI., J. Pharmacoi. Exp. Ther., 280:988-1000 (1997).
The ability of the compounds of the invention to treat autoimmune diabetes
can be demonstrated in an NOD mouse model according to the method of Hasagawa, et aI.,
Int. Immunol., 6:831-838 (1994), or in a murine streptozotocin-induced diabetes model
according to the method of Herrold, et aI., Cell ImmunoI., 157:489-500 (1994).
The ability of the compounds of the invention to treat inflammatory liver
injury can be demonstrated in a murine liver injury model according to the method of Tanaka,
et aI., J. ImmunoI., 151:5088-5095 (1993).
The ability of the compounds of the invention to treat inflammatory
glomerular injury can be demonstrated in a rat nephrotoxic serum nephritis model according to
the method of Kawasaki, et aI., J. ImmunoI., 150: 1074-1083 (1993).
WO 20121151525
The ability of the compounds of the invention to treat radiation-induced
enteritis can be demonstrated in a rat abdominal irradiation model according to the method of
Panes, et aI., Gastroenterology, 108: 1761-1769 (1995).
The ability of the PI3K delta selective inhibitors to treat radiation pneumonitis
can be demonstrated in a murine pulmonary irradiation model according to the method of
Hal1ahan, et a\., Proc. Natl. Acad. Sci (USA), 94:6432-6437 (1997).
The ability of the the compounds of the invention to treat reperfusion injury
can be demonstrated in the isolated heart according to the method of Tamiya, et aI.,
Immunopharmacology, 29:53-63 (1995), or in the anesthetized dog according to the model of
Hartman, et aI., Cardiovasc. Res., 30:47-54 (1995).
The ability of the the compounds of the invention to treat pulmonary
reperfusion injury can be demonstrated in a rat lung al10graft reperfusion injury model
according to the method of DeMeester, et aI., Transplantation, 62:1477-1485 (1996), or in a
rabbit pulmonary edema model according to the method of Horgan, et aI., Am. 1. Physiol.,
261:HI578-HI584 (1991).
The ability of the the compounds of the invention to treat stroke can be
demonstrated in a rabbit cerebral embolism stroke model according to the method of Bowes, et
aI., Exp. Neurol., 119:215-219 (1993), in a rat middle cerebral artery ischemia-reperfusion
model according to the method of Chopp, et a\., Stroke, 25:869-875 (1994), or in a rabbit
reversible spinal cord ischemia model according to the method of Clark, et aI., Neurosurg.,
75:623-627 (1991).
The ability of the compounds of the invention to treat cerebral vasospasm can
be demonstrated in a rat experimental vasospasm model according to the method of Oshiro, et
aI., Stroke, 28:2031-2038 (1997).
The ability of the compounds of the invention to treat peripheral artery
occlusion can be demonstrated in a rat skeletal muscle ischemiaireperfusion model according
to the method of Gute, et aI., Mol. Cel1 Biochem., 179: 169-187 (1998).
. The ability of the compounds of the invention to treat graft rejection can be
demonstrated in a murine cardiac al10graft rejection model according to the method of Isobe,
et aI., Science, 255: 1125-1127 (1992), In a murine thyroid gland kidney capsule model
according to the method of Talento, et aI., Transplantation, 55:418-422 (1993), in a
cynomolgus monkey renal allograft model according to the method of Cosimi, et aI., 1.
Immunol., 144:4604-4612 (1990), in a rat nerve allograft model according to the method of
Nakao, et aI., Muscle Nerve, 18:93-102 (1995), in a murine skin al10graft model according to
WO 20121151525
the method of Gorczynski and Wojcik, J. ImmunoI., 152:2011-2019 (1994), in a murine
corneal allograft model according to the method of He, et aI., Opthalmoi. Vis. Sci., 35:3218-
3225 (1994), or in a xenogeneic pancreatic islet cell transplantation model according to the
method of Zeng, et aI., Transplantation, 58:681-689 (1994).
The ability of the compounds of the invention to treat graft-versus-host disease
(GVHD) can be demonstrated in a murine lethal GVHD model according to the method of
Harning, et aI., Transplantation, 52: 842-845 (1991).
The ability of the the compounds of the invention to treat cancers can be
demonstrated in a human lymphoma metastasis model (in mice) according to the method of
Aoudjit, et aI., J. ImmunoI., 161:2333-2338 (1998).
Combination Treatment
The present invention also provides methods for combination therapies in
which an agent known to modulate other pathways, or other components of the same pathway,
or even overlapping sets of target enzymes are used in combination with a compound of the
present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or
derivative thereof. In one aspect, such therapy includes but is not limited to the combination of
the subject compound with chemotherapeutic agents, therapeutic antibodies, and radiation
treatment, to provide a synergistic or additive therapeutic effect.
In one aspect, the compounds or pharmaceutical compositions of the present
invention may present synergistic or additive efficacy when administered in combination with
agents that inhibit IgE production or activity. Such combination can reduce the undesired
effect of high level of IgE associated with the use of one or more PI3Ko inhibitors, if such
effect occurs. This may be particularly useful in treatment of autoimmune and inflammatory
disorders (AIID) such as rheumatoid arthritis. Additionally, the administration of PI3Ko or
PI3Koly inhibitors of the present invention in combination with inhibitors of mTOR may also
exhibit synergy through enhanced inhibition of the PI3K pathway.
In a separate but related aspect, the present invention provides a combination
treatment of a disease associated with PI3Ko comprising administering a PI3K 0 inhibitor and
an agent that inhibits IgE production or activity. Other exemplary PI3Ko inhibitors are
applicable for this combination and they are described, e.g., US Patent No. 6,800,620. Such
combination treatment is particularly useful for treating autoimmune and inflammatory
diseases (AIID) including but not limited to rheumatoid arthritis.
WO 20121151525
Agents that inhibit IgE production are known in the art and they include but
are not limited to one or more of TEI-9874, 2-(4-(6-cyclohexyloxy
naphtyloxy)phenylacetamide)benzoic acid, rapamycin, rapamycin analogs (i.e. rapalogs),
TORC IImTORC I inhibitors, mTORC2fTORC2 inhibitors, and any other compounds that
inhibit TORCl/mTORCl and mTORC2fTORC2. Agents that inhibit IgE activity include, for
example, anti-IgE antibodies such as for example Omalizumab and TNX- 901.
For treatment of autoimmune diseases, the subject compounds or
pharmaceutical compositions can be used in combination with commonly prescribed drugs
including but not limited to Enbrel®, Remicade®, Humira®, Avonex®, and Rebi~. For
treatment of respiratory diseaseses, the subject compounds or pharmaceutical compositions
can be administered in combination with commonly prescribed drugs including but not limited
to Xolair®, Advair®, Singulair®, and Spiriva®.
The compounds of the invention may be formulated or administered in
conjunction with other agents that act to relieve the symptoms of inflammatory conditions
such as encephalomyditis, asthma, and the other diseases described herein. These agents
include non-steroidal anti-inflammatory drugs (NSAIDs), e.g. acetylsalicylic acid; ibuprofen;
naproxen; indomethacin; nabumetone; tolmetin; etc. Corticosteroids are used to reduce
inflammation and suppress activity of the immune system. The most commonly prescribed
drug of this type is Prednisone. Chloroquine (Aralen) or hydroxychloroquine (Plaquenil) may
also be very useful in some individuals with lUpus. They are most often prescribed for skin
and joint symptoms of lUpus. Azathioprine (Imuran) and cyclophosphamide (Cytoxan)
suppress inflammation and tend to suppress the immune system. Other agents, e.g.
methotrexate and cyclosporin are used to control the symptoms of lUpus. Anticoagulants are
employed to prevent blood from clotting rapidly. They range from aspirin at very low dose
which prevents platelets from sticking, to heparin/coumadin.
In another one aspect, this invention also relates to a pharmaceutical
composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a
compound of the present invention, or a pharmaceutically acceptable salt, ester, prodrug,
solvate, hydrate or derivative thereof, in combination with an amount of an anti-cancer agent
(e.g. a chemotherapeutic agent). Many chemotherapeutics are presently known in the art and
can be used in combination with the compounds of the invention.
In some embodiments, the chemotherapeutic is selected from the group
consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics,
growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological
WO 20121151525
response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens. Non-limiting
examples are chemotherapeutic agents, cytotoxic agents, and non-peptide small molecules
such as Gleevec (Imatinib Mesylate), Velcade (bortezomib), Iressa (gefitinib), Sprycel
(Dasatinib), and Adriamycin as well as a host of chemotherapeutic agents. Non-limiting
examples of chemotherapeutic agents include alkylating agents such as thiotepa and
cyclosphosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan and
piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa;
ethylenimines and methylamelamines including altretamine, triethylenemelamine,
trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine; nitrogen
mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin,
phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine,
chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as
aclacinomysins, actinomycin, authramycin, azasenne, bleomycins, cactinomycin,
calicheamicin, carabicin, carminomycin, carzinophilin, Casodex™, chromomycins,
dactinomycin, daunorubicin, detorubicin, 6-diazooxo-L-norleucine, doxorubicin,
epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid,
nogalamycin, olivomycins, peplomycin, pK)tfiromycin, puromycin, quelamycin, rodorubicin,
streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such
as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denoptetin,
methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine,
thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine,
carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, androgens such
as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti
adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic
acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil;
bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomithine; elliptinium acetate;
etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone;
mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-
ethylhydrazide; procarbazine; PSK.Rn.c; razoxane; sizofiran; spirogermanium; tenuazonic
acid; triaziquone; 2,2',2" -trichlorotriethylamine; urethan; vindesine; dacarbazine;
mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiotepa; taxa!les, e.g. paclitaxel (TAXOLTM, Bristol-Myers Squibb
Oncology, Princeton, NJ.) and docetaxel (TAXOTERETM, Rhone- Poulenc Rorer, Antony,
WO 20121151525
France); retinoic acid; esperamicins; capecitabine; and pharmaceutically acceptable salts, acids
or derivatives of any of the above. Also included as suitable chemotherapeutic cell
conditioners are anti- hormonal agents that act to regulate or inhibit hormone action on tumors
such as anti-estrogens including for example tamoxifen (Nolvadex™), raloxifene, aromatase
inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, L Y 117018,
onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide,
bicalutamide (Casodex), leuprolide, and goserelin (Zoladex); chlorambucil; gemcitabine; 6-
thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and
carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C;
mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin;
aminopterin; xeloda; ibandronate; camptothecin-II (CPT-II); topoisomerase inhibitor RFS
2000; difluoromethylornithine (DMFO), I7a-Ethinylestradiol, Diethylstilbestrol, Testosterone,
Prednisone, Fluoxymesterone, Megestrolacetate, Methylprednisolone, Methyl-testosterone,
Prednisolone, Triamcinolone, chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide,
Medroxyprogesteroneacetate, matrix metalloproteinase inhibitors, EGFR inhibitors, Pan Her
inhibitors, VEGF inhibitors, including as anti-VEGF antibodies such as Avastin, and small
molecules such as ZD6474 and SU6668, vatalanib, BAY9006, SUI 1248, CP-547632, and
CEP-7055. Anti-Her2 antibodies (such as Herceptin from Genentech) may also be utilized.
Suitable EGFR inhibitors include gefitinib, erlotinib, and cetuximab. Pan Her inhibitors
include canertinib, EKB-569, and GW-572016. Further suitable anticancer agents include, but
are not limited to, Src inhibitors, MEK-I kinase inhibitors, MAPK kinase inhibitors, PI3
kinase inhibitors, and PDGF inhibitors, such as imatinib. Also included are anti-angiogenic
and anti vascular agents which, by interrupting blood flow to solid tumors, render cancer cells
quiescent by depriving them of nutrition. Castration which also renders androgen dependent
carcinomas non-proliferative, may also be utilized. Also included are IGFIR inhibitors,
inhibitors of non-receptor and receptor tyrosine kinases, and inhibitors of integrin signalling.
Additional anticancer agents include microtubule-stabilizing agents 7
methylthiomethylpaclitaxel (disclosed In U.S. Pat. No. 5,646,176), 4-desacetyl
methylcarbonatepaclitaxel, 3'-tert-butyl-3'-N-tert-butyloxycarbonyldesacetyl-3'-dephenyl-
3'-N-debenzoyl0-methoxycarbonyl-paclitaxel (disclosed in U.S. Ser. No. 091712,352 filed
on Nov. 14, 2000), C-4 methyl carbonate paclitaxel, epothilone A, epothilone B, epothilone C,
epothilone D, desoxyepothilone A, desoxyepothilone B, [I S
[I R *,3R *(E), 7R *, I OS*, II R *, 12R *, 16S*]]II-dihydroxy-8,8, 10, 12, 16-pentamethyl[ 1-
methyl(2-methylthiazolyl)ethenyl]aza-17 oxabicyclo [14.I.O]heptadecane-5,9-dione
WO 20121151525
(disclosed In WO 99/02514), [IS-[IR*,3R*(E),7R*, IOS*, llR *, 12R *, 16S*]][2-[2-
ethenyl]-7, II-dihydroxy-8,8, 10,12, 16-pentamethyl
(aminomethyl)thiazolyl]-I-methyl
l7-dioxabicyclo[14.1.0]-heptadecane-5,dione ( as disclosed in U.S. Pat. No. 6,262,094) and
derivatives thereof; and microtubule-disruptor agents. Also suitable are CDK inhibitors, an
antiproliferative cell cycle inhibitor, epidophyllotoxin; an antineoplastic enzyme; biological
response modifiers; growth inhibitors; anti hormonal therapeutic agents; leucovorin; tegafur;
and haematopoietic growth factors.
Additional cytotoxic agents
include, hexamethyl melamine, idatrexate, L-
asparaginase, camptothecin, topotecan, pyridobenzoindole derivatives, interferons, and
interleukins.Where desired, the compounds or pharmaceutical composition of the present
can be used in combination with commonly prescribed anti-cancer drugs such as
invention
Herceptin®, Avastin®, Erbitux®, Rituxan®, Taxol®, Arimidex®, Taxotere®, and Velcade®
This invention further relates to a method for using the compounds or
pharmaceutical composition in combination with radiation therapy in inhibiting abnormal cell
growth or treating the hyperproliferative disorder in the mammal. Techniques for
administering radiation therapy are known in the art, and these techniques can be used in the
combination therapy described herein. The administration of the compound of the invention in
this combination therapy can be determined as described herein.
Radiation therapy can be administered through one of several methods, or a
combination of methods, including without limitation external-beam therapy, internal
radiation therapy, implant radiation, stereotactic radiosurgery, systemic radiation therapy,
radiotherapy and permanent or temporary interstitial brachytherapy. The term
"brachytherapy," as used herein, refers to radiation therapy delivered by a spatially confined
radioactive material inserted into the body at or near a tumor or other proliferative tissue
disease site. The term is intended without limitation to include exposure to radioactive
isotopes (e.g. At-211, 1-131, 1-125, Y-90, Re-186, Re-188, Sm-153, Bi-212, P-32, and
radioactive isotopes of Lu). Suitable radiation sources for use as a cell conditioner of the
present invention include both solids and liquids. By way of non-limiting example, the
radiation source can be a radionuclide, such as 1-125, 1-131, Yb-169, Ir- 192 as a solid source,
1-125 as a solid source, or other radionuclides that emit photons, beta particles, gamma
radiation, or other therapeutic rays. The radioactive material can also be a fluid made from any
solution of radionuclides), e.g., a solution of 1-125 or 1-131, or a radioactive fluid can be
produced using a slurry of a suitable fluid containing small particles of solid radionuclides,
WO 20121151525
such as Au-198, Y -90. Moreover, the radionuclide(s) can be embodied in a gel or radioactive
micro spheres.
Without being limited by any theory, the compounds of the present invention
can render abnormal cells more sensitive to treatment with radiation for purposes of killing
and/or inhibiting the growth of such cells. Accordingly, this invention further relates to a
method for sensitizing abnormal cells in a mammal to treatment with radiation which
comprises administering to the mammal an amount of a compound of the present invention or
pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof, which
amount is effective is sensitizing abnormal cells to treatment with radiation. The amount of the
compound, salt, or solvate in this method can be determined according to the means for
ascertaining effecti ve amounts of such compounds described herein.
The compounds or pharmaceutical compositions of the present invention can
be used in combination with an amount of one or more substances selected from anti
angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2)
inhibitors, MMP-9 (matrix- metalloprotienase 9) inhibitors, and COX-H (cyclooxygenase II)
inhibitors, can be used in conjunction with a compound of the present invention and
pharmaceutical compositions described herein. Examples of useful COX-II inhibitors include
CELEBREXTM (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix
metalloproteinase inhibitors are described in WO 96/33172 (published October 24,1996), WO
96/27583 (published March 7,1996), European Patent Application No. 97304971.1 (filed July
8,1997), European Patent Application No. 99308617.2 (filed October 29, 1999), WO
98/07697 (published February 26,1998), WO 98/03516 (published January 29,1998), WO
98/34918 (published August 13,1998), WO 98/34915 (published August 13,1998), WO
98/33768 (published August 6,1998), WO 98/30566 (published July 16, 1998), European
Patent Publication 606,046 (published July 13,1994), European Patent Publication 931, 788
(published July 28,1999), WO 90/05719 (published May 31,1990), WO 99/52910 (published
October 21,1999), WO 99/52889 (published October 21, 1999), WO 99/29667 (published
June 17,1999), PCT International Application No. PCT/IB98/01113 (filed July 21,1998),
European Patent Application No. 99302232.1 (filed March 25,1999), Great Britain Patent
Application No. 9912961.1 (filed June 3, 1999), United States Provisional Application No.
60/148,464 (filed August 12,1999), United States Patent 5,863, 949 (issued January 26,1999),
United States Patent 5,861, 510 (issued January 19,1999), and European Patent Publication
780,386 (published June 25, 1997), all of which are incorporated herein in their entireties by
WO 20121151525
reference. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity
inhibiting MMP-I. More preferred, are those that selectively inhibit MMP-2 and/or AMP-9
relative to the other matrix-metalloproteinases (i. e., MAP-I, MMP-3, MMP-4, MMP-5,
MMP-6, MMP- 7, MMP-8, MMP-lO, MMP-II, MMP-12, and MMP-13). Some specific
examples of MMP inhibitors useful in the present invention are AG-3340, RO 32-3555, and
RS 13-0830.
The invention also relates to a method of and to a pharmaceutical composition
of treating a cardiovascular disease in a mammal which comprises an amount of a compound
of the present invention, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate
or derivative thereof, or an isotopically-labeled derivative thereof, and an amount of one or
more therapeutic agents use for the treatment of cardiovascular diseases.
Examples for use in cardiovascular disease applications are anti-thrombotic
agents, e.g., prostacyclin and salicylates, thrombolytic agents, e.g., streptokinase, urokinase,
tissue plasminogen activator (TPA) and anisoylated plasminogen-streptokinase activator
complex (APSAC), anti-platelets agents, e.g., acetyl-salicylic acid (ASA) and clopidrogel,
vasodilating agents, e.g., nitrates, calcium channel blocking drugs, antiproliferative agents,
e.g., colchicine and alkylating agents, intercalating agents, growth modulating factors such as
interleukins, transformation growth factor-beta and congeners of platelet derived growth
factor, monoclonal antibodies directed against growth factors, anti-inflammatory agents, both
steroidal and non-steroidal, and other agents that can modulate vessel tone, function,
arteriosclerosis, and the healing response to vessel or organ injury post intervention.
Antibiotics can also be included in combinations or coatings comprised by the invention.
Moreover, a coating can be used to effect therapeutic delivery focally within the vessel wall.
By incorporation of the active agent in a swellable polymer, the active agent will be released
upon swelling of the polymer.
Other exemplary therapeutic agents useful for a combination therapy include
but are not limited to agents as described above, radiation therapy, hormone antagonists,
hormones and their releasing factors, thyroid and antithyroid drugs, estrogens and progestins,
androgens, adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs;
inhibitors of the synthesis and actions of adrenocortical hormones, insulin, oral hypoglycemic
agents, and the pharmacology of the endocrine pancreas, agents affecting calcification and
bone turnover: calcium, phosphate, parathyroid hormone, vitamin 0, calcitonin, vitamins such
as water-soluble vitamins, vitamin B complex, ascorbic acid, fat-soluble vitamins, vitamins A,
K, and E, growth factors, cytokines, chemokines, muscarinic receptor agonists and
WO 20121151525
antagonists; anticholinesterase agents; agents acting at the neuromuscular junction and/or
autonomic ganglia; catecholamines, sympathomimetic drugs, and adrenergic receptor agonists
or antagonists; and 5-hydroxytryptamine (5-HT, serotonin) receptor agonists and antagonists.
Therapeutic agents can also include agents for pain and inflammation such as
histamine and histamine antagonists, bradykinin and bradykinin antagonists, 5-
hydroxytryptamine (serotonin), lipid substances that are generated by biotransformation of the
products of the selective hydrolysis of membrane phospholipids, eicosanoids, prostaglandins,
thromboxanes, leukotrienes, aspirin, nonsteroidal anti-inflammatory agents, analgesic
antipyretic agents, agents that inhibit the synthesis of prostaglandins and thromboxanes,
selective inhibitors of the inducible cyclooxygenase, selective inhibitors of the inducible
cyclooxygenase-2, autacoids, paracrine hormones, somatostatin, gastrin, cytokines that
mediate interactions involved in humoral and cellular immune responses, lipid-derived
autacoids, eicosanoids, p-adrenergic agonists, ipratropium, glucocorticoids, methylxanthines,
sodium channel blockers, opioid receptor agonists, calcium channel blockers, membrane
stabilizers and leukotriene inhibitors.
Additional therapeutic agents contemplated herein include diuretics,
vasopressin, agents affecting the renal conservation of water, rennin, angiotensin, agents
useful in the treatment of myocardial ischemia, anti-hypertensive agents, angiotensin
converting enzyme inhibitors, p-adrenergic receptor antagonists, agents for the treatment of
hypercholesterolemia, and agents for the treatment of dyslipidemia.
Other therapeutic agents contemplated include drugs used for control of gastric
acidity, agents for the treatment of peptic ulcers, agents for the treatment of gastroesophageal
reflux disease, prokinetic agents, antiemetics, agents used in irritable bowel syndrome, agents
used for diarrhea, agents used for constipation, agents used for inflammatory bowel disease,
agents used for biliary disease, agents used for pancreatic disease. Therapeutic agents used to
treat protozoan infections, drugs used to treat Malaria, Amebiasis, Giardiasis, Trichomoniasis,
Trypanosomiasis, and/or Leishmaniasis, and/or drugs used in the chemotherapy of
helminthiasis. Other therapeutic agents include antimicrobial agents, sulfonamides,
trimethoprim-sulfamethoxazole quinolones, and agents for urinary tract infections, penicillins,
cephalosporins, and other, p-Lactam antibiotics, an agent comprising an aminoglycoside,
protein synthesis inhibitors, drugs used in the chemotherapy of tuberculosis, mycobacterium
avium complex disease, and leprosy, antifungal agents, antiviral agents including nonretroviral
agents and antiretroviral agents.
WO 20121151525
Examples of therapeutic antibodies that can be combined with a subject
compound include but are not limited to anti-receptor tyrosine kinase antibodies (cetuximab,
panitumumab, trastuzumab), anti CD20 antibodies (rituximab, tositumomab), and other.
antibodies such as alemtuzumab, bevacizumab, and gemtuzumab.
Moreover, therapeutic agents used for immunomodulation, such as
immunomodulators, immunosuppressive agents, tolerogens, and immunostimulants are
contemplated by the methods herein. In addition, therapeutic agents acting on the blood and
the blood-forming organs, hematopoietic agents, growth factors, minerals, and vitamins,
anticoagulant, thrombolytic, and anti platelet drugs.
Further therapeutic agents that can be combined with a subject compound may
be found In Goodman and Gilman's "The Pharmacological Basis of Therapeutics" Tenth
Physician's Desk Reference, both of
Edition edited by Hardman, Limbird and Gilman or the
which are incorporated herein by reference in their entirety.
The compounds described herein can be used in combination with the agents
disclosed herein or other suitable agents, depending on the condition being treated. Hence, in
some embodiments the compounds of the invention will be co-administered with other agents
as described above. When used in combination therapy, the compounds described herein may
be administered with the second agent simultaneously or separately. This administration in
combination can include simultaneous ad.ministration of the two agents in the same dosage
form, simultaneous administration in separate dosage forms, and separate administration. That
is, a compound described herein and any of the agents described above can be formulated
together in the same dosage form and administered simultaneously. Alternatively, a compound
of the present invention and any of the agents described above can be simultaneously
administered, wherein both the agents are present in separate formulations. In another
alternative, a compound of the present invention can be administered just followed by and any
of the agents described above, or vice versa. In the separate administration protocol, a
compound of the present invention and any of the agents described above may be administered
a few minutes apart, or a few hours apart, or a few days apart.
The methods in accordance with the invention may include administering a
PI3-kinase 0 selective inhibitor with one or more other agents that either enhance the activity
of the inhibitor or compliment its activity or use in treatment. Such additional factors and/or
agents may produce an augmented or even synergistic effect when administered with a PI3-
kinase 0 selective inhibitor, or minimize side effects.
WO 20121151525
In one embodiment, the methods of the invention may include administering
formulations comprising a PI3-kinase 8 selective inhibitor of the invention with a particular
cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or
anti-inflammatory agent before, during, or after administration of the PI3-kinase 8 selective
inhibitor. One of ordinary skill can easily determine if a particular cytokine, lymphokine,
hematopoietic factor, thrombolytic of anti-thrombotic factor, and/or anti-inflammatory agent
enhances or compliments the activity or use of the P13-kinase 8 selective inhibitors in
treatment.
More specifically, and without limitation, the methods of the invention may
comprise administering a PI3-kinase 8 selective inhibitor with one or more of TNF, IL-I, IL-2,
IL-3, IL4, IL-S, IL-6, IL-7, IL-S, IL-9, IL-lO, IL-II, IL-I2, IL-I3, IL-I4, IL-IS, IL-I6, IL-17,
IL-IS, IFN, G-CSF, Meg-CSF, GM-CSF, thrombopoietin, stem cell factor, and erythropoietin.
Compositions in accordance with the invention may also include other known angiopoietins
such as Ang-2, Ang4, and Ang-Y, growth factors such as bone morphogenic protein-I, bone
morphogenic protein-2, bone morphogenic protein-3, bone morphogenic protein-4, bone
morphogenic protein-S, bone morphogenic protein-6, bone morphogenic protein-7, bone
morphogenic protein-S, bone morphogenic protein-9, bone morphogenic protein-l 0, bone
morphogenic protein-II, bone morphogenic protein-12, bone morphogenic protein-I3, bone
morphogenic protein-I4, bone morphogenic protein-IS, bone morphogenic protein receptor
lA, bone morphogenic protein receptor IB, brain derived neurotrophic factor, ciliary
neutrophic factor, ciliary neutrophic factor receptor a, cytokine-induced neutrophil
chemotactic factor I, cytokine-induced neutrophil chemotactic factor 2 alpha, cytokine
induced neutrophil chemotactic factor 2 beta, beta endothelial cell growth factor, endothelin I,
epidermal growth factor, epithelial-derived neutrophil attractant, fibroblast growth factor 4,
fibroblast growth factor S, fibroblast growth factor 6, fibroblast growth factor 7, fibroblast
growth factor S, fibroblast growth factor Sb, fibroblast growth factor Sc, fibroblast growth
factor 9, fibroblast growth factor 10, fibroblast growth factor acidic, fibroblast growth factor
aI, glial cell line-derived neutrophic
basic, glial cell line-derived neutrophic factor receptor
factor receptor a2, growth related protein, growth related protein a, growth related protein
.beta., growth related protein .gamma., heparin binding epidermal growth factor, hepatocyte
growth factor, hepatocyte growth factor receptor, insulin-like growth factor I, insulin-like
growth factor receptor, insulin-like growth factor II, insulin-like growth factor binding protein,
keratinocyte growth factor, leukemia inhibitory factor, leukemia inhibitory factor receptor
alpha, nerve growth factor, nerve growth factor receptor, neurotrophin-3, neurptrophin-4,
WO 20121151525
placenta growth factor, placenta growth factor 2, platelet derived endothelial cell growth
factor, platelet derived growth factor, platelet derived growth factor A chain, platelet derived
growth factor AA, platelet derived growth factor AB, platelet derived growth factor B chain,
platelet derived growth factor BB, platelet derived growth factor receptor a, platelet derived
growth factor receptor beta, pre-B cell growth stimulating factor, stem cell factor, stem cell
factor receptor, transforming growth factor alpha, transforming growth factor beta,
transforming growth factor beta I, transforming growth factor beta 1.2, transforming growth
factor beta 2, transforming growth factor beta 3, transforming growth factor beta 5, latent
transforming growth factor beta I, transforming growth factor beta binding protein I,
transforming growth factor beta binding protein II, transforming growth factor beta binding
protein III, tumor necrosis factor receptor type I, tumor necrosis factor receptor type II,
urokinase-type plasminogen activator receptor, and chimeric proteins and biologically or
immunologically active fragments thereof.
The following general methodology described herein provides the manner and
process of making and using the compound of the present invention and are illustrative rather
than limiting. Further modification of provided methodology and additionally new methods
may also be devised in order to achieve and serve the purpose of the invention. Accordingly, it
should be understood that there may be other embodiments which fall within the spirit and
scope of the invention as defined by the specification hereto.
Representative compounds of the present invention include those specified
above in Table I and pharmaceutically acceptable salts thereof. The present invention should
not be construed to be limited to them.
General Method of Preparation of Compounds of the Invention
The compounds of the present invention may be prepared by the following
R2, L , Cyl and C/) when
processes. Unless otherwise indicated, the variables (e.g., R, RI,
used in the below formulae are to be understood to present those groups described above in
relation to formula (I). These methods can similarly be applied to other compounds of formula
as provided herein above with or without modification.
Scheme 1 : This scheme provides a synthetic route for the preparation of a compound of
formula (10) wherein all the variables are as described herein above. The compound of
formula (10) can then be converted to the desired compounds of the invention as provided in
schemes 2 and 3 below.
WO 20121151525
Compound of formula (1) wherein PG is a protecting group such as an alkyl group can be
reacted with compound of formula (A) wherein R3 and R4 can be alkyl or alkoxy groups in
the presence of a suitable base such as n-butyl lithium or lithium diisopropylaminde to give
compound of formula (2). Compound of formula (2) can be reacted with a methyl Grignard
reagent such as methylmagnesium iodide to give compound of formula (3), which can be
oxidised by using an oxidising agent such as pyridinium dichromate to give compound of
formula (4).
Scheme 1
Base
)l R3
Me ~4 (8)
Oxidation
llAOPG
~CHO
Base
MeMgX Deprotection
llAOPG
Acid ~1
_1"-':: R
o R2
llAOH
7 6 5
Suzuki Coupling
9 10
Compound of formula (l) can also be reacted with a compound of formula (B) wherein R3
and R4 can be alkyl or alkoxy groups in the presence of a suitable base such as n-butyllithium
or lithium diisopropylaminde to give compound of formula (4). Compound of formula (4) can
be deprotected to give compound of formula (5) by using a suitable reagent such as boron
tribromide or aluminium chloride. Compound of of formula (5) can be acylated with a
compound of formula (C) in the presence of a suitable base such as pyridine to give
compound of formula (6). Compound of formula (6) can undergo Baker-venkataraman
rearrangement upon treatment with a suitable base such as a trialkylamine, a lithium
dialkylamide or a lithium disilylamide, e.g. lithium hexamethyl disilazide, to give compound
WO 20121151525
of formula (7). Compound of formula (7) can be reacted with an acid such as' hydrochloric
acid to give compound of formula (8). Compound of formula (8) can be halogenated to give
compound of formula (9) wherein X is a halogen by reacting with a halogenating agent such
as bromine or N-bromosuccinimide. Compound of formula (9) can be converted to give
compound of formula (10) by reacting with a boronic acid of formula Cyl-B(OHh wherein
Cyl IS aryl or heteroaryl In the presence of a palladium catalyst such as
tetrakis(triphenylphosphine)palladium(O) and a base such as sodium carbonate.
Scheme 1A: This scheme provides a synthetic route for the preparation of compound of
formula (10), (12), (14) and (15) wherein all the variables are as described herein in above,
the compound of formula (10), (12), (14) and (15) can then be converted to the desired
compounds of the invention as provided in scheme 2, 3 or 4 below.
This scheme provides a synthetic route for the preparation of compound of formula (I)
wherein all the variables are as described herein in above
SCHEME lA
R R 0
R ~_OH COl
~CHO
NH 0H.HCl ~Cy1
2 ~CN
I"" "" .
llAOpg Pyridine
llAOpg
h- OPg 1 h- OP Deprotection llAOH
5a g
1a 2a 3a 6a
1 Cyclisation
0 Cy1 6:X:~ 0 Cy1
AYY~;1
1 ~ 1 R1 2 • 1 h- 1 R1
-~O~R2- o 0 R Deprotection 0 R2
COcr
OH OPg
14 10 12 12a
Compound of formula (la) wherein PG is a protecting group such as alkyl group can be
reacted with hydroxylamine hydrochloride to give compound of formula (2a). Compound of
formula (2a) be reacted with N,N' -carbonyldiimidazole to give compound of formula (3a).
Compound of formula (3a) can be reacted with compound of formula (4a) to give compound
of formula (Sa). Compound of formula (Sa) can be de protected to compound of formula (6a)
by using a suitable reagent such as boron tribromide or aluminium chloride. Compound of
formula (6a) can be cyclised with benzyllactic acid to compound of formula (12a).
Compound of formula (12a) can be deprotected to compound of formula (12) by using a
suitable reagent such as boron tribromide or aluminium chloride. Compound of formula (12)
can be reacted with phosphorus halides to give compound of formula (10). Compound of
WO 20121151525
formula (10) can be reacted with sodium azide to give compound of formula (14). Compound
of formula (14) can be converted to give compound of formula (15) by reacting with
triphenylphosphine.
Illustration of scheme lA:
Step-l
N,OH Cc
CDI "" CN ~I "" MgCI
"" ~
I"" ----·1 +V
lAo Me Pyridine ~ OMe
~OMe ~OMe -
BBr j-78 c
"" ~
~ OH
OBn (R)-Benzyllactic acid
HATU
Step-2
Scheme 2: This scheme provides a synthetic route for the preparation of compound of
formula (lA-II) from compound of formula (10) wherein all the variables are as described
herein in above
Scheme 2
WO 20121151525
R 0 NH2
~C~1 + ~JY~'X Base
~OAfR2 x"NJl~-
X 11
Hydroxyl Substitution
N:i~'
R 0 X, I ,X
'N N
CY1 11 H
I.&- I R1
CQG o R2 Mitsunobu reaction
Compound of formula (10) can be reacted with compound of formula (11) in the presence of
a base such as a metal carbonate, e.g., potassium carbonate to give compound of formula (IA
I). Alternatively compound of formula (10) can be converted into compound of formula (12)
by reacting with a suitable reagent such as dimethyl sulfoxide. Compound of formula (12) can
be subjected to Mitsunobu reaction with compound of formula (11) in the presence of a
dialkyl azodicarboxylate and a triaryl phosphine such as triphenyl phosphine to afford
compound of formula (lA-I).
Scheme 3: This scheme provides a synthetic route for the preparation of compound of
formula (lA-II) from compound of formula (10) wherein all the variables are as described
herein in above
Compound of formula (10) can be reacted with compound of formula (l1a) in the presence of
a base such as a metal carbonate, e.g., potassium carbonate to give compound of formula (IA
II ). Alternatively compound of formula (10) can be converted into compound of formula
(12) by reacting with a suitable reagent such as dimethyl sulfoxide. Compound of formula
(12) can be subjected to Mitsunobu reaction with compound of formula (l1a) in the presence
of a dialkyl azodicarboxylate and a triaryl phosphine such as triphenyl phosphine to afford
compound of formula (lA-II).
SCHEME 3
WO 20121151525
R 0 NH2 R3
Base
I I R1
::::,....
I I R1
~:CN 00q'
o R2
X"N N
coy' ~ 0 R2
(lA-II) N ~ I /. N
11a
Hydroxyl Isu bstRutlon
R3 NH2
NH2 R3
~:CN
X'-N N I I R1
::::,....
H CQq'
I ~ I R1 •
lA-II ' I ' ~
o R2
Mitsunobu reaction
CrJG' N~ /. N
R3 NH2
Scheme 4: This scheme provides a synthetic route for the preparation of compound of
formula (lA-IV) from compound of formula (10) wherein all the variables are as described
herein in above
SCHEME4
CY1 Reduction
I' I R1
.& 0 R2
14 N3 R3 15
Br .
ClyYNH:h
~~N~
N,N Base
-X' X N
(11c)
(11b)H
Compound of formula (10) can be reacted with a metal azide such as sodium azide to give
compound of formula (14) which can be reduced to compound of formula (15) by using
methods known to those skilled in the art. Compound of formula (15) can be reacted with
compound of formula (lIb) or (lIc) in the presence of a suitable base such as N
ethyldiisopropylamine to give respectiley the compound of formula (lA-IV) and (lA-III).
Similar methodologies with certain modifications as known to those skilled in
the art can be used to synthesize compound of formula of (I) and (IA) wherein all the variable
WO 20121151525
are to be understood to present those groups described above in relation to formula (I) and
(IA) using suitable intermediates and reagents.
Experimental
The examples and preparations provided below further illustrate and exemplify
the compounds of the present invention and methods of preparing such compounds. It is to be
understood that the scope of the present invention is not limited in any way by the scope of the
following examples and preparations. In the following examples molecules with a single chiral
center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more
chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single
enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
List of Intermediates
F 0 '"
~CHO
I: I
~OMe ~O~
Intermediate 1
Intermediate 19
Intermediate 26
Intermediate 35
F 0 ?' I
('YO
~OMe N N
BrMF N, 1 "')
Intermediate 20
Intermediate 2
I -N
Intermediate 11 ~
NH:!
Intermediate 27
Intermediate 36
F Br
F""O Sf
I h I
;Z:J.y-yF J-..
llA Sf )-F
Intermediate 12
Intermediate 28
Intermediate 21
Intermediate 3
Intermediate 37
H~-~ ~ ~ 0
N'" -)-
\l /- NH F
;N1N"')
flAOH
Intermediate 4
Intermediate 13
Sf F ~-h H,N
Intermediate 22
Intermediate 29
F 0 7 F ~ N
N, r ~
flAo F ~ ;.; H,N
Intermediate 14 ~
Intermediate 23
Intermediate 30
Intermediate 5
Intermediate 39
OH 0
M F~
llAo~
Intermediate 6 OH
Intermediate 15
Intermediate 31
ntermediate23a
Intermediate 40
WO 20121151525
OMeO
0'0",0
m ~ 0
Intermediate 7 0
Intermediate 32
Intermediate 16
Intermediate 23b Intermediate 41
OMeO
C6(r
I ~ I W
Br h F
Intermediate 42
Intermediate 8
Intermediate 17
Intermediate 24
CC h 0 JXy
Sr ~ F
N, r ..,
O~ { 0c; -N
Intermediate 43
Intermediate 25
Intermediate 18
Intermediate 34
NC Et
( N, r ..,
_ -N
¢n- NC 5
'>- F
~ u H,N
d: HNy
B h N'
r H NC 0
NC 0-
)---
Intermediate 44 Intermediate 54
Intermediate 64
Intermediate 74
Intermediate 84
O'B'O
Q CN
N\ f\N~ l
Br ~ .&~.
Boc N'N NH
HNy ,t
Intermediate 45
Intermediate 75 Intermediate 85
Intermediate 55 Intermediate 65
N, ¥ "I
0'8",0
N, r ~
_ -N
N, ..-oN
~-B A~'
~ • u H,N
o H,N-N
6 Soc Js
(N F
Intermediate 76
Intermediate 46
Intermediate 66
Intermediate 56 Intermediate 86
Br F 0
,N N
N, V ~
NC S
ec: h 0
0 -N
::,... F
S H2N
<i NC [)
¢ o~
..... N,
Boc -
Intermediate 57 Intermediate 67 Intermediate 77 Intermediate 87
Intermediate 47
0'8,0
NC S N eN
F-Q ::,... F
<i >=< ~ h 0
..... N, N)
6 Intermediate 88
~ NH2
Intermediate 58
Intermediate 68
Intermediate 48 Intermediate 78
N~NH, Q H,N
(N CN
I ~ I
C(:N
N~ I )
/N, o~
... " OH
Intermediate 89
Intermediate 59 Intermediate 69
Intermediate 49
Intermediate 79
o~B'o -¢
F "..
N, r ~
"- F
N -N
HN'l "- F
(JH N
OH /N, Ph....J.....ph
Intermediate 90
Intermediate 50 Intermediate 60 Intermediate 80
Intermediate 70
WO 20121151525
o's'o
NC ~
HN't
() NC N-
OH /
Intermediate 91
Intermediate 61
Intermediate 51 Intermediate 71
# '"
-N CN
I: I
~F o
N~NH2
HN'lOH I
Intermediate 82
Intermediate 72
Intermediate 62
Intermediate 92
Intermediate 52
-++-
-++-
Intermediate 93
Intermediate 53
Intermediate 63 Intermediate 83
N6-N~
C;\, I~N
0) ()
Intermediate 112
Intermediate 103
Intermediate 121 Intermediate 130
Intermediate 94
N, r ~
N, r ~
_ -N ))
~ A (N
~ A H2N
j-F 0) ~
r CI
Intermediate 113 eN)
Intermediate 104
Intermediate 131
Intermediate 122
C;\,
HN,O V
OH NH
so,Me
Intermediate 114
Intermediate 96
Intermediate 123 Intermediate 132
CI,;y
HNyO
Intermediate 133
Intermediate 115 Intermediate 124
Intermediate 97
Intermediate 106
~oJy-
N\ r "/
, ~ ~ X
I -N
CI---Y
F ~ -:, H2N
Intermediate 134
Intermediate 116
Intermediate 98
Intermediate 125
Intermediate 107
Br~O
N, V ~ Intermediate 126
I -N
Intermediate 135
Intermediate 108
WO 20121151525
ntermediate 117
I }-
N, r ~
N, V '7 -N
~6 ~ 0
:-, # _NH
I -N
(N F
Intermediate 127
Intermediate 109
Intermediate 100
Intermediate 118
Intermediate 136
;~rN")
~r5<
F ~~ HN,
Intermediate 128
Intermediate 110
Intermediate 119
Intermediate 137
Intermediate 101
F NH2
~,~ 1~N~
HN I F N N
;o .&
() A-Ph
Ph Ph
Intermediate 111
Intermediate 102 Intermediate 120 Intermediate 138
Intermediate 129
Intermediate 145
Intermediate 147
Intermediate 139
Intermediate 141
Intermediate 143
'-": "'-
ct.?
.0 OMe
Intermediate 146
Intermediate 144 Intermediate 148
Intermediate 140
Intermediate 142
~ 0 Sr ~ 0 Sr
I h I
I h I
66:;
Intermediate 152 Intermediate 153
Intermediate 151
Intermediate 150
Intermediate 149
Intermediate 1: 2-fluoromethoxybenzaldehyde : n-BuLi (I.6M in hexane,
74.3 ml, O.IIS mol) was added dropwise to a solution of diisopropylamine (13.23 g, 0.130
mol) in THF (50 ml) at DoC, maintained for 15 min. and cooled to -7S°C. 3-F1uoroanisole (IS
g, O.IIS mol) in THF (5° ml) was added, stirred at -78°C for I h, and N,N-dimethylformamide
(6.75 ml) was added and stirred for further I h. The reaction mixture was quenched with 2N
HCI solution and extracted with ethyl acetate. The organic layer was dried over sodium
WO 20121151525
sulphate and concentrated to afford the title compound as a red waxy solid (17.45 g, 95%)
which was used without purification in the next step.
Intermediate 2: 1-(2-fluoromethoxyphenyl)ethanol:To an ice-cold solution
of methylmagnesium iodide prepared from magnesium (8.8 g, 0.366 mol) and methyliodide
(52.06 g, 0.366 mol) in diethyl ether (150 ml), intermediate 1 (18.85 g, 0.122 mol) in diethyl
ether( 50 ml) was added and warmed to room temperature. After 12h, the reaction mixture was
O°C, quenched with dilute aqueous HCl and extracted with ethyl acetate. The
cooled to
organic layer was dried over sodium sulphate and concentrated under reduced pressure to
afford the title compound as a red liquid (18.9 g, 99%) which was used without purification in
the next step.
Intermediate 3: 1-(2-fluoromethoxyphenyl)ethanone: Pyridinium
dichromate (44 g, 0.116 mol) was added to a solution of intermediate 2 (13.1 g, 0.077 mol) in
DMF (130 ml) and stirred at room temperature for 12h. Water (300 ml) was added to the
reaction mixture and diluted with ethyl acetate and filtered through celite. The organic layer
was washed with brine solution and dried over sodium sulphate and concentrated under
reduced pressure to afford the title compound as a brown colour liquid (9.2 g, 70%). 'H-NMR
(8 ppm, CDCb, 400 MHz): 7.73 (dd, J = 15.1,8.4 Hz, IH), 6.73 (m, 2H), 3.85 (s, 3H), 2.53
(s,3H).
Intermediate 4: 1-(2-fluorohydroxyphenyl)ethanone: To an ice-cold
solution of intermediate 3 (9.0 g, 53.5 mmol) in dichloromethane (70 ml), aluminium chloride
04.3 g, 0.107 mol) was added and warmed to room temperature. After 12h, the reaction
mixture was quenched with aqueous 2N HCl and extracted with ethyl acetate. The organic
layer was washed with water, dried over sodium sulphate and concentrated under reduced
pressure to afford the title compound as a brown liquid (5.48 g, 66%). 'H-NMR (8 ppm,
CDCb, 400 MHz): 12.72 (s, IH), 7.40 (m, IH), 6.78 (d, J= 8.5 Hz, IH), 6.62 (dd, J = 11.3,
8.3 Hz, IH), 2.69 (d, J = 7.2 Hz, 3H).
Intermediate 5: 2-acetylfluorophenyl acetate: Pyridine (7.8 ml) and acetyl
chloride (3.60 g, 45.93 mmol) were added to an ice-cold solution of intermediate 4 (5.9 g,
38.27 mmol) in dichloromethane (50 ml) and heated to 45°C. After 3h, water was added to the
mixture and extracted into ethyl acetate. The organic layer was washed with water, dried over
sodium sulphate and the solvents evaporated. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the title compound as a yellow
liquid (6.2 g, 82%). 'H-NMR (8 ppm, CDCb, 400 MHz): 7.45 (m, IH), 7·05 (t, J = 8.9 Hz,
lH), 6.93 ( d, J = 8.1 Hz, I H), 2.56 (d, J = 3.3 Hz, 3H), 2.27 (s, 3H).
WO 20121151525
Intermediate 6: 5-hydroxymethyl-4H-chromenone:To an ice-cold
solution of intermediate 5 (3.0 g, 15.29 mmol) in dimethylsulphoxide (15 mI), sodium hydride
(0.367 mg, 15.29 mmol) was added and heated to 100°e. After 12h, the reaction mixture was
quenched with aqueous 10% HCI and extracted with ethyl acetate. The organic layer was
washed with water, dried over sodium sulphate and concentrated under reduced pressure. The
crude product was purified by column chromatography with ethyl acetate: petroleum ether to
afford the title compound as a yellow liquid (1.3 g, 48%). IH-NMR (8 ppm, CDCI), 400
MHz): 12.54 (s, IH), 7.50 (t, J = 8.3 Hz, IH), 6.86 (d, J = 8.4 Hz, IH), 6.72 (d, J = 8.2 Hz,
1 H), 6.10 (s, lH), 2.38 (s, 3H).
Intermediate 7: 5-methoxymethyl-4H-chromenone:To a solution of
intermediate 6 (1.12 g, 15.29 mmol) in DMF (10 ml), potassium carbonate (1.31g, 9.53 mmol)
and methyl iodide were added and heated to 50-60°C. After 12h, water was added to the
mixture and extracted with ethyl acetate. The organic layer was washed with water, dried over
sodium sulphate and concentrated to afford the title compound as a yellow solid (0.85 g,
70%). IH-NMR (8 ppm, CDCI), 400 MHz): 7.52 (t, J = 8.4 Hz, IH), 6.97 (d, J = 8.4 Hz, IH),
6.78 (d, J = 8.3 Hz, IH), 6.07 (s,IH), 3.96 (s, 3H), 2.29 (s, 3H).
Intermediate 8: 3-bromomethoxymethyl-4H-chromenone: N-
Bromosuccinimide (0.795 g, 4.46 mmol) was added to a solution of intermediate 7 (0.85 g,
4.46 mmol) in DMF (10 ml), at RT. After 12h, water was added to the mixture and extracted
with ethyl acetate. The organic layer was washed with water, dried over sodium sulphate and
concentrated under reduced pressure to afford the title compound as a yellow solid (0.985 g,
82%). IH-NMR (8 ppm, CDCb, 400 MHz): 7.56 (t, J = 8.0 Hz, IH), 6.99 (d, J = 8.2 Hz. IH),
6.82 ( d, J = 8.1 Hz, IH), 3.96 (s, 3H), 2.58 (s, 3H).
Intermediate 9: 3-(3-fluorophenyl)methoxymethyl-4H-chromenone:
To a solution of Intermediate 8 (0.985 g, 3.66 mmoI) and 3-Fluorophenylboronic acid (0.819
g, 5.85 mmol) in dioxan (10 ml), potassium carbonate (1.51 g, 10.98 mmol) and water (2 mI)
were added and degassed for 30 min. Tetrakis(triphenylphosphine)palladium(O) (0.253 g,
0.219 mmoI) was added under nitrogen at RT and the reaction mixture refluxed for l2h. The
solvent was evaporated completely and water was added to the residue and extracted with
ethyl acetate, organic layer dried over sodium sulphate and concentrated. The residue obtained
was purified by column chromatography w to afford the title compound as a yellow solid
(0.875 g, 81 %). IH-NMR (8 ppm, CDCI , 400 MHz): 7.55 (t, J = 8.4 Hz, IH), 7.38 (dd, J =
13.9,7.8 Hz, IH), 7.06-6.99 (m, 4H), 6.79 (d, J = 8.3 Hz, IH), 3.94 (s, 3H), 2.25 (s, 3H).
WO 20121151525
Intermediate 2-(bromomethyl)(3-fluorophenyl)methoxy-4H-
chromenone:To a solution of Intermediate 9 (0.875 g, 3.07 mmol in carbon tetrachloride
(10 ml) N-bromosuccinimide (0.547 g, 3.07 mmol) was added and heated to 80°C,
azobisisobutyronitrile (20 mg) added and stirred at the same temperature for 12h. The reaction
mixture was cooled to RT, diluted with dichloromethane and washe~ with water. The organic
layer was dried over sodium sulphate and concentrated under reduced pressure. The crude
product was purified by column chromatography with ethyl acetate: petroleum ether to afford
the title compound as an off-white solid (0.440g, 39% yield) which was used without
purification in the next step.
Intermediate 11: 4-bromofluoro-l-isopropoxybenzene:To a solution of 4-
bromofluorophenol (lOg, 52.35 mmol) in THF (100ml), isopropyl alcohol (4.8ml, 62.62
mmol) and triphenylphosphine (20.6g, 78.52 mmol) were added and heated to 45°C followed
by diisopropylazodicarboxylate (l5.4ml, 78'52 mmol). The mixture was refluxed for lh,
concentrated and the residue was purified by column chromatography with ethyl acetate:
petroleum ether to afford the title compound as a colourless liquid (l3.1g, 99%) which was
used without purification in the next step.
Intermediate 12: 2-(3-fluoroisopropoxyphenyl)-4,4,5,5-tetramethyl-l ,3,2-
dioxaborolane:Potassium acetate (10.52 g, 107.2 mmol) and bis(pinacolato)diboron (l5g,
58.96 mmol) were added to a solution of intermediate 11 (10.52 g, 107.2 mmol) in dioxane
(125 ml), and the solution was degassed for 30 min. [1, 1'-
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (4.4g, 5.36 mmol) was
added under nitrogen atmosphere and heated to 80°C. After 12h. the reaction mixture was
filtered through celite and concentrated. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the title compound as a yellow
oil (l3.9g, 99%) which was used without purification in the next step.
Intermediate 13: 3-(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidinamine;To a solution of 3-iodo-1 H-pyrazolo[3,4-d]pyrimidinamine ( 11.0 g,
42.14 mmol) in DMF 110 ml), ethanol (55 ml) and water (55 ml), intermediate 12 (23.4 g,
84.28 mmol) and sodium carbonate (13.3 g, 126.42 mmol) were added and degassed for 30
min. Tetrakis(triphenylphosphine)palladium(O) (2.4 g, 2.10 mmol) was added under nitrogen
atmosphere and heated to 80°C. After 12h, the reaction mixture was filtered though celite,
concentrated and extracted with ethyl acetate. The organic layer was dried over sodium
sulphate and concentrated under reduced pressure. The crude product was triturated with
WO 20121151525
diethyl ether, filtered and dried under vacuum to afford the title compound as light brown solid
(3.2 g, 26% yield) which is used as such for the next step.
Intermediate 14: 5-fluoromethyl-4H-chromenone: To a solution of
Intermediate 5 (5.0 g, 25.48 mmol) in THF (70 ml) cooled to -78°C, lithium
bis(trimethylsilylamide) (1M in THF, 25.45 ml, 25.48 mmol) was added maintained at the
same temperature for 2h. The mixture was warmed to RT and stirred for 4h. The reaction was
quenched by the addition aqueous ammonium chloride solution and extracted with ethyl
acetate. The organic layer was washed with water, dried over sodium sulphate and the solvents
removed. The crude product was dissolved in dioxane (8 ml) and sulphuric acid (8 ml) was
added and heated to reflux for 4h. Aqueous sodium bicarbonate solution was added to the
mixture and extracted with ethyl acetate. The organic layer was washed with water, dried over
sodium sulphate and concentrated under reduced pressure. The crude product was purified by
column chromatography with ethyl acetate: petroleum ether to afford the title compound as an
off-white solid (0.91 g, 20 %). IH-NMR (8 ppm, CDCh, 400 MHz): 7.58 (m, IH), 7.22 (d, J =
8.5 Hz, IH), 7.03 (t, J = 9.7 Hz, IH), 6.11 (s, IH), 2.34 (s, 3H).
Intermediate 15 3-bromofluoromethyl-4H-chromenone:To a
solution of intermediate 14 (0.910 g, 5.10 mmol) in DMF (8 ml), N-bromosuccinimide (0.908
g, 5.10 mmol) was added at RT. After I2h, the reaction mixture was quenched with water and
extracted with ethyl acetate. The organic layer was washed with water, dried over sodium
sulphate and the solvent removed to afford the title compound as an off-white solid (0.410 g,
31 %). IH-NMR (8 ppm, CDCh, 400 MHz): 7.62 (m, IH), 7.25 (d, J = 8.28 Hz, lH), 7.09 (t, J
= 9.6 Hz, I H), 2.63 (s, 3H).
Intermediate 16: 5-fluoro(3-fluorophenyl)methyl-4H-chromenone:
To a solution of intermediate 15 (0.150 g, 0.583 mmol) and 3-fluorophenylboronic acid (0.129
g, 0.933 mmol) in dioxan (2 ml), potassium carbonate ( 0.241 g, 1.75 mmol) and water (0.5
ml) were added and degassed for 30 min. Tetrakis(triphenylphosphine)palladium(O) (0.040 g,
0.035 mmol) was added under nitrogen at RT and the reaction mixture was refluxed for 12h.
The solvent was evaporated completely and water was added to the residue and extracted with
ethyl acetate, dried over sodium sulphate and concentrated under reduced pressure. The crude
product was purified by column chromatography with ethyl acetate: petroleum ether to afford
the title compound as a yellow solid (0.100 g, 63%). IH-NMR (8 ppm, CDCh, 400 MHz):
7.61 (m, IH), 7.42 (dd, J = 14.2,8.0 Hz, IH), 7.09-6.99 (m, 4H), 2.29 (s, 3H).
Intermediate 17: 2-(bromomethyl)fluoro(3-fluorophenyl)-4H-chromen-
4-one:To a solution of Intermediate 16 (0.245 g, 0.900 mmol in carbon tetrachloride (5 ml) N-
WO 20121151525
bromosuccinimide (0.160 g, 0.900 mmol) was added and heated to 80°C,
azobisisobutyronitrile (10 mg) added and stirred at the same temperature for 12h. The reaction
mixture was cooled to RT, diluted with dichloromethane and washed with water. The organic
layer was dried over sodium sulphate and concentrated under reduced pressure to afford the
title compound as red semi solid (0.326 g) which was used without purification in the next
step.
Intermediate 18: 2-acetylfluorophenyl propionate: Pyridine (7.2 ml) and
propionyl chloride (3.85 g, 41.65 mmol) were added to an ice-cold solution of intermediate 4
(5.35 g, 37.70 mmol) in dichloromethane (40 ml) and heated to 45°C. After 3h, water was
added to the mixture and extracted into ethyl acetate. The organic layer was washed with
water, dried over sodium sulphate and the solvents evaporated. The crude product was purified
by column chromatography with ethyl acetate: petroleum ether to afford the title compound as
a yellow liquid (6.4 g, 81 %). IH-NMR (0 ppm, CDCh, 400 MHz): 7.44 (dt, J = 8.2,6.4, I H),
7'05 (t, J = 8.9 Hz, IH), 6.92 ( d, J = 8.2 Hz, IH), 2.59 (q, J = 7.5 Hz, 2H), 2.55 (s, 3H), 1.25
(t, J = 7.5 Hz, 3H).
Intermediate 19: 2-ethylfluoro-4H-chromenone:To a solution of
Intermediate 18 (5.1 g, 24.28 mmol) in DMSO (20 ml) cooled to OOC, sodium hydride (0.582g,
24.28 mmol) was added maintained at the same temperature for I h. The mixture was warmed
to RT and stirred for 12h. The reaction was quenched by the addition of 2N HCI and extracted
with ethyl acetate. The organic layer was washed with water, dried over sodium sulphate and
the solvents removed. The crude product was dissolved in dioxane (20 ml) and sulphuric acid
(6 ml) was added and heated to reflux for 12h. Aqueous sodium bicarbonate solution was
added to the mixture and extracted with ethyl acetate. The organic layer was washed with
water, dried over sodium sulphate and concentrated under reduced pressure. The crude product
was purified by column chromatography with ethyl acetate: petroleum ether to afford the title
compound as yellow liquid (2.49 g, 51 %). IH-NMR (0 ppm, CDCI , 400 MHz): 7.58 (dt, J =
13.9,5.6 Hz, IH), 7.54(d,J=5.6Hz, lH), 7.04(t,J=8.4 Hz, lH),6.14(s, IH),2.66(q, J
= 7.6 Hz, 2H), 1.32 (t, J = 7.5 Hz, 3H).
Intermediate 20 : 3-bromoethylfluoro-4H-chromenone :To a solution
of intermediate 19 (2.49 g, 12.95 mmol) in DMF (15 ml), N-bromosuccinimide (2.30 g, 12.95
mmol) was added at RT. After 12h, the reaction mixture was quenched with water and
extracted with ethyl acetate. The organic layer was washed with water, dried over sodium
sulphate and the solvent removed to afford the title compound as an reddish brown solid (2.60
WO 20121151525
g, 74 %). 'H-NMR (8 ppm, CDCh, 400 MHz): 7.62(dt, J = 13.8,S.S Hz, IH), 7.2S (d, J = S.6
Hz, IH), 7.09 (dt, J = 9.S,1.1 Hz, IH), 2.99 (q, J = 7.6 Hz, 2H), 1.37 (t, J = 7.6 Hz, 3H).
Intermediate 21: 2-ethyl-S-fluoro(3-fluorophenyl)-4H-chromenone : To
a solution of intermediate 20 (2.60 g, 9.S9 mmo!) and 3-fluorophenylboronic acid (2.13 g,
IS.34 mmol) in dioxan (IS ml), potassium carbonate ( 3.97 g, 28.77 mmol) and water (2 ml)
were added and degassed for 30 min. Tetrakis(triphenylphosphine)palladium(O) (0.664 g,
0.S7S mmol) was added under nitrogen at RT and the reaction mixture was refluxed for 12h.
The solvent was evaporated completely and water was added to the residue and extracted with
ethyl acetate, dried over sodium sulphate and concentrated under reduced pressure. The crude
product was purified by column chromatography with ethyl acetate: petroleum ether to afford
(1.20 g, 44%). 'H-NMR (8 ppm, CDCh, 400 MHz): 7.
the title compound as a off-white solid
61 (dt, J = 13.8,S.S Hz, IH), 7.41 (dd, J = 14.0,7.8 Hz, IH), 7.27 (d, J = 7.6 Hz, IH), 7.10-
6.98 (m, 4H), 2.S9 (q, J = 7.6 Hz, 2H), 1.27 (t, J = 7.S Hz, 3H).
Intermediate 22: 2-(l-bromoethyl)-S-fluoro(3-fluorophenyl)-4H-chromen-
4-one: To a solution of Intermediate 21 (O.SOO g, 1.86 mmol in carbon tetrachloride (S ml) N
bromosuccinimide (0.331 g, 0.900 mmol) was added and heated to 80°C,
azobisisobutyronitrile· (S mg) added and stirred at the same temperature for 12h. The reaction
mixture was cooled to RT, diluted with dichloromethane and washed with water. The organic
layer was dried over sodium sulphate and concentrated under reduced pressure to afford the
title compound as a off-white solid (0.460 g, 68%). 'H-NMR (8 ppm, CDCl , 400 MHz): 7.68
(dt, J = 8.4,S.4 Hz, IH), 7.46 (dd, J = 14.1,8.0 Hz, IH), 7.37 (d, J = 8.S Hz, IH), 7.IS-7.0S
(m, 4H), 4.91 (q, J = 6.9 Hz, IH), 1.98 (d, J = 6.9 Hz, 3H).
Intermediate 23: S-fluoro(3-fluorophenyl)(1-hydroxyethyl)-4H-
chromenone : To a solution of Intermediate 22 (0.9S0 g, 2.60 mmol ) in DMSO (9.S ml), n
butanol (0.47 ml) was added and heated to 120°C for 3h., The reaction mixture was cooled to
RT, quenched with water and extracted with ethyl acetate. The organic layer was dried over
sodium sulphate and concentrated under reduced pressure. The crude product was purified by
column chromatography with ethyl acetate: petroleum ether to afford the title compound as a
yellow solid (0.700 g, 89%). 'H-NMR (8 ppm, DMSO-D6, 400 MHz): 7.84 (dt, J = 14.2,S.7
Hz, I H), 7.S3 (d, J = 8.7 Hz, I H), 7.49 (m, I H), 7.27 (m, 2H), 7.1S (m, 2H), S.62 (d, J = 4.8
Hz, I H), 4.44 (m, 1 H), 1.37 (d, J = 6.S Hz, 3H).
Intermediate 23a and 23b: (+ )-S-fluoro(3-fluorophenyl)(l-
hydroxyethyl)-4H-chromenone and (-)-S-fluoro(3-fluorophenyl)( l-hydroxyethyl)-4H
chromenone : The two enantiomerically pure isomers were separated by preparative SFC
WO 20121151525
conditions from intermediate 23 (0.300 g) on a CHIRALPAK AD-H column (250 x 4.6 mm;
/lm) using methanol: C02 (20:80) as the mobile phase at a flow rate of 3.0 ml / min.
Intermediate 23a: Off-white solid (0.140 g). e.e. 100%. Rt: 2041 min. [a]25 4.17 (c = 1,
MeOH). Mass: 302.9 (M+).
Intermediate 23b: Off-white solid (0.143 g). e.e. 100%. Rt: 3.06 min. [a] o" -4.17 (c = 1,
MeOH). Mass: 302.9 (M+).
Intermediate 24: 2-acetylfluoro(3-fluorophenyl)-4H-chromenone
DMSO (0.657 ml, 9.26 mmol ) was added to dichloromethane (8 ml) cooled to -78°C,
followed by oxalyl chloride (0040 ml, 4.63 mmol). After 10 min. intermediate 23 (0.700 g,
2.31 mmol ) in dichloromethane (4 m!) was added dropwise and stirred for 20 min.
Triethylamine (l.3 ml) was added and stirred for Ih. The reaction mixture was quenched with
water and extracted with dichloromethane. The organic layer was dried over sodium sulphate
and concentrated under reduced pressure. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the title compound as a yellow
solid (00450 g, 65%). IH-NMR (8 ppm, CDCh, 400 MHz): 7.71 (dt, J = 11.2,2.9 Hz, IH),
7040 (m, 2H), 7.14-7.00 (m, 4H), 2.32 (s, 3H).
Intermediate 25: (R)/(S)fluoro(3-fluorophenyl)( l-hydroxyethyl)-4H-
chromenone : To intermediate 24 (0.280 g, 0.93 mmol ), S-Alpine borane (0.5M in THF, 10
m!) was added and heated to 70°C for 24h. The reaction mixture was quenched with aq. 2N
HCI, and extracted with ethyl acetate. The organic layer was dried over sodium sulphate and
concentrated under reduced pressure. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the title compound as an off
white solid (0.200 g, 71 %). Enantiomeric excess: 73%, enriched in the late eluting isomer
(retention time: 8.72 min. as determined by HPLC on a chiralpak AD-H column.
Intermediate 26: (R)/(S)fluoro(3-fluorophenyl)( l-hydroxyethyl)-4H-
chromenone : To intermediate 24 (0.280 g, 0.93 mmol ), R-Alpine borane (0.5M in THF,
2.8 m!) was added and heated to 60°C for 24h. The reaction mixture quenched with aq. 2N
HCI, and extracted with ethyl acetate. The organic layer was dried over sodium sulphate and
concentrated under reduced pressure. The crude product was purified by column
chromatography with ethyl acetate: petroleum ether to afford the title compound as a pale
yellow solid (0.110 g, 37%). Enantiomeric excess: 94.6%, enriched in the fast eluting isomer
(retention time: 7.16) as determined by HPLC on a chiralpak AD-H column.
Intermediate 27: 2-( 1-( 4-aminoiodo-l H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: To a solution of 3-iodo-1 H-
WO 20121151525
pyrazolo[3,4-d]pyrimidinamine (0.800 g, 2.88 mmol) in DMF (5 ml), potassium carbonate
(0.398 g, 2.88 mmol) was added and stirred at RT for 30 min. To this mixture intermediate 22
(0.500 g, 1.44 mmol) was added and stirred for 12h. The reaction mixture was diluted with
water and extracted with ethyl acetate. The organic layer was dried over sodium sulphate and
concentrated under reduced pressure. The crude product was purified by column
chromatography with methanol: dichloromethane to afford the title compound as a off-white
solid (0.300 g, 38%). IH-NMR (8 ppm, DMSO-d63, 400 MHz): 8.02 (s, IH), 7.94 (s, IH),
7.84 (dt, J = 8.4,5.7 Hz, IH), 7.47 (d, J = 8.6 Hz, IH), 7.29 (m, 3H), 7.09 (dt, J = 8.8,2.3 Hz,
IH), 6.87 (s, 2H), 5.88 (q, J = 7.0 Hz, IH), 1.82 (d, J = 7.0 Hz, 3H).
Intermediate 28: 3-bromo(1-bromoethyl)fluoro-4H-chromenone:
(3.60 g, 94%) by using a procedure that is
The title compound was obtained as a brown solid
similar to the one described for intermediate 22 from intermediate 20 (3.0 g, 11.06 mmol),
carbon tetrachloride (30 ml) N-bromosuccinimide (1.96 g, 11.06 mmol) and
azobisisobutyronitriIe (30 mg) which is used as such in a next step.
Intermediate 29: 2-( 1-(4-amino(3-fluoroisopropoxyphenyl)-1 H-
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)bromofluoro-4H-chromenone: The title
compound was obtained as a brown solid (0.800 g, 36%) by using a procedure that is similar
to the one described for intermediate 27 from intermediate 13 (1.11 g, 4.28 mmol), cesium
carbonate ( 1.39 g, 4.28 mmol), DMF (5 ml) and intermediate 28. IH-NMR (8 ppm, CDCb,
400 MHz): 8.37 (s, IH), 7.62 (dt, J = 8.4,5.4 Hz, IH), 7.45 (dd, J = 11.5,2.1 Hz, IH), 7.39
(m, I H), 7.22 (d, J = 8.6 Hz, I H), 7.14-7.04 (m, 2H), 6.60 (g, J = 7.1 Hz, I H), 5.67 (s, 2H),
4.65 (g, J = 6.0 Hz, I H), 2.08 (d, J = 7.1 Hz, 3H), 1.41 (d, J = 6.1 HZ,6H).
Intermediate 30: 2-ethylfluoro(4-fluorophenyl)-4H-chromenone: The
title compound was obtained as a off-white solid (0.680 g, 54%) by using a procedure that is
similar to the one described for intermediate 21 from intermediate 20 (1.20 g, 4.42 mmol) ,4-
fluorophenylboronic acid (0.991 g, 7.08 mmol), dioxan (9 ml), potassium carbonate ( 1.83 g,
13.27 mmol), water (1.2 ml) and tetrakis(triphenylphosphine)palladium(O) (0.306 g, 0.265
mmol): IH-NMR (8 ppm, CDCh, 400 MHz): 7.60 (dt, J = 8.3,5.5 Hz, IH), 7.27 (m, 3H), 7.
13 (t, J = 8.7 Hz, 2H), 7.04 (t, J = 9.1 Hz, IH), 2.55 (g, J = 7.6 Hz, 2H), 1.27 (t, J = 7.6 Hz,
3H).
Intermediate 31: 2-( l-bromoethyl)fluoro( 4-fluorophenyl)-4H-chromen-
4-one: The title compound was obtained as a brown solid (0.740 g, 85%) by using a procedure
that is similar to the one described for intermediate 22 from intermediate 30 (0.680 g, 2.37
mmol), carbon tetrachloride (10 ml) N-bromosuccinimide (0.423 g, 2.37 mmol) and
WO 20121151525
azobisisobutyronitrile (30 mg). IH-NMR (0 ppm, CDCb, 400 MHz): 7. 67 (dt, J = 8A, 5.5
Hz, IH), 7.37 (m, 3H), 7. 18 (t, J = 8.7 Hz, 2H), 7.09 (t, J = 8.5 Hz, IH), 4.92 (q, J = 6.9 Hz,
IH), 1.97(d, J=6.9Hz,3H).
Intermediate 32: 2-ethylfluorophenyl-4H-chromenone: The title
compound was obtained as a off-white solid (0.600 g, 50%) by using a procedure that is
similar to the one described for intermediate 21 from intermediate 20 (1.20 g, 4.42 mmol) ,
phenylboronic acid (0.864 g, 7.08 mmol), dioxan (9 ml), potassium carbonate ( 1.83 g, 13.27
mmol), water (1.2 ml) and tetrakis(triphenylphosphine)palladium(O) (0.306 g, 0.265 mmol).
IH-NMR (0 ppm, CDCh, 400 MHz): 7. 61 (dt, J = 8.4, 5.5 Hz, IH), 7A5 (m, 3H), 7.28 (m,
3H), 7.05 (dt, J = 8.5,1.3 Hz, IH), 2.60 (q, J = 7.6 Hz, 2H), 1.28 (t, J = 7.5 Hz, 3H).
Intermediate 33: 2-( I-bromoethyl)fluorophenyl-4H-chromenone:
The title compound was obtained as a brown solid (0.590 g, 76%) by using a procedure that is
similar to the one described for intermediate 22 from intermediate 32 (0.600 g, 2.23 mmol),
carbon tetrachloride (9 ml) N-bromosuccinimide (0.398 g, 2.37 mmol) and
azobisisobutyronitrile (30 mg). IH-NMR (0 ppm, CDCh, 400 MHz): 7. 66 (dt, J = 8.4, 5.5
Hz, IH), 7A8 (m, 3H), 7.37 (m, 3H), 7.08 (t, J = 9.8 Hz, IH), 4.95 (q, J = 6.8 Hz, IH), 1.97
(d, J = 6.9 Hz, 3H).
Intermediate 34: 2-( 1-( 4-aminoiodo-l H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone: To a solution of 3-iodo-1 H
pyrazolo[3,4-d]pyrimidinamine (0.800 g, 2.88 mmol) in DMF (5 ml), potassium carbonate
(0.398 g, 2.88 mmol) was added and stirred at RT for 30 min. To this mixture intermediate 22
(0.500 g, 1.44 mmol) was added and stirred for l2h. The reaction mixture was diluted with
water and extracted with ethyl acetate. The organic layer was dried over sodium sulphate and
concentrated under reduced pressure. The crude product was purified by column
chromatography with methanol: dichloromethane to afford the title compound as a off-white
solid (0.300 g, 38%). IH-NMR (0 ppm, DMSO-d , 400 MHz): 8.02 (s, IH), 7.94 (s, IH),
7.84 (dt, J = 8A,5.7 Hz, IH), 7A7 (d, J = 8.6 Hz, IH), 7.29 (m, 3H), 7.09 (dt, J = 8.8,2.3 Hz,
IH), 6.87 (s, 2H), 5.88 (q, J = 7.0 Hz, IH), 1.82 (d, J = 7.0 Hz, 3H).
Intermediate 35: 2-(l-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)isoindoline-I,3-dione: To a solution of phthalimide (OA20 g, 2.88 mmol) in DMF (4
ml), potassium carbonate (0.43 g, 2.88 mmol) was added and stirred at RT for 30 min. To this
mixture intermediate 22 (OAOO g, 2.88 mmol) was added and stirred for 12h. The reaction
mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried
over sodium sulphate and concentrated under reduced pressure. The crude product was
WO 20121151525
purified by column chromatography with ethyl acetatel: pet.ether to afford the title compound
as a off-white solid (0.350 g, 32%). IH-NMR (8 ppm, CDCI), 400 MHz): 7.77(m, 4H), 7.63
(dt, J = 8.4,5.4 Hz, IH), 7.34 (d, J = 8.5 Hz, IH), 7.28 (m, IH), 7.08 (m, IH), 6.97 (m, 2H),
6.86 (d, J = 7.4 Hz, IH), 5.79 (q, J = 7.2 Hz, IH), 1.81 (d, J = 7.2 Hz, 3H).
Intermediate 36: 2-(l-aminoethyl)fluoro(3-fluorophenyl)-4H-chromen-
4-one: To a solution of intermediate 35 (0.350 g, 0.847 mmol) in methanol ( 3.5 ml),
hydrazine hydrate (0.070 g, 1.27 mmol) was added and refluxed for 3h. The reaction mass
cooled, filtered and washed with chloroform. The filterate was concentrated to afford the title
compound as a brown solid (0.200 g, 78%). IH-NMR (8 ppm, DMSO-d , 400 MHz): 7.29
(dt, J = 8.0,6.4 Hz, 1 H), 7.19 (q, J = 8.2 Hz, 1 H), 7.02 (m, 3H), 6.69 (d, J = 8.2 Hz, I H), 6.59
(t, J = 8.8 Hz, IH), 4.12 (q, J = 6.6 Hz, IH), 1.32 (d, J = 6.7 Hz, 3H).
Intermediate 37: 4-bromo-I-(difluoromethoxy)fluorobenzene: To a
solution of 4-bromofluorophenol (1.00 g, 5.23 mmol) in DMF ( 17 ml) and water (2.3 ml),
sodiumchlorodifluoroacetate (l.60g, 1047 mmol) and potassium carbonate (0.866 g, 6.282
mmol)were added. The flask was purged with nitrogen for 15 min. and heated to 100°C. After
2.5h, cooled to room temperature, con.HCI (2.5 ml) and water (2.5 ml) were added and stirred
for Ih. The reaction mixture was cooled to O°C, quenched with aq. IN sodium hydroxide
solution, extracted with ethyl acetate and dried over sodium sulphate and concentrated. The
crude product was purified by column chromatography with ethyl acetatel: pet.ether to afford
the title compound as a colourless liquid (0.545 g, 43%). IH-NMR (8 ppm, CDCI), 400 MHz):
7.36 (dd, J = 9.7,2.3 Hz, I H), 7.28 (td, J = 8.7,1.5 Hz, I H), 7.15 (t, J = 8.3 Hz, IH), 6.71 (t, J
= 73.0 Hz, I H).
Intermediate 38: 2-(4-(difluoromethoxy)fluorophenyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane: The title compound was obtained as a yellow liquid (0.475 g, 76%) by
using a procedure that is similar to the one described for intermediate 12 from intermediate 35
(0.520 g, 2.15 mmol), potassium acetate (0.423 g, 4.31 mmol) , bis(pinacolato )diboron (0.602
g, 2.37 mmol) dioxane (10 ml) and[I,1 '-Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH CI (0.088 g, 0.107 mmol). IH-NMR (8 ppm, CDCh, 400 MHz): 7.59 (m,
2H), 7.23 (t, J = 7.9 Hz, I H), 6.75 (t, J = 73.5 Hz, I H), 1.35 (s, 12H).
Intermediate 39: 3-(4-(difluoromethoxy)fluorophenyl)-1 H-pyrazolo[3,4-
d]pyrimidinamine: The title compound was obtained as a light brown solid (0.321 g, 28%)
by using a procedure that is similar to the one described for intermediate 13 from intermediate
38 (1.70 g, 5.74 mmol), 3-iodo-IH-pyrazolo[3,4-d]pyrimidinamine ( 1.0 g, 3.83 mmol),
DMF (5 ml), ethanol (2.5 ml), water (2.5 ml) sodium carbonate (1.21 g, 11.49 mmol) and
WO 20121151525
tetrakis(triphenylphosphine)palladium(O) (0.221 g, 0.191 mmol) IH-NMR (0 ppm, DMSO-d6,
400 MHz): 13.66 (s, IH), 8.21 (s,IH), 7.62 dd, J = 10.6,5.4 Hz, IH), 7.51 (m, 2H), 7.48 (t, J
= 73.2 Hz, IH), 6.92 (s, 2H).
Intermediate 40: 4-(4-bromofluorophenoxy)tetrahydro-2H-pyran: To a
solution of 4-bromofluorophenol (3.89 g, 20.39 mmol) in THF (50 ml), 4-
hydroxytetrahydropyran (2.50 g, 24.47 mmol) and triphenylphosphine (8.02 g, 30.58 mmol)
were added and heated to reflux for 2h. The reaction mixture was cooled to O°C ,
diisopropylazodicarboxylate (6.02 ml, 30.58 mmol)was added anr hated to reflux for 12h. The
reaction mixture was concentrated and the crude product was purified by column
chromatography with ethyl acetatel: pet.ether to afford the title compound as a colourless
liquid (0.3.6 g, 83%). IH-NMR (0 ppm, CDCh, 400 MHz): 7.26 (dd, J = 10.4,2.1 Hz, IH),
7.18 (m, IH), 6.90 (t, J = 8.7 Hz, IH), 4.45 (m, IH), 4.01 (m ,2H), 3.57 (m, 2H), 2.02-1.76 (m,
4H).
Intermediate 41: 2-(3-fluoro(tetrahydro-2H-pyranyloxy)phenyl)-
4,4,5,5-tetramethyl-l,3,2-dioxaborolane: The title compound was obtained as a off-white solid
(2.50 g, 59%) by using a procedure that is similar to the one described for intermediate 12
from intermediate 40 (3.50 g, 16.49 mmol), potassium acetate (3.25 g, 32.99 mmol) ,
bis(pinacolato)diboron (4.60 g, 18.14 mmol) dioxane (40 ml) and[I,I'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH CIz (1.34 g, 1.64 mmol). IH_
NMR (0 ppm, CDCh, 400 MHz): 7.50 (m, 2H), 6.97 (t, J = 7.9 Hz, IH), 4.54 (m, IH), 4.00
(m, 2H), 3.57 (m, 2H), 2.02-1.76 (m, 4H), 1.31 (s, 12H).
Intermediate 42: 1-(4-bromofluorophenyl)methylpropan-l-01: To an
ice-cold solution of isopropylmagnesium bromide prepared from magnesium (8.8 g, 0.147
mol) and 2-bromopropane (18.1 g, 0.147 mol) in diethyl ether (80 ml), 4-bromo
fluorobenzaldehyde (10.0 g, 0.049 mol) in diethyl ether( 20 ml) was added and warmed to
room temperature. After 12h, the reaction mixture was cooled to O°C, quenched with dilute
aqueous HCI and extracted with ethyl acetate. The organic layer was dried over sodium
sulphate and concentrated under reduced pressure to afford the title compound as a brown
liquid (12.0 g, 99%) which was used without purification in the next step.
Intermediate 43: 1-( 4-bromofluorophenyl)methylpropan-l-one: The
title compound was obtained as a light brown liquid (0.5.8 g, 59%) by using a procedure that
is similar to the one described for intermediate 3 from intermediate 42 (10.0 g, 40.46 mmol),
pyridinium dichromate (22.8 g, 60.70 mmol) and DMF (50 ml) which was used without
purification in the next step.
WO 20121151525
Intermediate 44: 6-bromoisopropyl-IH-indazole: To a solution of
intermediate 42 (5.80 g, 23.66 mmol) in ethylene glycol (39 ml), hydrazine hydrate (2.3 g,
47.32 mmo!) was added and heated to 160°C for 12h. The reaction mixture was cooled and
quenched with ethyl acetate and extracted with ethyl acetate, dried over sodium sulphate and
concentrated to afford the title compound as pale yellow solid (3.0 g, 54%).). IH-NMR (0
ppm, CDCh, 400 MHz): 9.80 (s, IH), 7.63 (d, J = 8.7 Hz, IH), 7.61 (s, IH), 7.24 (dd, J = 8.5,
1.5 Hz, I H), 3.43 (quintet, J = 7.0 Hz, I H), 1.45 (d, J = 6.9 Hz, 6H).
Intermediate 45: tert-butyl 6-bromoisopropyl-1 H-indazole-l-carboxylate:
To a solution of intermediate 44 (2.0 g, 8.36 mmol) in acetonitrile (20 ml), 4-
dimethylaminopyridine (0.102 g, 0.836 mmo!), Boc-anhydride (1.82 g, 8.36 mmol) were
added at 20-25°C followed by triethylamine (0.846 g, 8.36 mmo!). After 12h, the reaction
mixture was concentrated and quenched with water, extracted with ethyl acetate, dried with
ethyl acetate and concentrated. The crude product was purified by column chromatography
with ethyl acetatel: pet.ether to afford the title compound as a colourless liquid (1.70 g, 61 %).
IH-NMR (0 ppm, CDCh, 400 MHz): 8.29(s, IH), 7.60 (d, J = 8.4 Hz, IH), 7.40 (dd, J =
8.5,1.5 Hz, IH), 3.41 (quintet,J= 7.0 Hz, IH), 1.71 (s,9H), 1.46(d,J=7.0 Hz, 6H).
Intermediate 46: tert-butyl 3-isopropyl(4,4,5,5-tetramethyl-I,3,2-
dioxaborolany!)-IH-indazole-I-carboxylate The title compound was obtained as a off-white -
solid (1.50 g, 79%) by using a procedure that is similar to the one described for intermediate
12 from intermediate 45 (1.70 g, 5.01 mmol), potassium acetate (0.980 g, 10.02 mmol) ,
bis(pinacolato)diboron (l.40 g, 5.51 mmol) dioxane (17 ml) and [1,1'
Bis(diphenylptlOsphino)ferrocene]dichloro palladium(II).CH CI (0.200 g, 0.250 mmol). IH_
NMR (0 ppm, CDCh, 400 MHz): 8.59 (s, IH), 7.74 (d, J = 7.4 Hz, IH), 7.68 (d, J = 8.1 Hz,
IH), 3.45 (quintet, J = 7.0 Hz, IH), 1.73 (s, 9H), 1.48 (d, J = 7.0 Hz, 6H), 1.36 (s, 12H).
Intermediate 47: tert-butyl 4-(4-bromofluorophenoxy)piperidine-l-
carboxylate: To a solution of 4-bromofluorophenol (1.66 g, 8.69 mmol) in THF (20 ml), 4-
hydroxy-l-Bocpiperidine (2.10 g, 10.43 mmol) and triphenylphosphine (3.42 g, 13.04 mmol)
\yere added and heated to 45°C. After 30 min. diisopropylazodicarboxylate (2.56 ml, 13.04
mmo!) was added and stirred for 12h. The reaction mixture was concentrated and the crude
product was purified by column chromatography with ethyl acetatel: peL ether to afford the
title compound as a colourless liquid (1.20 g, 38%). IH-NMR (0 ppm, CDCh, 400 MHz):
7.25 (dd, J = 8.7,2.7 Hz, IH), 7.18 (m, IH), 6.89 (t, J = 8.7 Hz, IH), 4.42 (septet, J = 3.6 Hz,
IH), 3.73 (m, 2H), 3.34 (m ,2H), 1.92-1.72 (m, 4H)., 1.46 (s, 9H).
WO 20121151525
Intermediate 48: tert-butyl 4-(2-fluoro( 4,4,5,5-tetramethyl-1 ,3,2-
dioxaborolanyl)phenoxy)piperidine-I-carboxylate: The title compound was obtained as a
pale yellow solid (1.90 g, 99%) by using a procedure that is similar to the one described for
intermediate 12 from intermediate 47 (1.10 g, 2.92 mmol), potassium acetate (0.573 g, 5.84
mmol) , bis(pinacolato)diboron (0.816 g, 3.21 mmol) dioxane (12 ml) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.230 g, 0.292 mmol). IH_
NMR (0 ppm, CDCh, 400 MHz): 7.51 (m, 2H), 6.98 (t, J = 7.9 Hz, IH), 4.53 (septet, J = 3.5
Hz, IH), 3.72 (m, 2H), 3.36 (m, 2H), 1.92-1.74 (m, 4H), lAS (s, 9H), 1.31 (s, 12H).
Intermediate 49: 2-(2-fluoronitrophenylamino) ethanol: To a solution of
3,4-difluoro--nitrobenzene (3.50 g, 22.0 mmol) in acetonitrile (35 ml), ethanolamine (1.98 ml,
33.0 mmo\) was added and heated at reflux for 4h. The reaction mass was concentrated and
residue was triturated with pet. ether and filtered and dried under vacuum to afford the tiltle
compound as a yellow solid (3.2 g, 73%) which was used without purification in the next step.
Intermediate 50: 2-(4-aminofluorophenylamino)ethanol: To a solution of
intermediate 49 (3.2 g, 15.98 mmol) in methanol, palladium on charcoal (0.800 g, 5% Pd/C)
was added and hydrogenated in an autoclave at 4kg/cm2 for 4h at room temeperature.The
reaction mass was filtered through celite, washed with methanol and concentrated under
vaccum to afford the title compound as brown liquid (3.00 g, 99%) which was used without
purification in the next step.
Intermediate 51: 2-( 4-bromofluorophenylamino )ethanol: To intermediate
50 (3.00 g, 17.62 mmol), 48% hydrobromic acid (36 ml) was added and cooled to DoC, sodium
nitrite (3.64 g, 52.88 mmol) in water (42 m\) was added dropwise and stirred at room
temperature for IS min. The reaction mixture was cooled again to DoC and copper(I)bromide
(3.79 g, 26044 mmol) was added and heated to 140°C for 4h. The reaction mass was cooled to
room temeperature and basified with saturated sodium bicarbonate solution, filtered through
celite , washed with ethyl acetate. The aqueous layer was extracted with ethyl acetate, dried
with sodium sulphate and concentrated. The crude product was purified by column
chromatography with ethyl acetate: pet.ether to afford the title compound as a brown liquid
(lAO g, 34%). IH-NMR (0 ppm, CDCh, 400 MHz): 7.14 (m, 2H), 6.61 (t, J = 8.7 Hz, IH),
4.21 (br s, I H), 3.86 (t, J = 5.1 Hz, 2H), 3.32 (t, J = 5.0 Hz, 2H),. 1.72 (s, 1 H).
Intermediate 52: 2-(2-fluoro(4,4,5,5-tetramethyl-I,3,2-dioxaborolan
yl)phenylamino)ethanol: The title compound was obtained as a brown liquid (lAO g, 58%) by
using a procedure that is similar to the one described for intermediate 12 from intermediate 50
(lAO g, 2.92 mmol), potassium acetate (1.17 g, 11.95 mmol) , bis(pinacolato)diboron (1.67 g,
WO 20121151525
6.57 mmol) dioxane (35 m!) and [1,1' -Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH CIz (0.240 g, 0.292 mmo!). IH-NMR (0 ppm, CDCI], 400 MHz): 7.46 (m,
1 H), 7.39 (m, 1 H), 6.71 (t, J = 8.2 Hz, 1 H), 4.07 (t, J = 5.2 Hz, 1 H), 3.86 (t, J = 5.2 Hz, 2H),
3.38 (t, J = 5.3 Hz, 2H), 1.97 (s, IH), 1.31 (s, 12H).
Intermediate 53: 2-fluoro-N-isopropylnitroaniline: To a solution of 3,4-
difluoro-nitrobenzene (4.00 g, 25.14 mmo!) in ethyl acetate (40 ml) and triethylamine (3.86
ml) cooled to O°C , isoprppylamine (2.30 ml, 27.65 mmol) was added slowly and stirred at
room temperature for 24h. The reaction mass quenchen with water, extracted with
ethylacetate, dried over sodium sulphate and concentrated. The crude product was purified by
column chromatography with ethyl acetate: pet.ether to afford the title compound as a yellow
liquid (l.80 g, 36%). IH-NMR (0 ppm, DMSO-d , 400 MHz): 7.94 dd, J = 9.1,l.5 Hz, IH),
7.89 (dd, J = 12.2,2.5 Hz, IH), 6.84 (t, J = 8.9 Hz, IH), 6.78 (d, J = 10.7 Hz, IH), 3.83 (m,
IH), 1.20 (d, J = 6.4 Hz, 6H).
Intermediate 54: 2-fluoro-N I-isopropylbenzene-I ,4-diamine: The title
compound was obtained as a brown liquid (1.30 g, 90%) by using a procedure that is similar to
the one described for intermediate 50 from intermediate S3 (1.70 g, 8.62 mmol), ethyl acetate
(20 m!) and palladium on charcoal (0.170 g, 5% PdlC) which was used without purification in
the next step.
Intermediate 55: 4-bromofluoro-N-isopropylaniline: The title compound
was obtained as a brown liquid (2.00 g, crude) by using a procedure that is similar to the one
describedforintermediate 51 from intermediate 54 (1.30 g, 7.73 mmol), 48% hydrobromic acid
(16 ml) , sodium nitrite (1.60 g, 23.21 mmo!) , water (19 ml) and copper(I)bromide (1.66 g,
22.21 mmol) which was used without purification in the next step.
Intermediate 56: 2-fluoro-N-isopropyl( 4,4,5,5-tetramethyl-1 ,3,2-
dioxaborolanyl)aniline: The title compound was obtained as a brown liquid (1.40 g, 58%)
by using a procedure that is similar to the one described for intermediate 12 from intermediate
55 (2.00 g, 8.65 mmol), potassium acetate (2.50 g, 25.97 mmol) , bis(pinacolato)diboron (2.60
g, 10.38 mmol) dioxane (20 m\) and [1,1' -Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH CIz (0.212 g, 0.259 mmol). IH-NMR (0 ppm, CDCI], 400 MHz): 7.45 (dd,
J = 8.1, 1.2 Hz, IH), 7.37 (dd, J = 12.3,1.2 Hz, IH), 6.67 (t, J = 8.1 Hz, IH), 3.95 (m, IH),
3.68 (m, I H), 1.26 (s, 12H), 1.24 (d, J = 6.3 Hz, 6H).
Intermediate 57: 2-fluoro-N,N-dimethylnitroaniline: The title compound
was obtained as a yellow liquid (2.70 g, 58%) by using a procedure that is similar to the one
described for intermediate 53 from of 3,4-difluoro-nitrobenzene (4.00 g, 25.14 mmol) in ethyl
WO 20121151525
acetate (40 ml) and triethylamine (7.36 ml) and dimethyl amine hydrochloride (2.25 g, 27.65
mmol). IH-NMR (8 ppm, CDCh, 400 MHz): 7.93 (dd, J = 9.1,2.6 Hz, IH), 7.89 (dd, J = 14.1,
2.6 Hz, IH), 6.73 (t, J = 9.1 Hz, IH), 3.09 (s, 6H).
Intermediate 58: 2-fluoro-N I ,N I-dimethylbenzene-I ,4-diamine: The title
compound was obtained as a brown liquid (2.10 g, 93%) by using a procedure that is similar to .
the one described for intermediate 50 from intermediate 57 (2.70 g, 14.67 mmol), ethyl acetate
(20 ml) and palladium on charcoal (0.270 g, 5% Pd/C) which was used without purification in
the next step.
Intermediate 59: 4-bromofluoro-N,N-dimethylaniline: The title compound
was obtained as a yellow liquid (2.20 g, 74%) by using a procedure that is similar to the one
described for intermediate 51 from intermediate 58 (2.10 g, 13.63 mmol), 48% hydrobromic
acid (26 ml) , sodium nitrite (2.30 g, 40.90 mmol) , water (30 ml) and copper(I)bromide (2.93
g, 20.45 mmol). IH-NMR (8 ppm, CDCh, 400 MHz): 7.17 (m, 2H), 6.76 (t, J = 8.6 Hz, IH),
2.86 (s, 6H).
Intermediate 60: 2-fluoro-N,N-dimethyl( 4,4,5,5-tetramethyl-1 ,3,2-
dioxaborolanyl)aniline: The title compound was obtained as a yellow liquid (0.950 g, 37%)
by using a procedure that is similar to the one described for intermediate 12 from intermediate
59 (2.10 g, 9.67 mmol), potassium acetate (2.84 g, 29.03 mmol) , bis(pinacolato)diboron (2.94
g, 11.61 mmol), dioxane (22 ml) and [1,1 '-Sis (diphenylphosphino)ferrocene]dichloro
palladium(II).CH CI (0.237 g, 0.290 mmol). IH-NMR (8 ppm, CDCh, 400 MHz): 7.48 (dd,
J = 8.0,1.4 Hz, 1 H), 7.43 (dd, J = 13.7,1.4 Hz, I H), 6.84 (t, J = 8.5 Hz, I H), 2.90 (s, 6H), 1.32
(s, 12H).
Intermediate 61: 2 4-(2-fluoro(4,4,5,5-tetramethyl-l,3,2-dioxaborolan
yl)phenyl)morpholine: The title compound was obtained as a off-white solid (2.00 g, 91 %) by
using a procedure that is similar to the one described for intermediate 12 from 4-(4-bromo
fluorophenyl)morpholine (1.90 g, 7.30 mmol ; for preparation see Bioorganic Med.
Chem.Lett.2006, 16, 176-180), potassium acetate (1.43 g, 14.60 mmol)
bis(pinacolato)diboron (2.00 g, 8.03 mmol), dioxane (48 ml) and [1,1 '-Bis
(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.290 g, 0.365 mmol). IH_
NMR (8 ppm, CDCh, 400 MHz): 7.51 (dd, J = 7.9,1.3 Hz, IH), 7.45 (dd, J = 13.5,1.3 Hz,
IH), 6.92 (t, J = 8.3 Hz, IH), 3.87 (t, J = 4.7 Hz, 4H), 3.14 (t, J = 4.7 Hz, IH), 1.32 (s, 12H).
Intermediate 62: 1-(4-bromofluorophenyl)methylpiperazine: The title
compound was obtained as a brown liquid (1.20 g, 31 %) by using a procedure that is similar to
the one described for intermediate 51 from 3-fluoro(4-methylpiperazin-l-yl)aniline (3.00 g,
WO 20121151525
14.31 mmol ; for preparation see Synth. Commun. 2010,40,789-798),48% hydrobromic acid
(35 ml) , sodium nitrite (2.96 g, 42.95 mmol) , water (40 ml) and copper(I)bromide (3.00 g,
21.47 mmol) which was used as such in next step.
ntermediate 63: 1-(2-fluoro( 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan
yl)phenyl)methylpiperazine: The title compound was obtained as a brown liquid (0.450 g,
24%) by using a procedure that is similar to the one described for intermediate 12 from
intermediate 62 (1.20 g, 4.38 mmol), potassium acetate (0.86 g, 8.77 mmol) ,
bis(pinacolato)diboron (1.22 g, 4.82 mmol), dioxane (30 ml) and [1,1 '-Bis
(diphenylphosphino)ferrocene]dichloro palladium(II).CH CIz (0.179 g, 0.219 mmol). IH_
NMR (8 ppm, CDCh, 400 MHz): 7.50 (dd, J = 8.0,1.8 Hz, IH), 7.44 (dd, J = 13.4,1.3 Hz,
IH), 6.91 (t, J = 8.3 Hz, IH), 3.23 (t, J = 4.7 Hz, 4H), 2.77 (t, J = 4.5 Hz, 4H),2.42 (s, 3H),
1.32 (s, 12H).
Intermediate 64: 2-(1-methoxypropylidene)malononitrile: To malononitrile
(2.24 g, 33.90 mmol), trimethylorthopropionate (5.0 g, 37.26 mmol) was added and heated to
reflu for 3h.The reaction mixture was concentrated, quenched with water, extracted with ethyl
acetate, dried over sodium sulphate and concentrated to afford the title compound as brown
solid (4.3 g, 93%) which was used as in a next step.
Intermediate 65: 5-aminoethyl-lH-pyrazolecarbonitrile: To a solution
of intermediate 64 (4.30 g, 31.58 mmol) in ethanol ( 15 ml), hydrazine hydrate (2.37 g, 47.37
mmol) was added and refluxed for 12h. The reaction mass was concentrated under reduced
pressure and to the residue ice was added and the precipitate formed was filtered and dried
under vacuum to afford the title compound as off-white solid (2.0 g, 47%). IH-NMR (8 ppm,
DMSO-d , 400 MHz): 11.61 (s, I H), 5.85 (s, 2H), 2.52 (q, J = 7.9 Hz, 2H), 1.16 (t, J = 7.6 Hz,
3H).
Intermediate 66: 3-ethyl-lH-pyrazolo[3,4-d]pyrimidinamine: To
intermediate 65 (1.00 g, 7.34 mmol), formamide (8.2 ml) was added and heated to l30 C for
12h. The reaction mass was quenched with water and the solid formed was filtered, dried
under vacuum to afford the title compound as off-white solid (0.600 g, 50%). IH-NMR (8
ppm, DMSO-d , 400 MHz): 12.90 (s, IH), 8.07 (s, IH), 7.09 (s, 2H), 2.95 (q, J = 7.4 Hz, 2H),
1.22 (t, J = 7.5 Hz, 3H).
Intermediate 67: 3-(benzo[b ]thiophenyl)-1 H-pyrazolo[3,4-d]pyrimidin
amine: The title compound was obtained as a light brown solid (0.600 g, 30%) by using a
procedure that is similar to the one described for intermediate 13 from benzothiphene-2borinic
acid (2.00 g, 11.23 mmol), 3-iodo-lH-pyrazolo[3,4-d]pyrimidinamine ( 1.95 g, 7.49 mmol),
WO 20121151525
1,2-dimethoxyethane (20 ml), water (10 ml) sodium carbonate (2.30 g, 22.47 mmol) and
[1, I' -Bis (diphenylphosphino )ferrocene ]dichloro paliadium(II).CH CI (1.20 g, 1.49 mmol) in
microwave oven (microwave power = lOOW, temperature = 100°C) for Ih which is used as
such in next step.
Intermediate 68: 2-(morpholino(propylthio)methylene)malononitrile: To a
solution 2-(bis(propylthio)methylene)malononitrile (1.00 g, 4.41 mmol ; for preparation see
J.Med.Chem.2003,46, 1229-1241) in ethanol ( 10 ml), morpholine (0.384 g, 4.41 mmol) was
added and refluxed for 4h. The reaction mass was quenched with water, extracted with ethyl
acetate, dried over sodium sulphate and concentrated to afford the title compound as brown
liquid (0.810 g, 77%) which is used as such in next step.
Intermediate 69: 5-aminomorpholino-l H -pyrazolecarbonitrile: To a
solution of intermediate 68 (0.800 g, 3.37 mmol) in ethanol ( 8 ml), hydrazine hydrate (0.32
ml, 6.75 mmol) was added stirred at room temperature for 4h .. The reaction mass was
concentrated and quenched with water, extracted with ethyl acetate, dried over sodium
(0.450 g, 69%) IH_
sulphate and concentrated to afford the title compound as brown solid
NMR (8 ppm, DMSO-d , 400 MHz): 11.05 (s, IH), 6.18 (s, 2H), 3.66 (t, J = 4.7 Hz, 4H), 3.11
(t, J = 4.7 Hz, 4H).
Intermediate 70: 3-morpholino-1 H-pyrazolo[3,4-d]pyrimidinamine: To
intermediate 69 (0.450 g, 2.32 mmo!), formam ide (4 m!) was added and heated to l30°C for
12h. The reaction mass was quenched with water, extracted with ethyl acetate, dried over
sodium sulphate and concentrated The crude product was purified by column chromatography
with methanol: ethyl acetate to afford the title compound as off-white solid (0.200 g, 39%).
IH-NMR (8 ppm, DMSO-d6, 400 MHz): 12.56 (s, IH), 8.08 (s, IH), 6.86 (s, 2H), 3.79 (t, J =
4.5 Hz, 4H), 3.07 (t, J = 4.6 Hz, 4H).
Intermediate 71: 2-«dimethylamino )(propylthio )methylene)malononitrile:
The title compound was obtained as a brown liquid (0.830 g, 96%) by using a procedure that
is similar to the one described for intermediate 68 from
(bis(propylthio)methylene)malononitrile (1.00 g, 4.41 mmo!) in ethanol ( 10 ml),
dimethylamine hydrochloride (0.360 g, 4.41 mmol) and triethylamine (0.446 g, 4.41 mmol)
which wass used as such in next step.
Intermediate 72: 5-amino(dimethylamino)-1 H-pyrazolecarbonitrile:
The title compound was obtained as a brown solid (0.510 g, 71 %) by using a procedure that is
similar to the one described for intermediate 69 from intermediate 71 (0.930 g, 4.76
WO 20121151525
mmol),ethanol ( 10 ml) and hydrazine hydrate (0.46 ml, 9.52 mmol) which wass used as such
in next step.
N3,N3-dimethyl-1 H-pyrazolo[3,4-d]pyrimidine-3,4-
Intermediate 73:
diamine: The title compound was obtained as a brown solid (0.280 g, 47%) by using a
procedure that is similar to the one described for intermediate 70 from intermediate 72 (0.510
g, 3.37 mmol) and formamide (5 mI). IH-NMR (8 ppm, DMSO-d6, 400 MHz): 12.37 (s, IH),
8.04 (s, I H), 6.88 (s, 2H), 2.76 (s, 6H).
Intermediate 74: 2-(piperidin-I-yl(propylthio)methylene)malononitrile: The
title compound was obtained as a brown liquid (0.840 g, 60%) by using a procedure that is
similar to the one described for intermediate 68 from 2-
(bis(propylthio)methylene)malononitrile (1.00 g, 4.41 mmol) in ethanol ( 10 ml), piperidine
(0.376 g, 4.41 mmol). IH-NMR (8 ppm, CDCh, 400 MHz): 3.79 (t, J = 5.0 Hz, 4H), 3.01 (t, J
= 7.2 Hz, 2H), 1.74 (m, 6H), 1.72 (m, 2H), 1.06 (t, J = 7.3 Hz, 3H).
Intermediate 75: 5-amino(piperidin-l-:-yl)-1 H-pyrazolecarbonitrile: The
title compound was obtained as a brown liquid (0.500 g, 73%) by using a procedure that is
similar to the one described for intermediate 69 from intermediate 74 (0.840 g, 3.56
mmol),ethanol ( 10 ml) and hydrazine hydrate (0.40 ml, 8.27 mmol). IH-NMR (8 ppm,
DMSO-d , 400 MHz): 10.92 (s, IH), 6.09 (s, IH), 3.12 (m,4H), 1.53 (m, 6H).
Intermediate 76: 3-(piperidin-I-yl)-1 H-pyrazolo[3,4-d]pyrimidinamine:
The title compound was obtained as a brown solid (0.600 g, 95%) by using a procedure that is
similar to the one described for intermediate 70 from intermediate 75 (0.550 g, 2.87 mmol)
and formamide (5 ml). IH-NMR (8 ppm, DMSO-d6, 400 MHz): 12.44 (s, IH), 8.07 (s, IH),
6.69 (s, 2H), 3.05 (t, J = 5.1 Hz,4H), 1.69 (m, 4H), 1.54 (m,2H).
Intermediate 77: 2-(propylthio(pyrrolidin-l-yl)methylene)malononitrile: The
title compound was obtained as a brown liquid (0.950 g, 97%) by using a procedure that is
similar to the one described for intermediate 68 from 2-
(bis(propylthio)methyIene)malononitrile (1.00 g, 4.41 mmol) in ethanol ( 10 ml), pyrrolidine
(0.314 g, 4.41 mmol) which was used as such in next step.
Intermediate 78: 5-amino(pyrrolidin-l-yl)-1 H-pyrazolecarbonitrile: The
title compound was obtained as a brown liquid (0.640 g, 84%) by using a procedure that is
similar to the one described for intermediate 69 from intermediate 77 (0.950 g, 4.29
mmoI),ethanoi ( 10 ml) and hydrazine hydrate (0.42 mI, 8.58 mmol) which was used as such
in next step.
WO 20121151525
Intermediate 79: 3-(pyrrolidin-l-yl)-1 H-pyrazolo[3,4-d]pyrimidinamine:
The title compound was obtained as a brown solid (0.350 g, 29%) by using a procedure that is
similar to the one described for intermediate 70 from intermediate 78 (0.640 g, 3.61 mmol)
and formamide (6 ml). IH-NMR (8 ppm, DMSO-d6, 400 MHz): 12.28 (s, IH), 8.02 (s, IH),
6.79 (s, 2H), 3.32 (t, J = 6.6 Hz, 4H), 1.89 (m, 4H).
Intermediate 80: I-benzhydryl(4-bromofluorophenoxy)azetidine: The
title compound was obtained as a colourless liquid (0.631 g, 30%) by using a procedure that is
similar to the one described for intermediate 47 from 4-bromofluorophenol (1.00 g, 5.23
mmol) in THF (12 ml), I-benzhydrylazetidin01 (1.25 g, 5.23 mmol) and tris(4-
methoxyphenyl)phosphine (2.70 g, 7.85 mmol) and diisopropylazodicarboxylate (1.60 ml,
7.85 mmol).). IH-NMR (8 ppm, CDCI], 400 MHz): 7.42 (m, 4H), 7.29-7.17 (m, 7H), 7.11
(m, IH), 6.59 (t, J = 8.8 Hz, IH), 4.80 (quintet, J = 5.8 Hz, IH), 4.43 (s, IH), 3.72 (dd, J =
6.1,2.0 Hz, 2H), 3.17 (dd, J = 5.7,1.9 Hz, 2H).
Intermediate 81: I-benzhydryl(2-fluoro( 4,4,5,5-tetramethyl-l ,3,2-
dioxaborolanyl)phenoxy)azetidine: The title compound was obtained as a off-white solid
(0.850 g, 76%) by using a procedure that is similar to the one described for intermediate 12
from intermediate 80 (1.00 g, 2.42 mmol), potassium acetate (0.713 g, 7.27 mmol),
bis(pinacolato)diboron (0.738 g, 2.90 mmol) dioxane (10 ml) and [1,1 '
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH CIz (0.059 g, 0.072 mmol). IH_
NMR (8 ppm, CDCI], 400 MHz): 7.49 (dd, J = 11.0,1.3 Hz, IH), 7.42 (m, 4H), 7.29 (m, 5H),
7.21 (m, 2H), 6.68 (t, J = 8.1 Hz, IH), 4.86 (quintet, J = 5.9 Hz, IH), 4.44 (s, IH), 3.74 (dd, J
= 6.1,1.9 Hz, 2H), 3.19 (dd, J = 5.8,1.9 Hz, 2H), 1.31 (s, 12H).
Intermediate 82: 3-(4-bromofluorophenoxy)oxetane: The title compound
(0.900 g, 54%) by using a procedure that is similar to the one
was obtained as a brown solid
described for intermediate 47 from 4-bromofluorophenol (1.28 g, 6.74 mmol) in THF (6
ml), 3-hydroxyoxetane (0.500 g, 6.74 mmol) and triphenylphosphine (2.65 g, 10.12 mmol)
and diisopropylazodicarboxylate (1.99 ml, 10.12 mmol). ). IH-NMR (8 ppm, CDCI], 400
MHz): 7.28 (dd, J = 12.9,2.4 Hz, IH), 7.17 (m, IH), 6.52 (t, J = 8.7 Hz, IH), 5.20 (m, IH),
4.96 (dd, J = 8.0,7.0 Hz, 2H), 4.82 (dd, J = 6.3,5.3 Hz, 2H).
Intermediate 83: 2-(3-fluoro(oxetanyloxy)phenyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane: The title compound was obtained as a brown liquid (0.800 g, 80%) by
using a procedure that is similar to the one described for intermediate 12 from intermediate 82
(0.900 g, 3.64 mmol), potassium acetate (1.00 g, 10.92 mmo\), bis(pinacolato)diboron (1.10 g,
4.37 mmo\) dioxane (10m\) and [1,1' -Bis(diphenylphosphino)ferrocene]dichloro
WO 20121151525
palladium(II).CH Ch (0.090 g, 0.109 mmol). IH-NMR (8 ppm, CDCh, 400 MHz): 7.53 (dd,
J = 11.8,1.4 Hz, IH),): 7.47 (d, J = 8.1 Hz, IH), 6.58 (t, J = 8.0 Hz, IH), 5.27 (m, IH), 4.98
(dd, J = 7.7,6.9 Hz, 2H), 4.83 (dd, J = 7.9,5.3 Hz, 2H), 1.32 (s, 12H).
Intermediate 84: 3-( 4-isopropoxymethylphenyl)-1 H-pyrazolo[3,4-
d]pyrimidinamine: The title compound was obtained as a pale yellow solid (0.143 g, 52 %)
by using a procedure that is similar to the one described for intermediate 13 from 4-
isopropoxymethylphenylboronic acid (0.241 g, 1.24 mmol), 3-iodo-1H-pyrazolo[3,4-
d]pyrimidinamine ( 0.250 g, 0.957 mmo\), DMF (1.5 ml), ethanol (0.6 ml), water (0.6 ml),
sodium carbonate (0.304 g, 2.87 mmo\) and tetrakis(triphenylphosphine)palladium(O) (0.055
g, 0.047 mmol) in microwave oven (microwave power = 100W, temperature = 100°C) for
3h. Mass: 284.1 (M+ + 1).
Intermediate 85: 2-isopropoxy(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan
y\)pyrimidine: The title compound was obtained as a brown liquid (0.400 g, 65% ) by using a
procedure that is similar to the one described for intermediate 12 from 5-bromo
isopropoxypyrimidine (0.500 g, 2.30 mmol for preparation see Organic. Lett. 2010, 12,4478-
4481.), potassium acetate (0.678 g, 6.91 mmol), bis(pinacolato)diboron (0.702 g, 2.76 mmol)
dioxane (5 ml) and [1,1' -Bis(diphenylphosphino )ferrocene ]dichloro palladium(II).CH CIz
(0.056 g, 0.069 mmol). IH-NMR (8 ppm, CDCh, 400 MHz): 8.77 (s, 2H), 5.35 (m, IH),
1.39 (d, J = 6.1 HZ,6H), 1.33 (s, 12H).
Intermediate 86: 3-(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidinamine: The title compound was obtained as a pale yellow solid (0.095 g, 20 %)
by using a procedure that is similar to the one described for intermediate 13 from intermediate
61 (0.393 g, 1.505 mmol), 3-iodo-lH-pyrazolo[3,4-d]pyrimidinamine ( 0.700 g, 2.25
mmol), DMF (2.5 ml), ethanol (1.5 ml), water 0.0 m\), sodium carbonate (0.478 g, 4.51
mmo\) and tetrakis(triphenylphosphine)palladium(O) (0.087 g, 0.075 mmol) in microwave
oven (microwave power = 100W, temperature = 100°C) for 2h. Mass: 315.0 (M++l).
Intermediate 87: 2-acetylfluorophenyl butyrate: Pyridine (7.2 ml) and
propionyl chloride (3.85 g, 41.65 mmol) were added to an ice-cold To a solution of
intermediate 4 (5.00 g, 32.43 mmol) in dichloromethane (750 ml), butyric acid (2.85 g, 32.43
mmol), dicyclohexyJcarbodiimide (6.67 g, 32.43 mmol) and 4-dimethylaminopyridine (0.79 g,
6.48 mmol) were added and stirred at room temperature for 12 h. The reaction mixture was
filtered, washed with dichloromethane and concentrated. The crude product was purified by
column chromatography with ethyl acetate: petroleum ether to afford the title compound as a
yellow liquid (2.80 g, 39%0 which was used as such in next step.
WO 20121151525
Intermediate 88: 5-fluoropropyl-4H-chromenone:To a solution of 87
(2.8 g, 12.55 mmo!) in DMSO (15 ml) cooled to oOe, sodium hydride (0.301 g, 12.55 mmol)
was added maintained at the same temperature for I h. The mixture was warmed to RT and
stirred for 12h. The reaction was quenched by the addition of 2N Hel and extracted with ethyl
acetate. The organic layer was washed with water, dried over sodium sulphate and the solvents
removed. The crude product was dissolved in dioxane (6 m!) and sulphuric acid (8 ml) was
added and heated to 100°C for 12h. Aqueous sodium bicarbonate solution was added to the
mixture and extracted with ethyl acetate. The organic layer was washed with water, dried over
sodium sulphate and concentrated under reduced pressure. The crude product was purified by
column chromatography with ethyl acetate: petroleum ether to afford the title compound as
yellow liquid (1.6 g, 62%) which was used as such in next step.
Intermediate 89: 3-bromofluoropropyl-4H-chromenone:To a
solution of intermediate 88 ( 1.50 g, 7.27 mmol) in DMF (9 ml), N-bromosuccinimide (1.29 g,
7.27 mmol) was added at RT. After 12h, the reaction mixture was quenched with water and
extracted with ethyl acetate. The organic layer was washed with water, dried over sodium
sulphate and the solvent removed to afford the title compound as off-white solid (1.60 g, 77
%) which was used as such in next step.
Intermediate 90: 5-fluorophenylpropyl-4H-chromenone: The title
compound was obtained as a off-white solid (1.10 g, 69%) by using a procedure that is similar
to the one described for intermediate 21 from intermediate 89 (1.60 g, 5.61 mmol) ,
phenylboronic acid (1.09 g, 8.97 mmol), dioxan (18 ml), potassium carbonate ( 2.32 g, 16.83
mmol), water (5 ml) and tetrakis(triphenylphosphine)palladium(O) (0.388 g, 0.336 mmol).
Mass: 283.4 (M+ +1).
Intermediate 91: 2-( l-bromopropyl)fluorophenyl-4H-chromenone:
The title compound was obtained as a off-white solid (1.3 g, 925%) by using a procedure that
is similar to the one described for intermediate 22-from intermediate 90 (1.10 g, 3.89 mmol),
carbon tetrachloride (22 m!) N-bromosuccinimide (0.69 g, 3.89 mmol) and
azobisisobutyronitrile (42 mg}. Mass: 362.8 (M+ + 1).
Intermediate 92: 2-( 1-(5-fluorooxophenyl-4H-chromen
yl)propyl)isoindoline-I,3-dione: To a solution of potassium phthalimide (0.97 g, 5.23 mmol)
in DMF (10 ml), intermediate 91 (2.0 g, 3.49 mmol) was added and stirred for 12h. The
reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer
was dried over sodium sulphate and concentrated under reduced pressure. The crude product
WO 20121151525
was purified by column chromatography with ethyl acetatel: pet.ether to afford the title
compound as a off-white solid (1.0 g, 67%). Mass: 428.1 (M+ + I).
Intermediate 93: 2-(1-aminopropyl)fluorophenyl-4H-chromenone:
To a solution of intermediate 92 (0.50 g, l.16 mmol) in methanol ( 5 ml), hydrazine hydrate
(0.087 g, 1.75 mmol) was added and refluxed for 3h. The reaction mass cooled, filtered and
washed with chloroform and concentrated. The crude product was purified by column
chromatography with dichloromethane: methanol to afford the title compound as a off-white
solid (0.34 g, 98%). Mass: 297.1 (M+).
Intermediate 94: N-(4-bromofluorophenyl)isobutyramide: To a solution
of 4-bromofluoroaniline (2.0g, 10.51 mmol) in dichloromethane (20 ml) cooled to O°C,
triethylamine ( 2.90 ml, 21.02) was added followed by isobutyryl chloride ( 1.20 ml, 12.61
mol). After stirring at room temperature for 8h, the reaction mixture was quenched with water,
extracted with dichloromethane, dried over sodium sulphate and concentrated to afford the
title compound as a off-white solid ( 2.60g, 96%). IH-NMR (0 ppm, CDCb, 400 MHz): 8.29
(t, J = 8.4 Hz, IH), 7.31 (br s, IH), 7.27 (m, 2H), 2.59 (quintet, J =6.9 Hz, IH), 1.27 (d, J =
6.9 Hz, 6H).
Intermediate 95: N-(2-fluoro( 4,4,5,5-tetramethyl-l ,3,2-dioxaborolan
yl)phenyl)isobutyramide: The title compound was obtained as a off-white solid (0.900 g, 77%
) by using a procedure that is similar to the one described for intermediate 12 from
intermediate 94 (1.00 g, 3.84 mmol), potassium acetate (0.750 g, 7.68 mmol),
bis(pinacolato)diboron (1.07 g, 4.22 mmol) dioxane (15 ml) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.62 g, 0.768 mmol) which
was used as such in next step.
Intermediate 96: N-(4-bromofluorophenyl)acetamide: To a solution of 4-
bromofluoroaniline (2.0g, 10.51 mmol) in dichloromethane (20 ml) cooled to O°C,
triethylamine ( 2.90 ml, 21.02) was added followed by acetyl chloride ( 0.90 ml, 12.61 mol).
After stirring at room temperature for 8h, the reaction mixture was quenched with water,
extracted with dichloromethane, dried over sodium sulphate and concentrated to afford the
title compound as a off-white solid (2.60g, 99%) which was used as such in next step.
Intermediate 97: N-(2-fluoro(4,4,5,5-tetramethyl-l,3,2-dioxaborolan
yl)phenyl)acetamide: The title compound was obtained as a off-white solid (0.800 g, 67% ) by
using a procedure that is similar to the one described for intermediate 12 from intermediate 96
(1.00 g, 4.30 mmol), potassium acetate (0.840 g, 8.61 mmol), bis(pinacolato)diboron (1.20 g,
WO 20121151525
4.74 mmol) dioxane (15 ml) and [I,I'-Bis(diphenylphosphino)ferrocene]dichloro
palladium(I1).CH Ch (0.70 g, 0.861 mmol) which was used as such in next step.
Intermediate 98: 3-iodo-N,N-dimethyl-1 H-pyrazolo[3,4-d]pyrimidin
To a solution of N,N-dimethyl-IH-pyrazolo[3,4-d]pyrimidinamine (0.500 g, 3.06
amine:
mmol for preeration see 1.Amer. Chern. Soc. 1956, 784-790.) in DMF (4 ml), N
Iodosuccinimide (1.00g, 4.59 mmol) was added and stirred at 80 C for 22h.The reaction
mixture was quenched with water, wxtracted with ethyl acetate, dried over sodium sulphate
and concentrated to afford the title compound as a brown solid (0.460 g, 46%) which was used
as such in next step.
Intermediate 3-(3 -fl uoroisopropoxyphen y 1)-N ,N -di methy I-I H-
pyrazolo[3,4-d]pyrimidinamine: The title compound was obtained as a light brown solid
(0.220 g, 50%) by using a procedure that is similar to the one described for intermediate 13
from intermediate 12 (0.581 g, 2.07 mmol), intermediate 98 ( 0.400 g, 1.38 mmol), DMF (3
mI), ethanol (1.5 ml), water (1.5 ml) sodium carbonate (0.440 g, 4.15 mmol) and
tetrakis(triphenylphosphine)palladium(O) (0.q80 g, 0.069 mmol). Mass: 316.3 (M+ + 1 ).
Intermediate 100: 3-iodo-N-methyl-1 H-pyrazolo[3,4-d]pyrimidinamine
To a solution of N-methyl-1H-pyrazolo[3,4-d]pyrimidinamine (1.10 g, 7.37 mmol, for
preeration see 1.Amer. Chern. Soc. 1956, 784-790) in DMF (8 ml), N-Iodosuccinimide (2.48
g, 11.06 mmol) was added and stirred at 80 C for 12h.The reaction mixture was quenched
with water, wxtracted with ethyl acetate, dried over sodium sulphate and concentrated to
afford the title compound as a brown solid (0.970 g, 48%). Mass: 275.9 (M++l ).
Intermediate 101: 5-fluoro(3-fluorophenyl)(1-(3-iodo
(methyl amino )-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-4H-chromenone
The title
compound was obtained as a light brown solid (0.230 g, 32%) by using a procedure that is
similar to the one described for intermediate 34 from intermediate 22 (0.650 g, 1.78 mmol),
intermediate 100 ( 0.350 g, 1.27 mmol), DMF (3 ml) and potassium carbonate (0.175 g, 1.27
mmol). Mass: 560.1 (M+ + 1 ).
Intermediate 102: 4-(1 H-pyrazolo[3,4-d]pyrimidinyl)morpholine : To a
solution of 4-chloro-1H-pyrazolo[3,4-d]pyrimidine (2.00 g, 12.97 mmol) in Dioxan (20 ml),
morpholine 5.65 g, 64.86 mmol) was added and refluxed for 2h.The reaction mixture was
quenched with water, filtered and dried under vacuum to afford the title compound as a brown
solid (2.40 g, 90%) . IH-NMR (8 ppm, CDCb, 400 MHz): 12.49 (s, IH), 8.33 (s, IH), 7.94 (s,
IH), 3.95 (t, J = 4.6 Hz, 4H), 3.83 (t, J = 5.2 Hz, 4H).
WO 20121151525
Intermediate 103: 4-(3-iodo-l H-pyrazolo[3,4-d]pyrimidinyl)morpholine :
To a solution of intermediate 102 (1.50 g, 7.31 mmol) in DMF (12 ml), N-Iodosuccinimide
(2.46 g, 10.97 mmol) was added and stirred at 80°C for 22h.The reaction mixture was
quenched with water, filtered, washed with pet. ether and dried under vacuum to afford the
title compound as a brown solid (1.90 g, 79%). IH-NMR (0 ppm, DMSO-D6, 400 MHz):
14.06 (s, IH), 8.34 (s, IH), 3.78 (t, J = 5.0 Hz, 4H), 3.73 (t, J = 5.0 Hz, 4H).
Intermediate 104: 4-(3-(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4~
d]pyrimidinyl)morpholine : The title compound was obtained as a light brown solid (0.180
g, 33%) by using a procedure that is similar to the one described for intermediate 13 from
intermediate 12 (0.634 g, 2.26 mmol), intermediate 103 (0.500 g, 1.51 mmol), DMF (4 ml),
. ethanol (2.0 ml), water (2.0 ml) sodium carbonate (0.480 g, 4.53 mmol) and
tetrakis(triphenylphosphine)palladium(O) (0.087 g, 0.075 mmol). Mass: 357.38 (M+ + 1 ).
Intermediate 105: 5-fluoro( 4-fluorophenyl)( 1-(3-iodomorpholino-
1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-4H-chromenone: The title compound was
(0.350 g, 53%) by using a procedure that is similar to the one
obtained as a light brown solid
described for intermediate 34 from intermediate 31 (0.734 g, 2.11 mmol), intermediate 103 (
0.350 g, 1.05 mmol), DMF (4 m)) and cesium carbonate (0.343 g, 1.05 mmol). Mass: 616.2
(M++l ).
Intermediate 106: 5-fluoro(3-fluorophenyl)(l-(3-iodomorpholino-
IH-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-4H-chromenone: The title compound was
obtained as a off-white solid (0.400 g, 54%) by using a procedure that is similar to the one
described for intermediate 34 from intermediate 22 (0.629 g, 1.81 mmol), intermediate 103 (
0.400 g, 1.20 mmol), DMF (4 m)) and potassium carbonate (0.167 g, 1.20 mmol). Mass:
616.2 (M++I ).
Intermediate 107: 2-(l-(4-amino(4-(difluoromethoxy)fluorophenyl)-
1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)bromofluoro-4H-chromenone : The title
compound was obtained as a brown solid (0.650 g, 68%) by using a procedure that is similar
to the one described for intermediate 27 from intermediate 39 (0.500 g, 1.69 mmol), potassium
carbonate ( 0.46 g, 3.38 mmol), DMF (10 ml) and intermediate 28 (0.82 g, 2.37 mmol) which
was used as such for next step.
Intermediate 108: 2-( 1-(4-aminoiodo-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluorophenyl-4H-chromenone : The title compound was obtained as a pale
brown solid (2.00 g, 64 %) by using a procedure that is similar to the one described for
intermediate 34 from intermediate 33 (2.10 g, 6.01 mmol), 3-iodo-l H-pyrazolo[3,4-
WO 20121151525
d]pyrimidinamine (3.13 g, 12.02 mmol), DMF (8.4 ml) and cesium carbonate (3.91 g,
12.02 mmol) which was used as in next step.
Intermediate 109: 5-f1uoro(4-f1uorophenyl)(l-hydroxyethyl)-4H-
The title compound was obtained as a pale brown solid (3.50 g, 78 %) by
chromenone :
using a procedure that is similar to the one described for intermediate 23 from intermediate 31
(5.50 g, 15.01 mmol), DMSO (55 ml) and n-butanol (2.75 ml). Mass: 303.1 (M++l ).
Intermediate 110: 5-f1uoro(l-hydroxyethyl)phenyl-4H-chromenone :
The title compound was obtained as a pale brown solid (2.60 g, 60 %) by using a procedure
that is similar to the one described for intermediate 23 from intermediate 33 (5.30 g, 15.26
mmol ), DMSO (40 ml) and n-butanol (2.20 mI). Mass: 284.8 (M+).
Intermediate 111: 2-acetylf1uoro( 4-f1uorophenyl)-4H-chromenone
The title compound was obtained as a pale yellow solid (2.20 g, 64 %) by using a procedure
that is similar to the one described for intermediate 24 from intermediate 109 (3.50 g, 11.54
mmol), DMSO (3.27 ml, 46.16 mmol ), dichloromethane (50 ml), oxalyl chloride (1.99 ml,
23.08 mmol) and triethylamine (7 ml) which was used as such in next step.
Intermediate 112:' 2-acetylf1uorophenyl-4H-chromenone: The title
compound was obtained as a pale yellow solid (1.80 g, 63 %) by using a procedure that is
similar to the one described for intermediate 24 from intermediate 110 (2.50 g, 8.76 mmol),
DMSO (2.48 ml, 35.05 mmol ), dichloromethane (42 ml), oxalyl chloride (1.51 ml, 17.52
as such in next step.
mmol) and triethylamine (5.5 ml) which was used
Intermediate 113: (R)/(S)f1uoro(4-f1uorophenyl)(l-hydroxyethyl)-
4H-chromenone : To a solution of intermediate III ( 0.568 g, 1.89 mmol) in DMF (4 ml)
under nitrogen purging, formic acid: trietylamine 5 : 2 azeotrope (1 ml) was added followed
by [(S,S)tethTsDpenRuCI] (3 mg). The reaction mixture was heated at 80°C for 1.5h under
continuous nitrogen purging. The reaction mixture was quenched with water, extected with
ethyl acetate, dried over sodium sulphate and concentrated. The crude product was purified by
column chromatography with ethyl acetate: petroleum ethert to afford the title compound as a
off-white solid (0420 g, 74%). Enantiomeric excess: 74%, enriched in the late eluting isomer
(retention time: 9.24 min. as determined by HPLC on a chiralpak AD-H column.
Intermediate 114: (R)/(S)f1uoro(4-f1uorophenyl)( I-hydroxyethyl)-
4H-chromenone : To a solution of intermediate III ( 0.568 g, 1.89 mmol) in DMF (4 ml)
under nitrogen purging, formic acid: trietylamine 5 : 2 azeotrope (1 ml) was added followed
by [(R,R)tethTsDpenRuCI] (3 mg). The reaction mixture was heated at 80°C for 1.5h under
continuous nitrogen purging. The reaction mixture was quenched with water, extected with
WO 20121151525
ethyl acetate, dried over sodium sulphate and concentrated. The crude product was purified by
column chromatography with ethyl acetate: petroleum ethert to afford the title compound as a
off-white solid (0430 g, 75%). Enantiomeric excess: 74%, enriched in the fast eluting isomer
(retention time: 7.75 min. as determined by HPLC on a chiralpak AD-H column.
Intermediate 115: (R)/(S)- 5-fluoro(l-hydroxyethyl)phenyl-4H-
chromenone : To a solution of intermediate 112 ( 0.568 g, l.89 mmol) in DMF (4 ml)
under nitrogen purging, formic acid: trietylamine 5 : 2 azeotrope (I ml) was added followed
by [(S,S)tethTsDpenRuCl] (3 mg). The reaction mixture was heated at 80°C for 1.5h under
continuous nitrogen purging. The reaction mixture was quenched with water, extected with
ethyl acetate, dried over sodium sulphate and concentrated. The crude product was purified by
column chromatography with ethyl acetate: petroleum ethert to afford the title compound as a
off-white solid (0.380 g, 66%). Enantiomeric excess: 64%, enriched in the late eluting isomer
(retention time: 8.85 min. as determined by HPLC on a chiralpak AD-H column.
Intermediate 116 (R)/(S)- 5-fluoro( l-hydroxyethyl)phenyl-4H-
chromenone : To a solution of intermediate 112 ( 0.568 g, l.89 mmol) in DMF (4 ml)
under nitrogen purging, formic acid: trietylamine 5 : 2 azeotrope (I ml) was added followed
by [(R,R)tethTsDpenRuCl] (3 mg). The reaction mixture was heated at 80°C for 1.5h under
continuous nitrogen purging. The reaction mixture was quenched with water, extected with
ethyl acetate, dried over sodium sulphate and concentrated. The crude product was purified by
column chromatography with ethyl acetate: petroleum ethert to afford the title compound as a
off-white solid (0.410 g, 72%). Enantiomeric excess: 64%, enriched in the fast eluting isomer
(retention time: 7.43 min. as determined by HPLC on a chiralpak AD-H column.
Intermediate 117: 3-(3-fluoromorpholinophenyl)-N,N-dimethyl-l H-
pyrazolo[3,4-d]pyrimidinamine : The title compound was obtained as a pale brown solid
(0.340 g, 36 %) by using a procedure that is similar to the one described for intermediate 13
from intermediate 61 (1.27 g, 4.15 mmol), intermediate 98 (0.800 g, 2.76 mmol), DMF (6
ml), ethanol (3 ml), water (3 ml), sodium carbonate (0.880 g, 8.30 mmol) and
tetrakis(triphenylphosphine)palladium(O) (0.160 g, 0.138 mmol) 10 microwave oven
(microwave power = 100W, temperature = 100°C) for 2h. Mass: 343.1 (M+ + 1).
Intermediate 118: 3-(3-fluoromorpholinophenyl)-N-methyl-l H-
pyrazolo[3,4-d]pyrimidinamine: The title compound was obtained as a off-white solid
(0.350 g, 29 %) by using a procedure that is similar to the one described for intermediate 13
from intermediate 61 (1.67 g, 5.45 mmol), intermediate 100 (1.00 g, 3.63 mmol), DMF (7
ml), ethanol (3.5 ml), water (3.5 ml), sodium carbonate (1.15 g, 10.89 mmol) and
WO 20121151525
tetrakis(triphenylphosphine)palladium(O) (0.209 g, 0.181 mmoI) In microwave oven
(microwave power = lOOW, temperature = 100°C) for 2h. Mass: 329.2 (M+ + 1).
Intermediate 119: 3-(3-fluoroisopropoxyphenyI)-N-methyl-lH-
pyrazolo[3,4-d]pyrimidinamine: The title compound was obtained as a brown solid (0.205
g, 19 %) by using a procedure that is similar to the one described for intermediate 13 from
intermediate 12 (1.52 g, 5.45 mmol), intermediate 100 (1.00 g, 3.63 mmol), DMF (7 ml),
ethanol (3.5 mI), water (3.5 ml), sodium carbonate (1.15 g, 10.89 mmol) and
tetrakis(triphenylphosphine)palladium(O) (0.209 g, 0.181 mmol) in microwave oven
(microwave power = lOOW, temperature = 100°C) for 2h. Mass: 301.9 (M+).
Intermediate 120: 4-(2-chloronitrophenyl)morpholine The title
compound was obtained as a yellow liquid (6.70 g, 53%) by using a procedure that is similar
to the one described for intermediate 53 from of 3,4-dichloro-nitrobenzene (10.00 g, 52.08
mmol) in ethyl acetate (83 ml) and triethylamine (7.99 ml) and morpholine (4.99 g, 57.29
mmol). IH-NMR (0 ppm, CDCh, 400 MHz): 08.25 (d, J = 2.6 Hz, IH), 8.12 (dd, J = 8.5,2.6
Hz, IH), 7.05 (d, J = 8.9 Hz, IH), 3.90 (t, J = 4.5 Hz, IH), 3.22 (t, J = 4.6 Hz, IH).
Intermediate 121: 3-chloromorpholinoaniline : To a solution of
intermediate 120 (6.00 g, 24.72 mmol) in ethanol (60 ml) and water (30 mI), iron (6.89 g,
123.60 mmoI) and ammonium chloride ( 2.64 g, 49.44 mmo\) were added and refluxed for 3h.
The reaction mixture was filtered through celite, washed with ethyl acetate. The organic layer
was dried over sodium sulphate and concentrated under reduced pressure to afford the title
compound was obtained as a brown solid (5.50 g) which was used without purification in the
next step.
Intermediate 122: 4-(4-bromochlorophenyl)morpholine : The title
compound was obtained as a brown liquid (5.20 g, 72%) by using a procedure that is similar to
the one described for intermediate 51 from intermediate 121 (5.50 g, 25.85 mmol), 48%
hydrobromic acid (64 m\) , sodium nitrite (5.35 g, 77.57 mmoI) , water (73 ml) and
copper(I)bromide (5.56 g, 38.78 mmol) which was used without purification in the next step.
Intermediate 123: 4-(2-chloro( 4,4,5,5-tetramethyl-l ,3,2-dioxaborolan
yl)phenyl)morpholine : The title compound was obtained as a colourless liquid (2.00 g, 89%)
by using a procedure that is similar to the one described for intermediate 12 from intermediate
122 (2.00 g, 7.23 mmol), potassium acetate (1.41 g, 14.46 mmol) , bis(pinacolato)diboron
(2.01 g, 7.95 mmol), dioxane (15 ml) and [1,1'-Bis (diphenylphosphino)ferrocene]dichloro
palladium(II).CH Ch (0.290 g, 0.360 mmol). IH-NMR (0 ppm, CDCh, 400 MHz): 7.80 (d, J
WO 20121151525
= 1.4 Hz, IH), 7.66 (dd, J = 8.0,1.4 Hz, IH), 7.04 (d, J = 8.0 Hz, IH), 3.89 (t, J = 4.4 Hz, 4H),
3.12 (t, J = 4.5 Hz, 4H), 1.33 (s, 12H).
Intermediate 124: 4-bromochloro-I-isopropoxybenzene: The title
compound was obtained as a colourless liquid (5.60 g, 93%) by using a procedure that is
similar to the one described for intermediate 47 from 4-bromochlorophenol (5.00 g, 24.10
mmol) in THF (50 ml), isopropanol (1.85 ml, 24.10 mmol), triphenylphosphine (9.48 g, 36.51
mmol) and diisopropylazodicarboxylate (7.10 ml, 36.51 mmol) which was used as such in
next step.
Intermediate 125: 2-(3-chloroisopropoxyphenyl)-4,4,5,5-tetramethyl-
1,3,2-dioxaborolane : The title compound was obtained as a yellow liquid (6.50 g, 99%) by
using a procedure that is similar to the one described for intermediate 12 from intermediate
124 (6.00 g, 24.04 mmol), potassium acetate (4.71 g, 48.08 mmol), bis(pinacolato)diboron
(6.71 g, 26.44 mmol) dioxane (95 ml) and [1,1'-Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH CIz (0.980 g, 12.02 mmol). IH-NMR (8 ppm, COCh, 400 MHz): 8 7.79 (d,
J = 1.4 Hz, I H), 7.63 (dd, J = 8.2,1.4 Hz, IH), 6.92 (d, J = 8.2 Hz, IH), 4.64 (quintet, J = 6.1
Hz, IH), 1.38 (d, J = 6.1 Hz, 6H), 1.25 (s, 12H).
Intermediate 126: 6-bromomethylbenzo[d]oxazole : To 2-amino
bromophenol ( l.OOg, 5.32 mmol) , acetic acid «0.006 ml) and triethylorthoacetate (1.75 ml,
9.58 mmol) were added and refluxed for 30 min. The reaction mixture was quenched with
water, extracted with ethyl acetate, dried over sodium sulphate and concentrated. The crude
product was column chromatographed with ethyl acetate : petroleum ether to afford the title
compound as a orange solid «0.756 g, 65%). IH-NMR (8 ppm, COCh, 400 MHz): 87.64 (d, J
= 1.7 Hz, IH), 7.51 (d, J = 8.4 Hz, IH), 7.43 (dd, J = 8.4,1.7 Hz, IH), 2.67 (s, 3H).
Intermediate 127: 2-methyl(4,4,5,5-tetramethyl-l,3,2-dioxaborolan
yl)benzo[d]oxazole : The title compound was obtained as a orange solid (0.965 g, 88%) by
using a procedure that is similar to the one described for intermediate 12 from intermediate
126 (0.900 g, 4.24 mmol), potassium acetate (0.833 g, 8.48 mmol), bis(pinacolato)diboron
g, 4.66 mmol) dioxane (10 ml) and [1, I' -Bis(diphenylphosphino)ferrocene]dichloro
(1.18
palladium(II).CH CIz (0.173 g, 0.212 mmol). IH-NMR (8 ppm, COCl , 400 MHz): 87.90(s,
IH), 7.76 (dd, J = 7.8, 0.5 Hz, IH), 7.64 (d, J = 7.9 Hz, IH), 2.64 (s, 3H), 1.36 (s, 12H).
Intermediate 128: 6-( 4,4,5,5-tetramethyl-l ,3,2-dioxaborolanyl)isoindolin-
I-one : The title compound was obtained as a off-white solid (0.850 g, 39%) by using a
procedure that is similar to the one described for intermediate 12 from 6-bromoisoindolin-l
one (1.00 g, 4.71 mmol for preparation see 1. Pharm. Science & Technol. 2010,2, 380-390.),
WO 20121151525
potassium acetate (1.60 g, 16.50 mmol), bis(pinacolato)diboron (1.30 g, 5.18 mmol) dioxane
(18 ml) and [1,1' -Bis(diphenylphosphino )ferrocene ]dichloro palladium(II).CH Ch (0.190 g,
0.235 mmol). 'H-NMR (8 ppm, CDCh, 400 MHz): 8 8.36 (s, IH), 8.00 (d, J = 7.5, Hz, IH),
7.47 (d, J = 7.6 Hz, IH), 6.55 (s, IH), 4.46 (s, 2H), 1.35 (s, 12H).
Intermediate 129: 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolanyI)isoindolin-
I-one: The title compound was obtained as a off-white solid (0.410 g, 84%) by using a
procedure that is similar to the one described for intermediate 12 from 5-bromoisoindolin-l
one (0.400 g, 1.88 mmoI), potassium acetate (0.645 g, 6.58 mmol), bis(pinacolato)diboron
(0.520 g, 2.07 mmol) dioxane (7 ml) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH Ch (0.076 g, 0.094 mmol). 'H-NMR (8 ppm, CDCh. 400 MHz): 87.93 (m,
J = 7.8 Hz, IH), 7.16 (s, IH), IH), 4.45 (s, 2H), 1.36 (s, 12H).
2H), 7.87 (d,
Intermediate 130: 1-(2-fluoro( 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan
yl)phenyl)ethanone : The title compound was obtained as a colourless liquid (1.50 g, 82%) by
using a procedure that is similar to the one described for intermediate 12 from 1-(4-bromo
fluorophenyl)ethanone (1.50 g, 6.91 mmol), potassium acetate (1.35 g, 13.82 mmol),
bis(pinacolato )diboron (1.92 g, 7.60 mmol) dioxane (30 ml) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.282 g, 0.345 mmol). 'H
NMR (8 ppm, CDCh, 400 MHz): 7.84 (t, J = 7.5 Hz, IH), 7.62 (dd, J = 7.6,0.6 Hz, IH), 7.55
(d, J = 11.0 Hz, 1 H),2.62 (d, J = 4.8 Hz, 3H), 1.35 (s, 12H).
Intermediate 131: 3-(3-chloromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidinamine: The title compound was obtained as a pale brown solid (0.250 g, 20 %)
by using a procedure that is similar to the one described for intermediate 13 from intermediate
123 ( 1.87 g, 5.74 mmol), 3-iodo-1H-pyrazolo[3,4-d]pyrimidinamine (1.00 g, 3.83 mmol),
DMF (6.4 ml), ethanol (2.1 ml), water (1.4 mI), sodium carbonate (1.21 g, 11.49 mmol) and
tetrakis(triphenylphosphine)palladium(O) (0.220 g, 0.190 mmoI) III microwave oven
(microwave power = WOW, temperature = 100°C) for I h. 'H-NMR (8 ppm, DMSO-D6, 400
MHz): 13.57 (s, IH), 8.20 (s, IH), 7.66 (d, J = 1.9 Hz, IH), 7.59 (dd, J = 8.2,1.9 Hz, IH),
. 7.30 (d, J = 8.3 Hz, IH), 6.79 (s, 2H), 3.77 (t, J = 4.3 Hz, 4H), 3.05 (t, J = 4.3 Hz, 4H).
Intermediate 132: N-(3-( 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan
yl)phenyI)methanesulfonamide : The title compound was obtained as a off-white solid (1.00 g,
84%) by using a procedure that is similar to the one described for intermediate 12 from N-(3-
bromophenyI)methanesulfonamide (1.00 g, 3.99 mmol), potassium acetate (0.78 g, 7.98
mmoI), bis(pinacolato)diboron (1.11 g, 4.39 mmoI) dioxane (10 ml) and [I, 1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.162 g, 0.199 mmol). 'H-
WO 20121151525
NMR (0 ppm, DMSO-D6, 400 MHz): 9.66 (s, IH), 7.51 (d, J = 1.3 Hz, IH), 7.41 (dd, J =
.2,0.9 Hz, IH), 7.35 (m, 2H), 2.94 (s, 3H), 1.28 (s, 12H).
Intermediate 133: 2-ethylfluoro(2-fluorophenyl)-4H-chromenone
The title compound was obtained as a brown solid (0.500 g, 47%) by using a procedure that is
similar to the one described for intermediate 21 from intermediate 20 (1.00 g, 3.68 mmol) , 2-
fluorophenylboronic acid (0.820 g, 5.90 mmol), dioxan (6 mI), potassium carbonate ( 1.50 g,
11.04 mmol), water (1.0 ml) and tetrakis(triphenylphosphine)palladium(O) (0.255 g, 0.220
mmol). Mass: 287.3 (M++l).
Intermediate 134: 2-(l-bromoethyl)fluoro(2-fluorophenyl)-4H-
chromenone : The title compound was obtained as a brown solid (0.510 g, 78%) by using a
procedure that is similar to the one described for intermediate 22 from intermediate 133 (0.500
g, 1.74 mmol), carbon tetrachloride (13 ml) N-bromosuccinimide (0.309 g, 1.74 mmol) and
azobisisobutyronitrile (30 mg) which was used as such for next step.
Intermediate 135: 5-fluoro(2-fluorophenyl)( l-hydroxyethyl)-4H-
chromenone: The title compound was obtained as a pale brown solid (0.210 g, 50 %) by
using a procedure that is similar to the one described for intermediate 23 from intermediate
134 (0.500 g, 1.36 mmol ), DMSO (5 ml) and n-butanol (I mI). Mass: 302.8 (M+ ).
Intermediate 136: 5-fluoro(3-fluorophenyl)propyl-4H-chromenone :
The title compound was obtained as a pale yellow solid (2.60 g, 69%) by using a procedure
21 from intermediate 89 (2.80 g, 9.89
that is similar to the one described for intermediate
mmol) , 3-fluorophenylboronic acid (2.20 g, 15.82 mmol), dioxan (18 ml), potassium
carbonate ( 4.10 g, 29.67 mmol), water (2.6 ml) and tetrakis(triphenylphosphine)palladium(O)
(0.685 g, 0.593 mmol) which was used as such in next step.
Intermediate 137: 2-( l-bromopropyl)fluoro(3-fluorophenyl)-4H-
chromenone : The title compound was obtained as a brown solid (2.95 g, 89%) by using a
procedure that is similar to the one described for intermediate 22 from intermediate 136 (2.60
g, 9.21 mmol), carbon tetrachloride (25 ml) N-bromosuccinimide (1.64 g, 9.21 mmol) and
azobisisobutyronitrile (0.247 g) which was used as such in next step.
Intermediate 138: 2-fluorotrityl-9H-purinamine : To a solution of 2-
fluoro-9H-purinamine (0.50 g, 3.26 mmol) in DMF (3 ml), pyridine (0.5 ml) followed bt
trityl chloride (1.00 g, 3.91 mmol). After stiring at room temperature for 12, the reaction mass
was quenched with water, the precipitate formed was filtered, washed with water and dried
as off-white solid (1.20 g, 93%) which was used as
under vacuum to afford the title compound
such in next step.
WO 20121151525
Intermediate 139: N,N-Dibocfluorotrityl-9H-purinamine : To a
solution of intermediate 138 (1.10 g, 2.78 mmol) in THF (11 ml) cooled to O°C, boc-anhydride
(1.40 ml, 6.12 mmol) and 4-dimethylaminopyridine (0.034 g, 0.278 mmolO were added and
stirred at room temperature for 15h. The reaction mass was quenched with water, extracted
with ethyl acetate, dried over sodium sulphate and concentrated under vacuum to afford the
title compound as off-white solid (1.60 g, 97%) which was used as such in next step.
Intermediate 140: tert-butyl 2-methoxy.trityl-9H-purinylcarbamate : To
a solution of intermediate 139 (1.50 g, 2.51 mmol) in methanol (6 ml), potassium carbonate
(0.34 g, 2.51 mmol) was added and heated to 90°C for 2h. The reaction mass was concentrated
quenched with water, extracted with ethyl acetate, dried over sodium sulphate and
concentrated under vacuum. The crude product was column chromatographed with ethyl
acetate: petroleum ether to afford the title compound as off-white solid (0.255 g g, 20%). IH_
NMR (8 ppm, DMSO-D6, 400 MHz): 10.00 (s, IH), 7.89 (s, IH), 7.89 (m, 9H), 7.19 (m, 6H),
3.33 (s, 3H), 1.44 (s, 9H).
Intermediate 141: (S)/(R)-I-(5-fluoro-~-(3-fluorophenyl)oxo-4H-
chromenyl)ethyl methanesulfonate : To a cooled solution of intermediate 23a (0.800 g, 2.63
mmol) in dichloromethane (16 ml) and triethylamine (1.10 ml, 7.91 mmol), methanesulphonyl
chloride (0.400 ml, 5.27 mmol) was added stirred at room temperature for 2h. The reaction
mass was quenched with water, extracted with dichloromehane ,dried over sodium sulphate
and concentrated to afford the title compound as brown solid (1.00 g, 100%) which was used
as such in next step
Intermediate 142: (S)/(R)( l-azidoethyl)fluoro(3-fluorophenyl)-4H-
chromenone : To a solution of intermediate 141 (0.900 g, 2.36 mmol) in DMF (18 ml),
sodium azide (0.306 g, 4.72 mmol) was added heated to 60°C. After 2h, reaction mass was
quenched with water, extracted with dichloromehane ,dried over sodium sulphate and
concentrated. The crude product was column chromatographed with ethyl acetate: petroleum
ether to afford the title compound as brownliquid (0.650 g , 84%) which was used as such in
next step.
Intermediate 143: (S)/(R)- 2 2-( l-aminoethyl)fluoro(3-fluorophenyl)-
4H-chromenone : To a solution of intermediate 142 (0.600 g, 1.82 mmol) in THF (2.4 ml)
and water (1.2 ml), triphenylphosphine ( 0.455 g, 1.73 mmol) was addedstirred at room
temperature for 14h. The reaction mass was quenched with water, extracted with ethyl
acetate, dried over sodium sulphate and concentrated. The crude product was column
WO 20121151525
chromatographed with methanol : dichloromethane to afford the title compound as brown
liquid (0.300 g ,55%) which was used as such in next step.
Intermediate 144: 2-methoxymethylbenzaldehyde oxime: To 2-methoxy-
6-methylbenzaldehyde (11.0 g, 73.25 mmol) in triethylamine (132 ml), hydroxylamine
hydrochloride (6.10 g, 69.49 mmol) was added and heated to 80°C. After 3h, the reaction
mass was concentrated, quenched with water, extracted with ethyl acetate, dried over sodium
sulphate and concentrated to afford the title compound as off-white solid (7.50 g , 62%). IH_
NMR (0 ppm, CDCh, 400 MHz): 8.54 (s, IH), 8.31 (s, IH), 7.24 (t, J = 7.9 Hz, IH), 6.84 (d,
J = 7.5 Hz, IH), 6.78 (d, J = 8.2 Hz, IH), 3.85 (s, 3H), 2.46 (s, 3H).
Intermediate 145: 2-methoxymethylbenzonitrile : To intermediate 144
(7.50 g, 45.41 mmol) in dichloromethane (55 mI), N,N'-dicarbonyl diimidazole (8.09 g, 49.95
mmol) was added and stirred at room temperature for 15h. The reaction mass was quenched
with water, extracted with dichloromethane, dried over sodium sulphate and concentrated to
afford the title compound as brown solid (5.0 g , 75%). IH-NMR (8 ppm, CDCh, 400 MHz):
7.41 (t, J = 8.1 Hz, IH), 6.87 (d, J = 7.7 Hz, IH), 6.78 (d, J = 8.5 Hz, IH), 3.91 (s, 3H), 2.50
(s,3H).
Intermediate 146: 1-(2-methoxymethylphenyl)phenylethanone : To
intermediate 145 (5.0 g, 34.03 mmoI) in THF (50 ml), benzylmagnesium chloride (34 ml, 2M
in THF, 68.02 mmol) was added at O°C over 30 min. and heated to reflux for 15 h. The
reaction mixture was cooled to room temperature, 2N HCl (200 ml) was added and again
refluxed for 4h. The reaction mixture was cooled and extracted with ethyl acetate, dried over
sodium sulphate and concentrated. The crude product was column chromatographed with ethyl
acetate: petroleum ether to afford to afford the title compound as brown liquid (3.7 g , 45%).
IH-NMR (8 ppm, CDCh, 400 MHz): 7.30-7.18 (m, 6H), 6.76 (m, 2H), 4.07 (s, 2H), 3.83 (s,
3H), 2.02 (s, 3H).
Intermediate 147: 1-(2-hydroxymethylphenyl)phenylethanone : To
intermediate 146 (2.0 g, 8.31 mmol) in dichloromethane (20 ml) at -78°C, boron tribromide
(2.84 ml, 1M in dichloromethane, 16.64 mmol) was added slowly and maintained for 4h. The
reaction mass was quenched at -78°C using 2N HCl (50 ml), extracted with ethyl acetate,
dried over sodium sulphate and concentrated. The crude product was column
chromatographed with ethyl acetate: petroleum ether to afford to afford the title compound as
off-white solid (1.20 g, 64%). IH-NMR (0 ppm, CDCI , 400 MHz): 11.18 (s, IH), 7.37-7.27
(m, 4H), 7.19 (m, 2H), 6.84 (d, J = 8.3 Hz, IH), 6.75 (d, J = 7.5 Hz, IH), 4.27 ·(s, 2H), 2.62 (s,
3H).
WO 20121151525
Intermediate 148: 2-( 1-(benzyloxy)ethyl)methylphenyl-4H-chromen
one : To intermediate 147 (0.400 g, 1.76 mmol) in dichloromethane (4 ml), R(+)
benzyloxypropionic acid (0.382 g, 2.12 mmol) and HATU (2.01 g, 5.30 mmol) were added
followed by triethylamine (2.6 ml, 19.08 mmol). After 20h at room temperature, the reaction
mixture was quenched with water, extracted with ethyl acetate, dried over sodium sulphate and
concentrated. The crude product was column chromatographed with ethyl acetate: petroleum
ether to afford to afford the title compound as off-white solid (0.080 g , 12%). IH-NMR (0
ppm, CDCh, 400 MHz): 7.55 (t, J = 8.1 Hz, IH), 7.43-7.13 (m, 12H), 4.47 (m, 2H), 4.30 (d, J
= 11.8 Hz, IH), 2.84 (s, 3H), 21.54(d, J = 6.5 Hz, 3H).
Intermediate 149: 2-( l-hydroxyethyl)methylphenyl-4H-chromenone
: To intermediate 148 (0.140 g, 0.377 mmol) in dichloromethane (2.0 ml) at -78°C, boron
tribromide (0.12 mI, I M in dichloromethane, 0.755 mmol) was added slowly and maintained
for 4h. The reaction mass was quenched at -78°C using 2N HCI (50 ml), extracted with ethyl
acetate, dried over sodium sulphate and concentrated. The crude product was column
chromatographed with ethyl acetate : petroleum ether to afford to afford the title compound
as pale-yellow liquid (0.100 g , 95%) which was used as such in next step.
Intermediate 150: 3-bromofluoro(l-hydroxyethyl)-4H-chromenone :
The title compound was obtained as a pale brown solid (1.90 g, 61 %) by using a procedure
that is similar to the one described for intermediate 23 from intermediate 28 (3.90 g, 11.14
mmol ), DMSO (40 ml) and n-butanol (3.0 ml) which was usedas such in next step.
Intermediate 151: 2-acetylbromofluoro-4H-chromenone : The title
compound was obtained as a pale yellow solid (0.80 g, 80 %) by using a procedure that is
similar to the one described for intermediate 24 from intermediate 150 (1.00 g, 3.48 mmol),
DMSO (0.98 ml, 13.92 mmol ), dichloromethane (104 ml), oxalyl chloride (0.59 ml, 6.96
mmol) and triethylamine (2 ml). IH-NMR (0 ppm, COCl , 400 MHz): 7.73 (dt, J = 8.4,5.4
J = 8.6,0.9 Hz, IH), 7.18 (m ,IH), 2.70 (s, 3H).
Hz, IH), 7.36 (td,
Intermediate 152: 2-acetylfluoro0-tolyl-4H-chromenone : The title
compound was obtained as a pale brown solid (0.165 g, 32%) by using a procedure that is
similar to the one described for intermediate 21 from intermediate 151 (0.500 g, 1.75 mmol) ,
2-methylphenylboronic acid (0.382 g, 2.80 mmol), dioxane (II ml), potassium acetate ( 0.573
g, 3.33 mmol) and tetrakis(triphenylphosphine)palladium(O) (0.162 g, 0.140 mmol) which was
used as such in next step.
Intermediate 153 (R)/(S)- 5-fluoro( l-hydroxyethyl)0-tolyl-4H-
chromenone : To a solution of intermediate 152 ( 0.155 g, 0.523 mmol) in DMF (2 ml)
WO 20121151525
under nitrogen purging, formic acid: trietylamine S : 2 azeotrope (O.S ml) was added followed
by [(S,S)tethTsDpenRuCI] (I mg). The reaction mixture was heated at 80°C for I.Sh under
continuous nitrogen purging. The reaction mixture was quenched with water, extected with
ethyl acetate, dried over sodium sulphate and concentrated. The crude product was purified by
column chromatography with ethyl acetate: petroleum ethert to afford the title compound as a
off-white solid (0.090 g, 66%) which was usedas such in next step.
EXAMPLES
Example 1
2-(6-Amino-9H-purinyl) methyl)(3-fluorophenyl)-S-methoxy-
4H-chromenone
2-(6-Amino-9H-purinyl)methyl)(3-fluorophenyl)-S-methoxy-4H-
chromenone:To a solution of adenine (0.030 g, 0.222 mmo!) in DMF (2 ml), potassium
carbonate (0.061 g, 0.444 mmol) was added and stirred at RT for 10 min. To-this mixture
intermediate 10 (0.120 g, 0.333 mmol) was added and stirred for 12h. The reaction mixture
was diluted with water and extracted with ethyl acetate. The organic layer was dried over
sodium sulphate and concentrated under reduced pressure. The crude product was purified by
column chromatography with methanol: dichloromethane to afford the title compound as an
off-white solid (0.028 g, 30 %). IH-NMR (8 ppm, DMSO-D6, 400 MHz): 8.09 (s, IH), 8.07
(s, IH), 7.64 (t, J = 8"4 Hz, IH), 7.46 (dd,J = IS.O, 6.7 Hz, IH), 7.22-7.20 (m, SH), 6.98 (d, J
=8.3Hz, IH), 6.91 (d,J=8.SHz, IH),S.26 (s, 2H), 3.81 (s,3H).
Example 2
2-( (4-Amino(3-fl uoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d]pyrimidin
yl)methyl)(3-fluorophenyl)-S-methoxy-4H-chromenone
2-« 4-Amino(3-fluoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d]pyrimidin-
l-yl)methyl)(3-fluorophenyl)-S-methoxy-4H-chromenone:To a solution of Inetermediate
13 (0.060 g, 0.220 mmol) in DMF (2 ml), potassium carbonate (0.060 g, 0.440 mmol) was
added and stirred at RT for 10 min. To this mixture intermediate 9 (0.120 g, 0.330 mmoles)
was added and stirred for 12h. The reaction mixture was diluted with water and extracted with
ethyl acetate. The organic layer was dried over sodium sulphate and concentrated under
reduced pressure. The crude product was purified by column chromatography with methanol:
dichloromethane to afford the title compound as a pale yellow solid (0.03Sg, 28%). MP: 14S-
148°C. IH-NMR (8 ppm, DMSO-D6, 400 MHz): 8.37 (s, IH), 7.S1 (t, J = 8.3 Hz, IH), 7.42-
7.29 (m, 3H), 7.18-7.09(m, 3H), 7.00 (t , J = 6.8 HZ, I H), 6.84 (d, J = 8.3 Hz, 1 H), 6.78 (d, J =
WO 20121151525
8.3 Hz, IH), 5.53(s, 2H), 5.47 (s, 2H), 4.66 (quintet, J = 6.0 Hz, IH), 3.98 (s, 3H), 1.41 (d, J =
.9 Hz, 6H).
Example 3
2-( (4-amino(3-fluoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d]pyrimidin-l
yl)methyI)-S-fluoro(3-fluorophenyl)-4H-chromenone
2-« 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)methyl)fluoro(3-fluorophenyl)-4H-chromenone:To a solution of Intermediate 13
(0.100 g, 0.367 mmol) in DMF (2 ml), potassium carbonate (0.101 g, 0.734 mmol) was added
and stirred at ~T for 10 min. To this mixture intermediate 17 (0.173 g, 0.550 mmoles) was
added and stirred for 12h. The reaction mixture was diluted with water and extracted with
ethyl acetate. The organic layer was dried over sodium sulphate and concentrated under
reduced pressure. The crude product was purified by column chromatography with methanol:
dichloromethane to afford the title compound as a pale brown solid (0.011 g, 5%). MP: 156-
159°C. IH-NMR (8 ppm, DMSO-D6, 400 MHz): 8.20 (s, IH), 8.79 (dd, J = 13.9,8.2 Hz, IH),
7.63-7.53 (m, 4H), 7.40-7.22 (m, 5H), 7.15 (m, 2H), 5.47 (s, 2H), 4.71 (quintet, J = 5.9 Hz,
IH), 1.32 (d, J = 5.9 Hz, 6H).
Example 4
2-« 4-amino(3-fluoro-S-methoxyphenyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)methyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
2-« 4-amino(3-fluoromethoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)methyl)fluoro(3-fluorophenyl)-4H-chromenone:To a solution of 3-(3-fluoro
methoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidinamine (0.150 g, 0.578 mmol) in DMF (2 ml),
potassium carbonate (0.159 g, 1.15 mmol) was added and stirred at RT for 10 min. To this
mixture intermediate 17 (0.564 g, 1.78 mmoles) was added and stirred for 12h. The reaction
mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried
over sodium sulphate and concentrated under reduced pressure. The crude product was
purified by column chromatography with methanol: dichloromethane to afford the title
compound as a pale brown solid (0.200 g, 65%) which is used as such for next step.
Example 5
2-« 4-amino(3-fluoro-S-hydroxyphenyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)methyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
2-« 4-amino(3-fluorohydroxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)methyl)fluoro(3-fluorophenyl)-4H-chromenone:To a solution example 4(0.200 g,
0.377 mmol) in dichloromethane (2 ml)at OoC, boron tribromide (1M in dichloromethane,
WO 20121151525
2ml) was added and warmed to RT and stirred for 12h. The reaction mixture was quenched by
the addition of aq.HCI solution and extracted with ethyl acetate. The organic layer was dried
over sodium sulphate and concentrated under reduced pressure to afford the title compound as
a pale brown solid (0.030 g, 15%). MP: 136-138°C. IH-NMR (0 ppm, DMSO-D6, 400 MHz):
.17 (s, IH), 8.22 (s, IH), 7.78 (dt, J = 14.2,8.3 Hz, IH), 7.63 (dd, J = 12.0,7.3 Hz, IH), 7.56
(m, IH), 7.38-7.23 (m, 3H), 7.14-7.07 (m , 3H), 6.85 (s, IH), 6.82 (d, J = 9.0 Hz, IH), 6.65 (d,
J = 10.8 Hz, IH), 5.50 (s, 2H).
Example 6
2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H,-chromenone
2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone:To a solution of 13 (0.120 g, 0.440
mmol) in DMF (2 ml), potassium carbonate (0.121 g, 0.881 mmol) was added and stirred at
RT for 10 min. To this mixture intermediate 22 (0.217 g, 0.661 mmoles) was added and stirred
for 12h. The reaction mixture was diluted with water and extracted with ethyl acetate. The
organic layer was dried over sodium sulphate and concentrated under reduced pressure. The
crude product was purified by column chromatography with methanol: dichloromethane to
afford the title compound as a off-white solid (0.120 g, 48%). MP: 228-230°C. IH-NMR (0
ppm, CDCh, 400 MHz): 8.23 (s, IH), 7.62 (dt, J = 8.4,5.9 Hz, IH), 7.44 (d, J = 11.5,1.8 Hz,
IH), 7.37 (d, J = 8.4 Hz, IH), 7.31 (m, 2H), 7.14 (t, J = 8.4 Hz, IH), 7.06 (m, 3H), 6.92 (d, J
= 9.5 Hz, IH), 6.07 (q, J = 7.1 Hz, IH), 5.52 (s, 2H), 4.65 (quintet, J = 6.1 Hz, IH), 1.99 (d, J
= 7.1 Hz, 3H), 1.42 (d, J = 6.1 Hz, 6H).
Example 7 and 8
(+ )(1-( 4-amino(3-fluoroisopropoxyphenyl)-1H -pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H -chromenone and (-)(1-( 4-amino(3-
fl uoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone
The two enantiomerically pure isomers were separated by preparative SFC
conditions from example 6 (0.300 g) on a CHIRALPAK AS-H column (250 x 4.6 mm; 5J.lm)
using methanol: CO (30:70) as the mobile phase at a flow rate of 3.0 ml / min.
Example 7: Off-white solid (0.145 g). e.e. 98.16%. Rt: 2.06 min. [a]25 177.47 (c = I,
CHCI ). MP: 217-220 dc. Mass: 571.2 (M+).
WO 20121151525
Example 8: Off-white solid (0.136 g). e.e. 100%. Rt: 2.73 min. [a]25 -173.56 (c = 1, CHCb).
MP: 218-221 dc. Mass: 571.8 (M+).
Example 9
2-(1-( 4-amino(3-methyl-IH -indazolyl)-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
S-fluoro(3-fluorophenyl)-4H-chromenone
2-(I-(4-amino(3-methyl-l H-indazolyl)-IH-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : To a solution of intermediate 27
(0.100 g, 0.183 mmol) in 1,2-dimethoxyethane (2 ml), and water (1 ml), 3-methyl(4,4,5,5-
tetramethyl-I,3,2-dioxaborolanyl)-IH-indazole (0.099 g, 0.275 mmol) and sodium
carbonate (0.058 g, 0.549 mmol) were added and the system is degassed for 30 min.
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.030 g, 0.036 mmol ) was
added under nitrogen atmosphere and degassed for 30 min and kept under microwave
irradiation (microwave power = 100W, temperature = 100°C) for I h .. The reaction mixture
was filtered through celite, washed with ethyl acetate, dried over sodium sulphate and
concentrated. The residue was dissolved in dichloromethane (2 ml) and triflutoacetic acid (2
ml ) was added and stirred for 1 h. The reaction mixture neutralised with aq.sodium
bicarbonate solution, extracted with ethyl acetate. The organic layer was dried over sodium
sulphate and concentrated under reduced pressure. The crude product was purified by column
chromatography with methanol: dichloromethane to afford the title compound as brown solid
(0.033 g, 33% yield). MP: 156-159°C. IH-NMR (8 ppm, CDCI), 400 MHz): 8.21 (s, IH),
7.86 (d, J = 8.2 Hz, IH), 7.73 (s,IH), 7.60 (dt, J = 8.4,5.5 Hz, IH), 7.45 (dd, J = 8.2,1.1 Hz,
IH), 7.29 (m, 2H), 7.06 -6.98 (m, 4H), 6.10 (q, J = 7.2 Hz, IH), 5.89 (m, IH), 2.64 (s, 3H),
1.96 (d, J = 7.2 Hz, 3H).
Example 9a and 9b
(+)- 2-(1-( 4-amino(3-methyl-lH-indazolyl)-iH-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H -chromenone and (-)- 2-(1-( 4-amino(3-
methyl-l H -indazoly 1)-1 H -pyrazolo[3,4-d] pyrimidin-l-yl )ethyl)-S-fluoro(3-
fluorophenyl)-4H-chromenone
The two enantiomerically pure isomers were separated by preparative SFC
conditions from example 9 (0.300 g) on a CHIRALPAK AD-H column (250 x 4.6 mm; 51lm)
using methanol: CO (30:70) as the mobile phase at a flow rate of 3.0 ml / min.
Example 9a: Brown solid (0.097 g). e.e. 98.12%. Rt: 4.54 min. [a]25 161.30 (c = 1,
CHCI).MP: 190-192 dc. Mass: 549.8 (M+).
WO 20121151525
Example 9b: Brown solid (0.098 g). e.e. 96.1 %. Rt: 5.92 min. [af5 -209.90 (c = I,
CHCI ).MP: 193-195 0c. Mass: 549.2 (M+).
Example 10
2-(1-( 4-amino(1 H -pyrazolyl)-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro-
3-(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino( I H-pyrazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)-
-fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as off-white
solid (0.016 g, 18%) by using a procedure that is similar to the one described for example 9
from intermediate 27 (0.100 g, 0.183 mmol), 1,2-dimethoxyethane (2 ml), water (1 ml), 1-
Boc-pyrazoleboronic acid (0.058 g, 0.275 mmot), sodium carbonate (0.058 g, 0.549 mmol)
and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.030 g, 0.036 mmol )
MP: 165-168°C. IH-NMR (8 ppm, CDCb, 400 MHz): 8.24 (s, IH), 7.94 (s, 2H), 7.59 (m,
IH), 7.28 (m, 2H), 7.04 -6.87 (m, 4H), 6.04 (q, J = 7.0 Hz, IH), 5.49 (s, 2H), 1.99 (d, J = 7.1
HZ,3H).
Example 11
2-(1-(6-amino-9H-purinyl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
2-( I-(6-amino-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromen-
4-one: The title compound was obtained as pale green solid (0.047 g, 26%) by using a
procedure that is similar to the one described for example 6 from adenine (0.116 g, 0.864
mmol), DMF (5 ml), potassium carbonate (0.140 g, 1.08 mmol) and intermediate 22 (0.150 g,
0.432 mmol) MP: 222-224°C. IH-NMR (8 ppm, DMSO-d , 400 MHz): 8.44 (s, IH), 8.03 (s,
IH), 7.82 (dt, J = 8.4,5.7 Hz, IH), 7.51 (m, 2H), 7.27-7.16 (m, 6H), 5.64 (q, J = 7.0 Hz, IH),
1.88 (d, J = 7.2 Hz, 3H).
Example 12
2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fl uoro( 4-fluorophenyl )-4 H -chromenone
22-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro( 4-fluorophenyl)-4H-chromenone: The title compound
was obtained as pale brown solid (0.085 g, 38%) by using a procedure that is similar to the
one described for example 6 from intermediate 13 (0.150 g, 0.522 mmol), DMF (2 ml),
potassium carbonate (0.152 g, 1.10 mmol) and intermediate 31 (0.272 g, 0.0.744 mmol) MP:
218-221°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.24 (s, IH), 7.61 (dt, J = 8.5,5.5 Hz, IH),
7.44 (dd, J = 11.5,2.0 Hz, I H), 7.35 (d, J = 9.0 Hz, IH), 7.23 (m, 3H), 7.15 (t, J = 8.4 Hz, I H),
WO 20121151525
7.08 (m, 3H), 6.06 (q, J = 7.1 Hz, 1 H), 5.79 (s, 2H), 4.67 (quintet, J = 6.1 Hz, I H), 1.99 (d, J =
7.1 Hz, 3H), 1.42 (d, J = 7.1 Hz,6H).
Example 13
2-(1-( 4-amino{3-fl uoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d] pyrimidin
yl)ethyl)fluorophenyl-4H-chromenone
2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
The title compound was obtained as off
l-yl)ethyl)fluorophenyl-4H-chromenone:
white solid (0.060 g, 25% ) by using a procedure that is similar to the one described for
example 6 from intermediate 13 (0.150 g, 0.522 mmol), DMF (2 ml), potassium carbonate
(0.152 g, 1.10 mmol) and intermediate 33 (0.291 g, 0.838 mmol) MP: 226-229°C. IH-NMR
(0 ppm, CDCh, 400 MHz): 8.22 (s, IH), 7.60 (dt, J = 8.5,5.5 Hz, IH), 7.44 (dd, J = 11.5,2.0
Hz, IH), 7.36 (m, 4H), 7.23 (m, 3H), 7.14 (t, J = 8.4 Hz, IH), 7.04 (t, J = 9.7 Hz, IH), 6.06
(q, J = 7.2 Hz, IH), 5.52 (s, 2H), 4.64 (quintet, J = 6.1 Hz, IH), 1.98 (d, J = 7.1 Hz, 3H), 1.42
(d, J = 6.0 Hz, 6H).
Example 14
2-(1-( 4-amino(benzofuranyl)-1 H -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fl uoro-
3-(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(benzofuranyl)-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)-
-fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as off-white
solid (0.026 g, 26%) by using a procedure that is similar to the one described for example 9
from intermediate 27 (0.100 g, 0.183 mmol), 1,2-dimethoxyethane (2 ml), water (l ml),
benzofuranboronic acid (0.045 g, 0.275 mmol), sodium carbonate (0.058 g, 0.549 mmol)
and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.062 g, 0.073 mmol )
MP: 238-241°C. IH-NMR (0 ppm, CDCh, 400 MHz): 8.27 (s, IH), 7.70 (d, J = 8.4 Hz, IH),
7.62-7.57 (m, 2H), 7.41 (s, IH), 7.39 (m, 3H), 7.28 (m, IH), 7.07-6.99 (m, 4H), 6.07 (q, J =
8.1 Hz, IH), 2.05 (d, J = 8.3 Hz, 3H).
Example 15
2-(I-(9H-purinylamino)ethyl)fluoro(3-fluoropheny1)-4H-chromenone
2-( 1-(9H -purinylamino )ethyl)fluoro(3- fl uorophenyl)-4H -chromen
one: To a solution of intermediate 36 (0.20 g, 0.663 mmol), tert-butanol (l.5 ml) N,N
diisopropylethylamine (0.23 ml, 1.32 mmol) and 6-chloropurine (0.102 g, 0.663 mmol) were
added and heated to reflux for 48h. The reaction mixture was concentrated, quenched with
water, extracted with ethyl acetate, dried with sodium sulphate and concentrated. The crude
product was purified by column chromatography with methanol : ethyl acetate to afford the
WO 20121151525
title compound as brown solid (0.080 g, 30% yield). MP: 195-198°C. IH-NMR (0 ppm,
DMSO-d , 400 MHz): 12.96 (s, IH), 8.17 (s, IH), 8.09 (s, IH), 7.21-6.94 (m, 5H), 6.71 (m,
2H), 5.64 (m, I H), 1.52 (br s, 3H).
Example 16
2-(1-( 4-amino-l H -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-fl uorophenyl)-
4H-chromenone
22-( 1-( 4-amino-I H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone: The title compound was obtained as brown solid (0.030 g,
%) by using a procedure that is similar to the one described for example 6 from IH
pyrazolo[3,4-dJpyrimidinamine (0.077 g, 0.576 mmol), DMF (1 ml), potassium carbonate
(0.099 g, 0.720 mmol) and intermediate 22 (0.100 g, 0.288 mmol) . MP: 267-269°C. IH-NMR
(0 ppm, CDC I), 400 MHz): 8.25 (s, IH), 7.92 (s, IH), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.32 (m,
2H), 7.06 (m, 3H), 6.92 (d, J = 9.7 Hz, IH), 6.02 (q, J = 7.1 Hz, IH), 5.41 (s,2H), 1.96 (d, J =
7.1 Hz, 3H).
Example 16a and 16b
(+ )(1-( 4-amino-1H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone and (-)- 2-(1-( 4-amino-IH -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
The two enantiomerically pure isomers were separated by preparative SFC
conditions from example 16 (0.300 g) on a CHIRALPAK AD-H column (250 x 4.6 mm; 5J.lm)
using methanol: CO (30:70) as the mobile phase at a flow rate of 3.0 ml / min.
Example 16a: Off-white solid (0.145 g). e.e. 98.07%. Rt: 2.49 min. [a]25 90.52 (c = 1,
CHCI).MP: 197-200 dc. Mass: 419.8 (M+).
Example 16b: Off-white solid (0.150 g). e.e. 98.8%. Rt: 3.56 min. [af5 -73.03 (c = 1,
CHCh).MP: 198-201 dc. Mass: 419.8 (M+).
Example 17
2-(1-( 4-amino( 4-(difluoromethoxy )fluorophenyl)-IH -pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fl uoro(3-fl uorophenyl )-4 H -chromen one
2-(1-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-pyrazolo[3,4-
dJpyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as pale brown solid (0.042 g, 27%) by using a procedure that is similar to the
one described for example 6 from intermediate 39 (0.081 g, 0.273 mmol), DMF (2 ml),
potassium carbonate (0.075 g, 0.546 mmol) and intermediate 22 (0.100 g, 0.0.273 mmol) MP:
WO 20121151525
230-233°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.26 (s, IH), 7.62 (dt, J = 8.4,5.4 Hz, IH),
7.56 (dd, J = 10.3,1.3 Hz, IH), 7.47 (m, 2H), 7.32 (d, J = 6.5 Hz, IH), 7.27 (m, IH), 7.06 (m,
J = 9.1 Hz, IH), 6.81 (t, J = 72.9 Hz, IH), 6.63 (s, 2H), 6.07 (q, J = 7.2 Hz, IH),
3H), 6.91 (d,
1.99 (d, J = 7.1 Hz, 3H).
Example 18
2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-IH -pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(IH-pyrazolyl)-4H-chromenone
2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(1 H-pyrazolyl)-4H-chromenone: The title compound was
obtained as brown solid (0.020 g, 20%) by using a procedure that is similar to the one
described for example 9 from intermediate 29 (0.100 g, 0.188 mmol), 1,2-dimethoxyethane (2
ml), water (1 ml), I-Boc-pyrazoleboronic acid (0.098 g, 0.282 mmol), sodium carbonate
(0.059 g, 0.565 mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch
(0.030 g, 0.037 mmol) MP: 181-184°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.34 (s, IH),
7.93 (s, 2H), 7.57 (dt, J = 8.4,5.5 Hz, IH), 7.47 (dd, J = 11.5,2.0 Hz, IH), 7.40 (d, J = 8.4 H"z,
IH), 7.24 (m, I H), 7.15 (t, J = 8.4 Hz, I H), 7.04 (dd, J = 10.2,8.9 Hz, I H), 6.36 (q, J = 7.1 Hz,
I H), 5.51 (s, 2H), 4.65 (q, J = 6.0 Hz, I H), 2.03 (d, J = 7.1 Hz, 3H), 1.42 (d, J = 6.0 Hz, 6H).
Example 19
2-(1-( 4-amino(3-fluoro( tetrahydro-2H -pyranyloxy )phenyl)-1 H -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(3-fluoro(tetrahydro-2H-pyranyloxy)phenyl)-1 H-
pyrazolo[3,4-d] pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H -chromenone: The
title compound was obtained as brown solid (0.022 g, 22%) by using a procedure that is
similar to the one described for example 9 from intermediate 27 (0.100 g, 0.183 mmol), 1,2-
dimethoxyethane (2 ml), water (I ml), intermediate 41 (0.070 g, 0.276 mmol), sodium
carbonate (0.038 g, 0.366 mmol) and bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH Ch (0.030 g, 0.036 mmol). MP: 234-23rc. IH-NMR (8 ppm, CDCh, 400
MHz): 8.24 (s, IH), 7.62 (dt, J = 8.4,5.5 Hz, IH), 7.46 (dd, J = 11.4,1.9 Hz, IH), 7.37 (d, J =
8.3 Hz, IH), 7.32 (m, 2H), 7.17 (t, J = 8.3 Hz, IH), 7.06-6.96 (m, 3H), 6.90 (d, J = 8.8 Hz,
I H), 6.08 (q, J = 7.0 Hz, I H), 5.44 (s, 2H), 4.58 (quintet, J = 3.9 Hz, I H), 4.05 (m, 2H), 3.62
(m, 2H), 2.09 (m, 2H), 1.99 (d, J = 7.1 Hz, 3H), 1.91 (m,2H).
Example 20
2-(1-( 4-amino(3-isopropyl-l H -indazolyl)-1 H -pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
WO 20121151525
2-(1-( 4-amino(3-isopropyl-1 H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(3-fluorophenyI)-4H-chromenone: The title compound was obtained
as brown solid (0.026 g, 13%) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.100 g, 0.183 mmoI), 1,2-dimethoxyethane (2 mI), water (1
ml), intermediate 46 (0.140 g, 0.276 mmol), sodium carbonate (0.038 g, 0.366 mmol) and
bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.030 g, 0.036 mmol). MP:
249-252°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.25 (s, IH), 7.94 (d, J = 8.3 Hz, IH), 7.74
(s, IH), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.44 (dd, J = 8.2,1.2 Hz, IH), 7.30 (m, 2H), 7.06-6.95
(m, 3H), 6.92 (d, J = 8.0 Hz, IH), 6.10 (q, J = 7.1 Hz, IH), 5.47 (s, 2H), 3.48 (q, J = 7.1 Hz,
IH), 2.02 (d, J = 7.1 Hz, 3H), 1.50 (d, J = 7.1 HZ,6H).
Example 21
2-(1-( 4-amino{3-fluoro{piperidinyloxy )phenyl )-1 H -pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)-S-fluoro{3-fluorophenyl)-4H -chromenone
2-( 1-( 4-amino(3-fluoro(piperidinyloxy)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.030 g, 13%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.100 g, 0.183 mmoI), 1,2-dimethoxyethane (2
ml), water (I mI), intermediate 48 (0.150 g, 0.276 mmoI), sodium carbonate (0.038 g, 0.366
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.030 g, 0.036
mmol). MP: 280-283°C. IH-NMR (0 ppm, DMSO-d , 400 MHz): 8.06 (s, IH), 7.83 (dt, J =
8.4,5.7 Hz, IH), 7.49 (d, J = 8.5 Hz, IH), 7.41 (dd, J = 12.6,1.5 Hz, IH), 7.34 (m, 4H), 7.07
(dt, J = 8.9,2.6 Hz, IH), 6.92 (m, 2H), 5.96 (q, J = 7.0 Hz, IH), 4.50 (m, IH), 3.40 (m, IH),
2.99 (m, 2H), 2.62 (m, 2H), 1.97 (m, 2H), 1.87 (d, J = 7.0 Hz, 3H), 1.54 (m, 2H).
Example 22
2-(1-( 4-amino{3-fl uoro{2-hydroxyethylamino) phenyl )-1 H -pyrazolo[3,4-
d]pyrimidinyl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(3-fluoro(2-hydroxyethylamino )phenyl)-I H-pyrazolo[3,4-
d]pyrimidin-I-yI)ethyI)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.018 g, 9%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1 ,2-dimethoxyethane (3
ml), water (1.5 ml), intermediate S2 (0.167 g, 0.411 mmol), sodium carbonate (0.058 g, 0.549
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.045 g, 0.054
mmol ). MP: 154-157°C. IH-NMR (0 ppm, CDCI , 400 MHz): 8.20 (s, IH), 7.61 (dt, J =
8.4,5.4 Hz, IH), 7.34-7.28 (m, 4H), 7.06-6.96 (m, 3H), 6.91 (d, J = 9.0 Hz, IH), 6.87 (t, J =
WO 20121151525
8.3 Hz, I H), 6.06 (q, J = 7.1 Hz, I H), 5.62 (s, 2H), 4.51 (s, 1 H), 3.92 (t, J = 5.1 Hz, 2H), 3.42
(t, J = 5.2 Hz, 2H), 2.09 (s, IH), 1.98 (d, J = 7.1 Hz, 3H).
Example 23
2-(1-( 4-amino(3-fl uoro(isopropylamino )phenyl)-lH -pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-(1-( 4-amino(3-fluoro(isopropylamino )phenyl)-I H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.065 g, 25%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.250 g, 0.457 mmol), 1,2-dimethoxyethane (4
ml), water (l ml), intermediate 56 (0.192 g, 0.686 mmol), sodium carbonate (0.097 g, 0.915
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.074 g, 0.091
mmol ). MP: 224-226°C. IH_ NMR (8 ppm, DMSO-d6, 400 MHz): 8.04 (s, IH), 7.83 (dt, J
= 8.4,5.6 Hz, IH), 7.49 (d, J = 8.6 Hz, IH), 7.28-7.21 (m, 4H), 7.06 (dt, J = 8.4,1.8 Hz, IH),
6.91-6.82 (m ,3H), 5.95 (q, J = 6.7 Hz, IH), 5.37 (d, J = 6.6 Hz, IH), 3.72 (m ,IH), 1.86 (d, J
= 7.0 Hz, 3H), 1.19 (d, J = 6.2 Hz, 6H).
Example 24
2-(1-( 4-amino( 4-( dimethylamino )fluorophenyl)-lH-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fl uoro(3-fluorophenyl)-4H -chromenone
2-( 1-( 4-amino( 4-(dimethylamino)fluorophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as off-white solid (0.070 g, 28%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.250 g, 0.457 mmol), I ,2-dimethoxyethane (4
ml), water (l ml), intermediate 60 (0.182 g, 0.686 mmol), sodium carbonate (0.097 g, 0.915
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.074 g, 0.091
mmol ). MP: 252-254°C. IH-NMR NMR (8 ppm, DMSO-d6, 400 MHz): 8.06 (s, IH), 7.83
(dt, J = 8.5,5.7 Hz, IH), 7.49 (d, J = 8.7 Hz, IH), 7.32-7.24 (m, 4H), 7.09 (m, 2H), 6.88
(m,2H), 5.95 (q, J = 7.0 Hz, IH), 2.85(s, 6H), 1.87 (d, J = 7.0 Hz, 3H).
Example 25
2-(1-( 4-amino(3-fluoromorpholinophenyl)-lH -pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as pale brown solid (0.055 g, 33%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane (3
WO 20121151525
ml), water (1.5 ml), intermediate 61 (0.127 g, 0.411 mmol), sodium carbonate (0.058 g, 0.549
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH2Ch (0.045 g, 0.054
mmol ). MP: 270-272°C. IH-NMR NMR (0 ppm, CDCh, 400 MHz): 8.24 (s, IH), 7.59 (dt,
J = 8.4,5.4 Hz, IH), 7.40 (m, 2H), 7.27 (m, 2H), 7.09-6.86(m,5H), 6.06 (q, J = 7.1 Hz, IH),
.43 (s, 2H), 3.91 (t, J = 4.6 Hz, 4H), 3.48 (t, J = 4.7 Hz, 4H), 1.99 (d, J = 7.1 HZ,3H).
Example 26
2-(1-( 4-amino(2-methyl-IH -benzo[ d]imidazolyl)-1 H -pyrazolo[3,4-d] pyrimidin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H -chromen one
2-(1-( 4-amino(2-methyl-l H-benzo( d]imidazolyl)-1 H-pyrazolo[3,4-
d] pyrimidi n-l-yl )eth y 1)-5 -fl uoro(3 -fl uoropheny 1)-4 H -chromenone: The. ti tIe compound
was obtained as pale brown solid (0.032 g, 13%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.250 g, 0.457 mmol), 1,2-dimethoxyethane (4
ml), water (I ml), teft-butyl 2-methyl(4,4,5,5-tetramethyl-l ,3,2-dioxaborolanyl)-1 H
benzo[d]imidazole-I-carboxylate (0.246 g, 0.686 mmol), sodium carbonate (0.097 g, 0.915
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.074 g, 0.091
mmol). MP: 236-238°C. IH-NMR NMR (0 ppm, CDCh, 400 MHz): 8.25 (s, IH), 7.81(br s,
IH), 7.66 (m, IH), 7.62 (dt, J = 8.4,5.4 Hz, IH), 7.52 (dd, J = 8.2,1.6 Hz, IH), 7.30 (m, 2H),
7.06-6.95 (m, 3H), 6.92 (d, J = 9.3 Hz, IH), 6.10 (q, J = 6.9 Hz, IH), 5.71 (s, 2H), 2.67 (s,
3H), 2.01 (d, J = 7.2 Hz, 3H).
Example 27
2-(1-( 4-amino(3-fluoro( 4-methyl piperazin-l-yl)phenyl)-IH -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-(1-( 4-amino(3-fluoro( 4-methylpiperazin-l-yl)phenyl)-1 H-
pyrazolo [3, 4-d]pyrimidin-l-yl )ethy 1)-5 -fl uoro-3 -(3-fl uoropheny 1)-4 H -chromenone: The
title compound was obtained as pale brown solid (0.080 g, 20%) by using a procedure that is
similar to the one described for example 9 from intermediate 27 (0.300 g, 0.549 mmol), 1,2-
dimethoxyethane (5 ml), water (2.5 ml), intermediate 63 (0.260 g, 0.604 mmol), sodium
carbonate (0.116 g, 1.09 mmol) and tetrakistriphenylphosphine palladium(O) (0.032 g, 0.027
mmol). MP: 246-249°C. IH-NMR NMR (0 ppm, CDCh, 400 MHz): 8.23 (s, IH), 7.61 (dt, J
= 8.4,5.4 Hz, IH), 7.38 (m, 2H), 7.29 (m, 2H), 7.08-6.96 (m, 4H), 6.91 (d, J = 9.2 Hz, IH),
6.07 (q, J = 7.2 Hz, IH), 5.51 (s, 2H), 3.22 (t, J = 4.6 Hz, 4H), 2.67 (t, J = 4.6 Hz, 4H), 2.37 (s,
3H), 1.98 (d, J = 7.2 Hz, 3H).
Example 28
WO 20121151525
2-(1-(4-( dimethylamino )-IH-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro(3-
fluorophenyl)-4 H -chromenone
2-( 1-( 4-(dimethylamino )-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)fluoro
(3-fluorophenyl)-4H-chromenone: The title compound was obtained as pale brown solid
(0.040 g, 18%) by using a procedure that is similar to the one described for example 6 from
N,N-dimethyl-1H-pyrazolo[3,4-d]pyrimidinamine (0.080 g, 0.49 mmol for preparation see
J.Amer. Chern. Soc. 1956,784-790), DMF (10 ml), cesium carbonate (0.319 g, 0.546 mmol)
and intermediate 22 (0.179 g, 0.0.490 mmol) MP: 200-202°C. IH-NMR NMR (8 ppm, CDCI ,
400 MHz): 8.20 (s, IH), 7.95 (s, IH), 7.60 (dt, ) = 8.4,5.5 Hz, IH), 7.31 (m, 2H), 7.05 (m,
3H), 6.86 (d,) = 9.2 Hz, I H), 6.02 (q,) = 7.1 Hz, IH), 3.36 (s, 6H), 1.93 (d,) = 7.1 Hz, 3H).
Example 29
2-(1-( 4-amino-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluorophenyl-4H
chromenone
2-( 1-( 4-amino-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)fluorophenyl-
4H-chromenone: The title compound was obtained as pale green solid (0.030 g, 25%) by
using a procedure that is similar to the one described for example 6 from I H-pyrazolo[3,4-
d]pyrimidinamine (0.061 g, 0.455 mmol), DMF (l mI), cesium carbonate (0.148 g, 0.455
mmol) and intermediate 33 (0.100 g, 0.0.303 mmol). MP: 223-226°C. IH-NMR NMR (8 ppm,
CDCl), 400 MHz): 8.23 (s, IH), 7.92 (s, IH), 7.57 (dt,) = 8.4,5.4 Hz, IH), 7.34 (m, 3H), 7.23
(s, IH), 7.19 (m,2H), 7.04 (dt,)= 8.2,0.9 Hz, IH), 6.01 (q,}=7.1 Hz, IH),5.40(s,2H), 1.95
(d, ) = 7.1 Hz, 3H).
Example 30
2-(1-( 4-amino-1H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluor0( 4-fluorophcnyl)-
4H -chromenone
2-( 1-(4-amino-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)fluoro(4-
fluorophenyI)-4H-chromenone: The title compound was obtained as pale green solid
(0.040 g, 34%) by using a procedure that is similar to the one described for example 6 from
I H-pyrazolo[3,4-d]pyrimidinamine (0.058 g, 0.432 mmoI), DMF (l ml), cesium carbonate
(0.140 g, 0.432 mmol) and intermediate 31 (0.100 g, 0.0.288 mmol). MP: 242-245°C. IH_
NMR NMR (8 ppm, CDCl), 400 MHz): 8.26 (s, IH), 7.92 (s, IH), 7.60 (dt, ) = 8.4,5.4 Hz,
IH), 7.25 (m, 3H), 7.07-7.00 (m, 3H), 6.01 (q,) = 7.2 Hz, IH), 5.45 (s, 2H), 1.96 (d, ) = 7.1
HZ,3H).
Example 31
WO 20121151525
2-(1-( 4-amino( 4-( difluoromethoxy )fl uorophenyl)-lH -pyrazolo[3,4-d] pyrimidin-
1-yl)ethyl)-S-fluoro(4-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro( 4-fluorophenyl)-4H-chromenone: The title compound
was obtained as off-white solid (0.053 g, 33%) by using a procedure that is similar to the one
described for example 6 from intermediate 39 (0.081 g, 0.273 mmol), DMF (2 ml), potassium
carbonate (0.075 g, 0.546 mmol) and intermediate 31 (0.100 g, 0.0.273 mmol) MP: 233-
235°C. IH-NMR (8 ppm, CDCI , 400 MHz): 8.28 (s, IH), 7.61-7.55 (m, 2H), 7.47 (m, 2H),
7.25 (m, 3H), 7.08 (m, 3H), 6.82 (t, J = 72.9 Hz, IH), 6.01 (q, J = 7.1 Hz, IH), 5.42(s, 2H),
1.99 (d, J = 7.2 Hz, 3H).
Example 32
2-(1-( 4-amino( 4-( difluoromethoxy )fluorophenyl)-1H -pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)-S-fluorophenyl-4 H -chromenone
2-( 1-(4-amino(4-(difluoromethoxy)fluorophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluorophenyl-4H-chromenone: The title compound was
obtained as off-white solid (0.021 g, 33%) by using a procedure that is similar to the one
described for example 6 from intermediate 39 (0.090 g, 0.303 mmol), DMF (2 ml), potassium
carbonate (0.084 g, 0.607 mmol) and intermediate 33 (0.100 g, 0.0.303 mmol) MP: 247-
250°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.22 (s, IH), 7.69-7.20 (m, IOH), 7.05 (dd, J =
9.5,8.5 Hz, I H), 6.81 (t, J = 72.9 Hz, 1 H), 6.08 (q, J = 7.1 Hz, 1 H), 5.43 (s, 2H), 1.99 (d, J =
7.1 Hz, 3H).
Example 33
2-(1-( 4-aminomethyl-1H -pyrazolo[3,4-d]pyrimidinyl)ethyl)-S-fluoro(3-
fluorophenyl)-4H -chromenone
2-( 1-( 4-aminomethyl-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro
(3-fluorophenyl)-4H-chromenone: The title compound was obtained as off-white solid
(0.025 g, 21 %) by using a procedure that is similar to the one described for example 6 from 3-
methyl-I H-pyrazolo[3,4-d]pyrimidinamine (0.043 g, 0.288 mmol for preparation see J.Org.
Chern. 1956,21, 1240-1256), DMF (2 ml), potassium carbonate (0.079 g, 0.576 mmol) and
intermediate 22 (0.100 g, 0.0.288 mmol). MP: 240-242°C. IH-NMR (8 ppm, CDCh, 400
MHz): 88.16 (s, IH), 7.59 (dt, J = 8.4,3.4 Hz, IH), 7.29 (m, 2H), 7.06-6.84(m, 4H), 5.94 (q, J
= 7.1 Hz, 1 H), 5.42 (s, 2H), 2.59 (s, 3H), 1.92 (d, J = 7.1 Hz, 3H).
Example 34
WO 20121151525
2-(1-( 4-aminoethyl-l H -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl )fluoro(3-
fluorophenyl)-4H-chromenone
2-(l-(4-aminoethyl-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone: The title compound was obtained as off-white solid (0.038
g, 30%) by using a procedure that is similar to the one described for example 6 from
intermediate 66 (0.048 g, 0.288 mmol), DMF (2 ml), potassium carbonate (0.079 g, 0.576
mmol) and intermediate 22 (0.100 g, 0.0.288 mmol) MP: 196-198°C. IH-NMR (8 ppm,
CDCI , 400 MHz): 8.18 (s, IH), 7.60 (dt, J = 8.4,3.0 Hz, IH), 7.29 (m, 2H), 7.05-6.78(m,
4H), 5.94 (q, J = 7.2 Hz, IH), 5.31 (s, 2H), 2.95(q,. J = 6.6 Hz, 2H), 1.93 (d, J = 7.2 Hz, 3H),
1.40(d, J = 76 Hz, 3H).
Example 35
2-(1-( 4-aminoisopropyl-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro(3-
fluorophenyl)-4H -chromenone
2-( 1-( 4-aminoisopropyl-l H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro-
3-(3-fluoro phenyl)-4H-chromenone: The title compound was obtained as off-white solid
(0.035 g, 18%) by using a procedure that is similar to the one described for example 6 from 3-
isopropyl-I H-pyrazolo[3,4-d]pyrimidinamine (0.079 g, 0.432 mmol for preparation see
J.Amer.Chem.Soc.2002,124, 12118), DMF (3 ml), potassium carbonate (0.119 g, 0.864 mmol)
and intermediate 22 (0.150 g, 0.0.432 mmol) MP: 212-214°C. IH-NMR (8 ppm, CDCb, 400
MHz): 88.19 (s, IH), 7.59 (dt, J = 8.5,5.4 Hz, IH), 7.32 (m, 2H), 7.03-6.92 (m, 4H), 5.93 (q, J
= 7.5 Hz, IH), 5.34 (s, 2H), 3.20 (m,IH), 1.93 (d, J = 7.2 Hz, 3H), 1.43 (d, J = 6.9 Hz, 3H),
1.42 (d, J = 6.8 Hz, 3H).
Example 36
2-(1-( 4-amino(benzo[b ]thiophenyl)-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(benzo[b ]thiophenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as
brown solid (0.070 g, 15%) by using a procedure that is similar to the one described for
example 6 from intermediate 67 (0.294 g, 1.10 mmol), DMF (3 ml), cesium carbonate (0.358
g, 1.10 mmol) and intermediate 22 (0.300 g, 0.0.864 mmol). MP: 248-250°C. IH-NMR (8
ppm, CDCb, 400 MHz): 8.28 (s, IH), 7.91 (m, 2H), 7.62 (s, IH), 7.60 (dt, J = 8.0,3.0 Hz,
IH), 7.44 (m, 2H), 7.29 (m, 2H), 7.06 (m, 4H), 6.08 (q, J = 7.1 Hz, IH), 5.73 (s, 2H), 2.02 (d,
J = 7.1 HZ,3H).
Example 37
WO 20121151525
2-(1-( 4-aminomorpholino-l H -py razolo[3,4-d] pyrimidin-l-yl )ethyl)-S-fluoro(3-
fluorophenyl)-4H-chromenone
2-( 1-( 4-aminomorpholino-1 H-pyrazo10[3,4-d]pyrimidin-I-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as yellow
solid (0.040 g, 18%) by using a procedure that is similar to the one described for example 6
from intermediate 70 (0.114 g, 0.518 mmol), DMF (2 ml), potassium carbonate (0.119 g,
0.864 mmol) and intermediate 22 (0.150 g, 0.0.432 mmol). MP: l71-173°C. IH-NMR (8
ppm, CDCI), 400 MHz): 8.15 (s, 1H), 7.62 (dt, J = 8.4,5.6 Hz, IH), 7.29-7.23 (m, 2H), 7.06-
6.99(m, 3H), 6.90 (d, J = 9.4 Hz, IH), 5.89 (d, J = 7.2 Hz, IH), 5.29 (s, 2H), 3.88 (t, J = 4.6
Hz, 4H), 3.32 (t, J = 4.6 Hz, 4H), 1.91 (d, J = 7.2 Hz, 3H).
Example 38
2-(1-( 4-amino( dimethylamino )-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro-
3-(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(dimethylamino )-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as brown
solid (0.032 g, 14%) by using a procedure that is similar to the one described for example 6
from intermediate 73 (0.092 g, 0.518 mmol), DMF (2 ml), cesium carbonate (0.119 g, 0.432
mmol) and intermediate 22 (0.150 g, 0.0.432 mmol). MP: 169-171°C. IH-NMR (8 ppm,
CDCh, 400 MHz): 8.14 (s, 1H), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.29 (m, 2H), 7.05 (m, 3H),
6.89 (d, J = 8.9 Hz, IH), 5.87 (q, J = 7.0 Hz, IH), 5.46 (s, 2H), 2.86 (s, 6H), 1.01 (d, J = 7.1
Hz,3H).
Example 39
2-(1-( 4-amino(piperidin-l-yl)-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-S-fluoro
(3-fluorophenyl)-4H-chromenone
2-(l-(4-amino(piperidin-I-yl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as brown
solid (0.014 g, 10%) by using a procedure that is similar to the one described for example 6
from intermediate 76 (0.063 g, 0.288 mmol), DMF (l ml), cesium hydroxide (0.048 g, 0.288
mmol) and intermediate 22 (0.100 g, 0.0.288 mmol). MP: 160-162°C. IH-NMR (8 ppm,
CDCh, 400 MHz): 8.14 (s, IH), 7.55 (dt, J = 8.4,5.5 Hz, IH), 7.29 (m, 2H), 7.05 (m, 3H),
6.89(d,J=8.9Hz, IH),5.85(q,J=7.1 Hz, IH), 5.41 (s,2H), 3.48 (t,J=7.1 HZ,4H), 1.90
(d, J = 7.1 Hz, 3H), 1.73-1.61 (m,6H).
Example 40
WO 20121151525
2-(1-( 4-amino( 6-isopropoxypyridinyl)-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-
-fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(6-isopropoxypyridinyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as
pale brown solid (0.028 g, 28%) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.100 g, 0.183 mmol), 1,.2-dimethoxyethane (2 ml), water (l
ml), 2-isopropoxy( 4,4,5,5-tetramethyl-l ,3,2-dioxaborolanyl)pyridine (0.072 g, 0.274
mmol), sodium carbonate (0.038 g, 0.366 mmol) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(Il).CH Ch (0.029 g, 0.036 mmol). MP:
196-199°C. I H-NMR NMR (8 ppm, CDCI), 400 MHz): 8.45 (d, J = 2.3 Hz, I H), 8.25 (s, I H),
J = 8.6,2.5 Hz, IH), 7.62 (dt, J = 8.4,5.5 Hz, IH), 7.32 (m, 2H), 7.06 (m, 3H), 6.92
7.87 (dd,
(d, J = 9.2 Hz, IH), 6.85 (d, J = 8.6 Hz, IH), 6.06 (q, J = 7.1 Hz, IH), 5.40 (quintet, J = 6.3
Hz, 1H), 5.37 (s, 2H), 1.99 (d, J = 7.1 Hz, 3H), 1.40 (d, J = 6.2 Hz, 6H).
Example 41
2-(1-( 4-amino(methylthio )-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-
fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(methylthio )-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as brown
solid (0.030 g, 22%) by using a procedure that is similar to the one described for example 6
from 3-(methylthio)-IH-pyrazolo[3,4-d]pyrimidinamine (0.078 g, 0.432 mmol for
preparation see J.Het.Chem.1990, 27, 775-783), DMF (2 ml), cesium carbonate (0.140 g,
0.432 mmol) and intermediate 22 (0.100 g, 0.228 mmol). MP: 102-105°C. IH-NMR (8 ppm,
CDC I), 400 MHz): 8.19 (s, IH), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.34 (m, 2H), 7.06 (m, 3H),
6.95 (d, J = 9.5 Hz, IH), 5.95 (q, J = 7.1 Hz, IH), 5.82 (s, 2H), 2.63 (s, 6H), 1.95 (d, J = 7.1
HZ,3H).
Example 42
2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-IH -pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate
2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate: To
example 6 (0.100 g, 0.174 mmol) in isopropanol ( 4 ml), p-toluenesulphonic acid (0.037 g,
0.192 mmol) was added and refluxed for I h.The reacrion mixture was concentrated, co
distilled with pet. ether and dried. To the residue water (3 ml) was added and stirred for 30
min. The solid was filtered, washed with pet. ether and dried under vacuum to afford the title
WO 20121151525
compound as off-white solid (0.102 g, 78%). MP: IS3-lS6°C. IH-NMR (8 ppm, CDCh, 400
MHz): 8.1S (s, IH), 7.80 (d, J = 8.1 Hz, 2H), 7.64 (dt, J = 8.4,S.4 Hz, IH), 7.42 (dd, J =
1l.2,2.0 Hz, IH), 7.34 (m, 3H), 7.22 (d, J = 8.0 Hz, 2H), 7.1S (t, J = 8.4 Hz, IH), 7.08-6.99 (m
, 3H),6.87 (m, 1 H), 6.07 (q, J = 7.1 Hz, 1 H), 4.67 (quintet, J = 6.1 Hz, 1 H), 2.37 (s, 3H), 2.01
(d, J = 7.2 Hz, 3H), 1.43 (d, J = 6.1 Hz, 6H).
Example 43
2-(1-( 4-amino(3-methyl-l H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-
-fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate
2-( 1-( 4-amino(3-methyl-l H-indazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone 4-methylbenzenesulfonate: The title
compound was obtained as off-white solid (0.120 g, 84%) by using a procedure that is similar
to the one described for example 43 from example 9 (0.10 g, 0.200 mmol), isopropanol (4 ml)
and p-toluenesulphonic acid (0.042 g, 0.220 mmol). MP: 172-17S°C. 8 IH-NMR (8 ppm,
CDCh, 400 MHz): 10.IS (s, IH), 8.08 (s, IH), 7.78 (d, J = 7.7 Hz, IH), 7.76 (s,IH), 7.73 (d, J
= 8.1 Hz, 2H), 7.61 (dt, J = 8.2,3.0 Hz, IH), 7.38 (m, 3H), 7.27 (m, IH), 7.11 -6.88 (m, 7H),
6.08 (q, J = 6.9 Hz, IH), 2.S3 (s, 3H), 2.28 (s, 3H), 2.04 (d, J = 7.2 Hz, 3H).
Example 44
2-(1-( 4-amino( 4-(I-benzhydrylazetidinyloxy )fluorophenyl)-IH-pyrazolo[3,4-
d]pyrimidin-l-yl )ethyl)fl uoro(3-fluorophenyl)-4H -chromenonc
2-( 1-( 4~amino( 4-( l-benzhydrylazetidinyloxy)fluorophenyl)-1 H-
pyrazolo[3, 4-d] pyrimidin-l-y I )eth yl)-S -fl uoro(3 -fl uoropheny I )-4 H -chromenone: The
title compound was obtained as off-white solid (0.03S g, 13%) by using a procedure that is
similar to the one described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-
dimethoxyethane (3 mI), water (l.S ml), intermediate 81 (0.2S2 g, O.SSO mmol), sodium
carbonate (0.116 g, 1.10 mmoI) and [I, I' -Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH CIz (0.060 g, 0.073 mmol). MP: 21 I-214°C. 0 IH-NMR (8 ppm, CDCh,
400 MHz): 8.23 (s, IH), 7.S9 (dt, J = 8.4,S.4 Hz, IH), 7.44 (m, SH), 7.29-7.18 (m, 9H), 7.0S
(m, 3H), 6.90 (m, IH), 6.86 (t, J = 8.4 Hz, IH), 6.04 (q, J = 7.2 Hz, IH), S.3S (s, 2H), 4.91
(quintet, J = 4.7 Hz, I H), 4.47 (s, I H), 3.78 (m, 2H), 3.23 (m, 2H), 1.97 (d, J = 7.2 Hz, 3H).
Example 45
2-(I-(4-amino(3-fluoro(trifluoromethoxy)phenyl)-lH-pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl )fl uoro(3-fl uorophenyl)-4 H -chromenone
2-( 1-( 4-amino(3-fluoro(trifluoromethoxy)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone: The title compound
WO 20121151525
was obtained as off-white solid (0.043 g, 19%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane (3
ml), water (1.5 ml), 3-fluoro(trifluoromethoxy)phenylboronic acid (0.122 g, 0.550 mmol
for preparation see J.Med. Chern. 2010, 53, 8421-8439), sodium carbonate (0.116 g, 1.10
mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH CIz (0.060 g,
0.073 mmol). MP: 247-249°C. Mass: 598.0 (M+)
Example 46
2-(1-( 4-amino(3-fluoro( oxctanyloxy )phenyl}-1H -pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(3-fluoro( oxetanyloxy)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as pale brown solid (0.040 g, 18%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane (3
ml), water (1.5 ml), intermediate 83 (0.162 g, 0.550 mmol), sodium carbonate (0.116 g, l.1O
mmol) and [1,1' -Bis(diphenylphosphino )ferrocene ]dichloro palladium(II).CH Ci (0.060 g,
0.073 mmol). MP: 235-237°C. Mass: 586.2.0 (M++l).
Example 47
2-(1-( 4-amino(pyrrolidinyl)-1H -pyrazolo[3,4-d]pyrimidinyl)ethyl)fluoro
(3-fluorophenyl)-4H-chromenone
2-(1-( 4-amino(pyrrolidin-l-yl)-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as yellow
solid (0.040 g, 10%) by using a procedure that is similar to the one described for example 6
from intermediate 79 (0.211 g, 1.03 mmol), DMF (4 ml), cesium carbonate (0.281 g, 0.864
mmol) and intermediate 22 (0.300 g, 0.0.864 mmol). MP: 203-205°C. Mass: 489.1 (M+ + I).
Example 48
N-( 4-( 4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-1H
pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide
N-( 4-( 4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-IH-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide: The title compound was
obtained as pale brown solid (0.047 g, 22 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), I ,2-dimethoxyethane (3
ml), water (1.0 ml), 4-isobutyramidophenylboronic acid (0.114 g, 0.550 mmol), sodium
carbonate (0.116 g, 1.10 mmol) and [1, I' -Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH Ch (0.060 g, 0.073 mmol). MP: 154-157°C. Mass: 581.1 (M+ + I).
WO 20121151525
Example 49
2-(1-( 4-amino( 4-iso butyl phenyl)-lH -pyrazolo[3,4-d]pyrimidinyl)ethyl )fluoro
(3-fluorophenyl)-4H -chromenone
2-(1-( 4-amino( 4-isobutylphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-
-fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as brown
solid (0.061 g, 30 %) by using a procedure that is similar to the one described for example 9
from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane (3 ml), water (1.0 ml), 4-
isobutylphenylboronic acid (0.098 g, 0.550 mmol), sodium carbonate (0.116 g, 1.10 mmol)
and [1,1' -Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.060 g, 0.073
mmol). MP: 221-223°C. Mass: 552.3 (M++l).
Example 50
2-(1-( 4-amino( 4-isopropoxymethylphenyl)-lH-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino( 4-isopropoxymethylphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as pale brown solid (0.038 g, 31 %) by using a procedure that is similar to the
one described for example 6 from intermediate 84 (0.060 g, 0.211 mmol), DMF (2 ml),
sodium carbonate (0.059 g, 0.423 mmol) and intermediate 22 (0.116 g, 0.317 mmol). MP:
185-188°C. Mass: 568.0 (M++l).
Example 51
2-(1-( 4-amino( 4-(5,6-dihydro-4H-1,3-oxazinyl)phenyl)-lH -pyrazolo[3,4-
d]pyrimidinyl)ethyl)-S-fl uoro(3-fluorophenyl)-4 H -chromenone
2-( 1-(4-amino(4-(5,6-dihydro-4H-I ,3-oxazinyl)phenyl)-1 H-
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The
title compound was obtained as brown solid (0.035 g, 17 %) by using a procedure that is
similar to the one described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-
dimethoxyethane (3 ml), water (1.0 ml), 4-(5,6-dihydro-4H-l,3-oxazinyl)phenylboronic
acid (0.113 g, 0.550 mmol), sodium carbonate (0.116 g, 1.10 mmol) and [1, 1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.060 g, 0.073 mmol). MP:
228-230°C. Mass: 579.1 (M+ + I).
Example 52
4-( 4-amino(1-(5-fl uoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-lH
pyrazolo[3,4-d]pyrimidinyl)-N-methylbenzenesulfonamide.
WO 20121151525
4-( 4-amino-I-O-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyI)-N-methylbenzenesulfonamide: The title compound was
obtained as brown solid (0.060 g, 28 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane
(3.5 mI), water (1.5 ml), 4-(N-methylsulfamoyI)phenylboronic acid (0.118 g, 0.550 mmol),
sodium carbonate (0.077 g, 0.732 mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro
Clz (0.060 g, 0.073 mmol ). MP: 175-178°C. Mass: 589.1 (M+ + I).
palladium(II).CH
Example 53
4-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-IH
pyrazolo[3,4-d]pyrimidinyl)fluoro-N-isopropylbenzamide
4-(4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyI)ethyI)-
IH-pyrazolo[3,4-d]pyrimidinyI)fluoro-N-isopropylbenzamide: The title compound was
obtained as brown solid (0.063 g, 29 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane
(3.5 mI), water (l.5 ml), 3-fluoro(isopropylcarbamoyl)phenylboronic acid (0.123 g, 0.550
mmol), sodium carbonate (0.077 g, 0.732 mmol) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.060 g, 0.073 mmol). MP:
254-25rc. Mass: 599.1 (M+ + I).
Example 54
2-(1-( 4-amino( 4-(5-(methylamino )-1 ,3,4-thiadiazolyl)phenyl)-IH -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino( 4-(5-(methylamino )-1 ,3,4-thiadiazolyl)phenyl)-1 H-
pyrazol 0[3, 4-d]pyrimidi n-I-y I )ethy 1)-5 -fl uoro-3 -(3 -fl uoropheny I)-4 H -chromenone: The
title compound was obtained as off-white solid (0.068 g, 41 %) by using a procedure that is
similar to the one described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-
dimethoxyethane (3.0 ml), water (1.5 ml), 4-(5-(methylamino )-1 ,3,4-thiadiazol
yl)phenylboronic acid (0.097 g, 0.411 mmol), sodium carbonate (0.058 g, 0.55 mmol) and
[1,1' -Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.045 g, 0.055 mmol ).
MP: 199-201°C. Mass: 609.0 (M+).
Example 55
N -( 4-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H-chromcnyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyl)benzyl)mcthanesulfonamidc
N-(4-(4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-I H-pyrazolo[3,4-d]pyrimidinyl)benzyl)methanesulfonamide: The title compound
WO 20121151525
was obtained as brown solid (0.055 g, 33 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), 4-(methylsulfonamidomethyl)phenylboronic acid (0.094 g, 0.411
mmol), sodium carbonate (0.058 g, 0.55 mmol) and [I, I '
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.045 g, 0.055 mmol). MP:
252-255°C. Mass: 603.0 (M+ + I ).
Example 56
4-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-IH
pyrazolo[3,4-d]pyrimidinyl)-N-isopropylbenzenesulfonamide
4-( 4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
I H-pyrazolo[3,4-d]pyrimidinyl)-N-isopropylbenzenesulfonamide: The title compound was
obtained as off-white solid (0.075 g, 44 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), 4-(N-isopropylsulfamoyl)phenylboronic acid (0.100 g, 0.411 mmol),
sodium carbonate (0.058 g, 0.55 mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro
palladium(I1).CH Ch (0.045 g, 0.055 mmol). MP: 21 I-214°C. Mass: 616.9 (M+).
Example 57
4-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-IH
pyrazolo[3,4-d]pyrimidinyl)-N-cyclopropylbenzenesulfonamide
4-( 4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
I H-pyrazolo[3,4-d]pyrimidinyl)-N-cyc\opropylbenzenesulfonamide: The title compound
was obtained as brown solid (0.043 g, 26 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), 4-(N-cyc\opropylsulfamoyl)phenylboronic acid (0.099 g, 0.411
mmol), sodium carbonate (0.058 g, 0.55 mmol) and [1, 1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.045 g, 0.055 mmol). MP:
225-228°C. Mass: 614.8 (M+).
Example 58
2-(1-( 4-amino(2-isopropoxypyrimidinyl)-1 H -pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-f1uorophenyl)-4H-chromenonc
2-( 1-(4-amino(2-isopropoxypyrimidinyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained
as off-white solid (0.025 g, 12 %) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane (3.0 ml), water
WO 20121151525
0.5 ml), intermediate 8S (0.146 g, 0.550 mmol), sodium carbonate (0.116 g, 1.10 mmol) and
[1,1' -Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.060 g, 0.073 mmol ).
MP: 230-232°C. Mass: 556.0 (M+ + I).
Example S9
(R)/(S)(I-( 4-amino(3-fluoromorpholinophenyl)-1 H -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
(R)/(S)( 1-( 4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as off-white solid (0.0 IS g, 10 %) by using a procedure that is similar to the one
described for example 7 from intermediate 86 (0.080 g, 0.254 mmol), intermediate 23b (0.077
g, 0.254 mmol), tris(4-methoxyphenyl)phosphine (0.134 g, 0.381 mmol), THF (2 ml) and
diisopropylazodicarboxylate ( 0.07 ml, 0.381 mmol). MP: 242-245°C. Enantiomeric excess:
96.21 % . Mass: 599.1 (M+ + 1).
Example 60
4-( 4-amino-l-(I-( S-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-1 H
pyrazolo[3,4-d]pyrimidinyl)benzenesulfonamide
4-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyI)oxo-4H-chromenyl)ethyI)-
IH-pyrazolo[3,4-d]pyrimidinyl)benzenesulfonamide: The title compound was obtained as
brown solid (0.060 g, 38 %) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane (3.0 ml), water
(1.5 ml), 4-sulfamoylphenylboronic acid (0.083 g, 0.411 mmol), sodium carbonate (0.058 g,
0.55 mrnoI) and [I,l'-Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.045
g, 0.055 mmol). MP: 232-235°C. Mass: 575.3 (M+ +1).
Example 61
methyl 4-( 4-amino-l-(I-(S-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)
IH-pyrazolo[3,4-d]pyrimidinyl)thiophenecarboxylate
methyl 4-(4-amino-I-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-I H-pyrazolo[3,4-d]pyrimidinyl)thiophenecarboxylate: The title compound was
obtained as brown solid (0.070 g, 46 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 mI), 5-(methoxycarbonyl)thiophenylboronic acid (0.076 g, 0.411
mmol), sodium carbonate (0.058 g, 0.55 mmol) and [I, I '
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH CI (0.045 g, 0.055 mmol). MP:
227-230°C. Mass: 560.2 (M+ +1).
WO 20121151525
Example 62
2-(1-( 4-amino( 5-methyl thiophenyl)-1 H -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(5-methylthiophenyl)-IH-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as
brown solid (0.045 g, 32 %) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane (3.0 ml), water
(1.5 ml), 5-methylthiophenylboronic acid (0.092 g, 0.411 mmol), sodium carbonate (0.058
g, 0.55 mmol) and [1,1' -Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch
(0.045 g, 0.055 mmol). MP: 223-226°C. Mass: 516.1 (M+ + I).
Example 63
2-(1-( 4-amino(IH -pyrrolo[2,3-b ]pyridinyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino( 1 H-pyrrolo[2,3-b ]pyridinyl)-1 H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.030 g, 20 %) by using a procedure that is similar to the one
. described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), IH-pyrrolo[2,3-b]pyridinylboronic acid (0.100 g, 0.411 mmol),
sodium carbonate (0.058 g, 0.55 mmol) and [1,1' -Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH Cb (0.045 g, 0.055 mmol). MP: 303-306°C. Mass: 536.4 (M+ + I).
Example 64
methyl 4-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)
IH-pyrazolo[3,4-d]pyrimidinyl)fluorobenzoate
methyl 4-( 4-amino-1 ~(I-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-I H-pyrazolo[3,4-d]pyrimidinyl)fluorobenzoate: The title compound was
obtained as brown solid (0.017 g, 8 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), I,2-dimethoxyethane
(3.0 ml), water (1.0 ml), 2-fluoro(methoxycarbonyl)phenylboronic acid (0.109 g, 0.550
mmol), sodium carbonate (0.116 g, 1.10 mmol) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.060 g, 0.073 mmol). MP:
258-260°C. Mass: 572.4 (M+ +1).
Example 65
2-(I-(9H-purinylamino)propyl)fluorophenyl-4H-chromenone
WO 20121151525
2-( 1-(9H-purinylamino )propyl)fluorophenyl-4H-chromenone: To a
solution of intermediate 93 (0.190 g, 0.639 mmol), tert-butanol (2 ml) N ,N
diisopropylethylamine (0.23 ml, 1.32 mmol) and 6-chloropurine (0.079 g, 0.511 mmol) were
added and heated to reflux for 48h. The reaction mixture was concentrated, quenched with
water, extracted with ethyl acetate, dried with sodium sulphate and concentrated. The crude
product was purified by column chromatography with methanol : ethyl acetate to afford the
compound as brown solid (0.030 g, 140% yield). MP: 21O-212°C. IH-NMR (0 ppm,
title
DMSO-d6, 400 MHz): 0 12.83 (s, IH), 8.19 (s, IH), 8.12 (s, IH), 7.20-7.14 (m, 6H), 6.69 (d, J
= 8.1 Hz, IH), 6.59 (t, J = 8.7 Hz, IH), 5.57 (m, IH), 2.98 (m, IH), 1.89 (m , 2H), 0.78 (t, J =
7.1 Hz, 3H).
Example 66
2-(1-( 4-amino(3-hydroxypropynyl)-1H -pyrazolo[3,4-d]pyrimidinyl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(3-hydroxyprop-l-ynyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: To a solution of intermediate 27
(0.200 g, 0.364 mmol) in THF (4 ml) propargyl alcohol (0.025 ml, 0.437 mmol) was added
and degassed with nitrogen for 10 min. Copper (I ) iodide (7 mg, 0.036 mmol),
tetrakistriphenylphosphine palladium (0 (0.042 g, 0.036 mmol) and diisopropylamine (0.23
ml, 1.82 mmol) were added and again degassed for 10 min. and heated to reflux. After 4h, the
reaction mixture was filtered through celite, washed with ethyl acetate, dried over sodium
sulphate and concentrated. The crude product was purified by column chromatography with
ethyl acetate : pet. ether to afford the title compound as brown solid (0.050 g, 29% yield).
MP: 220-222°C. Mass: 474.3 (M+ +1).
Example 67
(S)/(R)(1-( 4-amino(3-fl uoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d]
pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone 4-methyl
benzenesulfonate
(S)/(R)( 1-(4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
methylbenzenesulfonate: To example 7 (0.100 g, 0.174 mmol) in isopropanol ( 4 ml), p
toluenesulphonic acid (0.037 g, 0.192 mmol) was added and refluxed for I h.The reacrion
mixture was concentrated, co-distilled with pet. ether and dried. To the residue water (3 ml)
was added and stirred for 30 min. The solid was filtered, washed with pet. ether and dried
under vacuum to afford the title compound as off-white solid (0.110 g, 82%). MP: 152-
WO 20121151525
155°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.15 (s, IH), 7.81 (d, J = 8.1 Hz, 2H), 7.64 (dt, J
= 8.4,5.4 Hz, IH), 7.42 (dd, J = 11.3,2.0 Hz, IH), 7.34 (m, 3H), 7.22 (d, J = 8.0 Hz, 2H), 7.16
(t, J = 8.6 Hz, IH), 7.08-6.97 (m , 3H),6.88 (m, IH), 6.08 (q, J = 7.1 Hz, IH), 4.687 (quintet,
J = 6.0 Hz, IH), 2.37 (s, 3H), 2.02 (d, J = 7.2 Hz, 3H), 1.43 (d, J = 6.1 Hz, 6H).
Example 68
(+ )(1-(9H -purinylamino )ethyl)-S-fluoro(3-fluorophenyl)-
4H -chromenone
(+ )( 1-(9H-purinylamino )ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The
title compound was obtained as off-white solid (0.090 g, 43 %) by using a procedure that is
similar to the one described for example 7 from tert-butyl 9-trityl-9H-purinylcarbamate
(0.235 g, 0.494 mmol), intermediate 23b (0.150 g, 0.494 mmol), triphenylphosphine (0.194 g,
0.741 mmo!), THF (8 m!) and diisopropylazodicarboxylate ( 0.15 ml, 0.749 mmol), followed
by the cleavage of the intermediate with trifluoroacetic acid (1.8 ml) and dichloromethane (5
ml). MP: 194-197°C. Enantiomeric excess: 99.62% . [af5 142.00 (c = I, CHCI ). Mass:
420.1 (M+ +1).
Example 69
2-(I-(9H-purinylamino)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-(9H-purinylamino )ethy!)fluoro(3-fluoropheny!)-4H-chromen
one: The title compound was obtained as off-white solid (0.081 g, 39 %) by using a procedure
that is similar to the one described for example 7 from tert-butyl 9-trityl-9H-purin
ylcarbamate (0.235 g, 0.494 mmol), intermediate 23 (0.150 g, 0.494 mmol),
triphenylphosphine (0.194 g, 0.741 mmol), THF (8 ml) and diisopropylazodicarboxylate (
0.15 ml, 0.749 mmol), followed by the cleavage of the intermediate with trifluoroacetic acid
(1.3 ml) and dichloromethane (8 ml) .. MP: 247 -249°C. Mass: 420.1 (M+ + 1).
Example 70
(R)/(S)(1-( 4-amino(3-fluoromorpholinophenyl)-IH -pyrazolo[3,4-
d] pyrimidin-l-yl)ethyl)-S-fluoro(3-fluorophenyl)-4 H -chromenone
(R)/(S)( 1-( 4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-y!)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as off-white solid (0.022 g, II %) by using a procedure that is similar to the one
described for example 7 from intermediate 86 (0.100 g, 0.329 mmol), intermediate 23a (0.100
g, 0.329 mmol), tris( 4-methoxyphenyl)phosphine (0.174 g, 0.494 mmol), THF (2 ml) and
WO 20121151525
diisopropylazodicarboxylate ( 0.1 ml, 0.494 mmol). MP: 243-246°C. Enantiomeric excess:
85.4% . Mass: 599.4 (M+ +1).
Example 71
2-(1-( 4-amino( 4-methoxy-3,5-dimethyl phenyl)-1 H -pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino( 4-methoxy-3,5-dimethylphenyl)-1 H-pyrazolo[3,4-
1)-5 -fl uoro(3-fluoropheny I )-4 H -chromenone: The title compound
d]pyrimidin-I-yl )eth y
was obtained as brown solid (0.070 g, 46 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), 4-methoxy-3,5-dimethylphenylboronic acid (0.074 g, 0.411 mmol),
sodium carbonate (0.058 g, 0.55 mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro
palIadium(II).CH Cl (0.045 g, 0.055 mmol). MP: 232-235°C. Mass: 554.0 (M+ + 1).
Example 72
2-(1-( 4-amino( 4-(methoxymethyl )phenyl)-1 H -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-
-fluoro(3-fluorophenyl)-4H -chromenone
2-(1-( 4-amino( 4-(methoxymethyl)phenyl)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as
brown solid (0.062 g, 42 %) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane (3.0 ml), water
(1.5 ml), 4-(methoxymethyl)phenylboronic acid (0.068g, 0.411 mmol), sodium carbonate
(0.058 g, 0.55 mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro
palIadium(I1).CH Ch (0.045 g, 0.055 mmol). MP: 204-207°C. Mass: 540.3 (M+ + 1).
Example 73
2-(1-( 4-amino(imidazo[1 ,2-a ]pyridinyl)-1 H -pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(imidazo[ I ,2-a]pyridinyl)-I H-pyrazolo[3,4-d]pyrimidin-I-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as
brown solid (0.052 g, 36 %) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.274 mmol), I,2-dimethoxyethane (3.0 ml), water
I ,2-a]pyridinylboronic acid (0.066 g, 0.411 mmol), sodium carbonate
(1.5 ml), imidazo[
(0.058 g, 0.55 mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro
palIadium(II).CH Ch (0.045 g, 0.055 mmol). MP: 317-320°C. Mass: 536.3 (M+ +1).
Example 74
WO 20121151525
tert-butyl (5-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-IH-pyrazolo[3,4-d]pyrimidinyl)furanyl)methylcarbamate
teft-butyl (5-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen-
2-yl)ethyl)-1 H -pyrazolo[3,4-d]pyrimidinyl)furanyl)methylcarbamate: The title
compound was obtained as brown solid (0.100 g, 63 %) by using a procedure that is similar to
the one described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-
dimethoxyethane (3.0 mI), water (1.5 ml), 5-«tert-butoxycarbonylamino)methyl)furan
ylboronic acid (0.099 g, 0.411 mmol), sodium carbonate (0.058 g, 0.55 mmol) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.045 g, 0.055 mmol). MP:
163-166°C. Mass: 615.7 (M+ +1).
Example 75
2-(1-( 4-amino(2,4-dimethylthiazolyl)-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(2,4-dimethylthiazolyI)-1 H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained as
brown solid (0.050 g, 39 %) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane (3.0 ml), water
(1.5 ml), 2,4-dimethyl( 4,4,5,5-tetramethyl-l ,3,2-dioxaborolanyl)thiazole (0.098 g, 0.411
mmol), sodium carbonate (0.058 g, 0.55 mmoI) and [I, 1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.045 g, 0.055 mmol). MP:
252-255°C. Mass: 531.3 (M+ + I).
Example 76
2-(1-( 4-amino( 5-(morpholinomethyl )thiophenyl )-1 H -pyrazolo[3,4-d]pyrimidin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(5-(morpholinomethyl)thiophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yI)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.047 g, 29 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmoI), 1,2-dimethoxyethane
(3.0 mI), water (1.5 ml), 4-«5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolanyl)thiophen
(0.127 g, 0.411 mmol), sodium carbonate (0.058 g, 0.55 mmol) and
yl)methyl)morpholine
[I, I' -Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH CI (0.045 g, 0.055 mmol ).
MP: 193-196°C. Mass: 601.6 (M+ +1).
Example 77
WO 20121151525
2-(1-( 4-amino( 4-(5-amino-l,3,4-thiadiazolyl)phenyl)-IH -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-(1-( 4-amino(4-(5-amino-1 ,3,4-thiadiazolyl)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)f1uoro(3-f1uorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.071 g, 44 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), 4-(5-amino-l ,3,4-thiadiazolyl)phenylboronic acid (0.091 g, 0.411
mmol), sodium carbonate (0.058 g, 0.55 mmol) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Cb (0.045 g, 0.055 mmol). MP:
202-205°C. Mass: 595.6 (M+ +1).
Example 78
(-)(1-(9 H -purinylamino )ethyl)fluoro(3-fl uorophenyl)-4 H -chromen one
(-)( 1-(9H-purinylamino)ethyl)f1uoro(3-f1uorophenyl)-4H-chromen-
4-one: The title compound was obtained as off-white solid (0.075 g, 36 %) by using a
procedure that is similar to the one described for example 7 from tert-butyl 9-trityl-9H-purin-
6-yIcarbamate (0.235 g, 0~494 mmol), intermediate 23a (0.150 g, 0.494 mmol),
triphenylphosphine (0.194 g, 0.741 mmol), THF (8 ml) and diisopropylazodicarboxylate (
0.15 ml, 0.749 mmol), followed by the cleavage of the intermediate with trifluoroacetic acid
(0.50 ml) and dichloromethane (6 ml) .. MP: 205-208°C. Enantiomeric excess: 100% . [a]25
-180.47 (c = I, CHCI ). Mass: 420.5 (M+ + I).
Example 79
2-(1-( 4-amino(1,3-dimethyl-1H-indazolyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-(I-(4-amino( I ,3-dimethyl-IH-indaz<;>Iyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)f1uoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.039 g, 26 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), 1 ,3-dimethyl( 4,4,5,5-tetramethyl-1 ,3,2-dioxaborolanyl)-1 H
indazole (0.112 g, 0.411 mmol), sodium carbonate (0.058 g, 0.55 mmol) and [1, 1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Cb (0.045 g, 0.055 mmol). MP:
220-224°C. Mass: 564.0 (M+ + 1).
Example 80
WO 20121151525
2-(1-( 4-amino(2,3-dimethyl-2H -indazolyl )-1H -pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(2,3-dimethyl-2H-indazolyl)-1 H-pyrazolo[3,4- .
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound
was obtained as brown solid (0.060 g, 40 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), 2,3-dimethyl(4,4,5,5-tetramethyl-l,3,2-dioxaborolanyl)-2H
indazole (0.112 g, 00411 mmol), sodium carbonate (0.058 g, 0.55 mmol) and [1,1'
Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.045 g, 0.055 mmol). MP:
232-235°C. Mass: 563.8 (M+ ).
Example 81
N -(4-( 4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-1H
pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)isobutyramide
N-( 4-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
y l)ethy 1)-1 H -pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)isobutyramide: The title
compound was obtained as brown solid (0.061 g, 37 %) by using a procedure that is similar to
the one described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-
dimethoxyethane (3.0 ml), water (1.5 ml), intermediate 95 (0.125 g, 00411 mmol), sodium
carbonate (0.058 g, 0.55 mmol) and [1,1' -Bis(diphenylphosphino )ferrocene]dichloro
palladium(II).CH Ch (0.045 g, 0.055 mmol). MP: 249-252°C. Mass: 598.8 (M+ ).
Example 82
N-( 4-( 4-amino(1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-1H
pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)acetamide
N -( 4-( 4-amino-l-( 1-( 5 -fl uoro(3-fl uorophen y I )oxo-4 H -chromen
yl)ethyl)-1 H-pyrazolo[3,4-d]pyrimidinyl)fluorophenyl)acetamide: The title compound
was obtained as brown solid (0.030 g, 19 %) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.274 mmol), 1,2-dimethoxyethane
(3.0 ml), water (l.5 ml), intermediate 97 (0.114 g, 00411 mmol), sodium carbonate (0.058 g,
0.55 mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.045
g, 0.055 mmol). MP: 220-223°C. Mass: 571.198.8 (M+ + 1 ).
Example 83
, 162
WO 20121151525
2-(1-(4-( dimethylamino )(3-fluoroisopropoxyphenyl)-lH -pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-(dimethylamino )(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidinyl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound
was obtained as pale-yellow solid (0.050 g, 13 %) by using a procedure that is similar to the
one described for example 7 from intermediate 99 (0.200 g, 0.630 mmol), intermediate 23
(0.229 g, 0.756 mmol), trismethoxytriphenylphosphine (0.288 g, 0.819 mmol), THF (3 ml)
and diisopropylazodicarboxylate ( 0.18 ml, 0.945 mmol). MP: 122-124°C. Mass: 600.2 (M+
+1).
Example 84
-fl uoro(1-(3-(3-fl uoroisopropoxyphenyl)(methylamino )-1 H -pyrazolo[3,4-
d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone
5-fluoro( 1-(3-(3-fluoroisopropoxyphenyl)(methylamino )-1 H-
pyrazolo[3,4-d]pyrimidinyl)ethyl)(3-fluorophenyl)-4H-chromenone The title
compound was obtained as brown solid (0.038 g, 25 %) by using a procedure that is similar to
the one described for example 9 from intermediate 101 (0.150 g, 0.267 mmol), 1,2-
dimethoxyethane (3.0 ml), water (l.5 ml), intermediate 12 (0.1 IO g, 0.40 I mmol), sodium
carbonate (0.057 g, 0.535 mmol) and [1,1 '-Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH CIz (0.044 g, 0.053 mmol). MP: 193-196°C. Mass: 586.3 (M+ + 1).
Example 85
-fluoro(1-(3-(3-fluoroisopropoxyphenyl)morpholino-1H-pyrazolo[3,4-
d]pyrimidinyl )ethyl)(3-fluorophenyl)-4 H -chromenone
5-fluoro( 1-(3-(3-fluoroisopropoxyphenyl)morpholino-1 H-
pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)(3-fl uorophenyl)-4H -chromenone The title
compound was obtained as off-white solid (0.120 g, 46 %) by using a procedure that is
similar to the one described for example 7 from intermediate 104 (0.150 g, 0.402 mmol),
intermediate 23 (0.146 g, 0.483 mmol), trismethoxytriphenylphosphine (0.184 g, 0.523
mmol), THF (3 ml) and diisopropylazodicarboxylate ( 0.12 ml, 0.604 mmol). MP: 116-
119°C. Mass: 64l.8 (M+ +1).
Example 86
N-(2-fluoro(1-(1-(5-fluoro(4-fluorophenyl)oxo-4H-chromenyl)ethyl)
morpholino-1H-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide
WO 20121151525
N-(2-fluoro( 1-( 1-(S-fluoro( 4-fluorophenyl)oxo-4H-chromen
yl)ethyl)morpholino-1 H-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide: The title
compound was obtained as brown solid (0.030 g, 18 %) by using a procedure that is similar to
the one described for example 9 from intermediate 105 (O.ISO g, 0.243 mmol), 1,2-
dimethoxyethane (3.0 ml), water (1.S ml), intermediate 95 (0.111 g, 0.36S mmol), sodium
carbonate (O.OSI g, 0.487 mmol) and [I, I' -Bis(diphenylphosphino )ferrocene ]dichloro
palladium(I1).CH Ch (0.040 g, 0.048 mmol). MP: 16S-167°C. Mass: 669.2 (M+ +1).
Example 87
N -(2-fl uoro(I-(I-( 5-fl uoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl )
morpholino-IH -pyrazolo[3,4-d]pyrimidinyl)phenyl)isobu tyramide
N-(2-fluoro( 1-( 1-(S-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)morpholino-1 H-pyrazolo[3,4-d]pyrimidinyl)phenyl)isobutyramide : The title
compound was obtained as brown solid (O.OSO g, 31 %) by using a procedure that is similar to
the one described for example 9 from intermediate 106 (O.ISO g, 0.243 mmol), 1,2-
dimethoxyethane (3.0 ml), water (1.S ml), intermediate 95 (0.111 g, 0.36S mmol), sodium
carbonate (O.OSI g, 0.487 mmol) and [I, I' -Bis(diphenylphosphino )ferrocene]dichloro
palladium(I1).CH Ch (0.040 g, 0.048 mmol). MP: 168-170°C. Mass: 669.2 (M+ +1).
Example 88
(S)/(R)(1-( 4-amino(3-fl uoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d] pyrimidin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone sulphate
(S)/(R)( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone sulphate : The title
compound was obtained as off-white solid (0.120 g, 68 %) by using a procedure that is
similar to the one described for example 67 from example 6a (O.ISO g, 0.262 mmol),
isopropanol ( 6 ml), sulphuric acid (0.028 g, 0.288 mmol). MP: 20S-207°C. IH-NMR (8 ppm,
CDCh, 400 MHz): 8 8.12 (s, IH), 7.64 (dt, J = 8.4,S.4 Hz, IH), 7.41 (dd, J = 11.2,2.0 Hz, IH),
7.29 (m, 3H), 7.IS (t, J = 8.3 Hz, IH), 7.08 (m , 2H), 6.97 (d, J = 6.9 Hz, IH), 6.89 (d, J = 7.1
Hz, IH), 6.07 (q, J = 6.9 Hz, IH), 4.68 (quintet, J = 6.1 Hz, IH), 2.01 (d, J = 7.1 HZ,3H),
1.42 (d, J = 6.1 Hz, 6H).
Example 89
(S)/(R)- 2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fl uoro(3-fl uorophenyl )-4H -chromenone
benzenesulfonate
WO 20121151525
(S)/(R)( 1-( 4-amino(3-fluoroisopropoxyphenyl)-IH-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fl uoro(3-fluorophenyl)-4H -chromenone benzenesulfonate
The title compound was obtained as off-white solid (0.120 g, 62 %) by using a procedure that
is similar to the one described for example 67 from example 6a (0.150 g, 0.262 mmol),
isopropanol ( 6 ml), benzenesulphonic acid (0.045 g, 0.288 mmol). MP: 172-174°C. I H-NMR
(8 ppm, CDCh, 400 MHz): 88.14 (s, IH), 7.92 (dd, J = 6.8,1.7 Hz, 2H), 7.64 (dt, J = 8.4,5.4
Hz, IH), 7.42-7.28 (m, 7H), 7.16 (t, J = 8.3 Hz, IH), 7.11 (m, 3H), 6.87 (d, J = 7.1 Hz, IH),
6.08 (q, J = 7.0 Hz, IH), 4.68 (quintet, J = 6.1 Hz, IH), 2.02 (d, J = 7.1 Hz, 3H), 1.43 (d, J =
6.0 Hz, 6H).
Example 90
(S)/(R)- 2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-1H -pyrazolo[3,4-
d]pyrimidinyl)ethyl)-S-fluoro(3-fluorophenyl)-4H-chromenone
camphorsulphonate
(S)/(R)- 2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone camphorsulphonate:
The title compound was obtained as off-white solid (0.120 g, 57 %) by using a procedure that
is similar to the one described for example 67 from example 6a (0.150 g, 0.262 mmol),
isopropanol (6 ml), camphorsulphonic acid (0.066 g, 0.288 mmol). MP: 190-193°C. IH-NMR
(8 ppm, CDCh, 400 MHz): 88.23 (s, IH), 7.64 (dt, J = 8.4,5.4 Hz, IH), 7.42 (dd, J = 11.2,2.1
Hz, IH), 7.35 (m, 3H), 7.16 (t, J = 8.4 Hz, IH), 7.08 (m , 3H), 6.92 (d, J = 8.3 Hz, IH), 6.08
(q, J = 7.1 Hz, IH), 4.68 (quintet, J = 6.1 Hz, IH),), 3.36 (d, J = 4.4 Hz, IH), 2.95 (d, J = 4.6
Hz, IH), 2.59 (m, IH), 2.35 (m, IH), 2.09 (m, 2H), 2.02 (d, J = 7.2 Hz, 3H), 1.93-1.83 (m,
3H), 1.43 (d, J = 6.1 Hz, 6H), 1.07 (s, 3H), 0.84 (s, 3H).
Example 91
2-(1-( 4-amino( 4-( difluoromethoxy )fluorophenyl)-1 H -pyrazolo[3,4-d ]pyrimidin-
1-yl)ethyl)-S-fluoro(1H-pyrazolyl)-4H-chromenone
2-( 1-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro( I H-pyrazolyl)-4H-chromenone: The title compound
was obtained as brown solid (0.120 g, 30 %) by using a procedure that is similar to the one
described for example 9 from intermediate 107 (0.400 g, 0.708 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), I-boc-pyrazoleboronic acid (0.220 g, 1.06 mmol), sodium
carbonate (0.220 g, 2.12 mmol) and [1,1' -Bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH2CIz (0.115 g, 0.141 mmol). MP: 135-138°C. Mass: 552.0 (M+ + I).
WO 20121151525
Example 92
2-(1-( 4-amino(3-fluoromorpholinophenyl)-lH -pyrazolo[3,4-d]pyrimidin-l
yl)cthyl)fluorophenyl-4H-chromenone
2-(1-( 4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluorophenyl-4H-chromenone : The title compound was
obtained as brown solid (0.045 g, 27 %) by using a procedure that is similar to the one
described for example 9 from intermediate 108 (0.150 g, 0.285 mmol), 1,2-dimethoxyethane
(3.0 ml), water (1.5 ml), intermediate 61 (0.130 g, 0.427 mmol), sodium carbonate (0.060 g,
0.570 mmol) and [1, I' -Bis(diphenylphosphino )ferrocene ]dichloro palladium(II).CH Ch
(0.046 g, 0.057 mmol). MP: 256-258°C. IH-NMR (0 ppm, CDCh, 400 MHz): 0 8.23 (s, I H),
7.60 (dt, J = 8.4,5.5 Hz, IH), 7.40-7.32 (m, 2H), 7.23 (m, 6H), 7.09 (m, 2H), 6.09 (q, J = 7.1
Hz, IH), 5.38 (s, 2H), 3.91 (t, J = 4.5 Hz, 4H), 3.18 (t, J = 4.7 Hz, 4H), l.98 (d, J = 7.1 Hz,
3H).
Example 93
2-(1-( 4-amino(3-fluoromorpholinophenyl)-lH -pyrazolo[3,4-d]pyrimidin
yl)ethyl )fl uoro( 4-fluoropheny I )-4H -chromenone
2-( 1-( 4-amino(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro( 4-fluorophenyl)-4H-chromenone : The title compound
was obtained as brown solid (0.040 g, 24 %) by using a procedure that is similar to the one
described for example 9 from intermediate 34 (0.150 g, 0.275 mmol), 1,2-dimethoxyethane
(3.0 ml), water (l.5 m\), intermediate 61 (0.127 g, 0.412 mmo\), sodium carbonate (0.058 g,
0.550 mmol) and [1,1' -Bis(diphenylphosphino )ferrocene]dichloro palladium(II).CH Ch
(0.045 g, 0.055 mmol ): MP: 240-242°C. IH-NMR (0 ppm, CDCh, 400 MHz): 0 8.26 (s, IH),
7.60 (dt, J = 8.3,5.5 Hz, IH), 7.40 (m, 2H), 7.28 (m , 3H), 7.09-6.99 (m, 4H), 6.06 (q, J = 7.2
Hz, IH), 5.45 (s, 2H), 3.91 (t, J = 4.5 Hz, 4H), 3.18 (t, J = 4.6 Hz, 4H), l.99 (d, J = 7.1 Hz,
3H).
Example 94
(S)/(R)(1-( 4-amino(3-fl uoroisopropoxyphenyl)-1 H -pyrazolo[3,4-d] pyrimidin-
1-yl)cthyl )fl uoro( 4-fluorophenyl)-4 H -chromenone
(S)/(R)( 1-(4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(4-fluoropheny\)-4H-chromenone : The title compound
was obtained as off-white solid (0.033 g, 10 %) by using a procedure that is similar to the one
described for example 7 from intermediate 13 (0.199 g, 0.692 mmol), intermediate 113 (0.175
WO 20121151525
g, 0.577 mmol), trismethoxytriphenylphosphine (0.305 g, 0.865 mrno I) , THF (3 ml) and
diisopropylazodicarboxylate ( 0.17 ml, 0.865 mmol). MP: 192-194°C. lH-NMR (0 ppm,
CDCI , 400 MHz): 0 8.22 (s, IH), 7.58 (dt, J = 8.4,5.4 Hz, IH), 7.44 (dd, J = 11.5,2.0 Hz, IH),
7.37 (d, J = 8.4 Hz, IH), 7.23 (m, 2H), 7.15 (t, J = 8.3 Hz, IH), 7.07 (m, 3H), 6.04 (q, J = 7.1
Hz, 1 H), 5.42 (s, 2H), 4.65 (quintet, J = 6.2 Hz, I H), 1.99 (d, J = 7.1 Hz, 3H), 1.42 (d, J = 6.1
Hz, 6H). Enantiomeric excess: 68.2% as determined by HPLC on a chiralpak AD-H column,
enriched in the fast eluting isomer (retention time = 1O.43min.).
Example 95
(S)/(R)(1-( 4-amino-3~(3-fl uoroisopropoxyphenyl)-IH -pyrazolo[3,4-d]pyrimidin-
1-yl)ethyl)fluoro( 4-fluorophenyl)-4H -chromenone
(S)/(R)( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro( 4-fluorophenyl)-4H-chromenone : The title compound
was obtained as off-white solid (0.071 g, 18 %) by using a procedure that is similar to the one
described for example 7 from intermediate 13 (0.277 g, 0.791 mmol), intermediate 114 (0.200
g, 0.659 mmol), trismethoxytriphenylphosphine (0.348 g, 0.989 mmol), THF (4 ml) and
diisopropylazodicarboxylate ( 0.19 ml, 0.989 mrnol). MP: 209-212°C. lH-NMR (0 ppm,
CDCh, 400 MHz): 0 8.26 (s, IH), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.44 (dd, J = 11.4,2.0 Hz, IH),
7.37 (dd, J = 8.3,1.0 Hz, IH), 7.23 (m, 2H), 7.15 (t, J = 8.4 Hz, IH), 7.07 (m , 3H), 6.06 (q, J
= 7.1 Hz, 1 H), 5.42 (s, 2H), 4.66 (quintet, J = 6.1 Hz, IH), 1.99 (d, J = 7.1 Hz, 3H), 1.42 (d, J
= 6.0 Hz, 6H). Enantiomeric excess: 66% as determined by HPLC on a chiralpak AD-H
column, enriched in the late eluting isomer (retention time = 15.96 min.).
Example 96
(S)/(R)- 2-(1-( 4-amino( 4-( difluoromethoxy )fluorophenyl)-IH-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro( 4-fluorophenyl)-4H -chromenone
(S)/(R)( 1-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-
pyrazolo[3,4-d] pyrimidin-l-yl)ethyl)fluoro(4-fluorophenyl)-4H-chromenone : The
title compound was obtained as pale yellow (0.018 g, 5 %) by using a procedure that is
similar to the one described for example 7 from intermediate 39 (0.204 g, 0.692 mmol),
intermediate 113 (0.175 g, 0.577 mmol), trismethoxytriphenylphosphine (0.305 g, 0.865
mmol), THF (3 ml) and diisopropylazodicarboxylate ( 0.17 ml, 0.865 mmol). MP: 246-
248°C. lH-NMR (0 ppm, CDCh, 400 MHz): 08.28 (s, IH), 7.61 (m, 2H), 7.47 (m, 2H), 7.22
(m, 3H), 7.08 (m, 3H), 6.82 (t, J = 73 Hz, I H), 6.08 (q, J = 7.1 Hz, 1 H), 5.43 (s, 2H), 1.99 (d,
WO 20121151525
J = 7.1 Hz, 3H). Enantiomeric excess: 38.4% as determined by HPLC on a chiralpak AD-H
column, enriched in the fast eluting isomer (retention time = 10.34 min.).
Example 97
(S)/{R)- 2-{1-{ 4-amino{ 4-{ difluoromethoxy )fluorophenyl)-IH-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fl uoro{ 4-fluorophenyl)-4H -chromenone
{S)/(R)(l-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-
pyrazolo[3,4-d] pyrimidin-l-yl)ethyl)fluoro{ 4-fluorophenyl)-4H-chromenone : The
title compound was obtained as pale yellow solid (0.045 g, 12 %) by using a procedure that is
similar to the one described for example 7 from intermediate 39 (0.233 g, 0.791 mmol),
intermediate 114 (0.200 g, 0.659 mmol), trismethoxytriphenylphosphine (0.348 g, 0.989
mmol), THF (4 ml) and diisopropylazodicarboxylate ( 0.19 ml, 0.989 mmol). MP: 242-
244°C. IH-NMR (8 ppm, CDCb, 400 MHz): 88.29 (s, IH), 7.61 (m, 2H), 7.47 (m, 2H), 7.25
(m, 3H), 7.08 (m, 3H), 6.82 (t, J = 73 Hz, IH), 6.06 (q, J = 7.1 Hz, IH), 5.39 (s, 2H), 1.99 (d,
J = 7.1 Hz, 3H). Enantiomeric excess: 46.8% as determined by HPLC on a chiralpak AD-H
column, enriched in the late eluting isomer (retention time = 18.36 min.).
Example 98
2-(1-(4-( dimethylamino )(3-fluoromorpholinophenyl)-1 H -pyrazolo[3,4-
d]pyri midin-l-yl )ethyl)fl uoro(3-fl uorophenyl)-4 H -chromenone
2-( 1-( 4-(dimethylamino )(3-fluoromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound
was obtained as a off-white solid (0.085 g, 31 %) by using a procedure that is similar to the
one described for example 6 from intermediate 117 (0.150 g, 0.438 mrnol), DMF (2 ml),
potassium carbonate (0.073 g, 0.525 mmol) and intermediate 22 (0.224 g, .0.613 mmol). MP:
208-21 O°C. I H-NMR (8 ppm, CDCb, 400 MHz): 8.23 (s, I H), 7.62 (dt, J = 8.4,5.5 Hz, I H),
7.34 -7.28 (m, 4H), 7.06-6.92 (m, 4H), 6.83 (d, J = 8.1 Hz, I H), 6.10 (q, J = 7.1 Hz, I H), 3.91
(t, J = 4.5 Hz, 4H), 3.16 (t, '.! = 4.6 Hz, 4H), 2.92 (s, 6H), 1.96 (d, J = 7.1 HZ,3H).
Example 99
-fl uoro(I-(3-(3-fl uoromorpholinophenyl )(methylamino )-IH -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)(3-fluorophenyl)-4H-chromenone
5-fluoro(l-(3-(3-fluoromorpholinophenyl)(methylamin0)-1 H-
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)(3-fluorophenyl)-4H-chromenone The title
compound was obtained as a off-white solid (0.075 g, 27%) by using a procedure that is
similar to the one described for example 6 from intermediate 118 (0.150 g, 0.456 mmol), DMF
(2 ml), potassium carbonate (0.075 g, 0.540 mmol) and intermediate 22 (0.237 g, .0.630
WO 20121151525
mmol). MP: 238-240°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.30 (s, IH), 7.62 (dt, J =
8.4,5.5 Hz, IH), 7.36 -7.27 (m, 4H), 7.06-6.98 (m, 4H), 6.89 (d, J = 10.6 Hz, IH), 6.04 (q, J =
7.2 Hz, IH), 5.32 (q, J = 4.8 Hz, IH), 3.92 (t, J = 4.5 Hz, 4H), 3.19 (t, J = 4.6 Hz, 4H), 3.09
(d, J = 4.9 Hz, 3H), 1.97 (d, J = 7.2 Hz, 3H).
Example 100
(S)/(R)- 2-(1-( 4-amino(3-fl uoroisopropoxyphenyl)-lH -pyrazolo[3,4-
d] pyrimidinyl )ethyl)fluorophenyl-4H -chromenone
(S)/(R)(l-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrirnidin-l-yl)ethyl)fluorophenyl-4H-chromenone : The title compound was
obtained as off-white solid (0.050 g, 14 %) by using a procedure that is similar to the one
described for example 7 from intermediate 13 (0.212 g, 0.738 mmol), intermediate 115 (0.175
g, 0.615 mmol), trismethoxytriphenylphosphine (0.325 g, 0.923 mmol), THF (3 m!) and
diisopropylazodicarboxylate ( 0.18 ml, 0.923 mmol). MP: 205-208°C. IH-NMR (8 ppm,
CDCh, 400 MHz): 8 8.23 (s, IH), 7.60 (dt, J = 8.4,5.4 Hz, IH), 7.44 (dd, J = 11.5,2.0 Hz, IH),
7.37-7.29 9m, 4H), 7.23 (m, 3H), 7.14 (t, J = 8.4 Hz, IH), 7.04 (t, J = 10.1 Hz, IH), 6.08 (q, J
= 7.1 Hz, IH), 5.42 (s, 2H), 4.65 (quintet, J = 6.1 Hz, IH), 1.98 (d, J = 7.2 Hz, 3H), 1.42 (d, J
= 6.1 Hz, 6H). Enantiomeric excess: 81 % as determined by HPLC on a chiralpak AD-H
column, enriched in the fast eluting isomer (retention time = 1O.12min.).
Example 101
(S)/(R)- 2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-lH -pyrazolo[3,4-
d] pyrimidinyl )ethyl)fl uorophenyl-4 H -chromenone
(S)/(R)( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluorophenyl-4H-chromenone : The title compound was
obtained as off-white solid (0.067 g, 19 %) by using a procedure that is similar to the one
described for example 7 from intermediate 13 (0.212 g, 0.738 mmol), intermediate 116 (0.175
g, 0.615 mmol), trismethoxytriphenylphosphine (0.325 g, 0.923 mmol), THF (3 ml) and
diisopropylazodicarboxylate ( 0.18 ml, 0.923 mmol). MP: 185-188°C. I H-NMR (8 ppm,
CDCh, 400 MHz): 8 8.23 (s, I H), 7.60 (dt, J = 8.4,5.5 Hz, 1 H), 7.44 (dd, J = 11.5,2.0 Hz, I H),
7.37-7.29 (m, 4H), 7.23 (m, 3H), 7.14 (t, J = 8.3 Hz, IH), 7.04 (t, J = 9.9 Hz, IH), 6.08 (q, J =
7.1 Hz, IH), 5.43 (s, 2H), 4.64 (quintet, J = 6.0 Hz, IH), 1.98 (d, J = 7.2 Hz, 3H), 1.42 (d, J =
6.0 Hz, 6H). Enantiomeric excess: 73.5% as determined by HPLC on a chiralpak AD-H
column, enriched in the late eluting isomer (retention time = 13.20 min.).
Example 102
WO 20121151525
(S)/(R)- 2-(1-( 4-amino( 4-( difluoromethoxy )fluorophenyl)-IH -pyrazolo[3,4-
d]pyrimidin-l-yl )ethyl)fluorophenyl-4 H -chromenone
(S)/(R)( 1-( 4-amino(4-( di fl uoromethox y)fl uorophen y I )-1 H-
pyrazolo[3,4-dJpyrimidin-l-yl)ethyl)fluorophenyl-4H-chromenone: The title
compound was obtained as pale yellow solid (0.069 g, 20 %) by using a procedure that is
similar to the one described for example 7 from intermediate 39 (0.218 g, 0.738 mmol),
intermediate 115 (0.175 g, 0.615 mmol), trismethoxytriphenylphosphine (0.325 g, 0.923
mmol), THF (3 ml) and diisopropylazodicarboxylate ( 0.18 ml, 0.923 mmol). MP: 247-
250°C. IH-NMR (0 ppm, CDCh, 400 MHz): 08.26 (s, IH), 7.60 (m, 2H), 7.47 (m, 2H), 7.35
(m, 3H), 7.24 (m, 3H), 7.05 (t, J = 10.1 Hz, IH), 6.81 (t, J = 73 Hz, IH), 6.10 (q, J = 7.1 Hz,
IH), 5.39 (s, 2H), 1.99 (d, J = 7.1 Hz, 3H). Enantiomeric excess: 64.7% as determined by
HPLC on a chiralpak AD-H column, enriched in the fast eluting isomer (retention time = 9.78
min.).
Example 103
(S)/(R)- 2-(1-( 4-amino( 4-( difluoromethoxy )fluorophcnyl)-IH -pyrazolo[3,4-
d]pyrimidin-l-yl )cthyl)fluorophenyl-4H -chromcnone
(S)/(R)( 1-( 4-amino( 4-(difluoromethoxy)fluorophenyl)-1 H-
pyrazolo[3,4-dJpyrimidin-l-yl)ethyl)fluorophenyl-4H-chromenone: title
compound was obtained as pal yellow solid (0.033 g, 6 %) by using a procedure that is similar
to the one described for example 7 from intermediate 39 (0.218 g, 0.738 mmol), intermediate
116 (0.175 g, 0.615 mmol), trismethoxytriphenylphosphine (0.325 g, 0.923 mmo\), THF (3
ml) and diisopropylazodicarboxylate ( 0.18 ml, 0.923 mmol). MP: 217-220°C. IH-NMR (0
ppm, CDCb, 400 MHz): 0 8.26 (s, IH), 7.60 (m, 2H), 7.47 (m, 2H), 7.35 (m, 3H), 7.26 (m,
3H), 7.05 (t, J = 9.7 Hz, IH), 6.81 (t, J = 73 Hz, IH), 6.08 (q, J = 7.2 Hz, IH), 5.38 (s, 2H),
1.99 (d, J = 7.2 Hz, 3H). Enantiomeric excess: 47.4% as determined by HPLC on a chiralpak
AD-H column, enriched in the late eluting isomer (retention time = 14.01 min.).
Example 104
(+)- 5-fluoro(I-(3-(3-fluoroisopropoxyphcnyl)(mcthylamino )-IH
pyrazolo[3,4-d]pyrimidin-l-yl)cthyl)(3-fluorophenyl)-4H-chromcnonc
(+)- 5-fluoro( 1-(3-(3-fluoroisopropoxyphenyl)(methylamino )-1 H-
pyrazolo[3, 4-d] pyrimidin-l-y I )ethyl)-3 -(3 -fl uorophen yl )-4 H -chromenone The title
compound was obtained as off-white solid (0.212 g, 54 %) by using a procedure that is
similar to the one described for example 7 from intermediate 119 (0.218 g, 0.725 mmol),
intermediate 23b (0.200 g, 0.659 mmol), trismethoxytriphenylphosphine (0.348 g, 0.980
WO 20121151525
mmol), THF (4 ml) and diisopropylazodicarboxylate ( 0.19 ml, 0.989 mmol). MP: 199-
202°C. IH-NMR (0 ppm, CDCh, 400 MHz): 0 8.30 (s, IH), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.39
(dd, J = 11.5,2.1 Hz, IH), 7.31 (m, 3H), 7.15 (t, J = 8.4 Hz, IH), 7.06 (m, 3H), 6.90 (t, J = 9.9
Hz, IH), 6.04 (q, J = 7.1 Hz, IH), 5.31 (q, J = 4.9 Hz, IH), 4.66 (quintet, J = 6.1 Hz, IH),
3.09 (d, J = 4.9 Hz, 3H), 1.97 (d, J = 7.1 Hz, 3H), 1.43 (d, J = 6.1 Hz, 6H). Enantiomeric
excess: 96.5% as determined by HPLC on a chiralpak AD-H column, enriched in the fast
eluting isomer (retention time = 8.91 min.), [af5 181.67 (c = I, CHCh).
Example 105
(-)- 5-fluoro(1-(3-(3-fluoroisopropoxyphenyl)(methylamino )-lH
pyrazolo[3,4-d]pyrimidin-l-yl )ethyl)(3-fl uorophenyl)-4H -chromenone
(-)- 5-fluoro( 1-(3-(3-fluoroisopropoxyphenyl)(methylamino)-1 H-
pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)(3-fluorophenyl)-4H-chromenone The title
compound was obtained as off-white solid (0.201 g, 52 %) by using a procedure that is
similar to the one described for example 7 from intermediate 119 (0.218 g, 0.725 mmol),
intermediate 23a (0.200 g, 0.659 mmol), trismethoxytriphenylphosphine (0.348 g, 0.980
mmol), THF (4 ml) and diisopropylazodicarboxylate ( 0.19 ml, 0.989 mmol). MP: 216-
218°C. IH-NMR (0 ppm, CDCh, 400 MHz): 08.30 (s, IH), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.39
(dd, J = 11.5,2.1 Hz, IH), 7.31 (m, 2H), 7.27 (m, IH), 7.15 (t, J = 8.4 Hz, IH), 7.05 (m, 3H),
6.90 (t, J = 9.8 Hz, IH), 6.06 (q, J = 7.1 Hz, IH), 5.30 (q, J = 4.7 Hz, IH), 4.99 (quintet, J =
6.2 Hz, IH), 3.09 (d, J = 4.9 Hz, 3H), 1.97 (d, J = 7.2 Hz, 3H), 1.43 (d, J = 6.0 Hz, 6H).
Enantiomeric excess: 88.4% as determined by HPLC on a chiralpak AD-H column, enriched
in the late eluting isomer (retention time = 1.22 min.) [a]25 172.64 (c = I, CHCh) ..
Example 106
2-(1-(6-aminofluoro-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-4H
chromenone
2-( 1-( 6-aminofluoro-9H -purinyl)ethyl)fl uoro(3-fluoropheny 1)-4H-
chromenone : The title compound was obtained as a off-white solid (0.180 g, 63%) by
using a procedure that is similar to the one described for example 6 from 2-fluoro-9H-purin
amine (0.100 g, 0.653 mmol), DMF (2 ml), potassium carbonate (0.108 g, 0.783 mmol) and
intermediate 22 (0.330 g, .0.914 mmol). MP: 255-258°C. IH-NMR (0 ppm, CDC)3, 400
MHz): 8.42 (s, IH), 7.83 (m, 3H), 7.53 (d, J = 8.6 Hz, IH), 7.49 (m, IH), 7.28-7.13 (m, 4H),
.52 (q, J = 7.1 Hz, IH), 1.87 (d, J = 7.2 Hz, 3H). Mass: 437.7 (M+).
Example 107
WO 20121151525
2-(1-( 6-aminofluoro-9H -purinyl)ethyl )fluoro( 4-fluorophenyl )-4 H
chromenone
2-( 1-(6-aminofluoro-9H -purinyl)ethyl)fl uoro(4-fluorophenyl)-4H-
chromenone: The title compound was obtained as a off-white solid (0.120 g, 42%) by
using a procedure that is similar to the one described for example 6 from 2-fluoro-9H-purin
amine (0.100 g, 0.653 mmol), DMF (2 ml), potassium carbonate (0.108 g, 0.783 mmol) and
(0.330 g, .0.914 mmol). MP: 272-275°C. IH-NMR (8 ppm, CDCh, 400
intermediate 31
MHz): 8.41 (s, IH), 7.83 (m, 3H), 7.52 (d, J = 8.6 Hz, lH), 7.35-7.22 (m, 5H), 5.49 (g, J = 7.2
Hz, IH), 1.87 (d, J = 7.2 Hz, 3H).
Example 108
-fluoro( 4-fluorophenyl)(I-( 6-morpholino-9H -purinyl)ethyl )-4 H -chromen
5-fluoro(4-fluorophenyl)( 1-(6-morpholino-9H-purinyl)ethyl)-4H-
chromenone : The title compound was obtained as a off-white solid (0.090 g, 47%) by
using a procedure that is similar to the one described for example 6 from 4-(9H-purin
yl)morpholine (0.080 g, 0.389 mmol for preperation see Tetrahedron, 2007, 63, 5323-5328),
DMF (1.5 ml), potassium carbonate (0.064 g, 0.467 mmol) and intermediate 31 (0.185 g,
.0.506 mmol). MP: 186-189°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.26 (s, IH), 8.04 (s,
1H), 7.60 (dt, J = 8.4,5.4 Hz, I H), 7.37 (m, 2H), 7.26 (m, 3H), 7.04 (t, J = 9.4 Hz, 1 H), 5.89
(g, J = 7.3 Hz, I H), 4.29 br s, 4H), 3.84 (t, J = 4.9 Hz, 4H), 1.90 (d, J = 7.3 Hz, 3H).
Example 109
-fluoro( 4-fluorophenyl)(1-( 6-( 4-methyl piperazinyl)-9H -purinyl)ethyl)-
4H-chromenonc
5-fluoro( 4-fluorophenyl)( 1-(6-( 4-methylpiperazin-I-yl)-9H-purin
yl)ethyl)-4H-chromenone : The title compound was obtained as a off-white solid (0.012 g,
8%) by using a procedure that is similar to the one described for example 6 from 6-(4-
methylpiperazinyl)-9H-purine (0.060 g, 0.274 mmol), DMF (1.5 ml), potassium carbonate
(0.046 g, 0.329 mmol) and intermediate 31 (0.130 g, .0.357 mmol). MP: 157-160°C. IH_
NMR (8 ppm, CDCh, 400 MHz): 8.25 (s, 1H), 8.04 (s, 1H), 7.62 (dt, J = 8.4,5.4 Hz, IH),
7.37 (m, 2H), 7.25 (m, 3H), 7.07 (dt, J = 9.,0.7 Hz, IH), 5.90 (g, J = 7.2 Hz, IH), 4.31 br s,
4H), 2.54 (br s, 4H), 2.34 (s, 3H), 1.89 (d, J = 7.3 Hz, 3H).
Example 110
WO 20121151525
2-(1-( 6-( dimethylamino )-9H -purinyl)ethyl )fluoro(3-fluorophenyl)-4 H
chromenone
2-( 1-(6-(dimethylamino )-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-
4H-chromenone : The title compound was obtained as a brown solid (0.045 g, 20%) by
using a procedure that is similar to the one described for example 6 from N,N-dimethyl-9H
purinamine (0.080 g, 0.490 mmol for preparation see J .Het. Chern. 1983, 20, 295-199),
DMF (2 mI), potassium carbonate (0.081 g, 0.588 mmol) and intermediate 22 (0.250 g, .0.686
mmol). MP: 166-169°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.26 (s, IH), 8.00 (s, IH), 7.61
(dt, J = 8.5,5.5 Hz, IH), 7.48 (dd, J = 7.9,5.9 Hz, IH), 7.22 (m, 4H), 7.07 (dt, J = 8.3,0.8 Hz,
IH), 5.87 (q, J = 7.2 Hz, IH), 3.52 (s, 6H), 1.90 (d, J = 7.3 Hz, 3H).
Example 111
2-(1-( 6-( dimethylamino )-9H -purinyl)ethyl )fl uoro(3-fluorophenyl)-4 H
chromenone
5-fl uoro(3-fluorophenyl)( 1-( 6-(methylamino )-9H -purinyl )ethyl)-4H-
chromenone : The title compound was obtained as a off-white solid (0.020 g, 9%) by using
a procedure that is similar to the one described for example 6 from N-methyl-9H-purin
amine (0.080 g, 0.534 mmol for preperatuon see Bull.Soc. Jpn. 1986,62,3155-3160.
), DMF (2 ml), potassium carbonate (0.087 g, 0.641 mmol) and intermediate 22 (0.273 g,
.0.748 mmol). MP: 207-209°C. Mass: 433.9 (M+).
Example 112
-fluoro(3-fl uorophenyl)(1-(3-(3-mcthyl-l H -indazolyl )morpholino-l H
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)-4H -chromenone
5-fluoro(3-fluorophenyl)( 1-(3-(3-methyl-l H-indazolyl)
morpholino-l H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)-4H-chromenone : The title compound
was obtained as brown solid (0.050 g, 25%) by using a procedure that is similar to the one
described for example 9 from intermediate 106 (0.200 g, 0.325 mmol), 1,2-dimethoxyethane
(3 ml), water (1.5 ml), tert-butyI3-methyl(4,4,5,5-tetramethyl-I,3,2-dioxaborolanyl)-IH
indazole-l-carboxylate (0.174 g, 0.487 mmol), sodium carbonate (0.103 g, 0.975 mmol) and
bis(diphenylphosphino)ferrocene]dichloro paliadium(II).CH CI (0.053 g, 0.065 mmol ) MP:
l83-186°C. Mass: 619.8 (M+ +1).
Example 113
2-(1-( 4-amino(3-chloromorpholinophenyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
WO 20121151525
2-(1-( 4-amino(3-chloromorpholinophenyl)-1 H-pyrazolo[3,4-
dJpyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound
was obtained as brown solid (0.018 g, 10%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.150 g, 0.275 mmol), I ,2-dimethoxyethane (3
ml), water (1.5 ml), intermediate 123 (0.134 g, 0.412 mmol), sodium carbonate (0.058 g, 0.550
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.044 g, 0.055
mmol ) MP: 250-253°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.25 (s, IH), 7.71 (d, J = 2.0
Hz, IH), 7.59 (m, 2H), 7.27 (m, 2H), 7.19 (d, J = 8.3 Hz, IH), 7.05-6.99 (m, 4H), 6.06 (q, J =
7.1 Hz, 1 H), 5.38 (s, 2H), 3.92 (t, J = 4.5 Hz, 4H), 3.14 (t, J = 4.6 Hz, 4H), 1.99 (d, J = 7.2 Hz,
3H).
Example 114
(+) 2-(1-( 4-amino( 4-isopropoxymethylphenyl)-IH-pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
(+)- 2-( 1-( 4-amino( 4-isopropoxymethylphenyl)-1 H-pyrazolo[3,4-
dJpyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound
was obtained as off-white solid (0.083 g, 30 %) by using a procedure that is similar to the one
described for example 7 from intermediate 84 (0.150 g, 0.529 mmol), intermediate 23b (0.145
g, 0.481 mmol), trismethoxytriphenylphosphine (0.254 g, 0.721 mmol), THF (3 ml) and
diisopropylazodicarboxylate ( 0.14 ml, 0.721 mmol). MP: 217-220°C. IH-NMR (8 ppm,
CDCh, 400 MHz): 8 8.22 (s, IH), 7.61 (dt, J = 8.4,5.4 Hz, IH), 7.43 (m, 2H), 7.29 (m, 2H),
7.05-6.97 (m, 4H), 6.92 (d, J = 9.4 Hz, IH), 6.07 (q, J = 7.1 Hz, IH), 5.42 (s, 2H), 4.63
(quintet, J = 6.0 Hz, IH), 2.28 (s, 3H), 1.97 (d, J = 7.1 Hz, 3H), 1.39 (d, J = 6.0 Hz, 6H).
Enantiomeric excess: 100% as determined by HPLC on a chiralpak AD-H column, enriched in
the fast eluting isomer (retention time = 9.36 min.) [a]25 D 176.04 (c = 1, CHCh).
Example 115
(-) 2-(1-( 4-amino( 4-isopropoxymethylphenyl)-lH -pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
(-)- 2-(l-(4-amino(4-isopropoxymethylphenyl)-1 H-pyrazolo[3,4-
dJpyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound
was obtained as off-white solid (0.066 g, 28 %) by using a procedure that is similar to the one
described for example 7 from intermediate 84 (0.128 g, 0.453 mmol), intermediate 23a (0.125
g, 0.412 mmol), trismethoxytriphenylphosphine (0.217 g, 0.618 mmol), THF (3 ml) and
diisopropylazodicarboxylate ( 0.12 ml, 0.618 mmol). MP: 221-224°C. IH-NMR (8 ppm,
CDCh, 400 MHz): 8 8.22 (s, IH), 7.61 (dt, J = 8.4,5.5 Hz, IH), 7.43 (m, 2H), 7.29 (m, 2H),
WO 20121151525
7.05-6.95 (m, 4H), 6.92 (d, J = 9.5 Hz, IH), 6.05 (q, J = 7.1 Hz, IH), 5.40 (s, 2H), 4.62
(quintet, J = 6.0 Hz, IH), 2.28 (s, 3H), 1.99 (d, J = 7.2 Hz, 3H), 1.39 (d, J = 6.0 Hz, 6H).
Enantiomeric excess: 99.6 % as determined by HPLC on a chiralpak AD-H column, enriched
in the late eluting isomer (retention time = 11.43 min.) [a]25 -183.59 (c = 1, CHCh) ..
Example 116
(S)/(R)- 5-fluoro(1-(3-(3-fluoroisopropoxyphenyl )morpholino-1H
pyrazolo[3,4-d]pyrimidinyl )ethyl )(3-fluorophenyl)-4H -chromenone
(S)/(R)- 5-fluoro(1-(3-(3-fluoroisopropoxyphenyl)morpholino-lH-
pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)(3-fluorophenyl)-4H-chromenone The title
compound was obtained as pale yellow solid (0.044 g, 12 %) by using a procedure that is
similar to the one described for example 7 from intermediate 104 (0.243 g, 0.652 mmol),
intermediate 23a (0.180 g, 0.593 mmol), trismethoxytriphenylphosphine (0.272 g, 0.771
mmol), THF (3 ml) and diisopropylazodicarboxylate ( 0.17 ml, 0.890 mmol). MP: 136-
138°C. Mass: 642.0 (M+ ). Enantiomeric excess: 91.6 % as determined by HPLC on a
chiralpak AD-H column, enriched in the fast eluting isomer (retention time = 10.27 min.).
Example 117
2-(1-( 4-amino(3-chloroisopropoxyphenyl)-lH -pyrazolo[3,4-d] pyrimidi n
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(3-chloroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-I-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone : The title compound was obtained as brown
solid (0.039 g, 24%) by using a procedure that is similar to the one described for example 9
from intermediate 27 (0.150 g, 0.275 mmol), 1,2-dimethoxyethane (3 ml), water (1.5 ml),
intermediate 125 (0.107 g, 0.412 mmol), sodium carbonate (0.088 g, 0.825 mmol) and
bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH CIz (0.044 g, 0.055 mmol ). MP:
207-21O°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.24 (s, IH), 7.70 (d, J = 2.2 Hz, I H), 7.62
(dt, J = 8.3,5.3 Hz, IH), 7.51 (dd, J = 8.4,2.2 Hz, IH), 7.31 (m, 2H), 7.10 (d, J = 8.6 Hz, IH),
7.06 (m, 3H), 6.92(d, J = 9.6 Hz, IH), 6.06 (q, J = 7.2 Hz, IH), 5.38 (s, 2H), 4.66 (quintet, J
= 6.1 Hz, I H), 1.99 (d, J = 7.2 Hz, 3H). 1.44 (d, J = 6.0 Hz, 6H).
Example 118
2-(1-( 4-amino(2-methylbcnzo[ d]oxazolyl)-lH -pyrazolo[3,4-d]pyrimidin
yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(2-methylbenzo[d]oxazolyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone: The title compound was obtained
as brown solid (0.017 g, II %) by using a procedure that is similar to the one described for
WO 20121151525
example 9 from intermediate 27 (0.150 g, 0.275 mmol), 1,2-dimethoxyethane (3 ml), water
(l.5 ml), intermediate 127 (0.107 g, 0.412 mmol), sodium carbonate (0.088 g, 0.825 mmol)
and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH2Ch (0.044 g, 0.055 mmol ).
MP: 215-217°C. IH-NMR (8 ppm, CDCh, 400 MHz): 8.26 (s, IH), 7.81 (m, 2H), 7.63 (m,
2H), 7.30 (m, 2H), 7.06 (m, 3H), 6.94 (d, J = 9.3 Hz, IH), 6.10 (q, J = 7.1 Hz, IH), 5.48 (s,
2H), 2.70 (s, 3H), 2.01 (d, J = 7.1 Hz, 3H).
Example 119
-fluoro(3-fl uorophenyl)(1-( 6-morpholino-9H -purinyl)ethyl )-4 H -chromen
5-fluoro(3-fluorophenyl)( 1-( 6-morpholino-9H -purinYl)ethyl)-4H-
chromenone : The title compound was obtained as a yellow solid (0.060 g, 31 %) by using
a procedure that is similar to the one described for example 6 from 4-(9H-purin
yl)morpholine (0.080 g, 0.389 mmol for preparation see J.Med. Chern. 2010, 53, 8421-8439),
DMF (1.5 ml), potassium carbonate (0.064 g, 0.467 mmol) and intermediate 22 (0.185 g,
.0.506 mmol). MP: 239-241°C. Mass: 490.1 (M+ + 1).
Example 120
2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)ethyl)(3-fluorophenyl)morpholino-4H-chromenone
2-( 1-(4-amino(3-f1uoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)(3-fluorophenyl)morpholino-4H-chromenone : To a solution of example 6
( 0.100 g, 0.174 mmol) in dioxan (1 ml), morpholine (0.015 g, 0.174 mmol) was added and
refluxed for 3h. The reaction mixture was quenched with water, the product precipated was
filtered, washed with water, petroluem ether and dried under vacuum to afford the title
compound as a pale yellow solid (0.090 g, 80%). MP: 227-229°C. IH-NMR (8 ppm, CDCI ,
400 MHz): 8.23 (s, IH), 7.54 (t, J = 8.3 Hz, IH), 7.44 (dd, J = 11.5,2.0 Hz, IH), 7.37 (d, J =
8.3 Hz, IH), 7.29 (m, IH), 7.14 (t, J = 8.4 Hz, IH), 7.05 (d, J = 8.3 Hz, IH), 6.98 (m, 2H),
6.85 (m, 2H), 5.98 (q, J = 7.2 Hz, I H), 5.38 (s, 2H), 4.64 (quintet, J = 6.1 Hz, I H), 3.90 (t, J =
4.2 Hz, 4H), 3.07 (t, J = 4.2 Hz, 4H), 1.96 (d, J = 7.2 Hz, 3H), 1.42 (d, J = 6.0 Hz, 6H). Mass:
638.8 (M+).
Example 121
2-(1-( 4-amino(3-fl uo roisopropoxyphenyl)-1 H -pyrazolo[3,4-d] pyrimidin
yl)ethyl)morpholinophenyl-4H-chromenone
2-( 1-( 4-amino(3-f1uoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
l-yl)ethyl)morpholinophenyl-4H-chromenone : To a solution of example 13 ( 0.040
WO 20121151525
g, 0.072 mmol) in dioxan (1 mI), morpholine (0.007 g, 0.072 mmoI) was added and refluxed
for 3h. The reaction mixture was quenched with water, the product precipated was filtered,
washed with water, petroluem ether and dried under vacuum to afford the title compound as a
pale yellow solid (0.030 g, 67%). MP: 21 I-214°C. Mass: 621.2 (M+ +1).
Example 122
6-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-IH
pyrazolo[3,4-d]pyrimidinyl)isoindolin-l-one
6-( 4-amino-I-( 1-(5-fluoro(3-fluorophenyI)oxo-4H-chromenyI)ethyl)-
IH-pyrazolo[3,4-d]pyrimidinyl)isoindolin-l-one : The title compound was obtained as
brown solid (0.045 g, 30%) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.275 mmol), 1,2-dimethoxyethane (3 ml), water
(1.5 mI), intermediate 128 (0.106 g; 0.412 mmol), sodium carbonate (0.058 g, 0.550 mmol)
and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.044 g, 0.055 mmol ).
MP: 242-245°C. Mass: 551.0 (M+ +1).
Example 123
-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-IH
pyrazolo[3,4-d]pyrimidinyl)isoindolin-l-one
5-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromenyl)ethyl)-
1 H-pyrazolo[3,4-d]pyrimidinyl)isoindolin-l-one : The title compound was obtained as
brown solid (0.052 g, 35%) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.275 mmol), 1,2-dimethoxyethane (3 ml), water
129 (0.106 g, 0.412 mmol), sodium carbonate (0.058 g, 0.550 mmol)
(1.5 ml), intermediate
and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.044 g, 0.055 mmol ).
MP: 293-296°C. Mass: 550.7 (M+).
Example 124
2-(1-(3-( 4-acetylfl uorophenyl)amino-IH -pyrazolo[3,4-d]pyrimidin-l-yl)ethyl)
fluoro(3-fluorophenyl)-4H-chromenone
2-(1-(3-( 4-acetylfluorophenyl)amino-l H-pyrazolo[3,4-d]pyrimidin-l-
yl)ethyl)fluoro(3-fluorophenyI)-4H-chromenone : The title compound was obtained
as brown solid (0.045 g, 29%) by using a procedure that is similar to the one described for
example 9 from intermediate 27 (0.150 g, 0.275 mmol), 1,2-dimethoxyethane (3 ml), water
(1.5 ml), intermediate 130 (0.106 g, 0.412 mmol), sodium carbonate (0.087 g, 0.825 mmol)
and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Clz (0.044 g, 0.055 mmol ).
MP: 237-239°C. IH-NMR (8 ppm, CDCI), 400 MHz): 8.29 (s, IH), 8.08 (t, J = 7.7 Hz, IH),
WO 20121151525
7.62 (m, 3H), 7.32 (m, 2H), 7.07 (m, 3H), 6.92 (d, J = 9.1 Hz, IH), 6.09 (q, J = 7.1 Hz, IH),
.39 (s, 2H), 2.71 (d, J = 4.8 Hz, 3H),2.01 (d, J = 7.1 Hz, 3H).
Example 125
-fluoro(3-fluorophenyl)(I-(6-(4-methylpiperazin-l-yl)-9H-purinyl)ethyl)-
4H -chromenone
5-fluoro(3-fluorophenyl)( 1-(6-( 4-methylpiperazin-I-yl)-9H-purin
yl)ethyl)-4H-chromenone : The title compound was obtained as a off-white solid (0.052 g,
9%) by using a procedure that is similar to the one described for example 6 from 6-(4-
methylpiperazin-I-yl)-9H-purine (0.240 g, 1.09 mmol for preparation see Tetrahedron, 2007,
63,5323-5328.), DMF (4.8 ml), potassium carbonate (0.182 g, 1.3lmmol) and intermediate
(0.522 g, .1.429 mmol). MP: 199-201°C. Mass: 502.8 (M+).
Example 126
(S)/(R)- 2-(1-( 4-amino(3-chloromorpholinop henyl)-1 H -pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
(S)/(R)- 2-( 1-( 4-amino(3-chloromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound
was obtained as off-white solid (0.036 g, 12 %) by using a procedure that is similar to the one
described for example 7 from intermediate 131 (0.196 g, 0.592 mmoJ), intermediate 23b
(0.150 g, 0.494 mmol), trismethoxytriphenylphosphine (0.261 g, 0.741 mmoJ), THF (4 ml)
and diisopropylazodicarboxylate ( 0.13 ml, 0.741 mmol). MP: 256-258°C. IH-NMR (8 ppm,
CDCh, ~OO MHz): 88.24 (s, IH), 7.71 (d, J = 2.1 Hz, IH), 7.62 (dt, J = 8.4,5.4 Hz, IH), 7.55
(dd, J = 8.2,2.0 Hz, IH), 7.31 (m, 2H), 7.19 (d, J = 8.3 Hz, IH), 7.06 (m, 3H), 6.91 (d, J = 9.7
Hz, IH), 6.08 (q, J = 7.1 Hz, IH), 5.43 (s, 2H), 3.92 (t, J = 4.4 Hz, 4H), 3.14 (d, J = 4.5 Hz,
4H), 1.99 (d, J = 7.2 Hz, 3H). Enantiomeric excess: 98.8% as determined by HPLC on a
chiraJpak AD-H column, enriched in the fast eluting isomer (retention time = 15.07 min.).
Example 127
(S)/(R)- 2-(1-( 4-amino(3-chloromorpholinophenyl)-1 H -pyrazolo[3,4-
d] pyrimidin-l-yl )ethyl )-5 -fl uoro(3-fl uorophenyl )-4 H -chromenone
(S)/(R)- 2-( 1-( 4-amino(3-chloromorpholinophenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound
was obtained as off-white solid (0.085 g, 28 %) by using a procedure that is similar to the one
described for example 7 from intermediate 131 (0.196 g, 0.592 mmol), intermediate 23a
(0.150 g, 0.494 mmol), trismethoxytriphenylphosphine (0.261 g, 0.741 mmol), THF (4 ml)
WO 20121151525
and diisopropylazodicarboxylate ( 0.13 ml, 0.741 mmol). MP: 260-262°C. Mass: 616.9
(M++l).
Enantiomeric excess: 96% as determined by HPLC on a chiralpak AD-H column, enriched in
the late eluting isomer (retention time = 22.42 min.).
Example 128
N -(3-( 4-amino-l-(I-(5-fluoro(3-fluorophenyl)oxo-4H -chromenyl)ethyl)-1 H,.
pyrazolo[3,4-d]pyrimidinyl)phenyl)methanesulfonamide
N-(3-( 4-amino-l-( 1-(5-fluoro(3-fluorophenyl)oxo-4H-chromen
yl)ethyl)-1 H-pyrazolo[3,4-d]pyrimidinyl)phenyl)methanesulfonamide : The title compound
was obtained as brown solid (0.050 g, 23%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane (3
ml), water (1.5 ml), intermediate 132 (0.163 g, 0.549 mmol), sodium carbonate (0.116 g, 1.10
mmol) and bis(diphenylphosphino)ferrocene]dichloro palladium(II).CH Ch (0.059 g, 0.073
mmol ). MP: 259-261°C. IH-NMR (0 ppm, CDCI), 400 MHz): 9.90 (s, IH), 8.09 (s, IH),
7.83 (dt, J = 6.6,1.0 Hz, IH), 7.51 (m, 3H), 7.36-7.24 (m, 4H), 7.07 (dt, J = 8.5,2.5 Hz, IH),
6.93 (m, 2H), 5.99 (q, J = 7.1 Hz, IH), 3.04 (s, 3H), 1.88 (d, J = 7.1 Hz, 3H).
Example 129
(S)/(R)- 2-(1-(6-( dimethylamino )-9H -purinyl )ethyl )fluoro(3-fluorophcnyl)-
4H-chromenone
(S)/(R)( 1-(6-( dimethylamino )-9H -puriny I )ethyl)fluoro(3-
fluorophenyl)-4H-chromenone : The title compound was obtained as off-white solid (0.020
g, 9 %) by using a procedure that is similar to the one described for example 7 from N,N
dimethyl-9H-purinamine (0.088 g, 0.543 mmol), intermediate 23b (0.150 g, 0.494 mmol),
trismethoxytriphenylphosphine (0.261 g, 0.741 mmol), THF (4 ml) and
diisopropylazodicarboxylate (0.14 ml, 0.741 mmol). MP: 187-189°C. Mass: 448.0 (M+ + 1).
Enantiomeric excess: 100% as determined by HPLC on a chiralpak AD-H column, enriched
in the fast eluting isomer (retention time = 11.76 min.).
Example 130
(S)/(R)- 2-(I-(6-(dimethylamino)-9H-purinyl)ethyl)fluoro(3-fluorophenyl)-
4H-chromenone
(S)/(R)( 1-(6-( dimethyl amino )-9H-purinyl )ethyl)fl uoro(3-
fluorophenyl)-4H-chromenone : The title compound was obtained as off-white solid (0.016
g, 7 %) by using a procedure that is similar to the one described for example 7 from N,N-
WO 20121151525
dimethyl-9H-purinamine (0.088 g, 0.543 mmol), intermediate 23a (0.150 g, 0.494 mmol),
trismethoxytriphenylphosphine (0.261 g, 0.741 mmol), THF (4 ml) and
diisopropylazodicarboxylate (0.14 ml, 0.741 mmol). MP: I 98-200°C. Mass: 447.7 (M+).
Enantiomeric excess: 94.8% as determined by HPLC on a chiralpak AD-H column, enriched
in the late eluting isomer (retention time = 19.68 min.).
Example 131
2-(I-(9H-purinylamino)ethyl)-S-fluoro(2-fluorophenyl)-4H-chromenone
2-( 1-(9H -purinylamino )ethyl)fluoro(2-fluorophenyl)-4H -chromen
one : The title compound was obtained as pale-yellow solid (0.095 g, 33 %) by using a
procedure that is similar to the one described for example 7 from tert-butyl 9-trityl-9H-purin-
6-ylcarbamate (0.396 g, 0.831 mmol), intermediate 135 (0.210 g, 0.692 mmol),
triphenylphosphine (0.272 g, 1.03 mmol), THF (6 ml) and diisopropylazodicarboxylate ( 0.20
ml, 1.038 mmol), followed by the cleavage of the intermediate with trifluoroacetic acid (0.6
ml) and dichloromethane (3 ml) .. MP: 203-205°C. Mass: 419.7 (M+ ).
Example 132
2-(1-( 4-amino( 4-ethoxy ( trifluoromethyl)phenyl)-l H -pyrazolo[3,4-d] pyri midin
l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino( 4-ethoxy(trifluoromethyl)phenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-l-yl)ethyl)fluoro(3-fluorophenyl)-4H-chromen A-one : The title compound
was obtained as brown solid (0.026 g, 12%) by using a procedure that is similar to the one
described for example 9 from intermediate 27 (0.200 g, 0.366 mmol), 1,2-dimethoxyethane (3
ml), water (1.5 m}), 4-ethoxy(trifluoromethyl)phenylbororiic acid (0.128 g, 0.550 mmol),
sodium carbonate (0.116 g, 1.10 mmol) and bis(diphenylphosphino)ferrocene]dichloro
palladium(II).CH Ch (0.059 g, 0.073 mmol ). MP: 225-227°C. Mass: 608.1 (M+ + I).
Example 133
2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-IH-pyrazolo[3,4-d]pyrimidin-l
yl)propyl)fluoro(3-fluorophenyl)-4H-chromenone
2-( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-
1-yl)propyl)fluoro(3-fluorophenyl)-4H-chromenone : The title compound was
obtained as a off-white solid (0.062 g, 36%) by using a procedure that is similar to the one
described for example 6 from intermediate 13 (0.080 g, 0.293 mmol), DMF (2 ml), potassium
carbonate (0.081 g, 0.587 mmol) and intermediate 137 (0.130 g, .0.440 mmol). MP: 241-
243°C. 'H-NMR (b ppm, CDCb, 400 MHz): 8.25 (s, IH), 7.63 (dt, J = 8.4,5.4 Hz, 1H), 7.44
WO 20121151525
(dd, J = 11.5,2.0 Hz, I H), 7.35 (m, 3H), 7.14 (t, J = 8.4 Hz, 1 H), 7.06 (m, 3H), 6.92 (d, J = 7.5
Hz, IH), 5.85 (dd, J = 9.0,6.6 Hz, I H), 5.44 (s, 2H),4.66 (quintet, J = 6.2 Hz, 1 H), 2.64 (m,
IH), 2.46 (m, IH), 1.42 (d, J = 6.0 Hz, 6H), 0.91 (t, J = 7.3 Hz, 3H).
Example 134
(S)/(R)fluoro(3-fluorophenyl)(I-(2-methoxy -9 H -purinylamino )ethyl)-4H
chromenone
(S)/(R)- 5-f1 uoro(3-f1 uorophenyl)( 1-(2-methoxy-9H -purinylamino)
ethyl)-4H-chromenone : The title compound was obtained as pale-brown solid (0.055 g, 25
%) by using a procedure that is similar to the one described for example 7 from intermediate
140 (0.245 g, 0.494 mmol), intermediate 23b (0.150 g, 0.494 mmol), triphenylphosphine
(0.194 g, 0.741 mmol), THF (7 ml) and diisopropylazodicarboxylate (0.16 ml, 0.741 mmol),
followed by the cleavage of the intermediate with trifluoroacetic acid (0.6 ml) and
dichloromethane (8 ml). MP: 186-189°C. Mass: 449.8 (M+ ).
Example 135
(S)/(R)fl uoro(3-fluorophenyl)(1-(2-methoxy -9H -purinylamino )ethyl)-4 H
chromenone
(S)/(R)- 5-f1uoro(3-fluorophenyl)( 1-(2-methoxy-9H -purinylamino)
ethyl)-4H-chromenone : The title compound was obtained as pale-brown solid (0.056 g, 34
%) by using a procedure that is similar to the one described for example 7 from intermediate
140 (0.179 g, 0.362 mmol), intermediate 23a (0.110 g, 0.494 mmol), triphenylphosphine
(0.142 g, 0.544 mmol), THF (7 ml) and diisopropylazodicarboxylate (0.11 ml, 0.544 mmol),
followed by the cleavage of the intermediate with trifluoroacetic acid (0.6 ml) and
dichloromethane (7 mI) .. MP: 219-222°C. Mass: 449.8 (M+).
Example 136
(S)/(R)- 5-fluoro(I-(2-fluoro-9H-purinylamino)ethyl)(3-fluorophenyl)-4H
chromenone
(S)/(R)f1uoro( 1-(2-f1uoro-9H -purinylamino )ethyl)(3-f1uorophenyl)-
4H-chromenone : To a solution of intermediate 143 (0.22 g, 0.730 mmol), tert-butanol (1.5
ml) N,N-diisopropylethylamine (0.25 ml, 1.46 mmol) and 6-chlorofluoro-9H-purine (0.102
g, 0.663 mmol) were added and heated to reflux for 248h. The reaction mixture was
concentrated, quenched with water, extracted with ethyl acetate, dried with sodium sulphate
and concentrated. The crude product was purified by column chromatography with methanol:
ethyl acetate to afford the title compound as brown solid (0.042 g, 13% yield). MP: 183-
WO 20121151525
186°C. Mass: 437.9 (M+). Enantiomeric excess: 33% as determined by HPLC on a chiralpak
AD-H column, enriched in the fast eluting isomer (retention time = 7.21 min.).
Example 137
(S)/(R)- 2-(1-( 4-amino(3-fluoroisopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-
1-yl)ethy 1)methylphenyl-4H -chromenone
(S)/(R)( 1-( 4-amino(3-fluoroisopropoxyphenyl)-1 H-pyrazolo[3,4-
d]pyrimidin-I-yl)ethyl)methylphenyl-4H-chromen0ne : The title compound was
obtained as off-white solid (0.030 g, 15 %) by using a procedure that is similar to the one
described for example 7 from intermediate 13 (0.122 g, 0.425 mmol), intermediate 149 (0.100
g, 0.354 mmol), triphenylphosphine (0.140 g, 0.531 mmol), THF (1 ml) and
diisopropylazodicarboxylate (0.10 m!, 0.531 mmol). MP: 208-210°C. Mass: 549.7 (M+). IH_
NMR (8 ppm, CDCb, 400 MHz): 8.20 (s, IH), 7.48 (t, J = 7.6 Hz, IH), 7.43 (dd, J = 11.4,2.0
Hz, IH), 7.34 (m, 5H), 7.20-7.10(m, 4H), 6.09 (q, J = 7.1 Hz, IH), 4.67 (quintet, J = 6.1 Hz,
IH), 2.80 (s, 3H), 1.99 (d, J = 7.1 Hz, 3H), 1.42 (d, J = 6.0 Hz, 6H). Enantiomeric excess:
99.34 % as determined by HPLC on a chiralpak AD-H column, enriched in the fast eluting
isomer (retention time = 8.77 min).
Example 138
2-(1-(9H -purinylamino )ethyl)fluoroo-tolyl-4 H -chromenone
2-( 1-(9H-purinylamino)ethyl)fluoro0-tolyl-4H-chromenA-one : The
title compound was obtained as off-white solid (0.025 g, 20 %) by using a procedure that is
similar to the one described for example 7 from tert-butyl 9-trityl-9H-purinylcarbamate
(0.173 g, 0.362 mmol), intermediate 153 (0.090 g, 0.301 mmol), triphenylphosphine (0.119 g,
0.451 mmol), THF (2.3 ml) and diisopropylazodicarboxylate ( 0.10 ml, 0.451 mmol),
followed by the cleavage of the intermediate with trifluoroacetic acid (0.4 ml) and
dichloromethane (2 ml). MP: 275-277°C. Mass: 416.0 (M+).
BIOLOGICAL ASSAY
The pharmacological properties of the compounds of this invention may be
confirmed by a number of pharmacological assays. The pharmacological assays which can be
been carried out with the compounds according to the invention and/or their pharmaceutically
acceptable salts is exemplified below.
Assay 1: Fluorescent determination of PI3Kinase Kinase enzyme activity
Phosphoinositide 3 kinases (PI3K) belong to a class of lipid kinases that playa critical role in
the regulation of several key cellular processes. The PI3K are capable of phosphorylating the
3-hydroxy position of phosphoinositols thereby generating second messengers involved in
WO 20121151525
downstream signalling events. The homogenous time resolved fluorescence (HTRF) assay
allows detection of 3,4,5-triphosphate (PIP3) formed as a result of phosphorylation of
phosphotidylinositol 4,5-biphosphate (PIP2) by PI3K isoforms such as a, p, y or o.
PI3K isoform activity for a, p, y or 0 was determined using a PI3K human HTRFM Assay Kit
(Millipore, Billerica, MA) with modifications. All incubations were carried out at room
temperature. Briefly, 0.5 III of 40X inhibitor (in 100% OMSO) or 100% OMSO were added
to each well of a 384-well black plate (Greiner Bio-One, Monroe, NC) containing 14.5 III IX
reaction buffer IPIP2 (10 mM MgCh, 5 mM OTT, 1.38 IlM PIP2) mix with or without
enzyme and incubated for 10 min. After the initial incubation, 5 Ill/well of 400 IlM ATP was
added and incubated for an additional 30 minutes. Reaction was terminated by adding 5
Ill/well stop solution (Millipore, Billerica, MA). Five microliters of detection mix (Millipore,
Billerica, MA) were then added to each well and was incubated for 6-18 h in the dark. HRTF
ratio was measured on a microplate reader (BMG Labtech., Germany) at an excitation
wavelength of 337 nm and emission wavelengths of 665 and 620 nm with an integration time
of 400 Ilsec.
Table-2
% inhibition (PI3ky)
Examl2le % inhibition (PI3ku) % inhibition (PI3k8) % inhibition (PI3ko)
luM IC50 (nM) luM IC50 (nM) 300nM IC50 (nM) 300nM IC50 (nM)
C C B
- - - - -
0 0 B
- - - -
3. C
0 B +++ B ++++
- - - - -
. C
>10000 0 ++ - B
6. 0
>10000 C - A ++++ A +++++
7. C +++++
B +++++
- - -
8. 0 +++++
B ++ +++++
- - -
9. C +++++
C A ++++ A
9a 0 +++++
- C +++++
- - -
9b 0
C - ++ ++
. C
0 - A +++ C
11. B
B - C -
12. 0
C - A +++ -
13. 0
0 B - A +++++
14. C
0 A ++++ A ++++
- - - - -
WO 20121151525
ExamJ:!le % inhibition (PI3ka) % inhibition (PI3kjil % inhibition (PI3ky) % inhibition (PI3ko)
IC50 (nM) luM 300nM IC50 (nM) IC50 (nM)
luM IC50 (nMj 300nM
16. C
D D A ++++
17. D
C C A
D - A ++++
19. C
C A 8 -
- - -
. D
- C A ++++
- - - - -
22. C
D C A
- - - -
23. D
+++++ A ++++
D 8 C -
D C A
- +++++
D C A
++++
27. D
- C 8 C
D C 8 8
- - -
- - -
C D D
- - -
C 8 8
C - -
D 8 8 D
D C 8 8
D C 8 8
- - -
D 8 A
- - C
D C 8 D
C C D 8
C 8 D C
- --
C 8 D
- - 8
C C 8 8
- - - -
- - --
- - -
.........
D D C C
- - - -
D 8 8 C
- - - -
C - +++++ 8
- - 8
- --
51. 8
- - - - -
52. 8
C 8 8
- - -
D
- - -
54. 8
C C 8
- - -
55. 8
- - - -
56. 8
- - D
57. 8
- - - - -
WO 20121151525
Exam~le % inhibition (P13kaj % inhibition (P13kJl) % inhibition (PI3ky) % inhibition (PI3k&)
IC50 (nM) IC50 (nM)
luM IC50 (nM} luM IC50 (nM) 300nM 300nM
D B - B
>10000 C
- + - +++++ - +++
Exam~le % inhibition {PI3k&}
% inhibition (P13ka) % inhibition (PI3kl3) % inhibition (PI3ky)
IC50 (nM)
luM IC50 (nM) luM IC50 (nM) 100nM IC50 (nM) 100nM
D C C C
- - - -
C C B C -
D B C B
-- - - -
C D C C
- - - -
C C B
- - - -
C - C B D
- - -
C C C C
- - - -
- - - - -
C B B C
- - -
C A B
- - - - -
D C C C
- - -
- - - --
- --
- - - - - -
74. D C C B
75. D
76. C C C
77. C B C B ++++
78. C - B ++++
79. C C C D
80. B C C B
81. C C C B
82. C C C C
83. A +++++ A +++++
84. C + B +++++
85. C C C
86. D - C + B
87. C B D B +++
91. C C
92. D D
93. C
94. C C C C
WO 20121151525
ExamQle % inhibition {PI3ko}
% inhibition (PI3kv)
% inhibitio~ (PI3ku) % inhibition (PI3kB)
IC50 (nM) IC50 (nM)
1uM IC50 (nM) luM Ie50 (nM) 100nM 100 nM
95. D e
96. D
97. e C e e
100. B B B ++++ e +++
B B +++ D
101. e
e e D
102. B
103.
104. e D
105. e D
106. D
107. D e e D
lOS. e D e e
109. e
110. D e B ++++ A +++++
111. D e e
112. D B B
113. e D B ++++ B +++++
114. D - B B
115. e D e e
116. D D
117. B - e e
lIS. e D e e
119.
120.
121. e C B
122. D
123. D C D
124. e D D
125. D
126. D e D
127. D B D
12S. e B e ++++ ++++
129. D C C D
130. C C C
131. e D e e
132. C B
133.
WO 20121151525
% inhibition (PI3k&}
Exam~le
% inhibition (PI3ky)
% inhibition (PI3ka} % inhibition (PI3k(l)
IC50 (nM)
luM IC50 (nM) luM IC50 (nM) 100nM IC50 (nM) lOOnM
134.
135.
136.
137.
D B D C
Data were analyzed using Graphpad Prism (Graphpad software; San Diego CA) for IC
determination. Examples I-59 were tested at I uM for Pi3ka & Pi3k P and at 0.3 uM for y
and o. Examples 60-137 were tested at 1 uM for Pi3ka & Pi3k P and at 0.1 uM for y and o.
Percent inhibition was calculated based on the values for the blank and enzyme controls. The
results are as provided in Table 2 (wherein D= 0 to 25 % ; C = >25 to 50 % ; B = >50 to 75
%; A= >75 to 100 %; +++++ = ~ 50 nM; ++++ = >50 to ~ 100 nM; +++ = >100 to ~ 300
nM; ++ = >300 to ~ 500 nM; + = >500 nM)
Assay 2: In vitro cell proliferation assay in leukemic cell lines
Growth inhibition assays were carried out using 10% FBS supplemented media. Cells were
seeded at a concentration of 5000 - 20,000 cells/well in a 96-well plate. Test compound at a
concentration range from 0.0 I to 10000 nM were added after 24 h. Growth was assessed
using the 3-[4,5-dimethylthiazolyl]-2,5-diphenyltetrazolium bromide (MTT) dye reduction
test at 0 h (prior to the addition of the test compound) and 48 h after the addition of test
compound. Absorbance was read on a F1uostar Optima (BMG Labtech, Germany) at a wave
length of 450 nm. Data were analysed using GraphPad Prism and % inhibition due to the test
compound compared to the control was calculated accordingly. Exemplary compounds of the
present invention when tested @ 1 uM in THP-I; DLBCL; HL-60; MOLT-4, RPMI8226 and
TOLEDO cell lines showed a 20 to 80 % inhibition.
Assay 3: Inhibition of AKT phosphorylation in leukemic cell lines:
Inhibition of AKT phosphorylation in leukemic cell lines: THP-I, HL-60, MOLT-4, RPMI-
8226, or DLBCL cells were incubated with desired concentrations of compound for 48 h.
Cells were lysed and pAKT was determined by Western Blotting. Bands were quatified using
ImageJ and normalized to actin. Exemplary compounds of the present invention when tested
@ I uM in showed a 50 to 90 % inhibition.
Assay 4: Inhibition of PI3Ko signalling in basophils from Human Whole
Blood
WO 20121151525
PI3K8 signalling in basophils manifested by an alteration of anti-FceRI induced CD63
expression is a useful pharmacodynamic marker determined using the Flow2CAST® kit
(Buhlmann Laboratories, Switzerland). Briefly, it involves the following steps:
>- Mix the anti-coagulated blood sample by inverting the venipuncture tube several times
>- Prepare fresh and pyrogen-free 3.S ml polypropylene or polystyrene tubes suitable for
Flow Cytometry measurements
>- Add 49 ~I of patient's whole blood to each tube.
>- Add I ~I of 10% DMSO (background) or compound (10% DMSO) to the assigned
tubes and mix gently. Incubate at room temperature for IS min
>- Pipet SO ~I of the Stimulation buffer (background) or anti- FCERI Ab to each tube
>- Add 100 ~I of Stimulation Buffer to each tube
>- Mix gently. Add 20 ~I Staining Reagent (1: 1 mix of FITC-CD63 and PE-CCR3) to
each tube
>- Mix gently, cover the tubes and incubate for IS minutes at 37°C in a water bath.
(using an incubator will take about 10 minutes longer incubation time due to less
efficient heat transfer)
>- Add 2 ml pre-warmed (lS-2S°C) Lysing Reagent to each tube, mix gently
>- Incubate for S -10 minutes at IS-2SoC
>- Centrifuge the tubes for S minutes at SOO x g
>- Decant the supernatant by using blotting paper
>- Resuspend the cell pellet with 300-S00 ~l of Wash Buffer
>- Vortex gently and acquire the data on the flow cytometer within the same day.
Percent CD63 positive cells within the gated basophil population are to be determined in
different treatment groups and normalized to vehicle control.
Assay 5: Inhibition of apoptosis in leukemic cell lines Apoptosis in
leukemic cells was determined using an in-situ Caspase 3 kit (Millipore, US) as
outlined below:
>- Seed leukemic cells - at a density of 1 X 1 0 cells/well in a 6 well plate
>- Add test compoundlDMSO at desired concentrations
>- Incubate the plate for 24 hrs at 37°C in S% CO incubator
>- Collect cells in a 2ml centrifuge tube
>- Add 1.6 ~L of freshly prepared SX FUCA reagent and mix cells by slightly
flicking the tubes
>- Incubate tubes for 1 hour at 37°C under S% CO
>- Add 2 ml of 1 X wash buffer to each tube and mix
>- Centrifuge cells at <400 x g for S minutes at room temperature.
>- Carefully remove and discard supernatant, and gently vortex cell pellet to disrupt any
cell-to-cell clumping.
>- Resuspend cell pellet in 300ul of I X wash buffer
>- Place 1 00 ~L of each cell suspension into each of two wells of a black microtiter
plate. A void creation of bubbles.
WO 20121151525
> Read absorbance of each microwell using an excitation wavelength of 490 nm and
an emission wavelength of 520 nm
> Percent increase in caspase-3 activity manifested by an increase in fluorescence
compared to the control blank is to be calculated.
Assay 6 : Lipopolysaccharide induced pulmonary neutrophilia in male
Sprague-Dawley rat model:
An exaggerated recruitment and subsequent activation of neutrophil is likely to be important
for the development and course of several inflammatory diseases in the airways and lungs,
such as severe asthma, chronic obstructive pulmonary disease, cystic fibrosis, and acute
respiratory distress syndrome. The mechanisms by which neutrophil contribute to these
diseases may involve the release of proteolytic enzymes, such as neutrophil elastase, and free
oxygen radicals. When released, these compounds can cause bronchoconstriction, bronchial
hyperreactivity, hyper-secretion, epithelial damage, and tissue remodelling in the airways.
After the quarantine period, fasted animals are to be randomized and divided into various
groups depending on their body weights. Test compound is to be prepared as a suspension in
a vehicle consisting of 0.5% methylcellulose in which Tween 80 as a suspending agent. The
compound or vehicle is to be administered by oral gavage in a volume of lOmUkg. Animals
are to be anaesthetized with ketamine and LPS solution was administered intratracheally one
hour after compound administration at a dose of I mglkg. 6 h after LPS instillation, animals
are to be exsanguinated under anaesthesia, and then trachea is to be cannulated and the lungs
are to be lavaged with 5-ml aliquots of heparinised PBS (1 unitlml) four times through
tracheal cannula (total volume 20 mI). BAL fluid has to be stored at 2-8 °C until assayed for
total cell and differential leukocyte count. Bronchioalveolar fluid is to be centrifuged (500xg
for 10 min) and the resulting cell pellet is to be resuspended in 0.5 ml of heparinised saline.
The total numbers of white blood cells are to be determined in BAL fluid or blood by using a
blood cell counter and has to be adjusted to I x 10 cellfm!' Differential cell count has to be
calculated manually. One hundred microliters of the cell suspension is to be centrifuged using
cytospin 3 to prepare a cell smear. The cell smear has to be stained with a blood staining
solution for differentiation and slides have to be microscopically observed to identify
eosinophil according to their morphological characteristics. The number of each cell type
among 300 white blood cells in the cell smear is to be determined and expressed as a
percentage. The number of eosinophil in each BALf or blood is to be calculated.
Assay 7: Lipopolysaccharide-Mediated Rat Air Pouch Model of
Inflammation:
WO 20121151525
Leukocyte recruitment and the formation of pro-inflammatory mediators, including different
cytokines, are the hallmark of an inflammatory response. The air-pouch model was originally
developed as a facsimile synovium for the study of inflammatory processes that occur in RA.
The model allows the differential quantification of leukocyte species that accumulate in the
air-pouch wall (tissue) as well as those that transmigrate into the air-pouch cavity (lavage),
and it allows the characterization of the chemokines and adhesion molecules responsible for
diapedesis induced by a variety of inflammatory stimuli.
Male Wistar rats (175-200 g) are to be acclimatized for seven days prior to the start of the
experiment. Animals are then to be randomly distributed to various groups based on their
body weights. Animals are to be anaesthetised with ether and subcutaneous air pouches are to
ml of sterile air under the skin in the intra-scapular area (day 0) and
be formed by injecting
maintained with a second 10-ml injection of sterile-filtered air on day 4. On day 6, oral
treatment is to be commenced I h prior to induction of inflammation by s.c. injection of LPS
solution on day 6. A volume of 5-ml of LPS solution dissolved in sterile saline (100~g/kg) is
to be injected into each pouch. Samples of pouch fluid are to be taken at 6 h after
administration of LPS by flushing the pouch with 5 ml of sterile saline and withdrawing 4 ml
of fluid. The numbers of leukocytes present in pouch fluid has to be determined
microscopically using a haemocytometer. Differential cell content has to be determined by
microscopic examination of fluid smears stained with Diff-Quik.
Assay 8: Lipopolysaccharide Induced TNF-a Production:
Fasted female wistar rats are to be randomized in to different groups depending on their body
weights. Test compound has to be prepared as a suspension in a vehicle consisting of 0.5%
methyicellulose. The compound or vehicle is to be administered by oral gavage in a volume
of 10mL/kg. LPS solution is to be administered intraperitoneally one hour after compound
administration at a dose of 0.3 mglkg. Blood has to be collected in serum separator tubes via
cardiac puncture ninety minutes after LPS injection. Serum has to be separated and stored at -
°C and will be analysed for TNFa by ELISA.
Assay 9: Ovalbumin induced pulmonary eosinophilia in male guinea pigs:
Airway inflammation and hyper-responsiveness (AHR) are hallmarks and distinguishing
features of bronchial asthma. Provocation of pre-sensitized mice with the same allergen
induces airway inflammation with preferential eosinophilic infiltration and, as a consequence,
AHR. Pulmonary eosinophilia and airway remodelling in conjunction with altered neural
control of airway tone and airway epithelial desquamation may contribute to AHR in asthma.
WO 20121151525
After the quarantine period, 0.3 mL of blood samples is to be collected from orbital vein by
retro-orbital plexus method from each individual animal and analysed on a _ cell analyser
(ADVIA 2120, Siemens). Based on their total cell count, guinea pigs are to be randomized
and divided into various groups. Ear pinna is to be marked with an indelible marking pen for
identification. On day 0, weights are to be recorded and animals are then to be sensitized with
50llg of Ovalbumin and 10 mg of alum solution (1 mL) intraperitoneally. On day 7 and day
14, the above sensitization protocol has to be repeated. On day 18, animals are to be treated
with test compound by oral/intranasal route. On day 19, & 20, animals are to be treated with
test compound by oral/intranasal administration and exposed to 0.5 % w/v Ovalbumin for 10
min using ultrasonic nebulizer with flow rate of 0.2 ml per min. On day 21, fasted animals are
to be treated with test compound by oral/intranasal administration and 15 min after dosing,
animals are to be nebulized with 1 % w/v Ovalbumin solution for 10 min. Control group
animals are to be treated with 0.5% w/v methyl cellulose (vehicle). Sham control groups are
to be sensitized with 10 mg of alum on day 0, 7 & 14 and exposed to saline solution with the
same nebulization rate on d 19, d20 & d21. Twenty four hours after OVA challenge, blood
samples and BAL fluid has to be collected. Samples are to be analysed for total cell count by
using blood analyser (ADVIA 2120, Siemens) and differential leukocyte count is to be done
manually.
Assay 10: Collagen Induced Arthritis in Wistar Rats:
Female wistar rats are to be acclimatized for seven days prior to the start of the experiment
and are randomly distributed to various groups based on their body weights. On day 0,
animals are to be treated by intradermal injection of 500 Ilg of bovine collagen type n
emulsified with complete Freund's adjuvant (IFA) containing MTB (4 mg/mL) delivered at
the base of the tail. On day 7 after primary immunization, animals are to be treated by booster
injection of 300 Ilg cn in incomplete Freund's adjuvant by intradermal injection at the base of
the tail. Onset of arthritis in ankle joints usually became visually apparent between days 12
and 14. Animals are to be treated with test compound or vehicle (orally administered) from
the day after onset of arthritis until end of the experiment (day 28) as a therapeutic group.
Arthritis Scores have to be taken by visually examination for signs of joint inflammation
regularly throughout the study period. Body weights and paw volumes, paw thickness have to
be taken on day 0, 3, 7, 10, 12, 14, 17 21, 24 and 28. On d28, at the end of the study, blood
has to be withdrawn at necropsy and processed to serum or plasma and all joints are to be
taken and both fore paw and hind paws are to be fixed in 10% formalin for histopathology
analysis after taking the small piece of tissue from each joint and stored at -80 C for cytokine
WO 20121151525
analysis in tissue homogenate. Clinical Scoring Criteria for Fore and Hind Paws: O=normal;
1=1 hind or fore paw joint affected or minimal diffuse erythema and swelling; 2=2 hind or
fore paw joints affected or mild diffuse erythema and swelling; 3=3 hind or fore paw joints
affected or moderate diffuse erythema and swelling; 4= Marked diffuse erythema and
swelling, or =4 digit joints affected); 5=Severe diffuse erythema and severe swelling entire
paw, unable to flex digits)
Assay 11: Acute CSE induced cell infiltration in Male Balb/c mice:
Animals are to be acclimatized for seven days prior to the start of the experiment. Animals
are to be randomly distributed to various groups based on their body weights. On day 1, mice
are to be administered by test compound or vehicle by oral/intranasal route and after 1 hr test
compound administration animals are to be anaesthetised with ether and cigarette smoke
extract is to be administered by intranasal route in volume of 50l-tl/mouse and repeated the
CSE exposure to animals daily after the test compound administration for four days (dl to
d4). On day 5, 24 hours after last CSE exposure animals are to be exsanguinated under
anesthesia, and the trachea is to be cannulated and the lungs are lavaged with 0.5-ml aliquots
of heparinised PBS (1 unitlml) four times through tracheal cannula (total volume 2 ml). BAL
stored at 2-8 °C until assayed for total cell and differential leukocyte count. Bronchioalveolar
fluid is to be centrifuged (500xg for 10 min) and the resulting cell pellet has to be
resuspended in 0.5 ml of heparinised saline. The total number of white blood cells is to be
determined in BAL fluid and blood using a blood cell counter and adj usted to I x 10 cell/mi.
Differential cell count is to be calculated manually. Forty microliters of the cell suspension is
to be centrifuged using cytospin 3 to prepare a cell smear. The cell smear is to be stained with
a blood staining solution for differentiation and microscopically has to be observed to identify
eosinophil according to their morphological characteristics. The number of each cell type
among 300 white blood cells in the cell smear are to be determined and has to be expressed as
a percentage, and the number of neutrophils & macrophages in each BALf are to be
calculated.
Assay 12: Sub-chronic CSE induced cell infiltration in Male Balb/c mice:
Animals are to be acclimatized for seven days prior to the start of the experiment. Animals are
to be randomly distributed to various groups based on their body weights. On day 1, animals
are to be anaesthetised with ether and cigarette smoke extract is to be administered by
intranasal route in volume of 50)ll/mouse and repeated the CSE exposure to animals daily for
eight days (dl to d8). On day 9, mice are to be administered by test compound or vehicle by
oral/intranasal route and after 1 hr test compound administration animals are to be
WO 20121151525
anaesthetised with ether and cigarette smoke extract is to be administered by intranasal route
in volume of 50,.tl/mouse and animals are to be exposed to CSE daily after the test compound
administration for next three days (d9 to dll), on day 12, twenty four hours after last CSE
exposure animals are to be exsanguinated under anesthesia, and the trachea is to be cannulated
and the lungs are to be lavaged with 0.5-ml aliquots of heparinised PBS (1 unit/ml) four times
through tracheal cannula (total volume 2 ml). BAL stored at 2-8 °C until assayed for total cell
and differential leukocyte count. Bronchioalveolar fluid was centrifuged (500xg for 10 min)
and the resulting cell pellet is to be resuspended in 0.5 ml of heparinised saline. The total
numbers of white blood cells are to be determined in BAL fluid and blood using a blood cell
counter and adjusted to lx10 ceIUml. Differential cell count was calculated manually. Forty
microliters of the cell suspension is to be centrifuged using cytospin 3 to prepare a cell smear.
The cell smear is to be stained with a blood staining solution for differentiation and
microscopically observed to identify eosinophil according to their morphological
characteristics. The number of each cell type among 300 white blood cells in the cell smear
has to be determined and expressed as a percentage, and the number of neutrophils &
macrophages in each BALf are to be calculated.
Assay 13:Reversal of Corticosteroid insentivity in cigarette smoke extract
induced pulmonary inflammation (COPD) model:
Female Balb/c mice are to be acclimatized for seven days prior to the start of the experiment.
Animals are then to be randomly distributed to various groups based on their body weights.
On day I, animals are to be anaesthetised with ether and cigarette smoke extract is to be
administered by intranasal route in volume of 50,..t1/mouse and animals are to be exposed to
CSE daily for next five days (dl to d6). On day 7, mice are to be administered by
dexamethasone at 10 mglkg by oral gavage and 60 mins later, mice are to be administered
with CSE by intranasal route and it has to be repeated for next four days (d7 to dll). From day
9 to day II, animals are to be administered by test compound or vehicle by orallintranasal
route and 30 mins after dexamethasone administration and 30 mins later animals are to be
anaesthetised with ether and cigarette smoke extract is to be administered by intranasal route
in volume of 50lll/mouse and animals are to be exposed to CSE daily after the test compound
administration for next two days (i.e. d9 to d II), on d 12, twenty four hours after last CSE
exposure animals are to be exsanguinated under anesthesia, and the trachea is to be cannulated
and the lungs are to be lavaged with 0.5-ml aliquots of heparinised PBS (l unit/ml) four times
BAL has to be stored at 2-8 °C until assayed for
through tracheal cannula (total volume 2 ml).
total cell and differential leukocyte count. Bronchioalveolar fluid is to be centrifuged (500xg
WO 20121151525
for 10 min) and the resulting cell pellet has to be resuspended in 0.5 ml of heparinised saline.
The total number of white blood cells is to be determined in BAL fluid and blood using a
blood cell counter and adjusted to 1 x 10 celllml. Differential cell count is to be calculated
manually. Forty microliters of the cell suspension is to be centrifuged using cytospin 3 to
prepare a cell smear. The cell smear is to be stained with a blood staining solution for
differentiation and microscopically has to be observed to identify eosinophil according to their
morphological characteristics. The number of each cell type among 300 white blood cells in
the cell smear are to be determined and will be expressed as a percentage, and the number of
neutrophils and macrophages in each BAL fluid are to be calculated.
Assay 14: Acute Cigarette smoke induced cell infiltration in Male Balb/c
mice:
Animals are to be acclimatized for seven days prior to the start of the experiment. Animals are
then to be randomly distributed to various groups based on their body weights. On day I, mice
is to be administered test compound or vehicle by oral/intranasal route and after I hr test
compound administration animals are to be placed in whole body exposure box. On day I and
d2 mice are exposed to the mainstream smoke of 6 cigarettes and of 8 cigarettes on day 3, and
of 10 cigarettes on day 4. Exposure to the smoke of each cigarette lasts for 10 min (cigarette
are to be completely burned in the first two minutes and followed by an air flow with animal
ventilator and next 20 min exposure with fresh room air. After every second cigarette an
additional break of 20 min with exposure to fresh room air is to be conducted. Control animals
are to be exposed to room air chamber. From day I to d4 animals are administered by test
compound either oral or intranasal route. On day 5, 24 hours after last cigarate smoke (CS)
exposure animals are exsanguinated under anesthesia, and the trachea is to be cannulated and
the lungs are lavaged with 0.5-ml aliquots of heparinised PBS (1 unit/ml) four times through
tracheal cannula (total volume 2 ml). Bronchioalveolar (BAL) collected is to be stored at 2-8
°C until assayed for total cell and differential leukocyte count. BAL fluid is to be centrifuged
(500xg for 10 min) and the resulting cell pellet is resuspended in 0.5 ml of heparinised saline.
The total number of white blood cells is to be determined in BAL fluid and blood using a
blood cell counter and adjusted to 1 x 10 cell/ml. Differential cell count is calculated manually.
Forty microliters of the cell suspension is centrifuged using cytospin 3 to prepare a cell smear.
The cell smear is stained with a blood staining solution for differentiation and microscopically
observed to identify eosinophil according to their morphological characteristics. The number
of each cell type among 300 white blood cells in the cell smear are to be determined and
WO 20121151525
expressed as a percentage, and the number of neutrophils & macrophages in each BAL fluid
are to be calculated.
Assay 15: Ovalbumin-induced nasal eosinophil and neutrophil
accumulation in mice:
Animals are to be acclimatized for seven days prior to the start of the experiment. Animals are
then to be randomly distributed to various groups based on their body weights. Animals are to
be immunized with OVA (40 Ilglkg i.p.) on day 1 and 5. In order to elicit local inflammatory
responses in the nose, mice are to be repeatedly challenged intra-nasally (1 o ilL/per nostril) on
days 12-19 with OVA (3% OVA in saline). On day 19 non-fasted mice are to be dosed intra
nasally (lOllL/nostril) with either vehicle or test compound 2 hours before to the start of the
final OVA challenge. Two hrs later, each animal is to be received a final intranasal OVA (3%)
challenge). After a further 8 hr, each animal is to be anaesthetized and nasal lavage is to be
carried out by instilling 1 ml of PBS into the posterior nares via a rostrally implanted tracheal
cannula extending to a position that is approximately 1 mm before the posterior nares. This
procedure has to be repeated to give a yield of approximately 2 ml of lavage fluid. Total cell
numbers in the nasal lavage fluid samples are to be measured using a haemocytometer.
Cytospin smears of the nasal lavage fluid samples are to be prepared by centrifugation at 1200
rpm for 2 min at RT and stained using a Diff-Quik stain system (Dade Behring) for differential
cell counts. Cells are to be counted using oil immersion microscopy.
Assay 16: Poly-I:C-induced cell accumulation in mice:
Specific pathogen-free A/l mice (males, 5 weeks old) are to be acclimatized for seven days
prior to the start of the experiment. Animals are then to be randomly distributed to various
groups based on their body weights. Animals are to be administered with poly (I:C)-LMW
40 ilL) intranasally twice daily for 3 days under anaesthesia with 3%
(poly-IC; 1 mg/mL,
isoflurane. Animals are to be treated with test compound by intra-nasally (35 ilL of solution in
50% DMSOIPBS) 2hr before each poly-I:C treatment. Twenty four hr after the last poly-l:C
challenge, animals are to be anesthetized, the trachea has to be cannulated and BALF is to be
collected. The concentrations of alveolar macrophages and neutrophils in BALF are to be
determined by using a blood cell counter and adjusted to 1 x 10 cell/m!. Differential cell count
is calculated manually. Forty microliters of the cell suspension is centrifuged using cytospin 3
to prepare a cell smear. The cell smear is stained with a blood staining solution for
differentiation and microscopically observed to identify eosinophil according to their
The number of each cell type among 300 white blood cells in
morphological characteristics.
WO 20121151525
the cell smear are to be determined and expressed as a percentage, and the number of
neutrophils & macrophages in each BAL fluid are to be calculated.
Although the invention herein has been described with reference to particular
embodiments, it is to be understood that these embodiments are merely illustrative of the
principles and applications of the present invention. It is therefore to be understood that
numerous modifications may be made to the illustrative embodiments and that other
arrangements may be devised without departing from the spirit and scope of the present
invention as described above. It is intended that the appended claims define the scope of the
invention and that methods and structures within the scope of these claims and their
equivalents be covered thereby.
All publications and patent and/or patent applications cited in this application
are herein incorporated by reference to the same extent as if each individual publication or
paterit application was specifically and individually indicated to be incorporated herein by
reference.
Claims (1)
1. A compound of formula 5 (I) or a tautomer thereof, N-oxide thereof, pharmaceutically acceptable ester thereof, or pharmaceutically acceptable salt thereof, wherein each occurrence of R is independently selected from fluoro, methyl, methoxy or morpholine; 10 R and R may be the same or different and are independently selected from hydrogen, halogen, and substituted or unsubstituted C alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted 1 2 cycloalkylalkyl, and substituted or unsubstituted heterocyclyl, or both R and R directly 15 bound to a common atom, may be joined to form an oxo group (=O) or a substituted or unsubstituted, saturated or unsaturated 3-10 member ring (including the carbon atom to which R and R are bound), which may optionally include one or more heteroatoms which may be the same or different and are selected from O, NR and S; Cy is selected from substituted or unsubstituted cycloalkyl, substituted or 20 unsubstituted heterocyclic group, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; Cy is selected from a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl; a b a L is absent or selected from –(CR R ) -, -O-, -S(=O) -, -NR - or –C(=Y)-. 1 q q 25 each occurrence of R and R may be the same or different and are independently selected from hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted (C c d c d )alkyl, -NR R (wherein R and R are independently hydrogen, halogen, hydroxy, cyano, substituted or unsubstituted (C )alkyl, or (C )alkoxy) and -OR (wherein R is 1-6 1-6 139095.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1542/CHE/2011 | 2011-05-04 | ||
IN1542CH2011 | 2011-05-04 | ||
IN81CH2012 | 2012-01-09 | ||
IN81/CHE/2012 | 2012-01-09 | ||
PCT/US2012/036594 WO2012151525A1 (en) | 2011-05-04 | 2012-05-04 | Novel compounds as modulators of protein kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ616834A NZ616834A (en) | 2015-10-30 |
NZ616834B2 true NZ616834B2 (en) | 2016-02-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11020399B2 (en) | Intermediates useful in the synthesis of compounds as modulators of protein kinases | |
US11858907B2 (en) | Kinase modulators | |
NZ616834B2 (en) | Novel compounds as modulators of protein kinases | |
OA16775A (en) | Novel compounds as modulators of protein kinases. |